{
  "symbol": "MDXH",
  "company_name": "Mdxhealth Sa ADR",
  "ir_website": "https://mdxhealth.com/shareholder-information/",
  "structured_data": [
    {
      "section_name": "Investor Relations Contact",
      "links": [
        {
          "title": "Investor Relations Contact",
          "url": "https://mdxhealth.com/contact-us/",
          "content": "![logo](data:,)\n\n## This website uses cookies\n\nWe use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. You consent to our cookies if you continue to use our website.\n\nDo not sell or share my personal information\n\n[Use necessary cookies only ](#)[Allow all cookies ](#)[Show details](#)\n\n[OK](#)\n\n[Use necessary cookies only ](#)[Allow selection ](#)[Allow all cookies](#)\n\nNecessary\n\nPreferences\n\nStatistics\n\nMarketing\n\n[Show details](#)\n\n[Cookie declaration ](#)[[#IABV2SETTINGS#] ](#)[About](#)\n\n[Necessary (15)](#) [Preferences (1)](#) [Statistics (11)](#) [Marketing (32)](#) [Unclassified (7)](#)\n\nNecessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \n__RequestVerificationToken| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Helps prevent Cross-Site Request Forgery (CSRF) attacks.| Session| HTTP Cookie  \nak_bmsc| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| 1 day| HTTP Cookie  \nbm_mi| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Used in context with the website's BotManager. The BotManager detects, categorizes and compiles reports on potential bots trying to access the website.| Session| HTTP Cookie  \n_GRECAPTCHA| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| 180 days| HTTP Cookie  \nrc::a| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| Persistent| HTML Local Storage  \nrc::b| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. | Session| HTML Local Storage  \nrc::c| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. | Session| HTML Local Storage  \nrc::f| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. | Persistent| HTML Local Storage  \n1.gif| [Cookiebot](https://www.cookiebot.com/goto/privacy-policy/ \"Cookiebot's privacy policy\")| Used to count the number of sessions to the website, necessary for optimizing CMP product delivery. | Session| Pixel Tracker  \nCookieConsent| [Cookiebot](https://www.cookiebot.com/goto/privacy-policy/ \"Cookiebot's privacy policy\")| Stores the user's cookie consent state for the current domain| 1 year| HTTP Cookie  \nelementor| mdxhealth.com| Used in context with the website's WordPress theme. The cookie allows the website owner to implement or change the website's content in real-time.| Persistent| HTML Local Storage  \nwpEmojiSettingsSupports| mdxhealth.com| This cookie is part of a bundle of cookies which serve the purpose of content delivery and presentation. The cookies keep the correct state of font, blog/picture sliders, color themes and other website settings.| Session| HTML Local Storage  \nASP.NET_SessionId| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Preserves the visitor's session state across page requests.| Session| HTTP Cookie  \n__cf_bm| [Vimeo](https://vimeo.com/privacy \"Vimeo's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| 1 day| HTTP Cookie  \n_cfuvid| [Vimeo](https://vimeo.com/privacy \"Vimeo's privacy policy\")| This cookie is a part of the services provided by Cloudflare - Including load-balancing, deliverance of website content and serving DNS connection for website operators. | Session| HTTP Cookie  \n  \nPreference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nFormsWebSessionId| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| The cookie is used if the visitor has filled in personal information on a formula. This information will be filled in automatically on other formulas. This process is used to optimize visitor experience. | 30 days| HTTP Cookie  \n  \nStatistic cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nc.gif| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Collects data on the user’s navigation and behavior on the website. This is used to compile statistical reports and heatmaps for the website owner.| Session| Pixel Tracker  \ncollect| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.| Session| Pixel Tracker  \nhjActiveViewportIds| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| This cookie contains an ID string on the current session. This contains non-personal information on what subpages the visitor enters – this information is used to optimize the visitor's experience.| Persistent| HTML Local Storage  \nhjViewportId| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| Saves the user's screen size in order to adjust the size of images on the website.| Session| HTML Local Storage  \n_ga| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Registers a unique ID that is used to generate statistical data on how the visitor uses the website.| 2 years| HTTP Cookie  \n_ga_#| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used by Google Analytics to collect data on the number of times a user has visited the website as well as dates for the first and most recent visit. | 2 years| HTTP Cookie  \n_gat| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used by Google Analytics to throttle request rate| 1 day| HTTP Cookie  \n_gid| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Registers a unique ID that is used to generate statistical data on how the visitor uses the website.| 1 day| HTTP Cookie  \n_hjSession_#| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| Collects statistics on the visitor's visits to the website, such as the number of visits, average time spent on the website and what pages have been read.| 1 day| HTTP Cookie  \n_hjSessionUser_#| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| Collects statistics on the visitor's visits to the website, such as the number of visits, average time spent on the website and what pages have been read.| 1 year| HTTP Cookie  \nvuid| [Vimeo](https://vimeo.com/privacy \"Vimeo's privacy policy\")| Collects data on the user's visits to the website, such as which pages have been read.| 2 years| HTTP Cookie  \n  \nMarketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nMR [x2]| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences. | 7 days| HTTP Cookie  \nMUID [x3]| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")forms.cloud.microsoft| Used widely by Microsoft as a unique user ID. The cookie enables user tracking by synchronising the ID across many Microsoft domains.| 1 year| HTTP Cookie  \nSRM_B| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Tracks the user’s interaction with the website’s search-bar-function. This data can be used to present the user with relevant products or services. | 1 year| HTTP Cookie  \nANONCHK| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Registers data on visitors from multiple visits and on multiple websites. This information is used to measure the efficiency of advertisement on websites. | 1 day| HTTP Cookie  \nSM| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Registers a unique ID that identifies the user's device during return visits across websites that use the same ad network. The ID is used to allow targeted ads.| Session| HTTP Cookie  \nNID| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 6 months| HTTP Cookie  \nGNWTracker| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Used to implement blog or article content onto the website from other websites. This implementation also allows the origin-website to track on the website. | Session| HTTP Cookie  \ntimes_to_show| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used to determine when and where certain pop-ups on the website should be presented for the user and remember whether the user has closed these, to keep them from showing multiple times.| Persistent| HTML Local Storage  \n#-#| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTML Local Storage  \n__Secure-ROLLOUT_TOKEN| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Pending| 180 days| HTTP Cookie  \niU5q-!O9@$| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Registers a unique ID to keep statistics of what videos from YouTube the user has seen.| Session| HTML Local Storage  \nLAST_RESULT_ENTRY_KEY| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTTP Cookie  \nLogsDatabaseV2:V#||LogsRequestsStore| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Persistent| IndexedDB  \nnextId| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTTP Cookie  \nremote_sid| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Necessary for the implementation and functionality of YouTube video-content on the website. | Session| HTTP Cookie  \nrequests| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTTP Cookie  \nTESTCOOKIESENABLED| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| 1 day| HTTP Cookie  \nVISITOR_INFO1_LIVE| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Tries to estimate the users' bandwidth on pages with integrated YouTube videos.| 180 days| HTTP Cookie  \nYSC| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Registers a unique ID to keep statistics of what videos from YouTube the user has seen.| Session| HTTP Cookie  \nyt.innertube::nextId| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Registers a unique ID to keep statistics of what videos from YouTube the user has seen.| Persistent| HTML Local Storage  \nytidb::LAST_RESULT_ENTRY_KEY| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Persistent| HTML Local Storage  \nYtIdbMeta#databases| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Persistent| IndexedDB  \nyt-remote-cast-available| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-cast-installed| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-connected-devices| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Persistent| HTML Local Storage  \nyt-remote-device-id| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Persistent| HTML Local Storage  \nyt-remote-fast-check-period| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-session-app| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-session-name| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \n  \nUnclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nMuidSyncDomain| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Pending| Persistent| HTML Local Storage  \nMuidSyncTimestamp| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Pending| Persistent| HTML Local Storage  \nRevSpringHistory| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 1 year| HTTP Cookie  \nRevSpringRef| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 1 day| HTTP Cookie  \nRevSpringUserAlias| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 1 year| HTTP Cookie  \nRevSpringVisit| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| Session| HTTP Cookie  \nGNWUserSessionId| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Pending| Session| HTTP Cookie  \n  \n[[#IABV2_LABEL_PURPOSES#]](#) [[#IABV2_LABEL_FEATURES#]](#) [[#IABV2_LABEL_PARTNERS#]](#)\n\n[#IABV2_BODY_PURPOSES#]\n\n[#IABV2_BODY_FEATURES#]\n\n[#IABV2_BODY_PARTNERS#]\n\nCookies are small text files that can be used by websites to make a user's experience more efficient.The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission.This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.You can at any time change or withdraw your consent from the Cookie Declaration on our website.Learn more about who we are, how you can contact us and how we process personal data in our Privacy Policy.\n\nCookie declaration last updated on 12/1/24 by [Cookiebot](https://www.cookiebot.com \"Cookiebot\")\n\n  * [ Physician Portal ](https://mdxhealthsecure.com/)\n  * [ Pay My Bill ](/paymybill/)\n\n\n\n[ ![MDxHealth Logo_Full Color_KO_RGB](/wp-content/uploads/elementor/thumbs/MDxHealth-Logo_Full-Color_KO_RGB-1-qn8ye5yd7qzmvsyx0iqzls921um9s37hndqaovfadq.png) ](https://mdxhealth.com)\n\n  * [About](https://mdxhealth.com/about/)\n\n##### About\n\n    * [ Mission ](/about/#mission)\n    * [ Leadership ](/about/#leadership)\n    * [ Licensure & Accreditations ](/about/#licensure&accreditations)\n\n    * [ Science ](/science/)\n    * [ Careers ](/careers/)\n    * [ Multimedia ](/multimedia/)\n\n    * [ Mission ](https://mdxhealth.com/about/#mission)\n    * [ Leadership ](https://mdxhealth.com/about/#leadership)\n    * [ Licensure & Accreditations ](https://mdxhealth.com/about/#licensure&accreditations)\n    * Science\n    * Careers\n    * [ Multimedia ](https://mdxhealth.com/multimedia/)\n\n  * [Tests](https://mdxhealth.com/tests/)\n\n##### Prostate Cancer \n\n###### For Physicians\n\n    * [ Select mdx ](/select-mdx-for-physicians/)\n    * [ Confirm mdx ](/confirm-mdx-for-physicians/)\n    * [ Genomic Prostate Score ](/gps-physician/)\n\n###### For Patients\n\n    * [ Select mdx ](/select-mdx-for-patients/)\n    * [ Confirm mdx ](/confirm-mdx-for-patients/)\n    * [ Genomic Prostate Score ](/gps-patient/)\n\n##### Infectious Disease\n\n###### For Physicians\n\n    * [ Resolve mdx ](/resolve-mdx-for-physicians/)\n\n###### For Patients\n\n    * [ Resolve mdx  ](/resolve-mdx-for-patients/)\n\n###### Prostate Cancer (For Physicians)\n\n    * [ Select mdx ](https://mdxhealth.com/select-mdx-for-physicians/)\n    * [ Confirm mdx ](https://mdxhealth.com/confirm-mdx-for-physicians/)\n    * [ Genomic Prostate Score ](https://mdxhealth.com/gps-physician/)\n\n###### Prostate Cancer (For Patients)\n\n    * [ Select mdx ](https://mdxhealth.com/select-mdx-for-patients/)\n    * [ Confirm mdx ](https://mdxhealth.com/confirm-mdx-for-patients/)\n    * [ Genomic Prostate Score ](https://mdxhealth.com/gps-patient/)\n\n###### Infectious Disease (For Physicians)\n\n    * [ Resolve mdx  ](https://mdxhealth.com/resolve-mdx-for-physicians/)\n\n###### Infectious Disease (For Patients)\n\n    * [ Resolve mdx  ](https://mdxhealth.com/resolve-mdx-for-patients/)\n\n  * [Investors](https://mdxhealth.com/financials/)\n\n##### Investors\n\n    * [ Financials ](/financials/)\n    * [ Shareholder Information ](/shareholder-information/)\n    * [ Transition to Nasdaq ](/proposed-transition-to-a-single-listing-on-nasdaq/)\n\n    * [ Analyst Coverage ](/analyst-coverage/)\n    * [ Presentations & Events ](/presentations-events/)\n    * [ Press Releases ](/press-releases-events/)\n\n    * [ Financials ](https://mdxhealth.com/financials/)\n    * [ Shareholder Information ](https://mdxhealth.com/shareholder-information/)\n    * [ Transition to Nasdaq ](https://mdxhealth.com/proposed-transition-to-a-single-listing-on-nasdaq/)\n    * [ Analyst Coverage ](https://mdxhealth.com/analyst-coverage/)\n    * [ Presentation & Events ](https://mdxhealth.com/presentations-events/)\n    * [ Press Releases ](https://mdxhealth.com/press-releases-events/)\n\n  * [Support](https://mdxhealth.com/xpert-one/)\n\n    * [ Xpert One Support ](/xpert-one/)\n    * [ Contact Us ](/contact-us/)\n\n\n\n\n[ ](https://mdxhealth.com)\n\nX\n\n## Contact Us \n\n### U.S. Locations\n\n##### California Office and Laboratory\n\n15279 Alton ParkwaySuite 100Irvine, CA 92618 U.S.\n\n  * Toll Free **[+1 (866) 259-5644](tel:1-866-259-5644)**\n  * Office **[+1 (949) 812-6979](tel:1-949-812-6979)**\n  * Fax **[+1 (949) 788-0014](tel:1-949-788-0014)**\n  * Email **info@mdxhealth.com**\n\n\n\n##### Texas Laboratory\n\n7000 Preston RoadSuite 1500Plano, TX 75024 U.S.\n\n  * Toll Free **[+1 (866) 259-5644](tel:1-866-259-5644)**\n  * Office **[+1 (949) 812-6979](tel:1-949-812-6979)**\n  * Fax **[+1 (949) 788-0014](tel:1-949-788-0014)**\n  * Email **info@mdxhealth.com**\n\n\n\n### EU Locations\n\n##### Belgium Office\n\nCAP Business CenterRue d’Abhooz, 314040 HerstalBelgium\n\n  * Email **info@mdxhealth.com**\n\n\n\n##### The Netherlands Office and Laboratory\n\nNovio Tech CampusTransistorweg 56534 AT NijmegenThe Netherlands\n\n  * Office **[+31 (0) 88 32 72 727](tel:31-0-88-32-72-727)**\n  * Fax **[+31 (0) 88 32 72 728](tel:31-0-88-32-72-728)**\n  * Email **clientservices.eu@mdxhealth.com**\n\n\n\n### Contact a Local Representative\n\nQuestions about our tests or ready to set up a new account?\n\n[ Connect with Your Local Rep ](https://mdxhealth.com/connect/)\n\n### Receive Updates from mdxhealth\n\nPlease fill in your contact information and click the submit button.\n\n[ Receive Updates ](https://mdxhealth.com/updates/)\n\n### Investor Relations Contact\n\n##### For all investor related questions please call or email:\n\nLifeSci Advisors (IR & PR)\n\n  * US: +1 949 271 9223\n  * ir@mdxhealth.com\n\n\n\n[ ![](/wp-content/uploads/2022/04/MDxHealth-Logo_Full-Color_KO_RGB-1.png) ](https://mdxhealth.com)\n\nToll Free: (866) 259-5644 Email: info@mdxhealth.com\n\n[ Facebook ](https://www.facebook.com/mdxhealth/) [ Twitter ](https://twitter.com/mdxhealth?s=11&t=RI_iHL03YQlKMvkiHxV93g) [ Linkedin ](https://www.linkedin.com/company/1344641/admin/feed/posts/)\n\n###### Our Company\n\n  * [ About  ](https://mdxhealth.com/about/)\n  * [ Science ](https://mdxhealth.com/science/)\n  * [ Careers ](https://mdxhealth.com/careers/)\n  * [ News ](https://mdxhealth.com/press-releases-events/)\n  * [ Contact Us ](https://mdxhealth.com/contact-us/)\n  * [ Connect with a rep ](https://mdxhealth.com/connect/)\n  * [ Xpert One Support ](https://mdxhealth.com/xpert-one/)\n\n\n\n###### Tests\n\nFor Physicians\n\n  * [ Select mdx ](https://mdxhealth.com/select-mdx-for-physicians/)\n  * [ Confirm mdx  ](https://mdxhealth.com/confirm-mdx-for-physicians/)\n  * [ Genomic Prostate Score ](https://mdxhealth.com/gps-physician/)\n  * [ Resolve mdx  ](https://mdxhealth.com/resolve-mdx-for-physicians/)\n  * [ Physician Portal ](https://mdxhealthsecure.com)\n  * [ Report Access ](https://mdxhealth.com/securemdx/)\n  * [ Order Supplies ](https://mdxhealth.com/testkits/)\n  * [ FedEx Pick Up ](https://mdxhealth.com/fedex/)\n\n\n\nFor Patients\n\n  * [ Select mdx ](https://mdxhealth.com/select-mdx-for-patients/)\n  * [ Confirm mdx ](https://mdxhealth.com/confirm-mdx-for-patients/)\n  * [ Genomic Prostate Score ](https://mdxhealth.com/gps-patient/)\n  * [ Resolve mdx ](https://mdxhealth.com/resolve-mdx-for-patients/)\n  * [ Pay My Bill ](https://mdxhealth.com/paymybill/)\n\n\n\n###### Investors\n\n  * [ Financials ](https://mdxhealth.com/financials/)\n  * [ Shareholder Information ](https://mdxhealth.com/shareholder-information/)\n  * [ Transition to Nasdaq ](https://mdxhealth.com/proposed-transition-to-a-single-listing-on-nasdaq/)\n  * [ Analyst Coverage ](https://mdxhealth.com/analyst-coverage/)\n  * [ Presentations & Events ](https://mdxhealth.com/presentations-events/)\n  * [ Press Releases  ](https://mdxhealth.com/press-releases-events/)\n\n\n\n#### Shadowbox User Guides for download\n\n  * [Clinician User Guide](/wp-content/uploads/2024/10/SB-MKT-SHADOWBOX-IRIS-USER-GUIDE-2024.pdf)\n  * [IRIS Update Prompts Guide](/wp-content/uploads/2024/10/SB-MKT-SHADOWBOX-IRIS-UPDATE-PROMPTS-FOR-INSTALL-2024.pdf)\n  * [IRIS Install (with login automatically selected) Guide](/wp-content/uploads/2024/10/SB-MKT-SHADOWBOX-IRIS-INSTALL-WITH-LOGIN-AUTOMATICALLY-SELECTED-2024.pdf)\n\n\n\nCLOSE \n\n### How to Order Resolve mdx\n\n  1. To order Resolve mdx urine transport kits or test requisition forms: [Order Supplies Online](https://mdxhealthdotcom-dev.azurewebsites.nettestkits/) Call: 866.259.5644 Email: client.services@mdxhealth.com\n  2. Once urine transport kits are received, complete the Resolve mdx’s test requisition form in its entirety.\n  3. Carefully follow the steps in the enclosed Instructions For Use to collect the urine specimen.\n  4. Send completed test request form along with the sealed urine transportation kit to: 7000 Preston Road, Suite 1500, Plano, TX 75024\n\n\n\n[Schedule FedEx Pick Up](https://mdxhealthdotcom-dev.azurewebsites.netfedex/)\n\nView and Download [Resolve mdx Test Requisition Form (TRF)](/wp-content/uploads/2024/10/PL-FORM-0095-R06-Resolve-mdx-Test-Requisition-Form-for-UTI-and-STI-FNL.pdf) View and Download [Resolve mdx Specimen Collection and Shipping Instructions](/wp-content/uploads/2022/08/Resolve-mdx-Specimen-Collection-and-Shipping-Instructions.pdf) View and Download Resolve mdx [Specimen Requirements and Patient Eligibility](/wp-content/uploads/2022/08/Resolve-mdx-Specimen-Requirements.pdf)\n\nCLOSE \n\n# Licensure & Accreditations\n\n### United States:\n\n**Irvine, CA Laboratory**\n\n[College of American Pathologists (CAP) Accreditation](/wp-content/uploads/2024/06/CAP-2024.pdf)\n\n[Centers for Medicare & Medicaid Services Certificate of Accreditation (CLIA)](/wp-content/uploads/2022/06/Certificate-of-Accreditation-Ruben-Gamez.pdf)\n\n[New York State Department of Health License](/wp-content/uploads/2024/07/New-York-State-Clinical-Laboratory-Permit-exp-2025JUN30.pdf)\n\n[State of California Department of Public Health Clinical Laboratory License](/wp-content/uploads/2024/01/CDPH-License-Certificate_CDF-00341675-exp-13FEB2025.pdf)\n\n[State of Maryland License](/wp-content/uploads/2023/05/Maryland-State-License-Irvine.pdf)\n\n[State of Pennsylvania License](/wp-content/uploads/2022/06/PA-Irvine-Laboratory-Permit-EXP-08-25.pdf)\n\n[State of Rhode Island License](/wp-content/uploads/2024/02/Rhode-Island-License.pdf)\n\n[Health Canada License](/wp-content/uploads/2022/06/Health-Canada-Medical-Device-Establishment-License-scaled-2.jpg)\n\n**Plano, Texas Laboratory**\n\n[College of American Pathologists (CAP) Accreditation ](/wp-content/uploads/2023/03/PLANO-CAP_CERT.pdf)\n\n[Centers for Medicare & Medicaid Services Certificate of Accreditation (CLIA)](/wp-content/uploads/2023/05/CLIA_LICENSE_2023_PLANO.pdf)\n\n[State of California Department of Public Health Clinical Laboratory ](/wp-content/uploads/2024/10/CA-License-Certificate_CDS-90008054_Exp-2025OCT24.pdf)\n\n[State of Maryland License](/wp-content/uploads/2023/04/MARYLAND_STATE_LICENSE.pdf)\n\n[State of Pennsylvania License](/wp-content/uploads/2022/06/PA-Plano-Laboratory-Permit-EXP-08-25.pdf)\n\n[State of Rhode Island License ](/wp-content/uploads/2023/05/RHODE_ISLAND_LICENSE.pdf)\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/hardison.png)\n\n## Don Hardison\n\n### Independent Director\n\nMr. Hardison was most recently the President and Chief Executive Officer, and served on the board of directors, of Biotheranostics, Inc., a molecular diagnostic company focused on oncology, from February 2017 until it was acquired by Hologic, Inc. in February 2021. From April 2010 to March 2016, Mr. Hardison was the President and Chief Executive Officer of Good Start Genetics, a molecular genetic testing and information company. For more than 20 years prior to that, Mr. Hardison held various executive and senior management positions at companies including Laboratory Corporation of America (LabCorp), Exact Sciences Corporation, Quest Diagnostics Inc., and Smith Kline Beecham Corporation. He currently serves as an independent director on the boards of directors of Stemina Biomarker Discovery, Inc., Seventh Sense Biosystems, BioPorto, Inc. and IQuity, Inc. He also formerly served on the board of directors of Exact Sciences Corporation (Nasdaq: EXAS) from May 2000, through its initial public offering in February 2001, until August 2007. Mr. Hardison received his Bachelor of Arts degree, in political science, from the University of North Carolina, Chapel Hill.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.net/wp-content/uploads/2024/07/SSiegel.png)\n\n## Sanford J. Siegel, M.D. \n\n### Independent Director\n\nDr. Siegel has more the 45 years of experience as a practicing urologist and over 35 years of executive leadership experience. Dr. Siegel currently serves as the Chairman of the Board of United Urology Group, having previously served as its Chief Executive Officer. United Urology Group, which was acquired by Audax in 2016, was formed under Dr. Siegel’s leadership and is one of the nation’s leading urology networks. Previously, Dr. Siegel served as the President and Chief Executive Officer of Chesapeake Urology Associates, which he founded in 1999. Dr. Siegel is a founding member of the Large Urology Group Practice Association (LUGPA), which was formed in 2008. He was a board member of the Urology Care Foundation (UCF) from 2016 until 2023 and The Urology Times. As a recognized leader in the field of medicine, Dr. Siegel has been honored with official citations for outstanding commitment and leadership from both the Governor and the General Assembly of Maryland. Dr. Siegel earned his medical degree from the University of Maryland School of Medicine and completed his specialty training in urology at Temple University Hospital in Philadelphia. He has been certified by the American Board of Urology and as Fellow of the American College of Surgeons.\n\nCLOSE \n\n### How to Order Select mdx\n\n##### United States\n\n  1. To order Select mdx urine transport kits or test requisition forms: [Order Supplies Online](/testkits/) Call: 866.259.5644 Email: cs@mdxhealth.com\n  2. Once urine transport kits are received, complete the Select mdx’s test requisition form in its entirety.\n  3. Carefully follow the steps in the enclosed Instructions For Use to collect the urine specimen.\n  4. Send completed test request form along with the sealed urine transportation kit to: 15279 Alton Parkway, Suite 100, Irvine, CA 92618\n\n\n\n[Schedule FedEx Pick Up](/fedex/) View and Download [Select mdx Test Requisition Form (TRF)](/wp-content/uploads/2024/01/Select-mdx-Test-Requisition-Form7497-2.pdf) View and Download [Urine Collection and Preparation Instructions](/wp-content/uploads/2024/01/Urine-Collection-and-Transportation-Instructions-Brochure.pdf) View and Download [Specimen Requirements and Patient Eligibility](/wp-content/uploads/2024/01/Select-mdx-Specimen-Requirements.pdf)\n\n##### Europe\n\n  1. To order Select mdx urine transportation kits contact MDxHealth at +31 (0) 88 327 2727 or email clientservices.eu@mdxhealth.com.\n  2. Once urine transportation kits are received, please fill out the Select mdx test request form in its entirety.\n  3. Carefully follow the instructions for use to collect the urine specimen.\n  4. Place the completed test request form and urine specimen inside the Select mdx urine transportation kit. Follow the instructions on the kit to contact your local DHL office and arrange the return shipment to the mdxhealth laboratory.\n\n\n\nView and Download Test Request Form [DE](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_DE-v7_PRINT.pdf) | [EN](/wp-content/uploads/2022/06/MDX500-Requisition-form_EN-v4-2.pdf) | [ES](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_ES-v6-FER_elec.pdf) | [FR](/wp-content/uploads/2022/06/MDX500-Requisition-form_FR-v2.pdf) | [IT](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_IT-v9_PRINT.pdf) | [NL](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_NL-v7_PRINT.pdf) | [PL](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_PL-v4.pdf) View and Download [Select mdx Instructions for Use](/wp-content/uploads/2022/06/MDX521-SelectMDx-IFU-Booklet-v5.pdf) View and Download [UrNCollect Instructions for Use ](/wp-content/uploads/2022/06/MDX514-UrNCollect-v3.pdf)\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/regine-Slagmulder.png)\n\n## Regine Slagmulder\n\n### Independent Director, representing Regine Slagmulder BV\n\n**_Dr. Regine Slagmulder_** , Independent Non-Executive Director of our Company, is a full professor in management accounting & control at Vlerick Business School, a visiting professor of accounting & control at INSEAD, and the Knowledge & Academic Director (a.i.) at Guberna, the Belgian Institute for Directors. Previously, she worked as a strategy practice consultant at McKinsey & Company. She also previously worked as a professor of management accounting at INSEAD and at the University of Tilburg. She serves as an independent director and member of the audit committee on the board of the investment company Quest for Growth (since 2011) and as an independent director and chair of the audit committee of Ekopak (since 2021), both listed on Euronext. Dr. Slagmulder graduated in civil electrotechnical engineering and industrial management from the University of Gent, after which she received a management doctorate at Vlerick Business School. As part of her research activities, she was a research fellow attached to INSEAD, Boston University (USA) and the P. Drucker Graduate Management Center at Claremont University (USA). She is an INSEAD certified director (IDP-C).\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Hilde-Windels.png)\n\n## Hilde Windels\n\n### Independent Director, representing Hilde Windels BVBA\n\n**_Hilde Windels_** , Independent Non-Executive Director of our Company, has over 20 years of experience in the biotechnology sector with a track record of building and structuring organizations, fundraising, M&A, public capital markets and corporate strategies. Currently, Mrs. Windels serves as a board member at PHAXIAM Therapeutics, GIMV NV, MCROPHYT SA, and Celyad. Previously, she served as CEO of immunodiagnostic company Antelope Dx BV, and as CEO ad interim and Deputy CEO of Biocartis from September 2015 until September 2017 and as CFO of Biocartis from 2011 until September 2015. Mrs. Windels has also worked as independent CFO for several private biotech companies and from 1999 to 2008 she was CFO of Devgen. In the past, she also served on the boards of Devgen, Biocartis, Ablynx, VIB and FlandersBio. Mrs. Windels holds a Masters in Economics (commercial engineer) from the University of Leuven, Belgium.\n\nCLOSE \n\n### How to Order Confirm mdx\n\n##### Physician Office\n\nTo Order Pre-printed Test Requisition Forms:\n\n[Order Supplies Online](https://mdxhealthdotcom-dev.azurewebsites.nettestkits/) Call: 866.259.5644 Email: cs@mdxhealth.com\n\nView and Download [Confirm mdx Test Requisition Form (TRF)](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2024/01/Confirm-mdx-Test-Requisition-Form.pdf) View and Download [Confirm mdxSpecimen Requirements and Patient Eligibility](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2024/02/Confirm-mdx-Specimen-Requirements.pdf)\n\n  1. Complete the Confirm mdx test requisition form (TRF). Include patient demographics, copy of insurance card(s), and pathology report.\n  2. Forward the completed Confirm mdx TRF to MDxHealth Client Services. Mdxhealth will contact the pathology laboratory and request specimens as indicated on the TRF in “Section 7 – ConfirmMDx Specimen Request”.\n\n\n\n##### Pathology Laboratory\n\nTo order Confirm mdx Tissue Transport Kits:\n\n[Order Supplies Online](https://mdxhealthdotcom-dev.azurewebsites.netorder-supplies/) Call: 866.259.5644 Email: client.services@mdxhealth.com\n\n  1. Pathology lab will include specimens, completed test requisition form (including copies of patient demographics, insurance, and pathology report) inside the transportation kit.\n  2. Ship to: mdxhealth, 15279 Alton Parkway, Suite 100, Irvine, CA 92618.\n\n\n\n[Schedule FedEx Pick Up](https://mdxhealthdotcom-dev.azurewebsites.netfedex/)\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2023/11/Jason-Poole.png)\n\n## Jason Poole\n\n### Chief Scientific Officer\n\nDr. Poole has more than 25 years of research experience and specializes in the development of high complexity diagnostic testing for use in human health and disease. His expertise lies in product development using advanced technologies such as Next Generation Sequencing, qPCR, and nucleic acid sample preparation. Mr. Poole was most recently the VP of R&D at Active Motif, Inc. he spear-headed the development of products in the epigenetic research space including DNA methylation, chromatin modifications and epigenetic specific antibody development. Dr. Poole received his M.S. in Molecular Endocrinology from Northwestern University and his Ph.D. in Molecular Genetics from the University of Illinois College of Medicine in Chicago, IL.\n\nCLOSE \n\n## Tailored reports that connect insights for the next step in care\n\n### Low-Risk Report\n\n**The low-risk report integrates clinical, pathological, and genomic insights into actionable information on active surveillance 1**\n\n  * Predicts tumor aggressiveness to help inform the decision between active surveillance and immediate treatment\n  * Focuses on an actionable endpoint adverse pathology, with the most comprehensive definition\n  * The Genomic Prostate Score(GPS) test is the only commercially available test to provide all these endpoints: \n    * Risk of high-grade (≥Grade Group 3) disease\n    * Risk of pT3a+ disease\n    * Risk of metastasis within 10 years\n    * Risk of PCa-specific death within 10 years\n\n\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/212-low-risk-report-1024x627.png)\n\n##### [DOWNLOAD LOW-RISK SAMPLE REPORT](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2023/07/MDX.Brochures.GPS_.LowRiskReport_r2-SAMPLE.pdf)\n\n### High-Risk Report\n\n**The high-risk report provides a defined cut point with actionable information on treatment intensity 2**\n\n  * Helps determine the right level of treatment\n  * Clearly stratifies patient risk into lower or higher likelihood of disease progression\n  * Simple bell curve helps you and your patient understand the patient’s risk relative to other patients of same clinical risk group\n\n\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/211and212highrisk-1024x380.png)\n\n##### [DOWNLOAD HIGH-RISK SAMPLE REPORT](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2023/07/MDX.Brochures.GPS_.HighRiskReport_r3-SAMPLE.pdf)\n\nReferences:\n\n  1. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.  _Eur Urol_. 2014;66(3):550-560.\n  2. Cullen J, Kuo HC, Shan J, Lu R, Aboushwareb T, Van Den Eeden SK. The 17-gene genomic prostate score test as a predictor of outcomes in men with unfavorable intermediate risk prostate cancer. _Urology_. 2020;143:103-111.\n\n\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Mike-M.-Headshot-website.png)\n\n## Michael K. McGarrity\n\n### Chief Executive Officer, Director\n\nMr. McGarrity has more than 25 years of experience in the healthcare industry with a unique combination of device, diagnostics and biotechnology experience. Mr. McGarrity was most recently the CEO of Sterilis Medical. Prior to Sterilis Mr. McGarrity was the CEO of Nanosphere (NASDAQ: NSPH), a nanotechnology-based molecular diagnostics company, where he engineered an operational and strategic turnaround that resulted in its successful sale to Luminex (NASDAQ: LMNX) in 2016. Prior to Nanosphere, Mr. McGarrity spent 13 years at Stryker Corporation (NYSE: SYK) where he served in leadership roles in sales and marketing and led Stryker into new growth markets such as post-operative pain management, surgical fluid waste management and interventional pain management. Mr. McGarrity also had executive general management responsibility for a newly created business unit focused on interventional spine pain management. Mr. McGarrity received a Bachelor of Arts degree from the University of Notre Dame and began his career in commercial banking.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Ron-K-headshot-website.png)\n\n## Ron Kalfus\n\n### Chief Financial Officer\n\nMr. Kalfus has over 20 years of leadership experience in both public and private companies within diagnostics/biotech and other sectors, and brings extensive knowledge in financial operations, management, and strategic transactions. Mr. Kalfus joined mdxhealth from Rosetta Genomics, where he helped lead efforts to reposition the company for commercial success with its oncology diagnostic products, and raised over $60 million in capital to fund these efforts. Prior to Rosetta, Mr. Kalfus served as the CFO and Treasurer of MabCure, a Belgium-based publicly-traded biotechnology startup in the field of early cancer detection using antibodies. Mr. Kalfus received his Master’s degree in Accounting from Fairleigh Dickinson University and his Bachelor’s degree in Finance from the University of Georgia. Mr. Kalfus is a Certified Public Accountant, licensed in the State of New Jersey.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Valiance-Jan-Pensaert.png)\n\n## Mr. Jan Pensaert\n\n### Director, representing Valiance Advisors LLP\n\nJan Pensaert is the Founding Managing Partner of Valiance. He brings over 20 years of experience in growth investing. He leads the Investment Committee for the Valiance Funds and is responsible for all aspects of the Funds’ investment processes. Jan currently serves on the Board of several Valiance entities funds and portfolio companies including MDxHealth, JenaValve, NeoSync, and 4Tech. Prior to founding Valiance, Jan was CEO of La Fayette, where during his tenure the La Fayette Funds increased in AUM from $750 million to $5.5 billion. Before that, he was responsible for the Permal Group’s European-based investment management and research activities, and prior to that, he worked at Lazard in Corporate Finance M&A. Jan holds a BA in Business Economics from Gent University in Belgium, and a Masters in Banking & Finance from the University of Aix-Marseille, France.\n\nCLOSE \n\n**Analytical Validity**  \n---  \n· Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, et al. Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 2013;14: 690.  \n**Economic Utility**  \n· Albala D, Kemeter MJ, Febbo PG, Lu R, John V, Stoy D et al. Health economic impact and prospective clinical utility of Oncotype DX Genomic Prostate Score. Rev Urol. 2016; 18(3):123-132.  \n**Clinical Utility**  \n· Albala D, Kemeter MJ, Febbo PG, Lu R, John V, Stoy D et al. Health economic impact and prospective clinical utility of Oncotype DX Genomic Prostate Score. Rev Urol. 2016; 18(3):123-132. · Dall’Era MA, Maddala T, Polychronopoulos L, Gallagher JR, Febbo PG, and Denes BS. Utility of the Oncotype DX® Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A Retrospective Chart Review Analysis. Urology Practice. 2015;2(6):343-348. · Eure G, Germany R, Given R, Lu R, Shnidel AW, Rothney M, et al. Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort. Urology. 2017;107:67-75. · Lynch JA, Rothney MP, Salup RR, Ercole CE, Mathur SC, Duchene DA, et al. Improving Risk Stratification Among Veterans Diagnosed With Prostate Cancer: Impact of the 17-Gene Genomic Prostate Score Assay. Am J Manag Care. 2017;24(1 Suppl):S4-S10. · Murphy AB, Abern MR, Liu L, Wang H, Hollowell CMP, Sharifi R, Vidal P, et al. Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial. J Clin Oncol. 2021;39(15):1660-1670.  \n**Clinical Validity**  \n· Brooks MA, Thomas L, Magi-Galluzzi C, Li J, Crager MR, Lu R et al. GPS assay association with long-term cancer outcomes: twenty-year risk of distant metastasis and prostate cancer-specific mortality. JCO Precis Oncol. 2021;5:PO.20.00325. · Brooks MA, Thomas L, Magi-Galluzzi C, Li J, Crager MR, Lu R et al. Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy. Urol Oncol. 2022;40(3):104.e1-104.e7. · Covas Moschovas M, Chew C, Bhat S, Sandri M, Rogers T, Dell’Oglio P, et al. Association Between Oncotype DX Genomic Prostate Score and Adverse Tumor Pathology After Radical Prostatectomy. Eur Urol Focus. 2022;8(2):418-424. · Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol. 2015;69(1):123-131. · Cullen J, Kuo HC, Shan J, Aboushwareb T, and Van Den Eeden SK. The 17-gene genomic prostate score test as a predictor of outcomes in men with unfavorable intermediate-risk prostate cancer. Urology. 2020;143:103-111. · Cullen J, Lynch JA, Klein EA, Van Den Eeden SK, Carroll PR, Mohler JL, et al. Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer. J Urol. 2021;205(4):1047-1054. · Eggener S, Karsh LI, Richardson T, Shindel AW, Lu R, Rosenberg A et al. A 17-gene panel for prediction of adverse prostate cancer pathologic features: prospective clinical validation and utility. Urology. 2019;126:76-82. · Helfand BT, Paterakos M, Wang CH, Talaty P, Abran J, Bennett J et al. The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer. PLoS One. 2022;17(9):e0273782. · Helfand BT, Paterakos M, Wang CH, Talaty P, Abran J, Bennett J et al. The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer. PLoS One. 2022;17(9):e0273782. · Janes JL, Boyer MJ, Bennett JP, Thomas VM, De Hoedt AM, Edwards DK, et al. Prognostic for outcomes after primary external beam radiation therapy in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2023;115(1):120-131. · Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. _Eur Urol._ 2014;66(3):550–560. · Kornberg Z, Cowan JE, Westphalen AC, Cooperberg MR, Chan JM, Zhao S, et al. Genomic prostate score, PI-RADS version 2 and progression in men with prostate cancer on active surveillance. J Urol. 2019;201:300-307. · Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg M, et al. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate-risk prostate cancer. PLoS One. 2017;12(10):e0185535. · Lin D, Zheng Y, McKenney JK, Brown MD, Lu R, Crager M, et al. 17-gene genomic prostate score test results in the Canary Prostate Active Surveillance Study (PASS) cohort. J Clin Oncol. 2020;38(14):1549-1557. · Magi-Galluzzi C, Isharwal S, Falzarano SM, Tsiatis A, Dee A, Maddala T et al. The 17-gene genomic prostate score assay predicts outcomes after radical prostatectomy independent of PTEN status. Urology. 2018;121:132-138. · Murphy AB, Carbunaru S, Nettey OS, Gornbein C, Dixon MA, Macias V, et al. A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men. Urology. 2020; 142:166-173. · Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk Jr AE et al. A 17-gene Genomic Prostate Score assay provides independent information on adverse pathology in the setting of combined multiparametric magnetic resonance fusion-targeted and systematic prostate biopsy. J Urol. 2018;200(3):564-572. · Van Den Eeden SK, Lu R, Zhang N, Queensberry Jr CP, Shan J, Han JS, et al. A biopsy-based 17-gene genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease. Eur Urol. 2017;73(1):129-138.  \n**Meta-analysis**  \n· Bennett J, Flake D. Patient-specific meta-analysis of three clinical validation studies to predict risk of distant metastasis and prostate cancer death in higher risk prostate cancer patients after definitive radiotherapy of radical prostatectomy. EXAS Internal Data 2022. · Brand TC, Zhang N, Crager MR, Maddala T, Dee A, Sesterhenn IA, et al. Patient-specific meta-analysis of 2 clinical validation studies to predict pathologic outcomes in prostate cancer using the 17-gene Genomic Prostate Score. Urology. 2016;89:69-75.  \n  \nCLOSE \n\n### Insurance & Billing Policy\n\nWe are committed to making our tests accessible and affordable to your patients. Mdxhealth’s Patient First Promise Program was created to assist patients throughout the billing process. We will work directly with each patient to ensure their complete satisfaction.\n\n##### Dedicated Patient Advocate Team\n\n  * Our specially trained Patient Advocates are ready to answer patients’ questions about insurance coverage and personalized payment options.\n  * Toll Free: 866-259-7001, Monday – Friday, 6:00AM – 4:30PM PT\n  * Email: patientfirst@mdxhealth.com\n\n\n\n##### Personalized Payment Options\n\n  * Interest-Free Payment Plan\n  * Financial Assistance Program\n\n\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Koen-Hoffman.png)\n\n## Mr. Koen Hoffman\n\n### Chairman and Independent Director, representing Ahok BV\n\nKoen Hoffman has served as Independent Chairman of the Board of Directors of Fagron NV since May 8, 2017. He obtained a Master in Applied Economics at the University of Ghent in 1990 and a Master in Business Administration at Vlerick Business School in Ghent in 1991. Mr. Hoffman was appointed Chief Executive Officer of Value Square in August 2016. Prior to joining Value Square, he was Chief Executive Officer of KBC Securities, member of the supervisory board of Patria Securities and member of the board of directors of Omnia Travel Belgium. He started his career at the corporate finance department of KBC Bank in 1992.\n\nCLOSE \n\n## Understanding your GPS results\n\n### Deciding the most appropriate course of treatment for your prostate cancer is important. Your GPS result may help.\n\nThe GPS test measures prostate cancer gene levels to assess how aggressively your cancer will grow or spread. Since certain genes influence this more than others, knowing which ones are active in your tumor helps determine your personal GPS result.\n\n### Your personal GPS result and risk category\n\nYour score is based on a scale of 0-100. Your genomic risk will indicate how your tumor behaves and can help you and your doctor determine the most appropriate course of treatment.\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/211and212highrisk-1024x380.png)\n\n### Current and future risk\n\nThese results can predict both your chance of:\n\n  1. Dying from prostate cancer and\n  2. Your cancer spreading (metastasis) in the next 10 years\n\n\n\n### Personalized assessment for individualized treatment\n\nThe GPS test provides a personalized assessment of how aggressive your prostate cancer is, helping you and your doctor discuss next steps with confidence.\n\n[**DOWNLOAD SAMPLE REPORT OVERVIEW FOR CLINICALLY HIGH-RISK PROSTATE CANCER**](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/Clinically-High-Risk-Report-Overview-PDF.pdf)\n\nCLOSE \n\n## Understand your test results\n\n### Deciding between active surveillance and immediate treatment for your prostate cancer is important. Your GPS result may help.\n\nThe GPS test measures prostate cancer gene levels to assess how aggressively your cancer will grow or spread. Since certain genes influence this more than others, knowing which ones are active in your tumor helps determine your personal GPS result.\n\n### Your personal GPS result\n\nThe bell curve illustrates where your GPS result falls in relation to the GPS results of other men in the same risk category.\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/212-low-risk-report-1024x627.png)\n\n### Current and future risk\n\nThese results can predict both your chance of:\n\n  1. Your cancer spreading (metastasis) and\n  2. Dying from prostate cancer in the next 10 years\n\n\n\n## Personalized assessment for individualized treatment\n\n### Additional pathology endpoints (provided for men with Gleason score 3+4)\n\n  1. **Adverse Pathology** predicts the probability your doctor would find more aggressive disease than expected from your biopsy. This helps your doctor know if you are a candidate for active surveillance or if immediate treatment is most appropriate for you.\n  2. **High-Grade Disease** shows the likelihood that cancer cells within your tumor are abnormal when compared to typical cells.\n  3. **Non–Organ-Confined Disease** indicates the likelihood that your cancer has already spread outside your prostate.\n\n\n\nThe GPS test provides a personalized assessment of how aggressive your prostate cancer is, helping you and your doctor discuss next steps with confidence.\n\n[**DOWNLOAD SAMPLE REPORT OVERVIEW FOR CLINICALLY LOW-RISK PROSTATE CANCER**](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/Clinically-Low-Risk-Report-Overview-PDF.pdf)\n\nCLOSE \n\n### Test Cancellation Policy\n\nMdxhealth will honor test cancellation requests any time prior to the start of the analytical testing phase. Test cancellation requests must be submitted from the person authorized to cancel a test, following the instructions below:\n\nContact Client Services at **866-259-5644** for test cancellation.\n\nA Test Cancellation Form will be sent to the authorized person for signature.\n\nReturn the completed and signed Test Cancellation Form by fax to mdxhealth **949-788-0014**.\n\nIf the cancellation request is received after the specimen has entered in the analytical testing phase, the request cannot be honored and the usual test charge will be assessed.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Eric-Bednarski.png)\n\n## Eric Bednarski\n\n### Director\n\nDr. Bednarski currently serves as a Partner of MVM Partners LLP. Before joining MVM in 2008, he was a Partner at Advent Healthcare Ventures and a Principal at Advent International Corporation. Prior to Advent, he was a Director in the Corporate Finance Group of Silicon Valley Bank. Dr. Bednarski has a B.S. degree in Neural Science from Brown University and a Ph.D. in Biological Sciences from the University of California, Irvine.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Mike-M-Headhsot-BW.png)\n\n## Michael K. McGarrity\n\n### Chief Executive Officer, Director\n\nMr. McGarrity has more than 25 years of experience in the healthcare industry with a unique combination of device, diagnostics and biotechnology experience. Michael was most recently the CEO of Sterilis Medical. Prior to Sterilis Michael was the CEO of Nanosphere (NASDAQ: NSPH), a nanotechnology-based molecular diagnostics company, where he engineered an operational and strategic turnaround that resulted in its successful sale to Luminex (NASDAQ: LMNX) in 2016. Prior to Nanosphere, McGarrity spent 13 years at Stryker Corporation (NYSE: SYK). McGarrity served in leadership roles in sales and marketing and led Stryker into new growth markets such as post-operative pain management, surgical fluid waste management and interventional pain management. He also had executive general management responsibility for a newly created business unit focused on interventional spine pain management. Michael received a Bachelor of Arts degree from the University of Notre Dame and began his career in commercial banking.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/John-B-headshot-website.png)\n\n## John Bellano\n\n### Chief Commercial Officer\n\nMr. Bellano has more than 25 years of experience in the Healthcare Industry. Mr. Bellano started his career in Pharmaceuticals and transitioned to molecular diagnostics where he has spent the past 20 years of his career. Most recently the Chief Commercial Officer of Sterilis Solutions Prior to Sterilis Solutions he served as the commercial leader for Pharmacogenomic companies Assurex Health and AltheaDx. While at Assurex Health (Myriad Genetics) revenue grew from $700k to a run rate of $100 Million during his 5 year span with the organization.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Mimi-Reyes-headshot_.png)\n\n## Miriam Reyes\n\n### Executive Vice President of Operations\n\nMiriam Reyes has 25 years of experience in life science and laboratory operations, and R&D. She has served as Operations Leader at MDxHealth since its US inception in 2011. Prior to MDxHealth, Mrs. Reyes was Director of Laboratory Operations at Agendia where she established/built and led the CLIA lab for the Agendia’s FDA cleared MammaPrint breast cancer test. In addition to Agendia, she established laboratory operations at Combimatrix (Invitae) Molecular Diagnostics and developed commercial assays at both IBIS Biosciences and US Labs (LabCorp.).\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Joe-Sollee-Headshot.png)\n\n## Joseph Sollee\n\n### Executive Vice President of Corporate Development and General Counsel\n\nMr. Sollee has more than 20 years of experience in the healthcare industry, including senior management roles in both private and publicly listed pharmaceuticals, health information technology and molecular diagnostics companies. He has served as chief legal counsel to MDxHealth since its inception in 2003. Prior to MDxHealth, he led the Life Sciences Practice Group at the law firm of Kennedy Covington (now K&LGates) and held senior legal and management positions at TherapyEdge and Triangle Pharmaceuticals. In addition, he has practiced as a corporate attorney in the Washington D.C. legal firm Swidler & Berlin and as an investment banker at Smith Barney in New York. Mr. Sollee received a Juris Doctorate in Law and a Masters degree in International Law from Duke University, a BA degree from Harvard University, and has been awarded New York, Washington D.C. and North Carolina legal bar certifications.\n\nCLOSE \n"
        }
      ]
    },
    {
      "section_name": "Shareholder Meetings",
      "links": [
        {
          "title": "Extraordinary General Shareholders’ Meeting (June 20, 2024)",
          "url": "https://mdxhealth.com/wp-content/uploads/2024/06/Convening-Notice-ENG.pdf",
          "content": "Unofficial English translation – For informational purposes only\nMDxHealth SA\nLimited Liability Company\n(société anonyme)\nCAP Business Center\nZone Industrielle des Hauts-Sarts\nRue d'Abhooz 31\n4040 Herstal, Belgium\nVAT BE 0479.292.440 (RLP Liège, division Liège)\nINVITATION\nEXTRAORDINARY GENERAL MEETING\nto be held on Thursday, 20 June 2024, at 3:00 p.m.\nAs the quorum for the deliberation and voting on the matters on the agenda of the extraordinary general meeting\nof MDxHealth SA (the \"Company\") held on 30 May 2024 was not reached, the holders of securities of the\nCompany are invited to attend a second extraordinary general shareholders' meeting of the Company before the\nnotary public.\nGENERAL INFORMATION\nDate, hour and venue: The extraordinary general shareholders' meeting will be held on Thursday, 20 June\n2024 at 3:00 p.m. at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent,\nBelgium, or at such other place as will be indicated at that place at that time.\nOpening of the doors: In order to facilitate the keeping of the attendance list on the day of the extraordinary\ngeneral shareholders' meeting, holders of securities and their representatives are invited to register as of 2:15\np.m.\nEXTRAORDINARY GENERAL MEETING\nAgenda and proposed resolutions: The agenda and proposed resolutions of the extraordinary general\nshareholders' meeting of the Company which, as the case may be, can be amended at the meeting on behalf of\nthe board of directors, are as follows:\n1. Submission of reports - 2024 Share Option Plan\nSubmission of and discussion on:\n(a) the report of the board of directors of the Company, prepared in accordance with articles 7:180\nand 7:191 of the Belgian Companies and Associations Code, in relation to the proposal to\nissue 2,000,000 new subscription rights for shares of the Company (the \"2024 Share\nOptions\"), pursuant to a share option plan named \"the 2024 Share Option Plan\", and to dis-\napply, in the interest of the Company, the preferential subscription right of the existing\nshareholders of the Company and, insofar as required, of the holders of outstanding\nsubscription rights (share options) of the Company, for the benefit of the members of the\npersonnel of the Company and its subsidiaries from time to time, within the meaning of article\n1:27 of the Belgian Companies and Associations Code (the \"Selected Participant\"); and\n(b) the report of the statutory auditor of the Company, prepared in accordance with articles 7:180\nand 7:191 of the Belgian Companies and Associations Code, in relation to the proposal to\nissue 2,000,000 2024 Share Options, and to dis-apply, in the interest of the Company, the\npreferential subscription right of the existing shareholders of the Company and, insofar as\nrequired, of the holders of outstanding subscription rights (share options) of the Company, to\nthe benefit of the Selected Participants.\n1\nUnofficial English translation – For informational purposes only\n2. Proposal to issue 2,000,000 2024 Share Options\nProposed resolution: The general shareholders' meeting resolves to approve the issuance of 2,000,000\n2024 Share Options, pursuant to a share option plan named the \"2024 Share Option Plan\", and to dis-\napply, in the interest of the Company, the preferential subscription right of the existing shareholders of\nthe Company and, insofar as required, of the holders of outstanding subscription rights (share options)\nof the Company, for the benefit of Selected Participant. In view thereof, the general shareholders'\nmeeting resolves as follows:\n(a) Terms and conditions of the 2024 Share Options: The terms and conditions of the 2024 Share\nOptions (including, but not limited to, the exercise price of the 2024 Share Options) shall be\nas set out in the annex to the report of the board of directors referred to in item 1.(a) of the\nagenda (for the purpose of this resolution, the \"Plan\"), a copy of which shall remain attached\nto the minutes recording the present resolution. The 2024 Share Options have a term of ten\nyears as from their issue date.\n(b) Underlying shares: Each 2024 Share Option shall entitle the holder thereof to subscribe for\none new share to be issued by the Company. The new shares to be issued at the occasion of\nthe exercise of the 2024 Share Options shall have the same rights and benefits as, and rank\npari passu in all respects, including as to entitlements to dividends and other distributions,\nwith the existing and outstanding shares of the Company at the moment of their issuance, and\nwill be entitled to dividends and other distributions in respect of which the relevant record\ndate or due date falls on or after the date of issue of the new shares.\n(c) Dis-application of the preferential subscription right for the benefit of the Selected\nParticipants: The general shareholders' meeting resolves, in accordance with article 7:191 of\nthe Belgian Companies and Associations Code, to dis-apply, in the interest of the Company,\nthe preferential subscription right of the existing shareholders of the Company and, insofar as\nrequired, of the holders of outstanding subscription rights (share options) of the Company, for\nthe benefit of the Selected Participants, and to approve the possibility for the Company to\ngrant the 2024 Share Options to the Selected Participants, as further explained in the report of\nthe board of directors referred to in item 1.(a) of the agenda and the terms and conditions of\nthe Plan.\n(d) Confirmation of the subscription of 2024 Share Options by the Company: The general\nshareholders' meeting resolves to approve and confirm that the Company will be able to\nsubscribe for the 2024 Share Options, with a view to creating a pool of outstanding 2024\nShare Options available for further grants to Selected Participants. The Company may not,\nhowever, exercise the 2024 Share Options for its own account.\n(e) Conditional capital increase and issue of new shares: The general shareholders' meeting\nresolves, subject to, and to the extent of the exercise of the 2024 Share Options, to increase the\nCompany's share capital and to issue the relevant number of new shares issuable upon the\nexercise of the 2024 Share Options. Subject to, and in accordance with, the provisions of the\nPlan, upon exercise of the 2024 Share Options and issue of new shares, the aggregate amount\nof the exercise price of the 2024 Share Options will be allocated to (as the case may be,\nfollowing conversion into the Company's share capital currency, on the basis of the relevant\nUSD/EUR exchange ratio as shall be published by the European Central Bank, as provided for\nin section 5.2 of the Plan) the share capital of the Company. To the extent that the amount of\nthe exercise price of the 2024 Share Options, per share to be issued upon exercise of the 2024\nShare Options, exceeds the fractional value of the then existing shares of the Company\nexisting immediately prior to the issue of the new shares concerned, a part of the exercise\nprice, per share to be issued upon exercise of the 2024 Share Options, equal to such fractional\nvalue shall be booked as share capital, whereby the balance shall be booked as issue premium.\nFollowing the capital increase and issuance of new shares, each new and existing share shall\nrepresent the same fraction of the share capital of the Company.\n(f) Issue premium: Any issue premium that will be booked in connection with the 2024 Share\nOptions shall be accounted for on a non-distributable account on the liabilities side of the\nCompany's balance sheet under its net equity, and the account on which the issue premium\n2\nUnofficial English translation – For informational purposes only\nwill be booked shall, like the share capital, serve as a guarantee for third parties and can only\nbe reduced on the basis of a lawful resolution of the general shareholders' meeting passed in\nthe manner required for an amendments to the Company's articles of association.\n(g) Powers of attorney: The board of directors is authorised to implement and execute the\nresolutions passed by the general shareholders' meeting in connection with the 2024 Share\nOptions, and to take all steps and carry out all formalities that shall be required by virtue of\nthe Plan, the Company's articles of association and applicable law in order to issue or transfer\nthe shares upon exercise of the 2024 Share Options. Furthermore, each of the Company's\ndirectors, Joe Sollee and Ron Kalfus, each such person acting individually and with possibility\nof sub-delegation and the power of subrogation, shall have the power, upon exercise of the\n2024 Share Options, (i) to proceed with the recording of (A) the capital increase and issue of\nnew shares resulting from such exercise, (B) the allocation of the share capital and (as\napplicable) the issue premium, and (C) the amendment of the Company's articles of\nassociation in order to reflect the new share capital and number of outstanding shares\nfollowing the exercise of the 2024 Share Options, (ii) to sign and deliver, on behalf of the\nCompany, the relevant Euroclear, Computershare, Nasdaq, bank and/or other documentation,\nthe share register and all other necessary documents in connection with the issuance and\ndelivery of the shares to the Selected Participants concerned and the admission to listing and\ntrading of such shares, and (iii) to do whatever may be necessary or useful (including but not\nlimited to the preparation and execution of all documents and forms) for the admission of the\nshares issued upon the exercise of the 2024 Share Options to trading on Nasdaq (or such other\nmarkets on which the Company's shares will be trading at that time).\n3. Submission of reports – Exact Sciences Warrants\nSubmission of and discussion on:\n(a) the report of the board of directors of the Company, prepared in accordance with articles\n7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code, in relation to the\nproposal to issue, for the benefit of Genomic Health, Inc. (a subsidiary of Exact Sciences\nCorporation referred to herein as \"Exact Sciences\") 1,000,000 new subscription rights for\nshares of the Company (the \"Exact Sciences Warrants\"), and to dis-apply, in the interest of\nthe Company, the preferential subscription right of the Company's existing shareholders and,\ninsofar as required, of the holders of subscription rights (share options) of the Company, for\nthe benefit of Exact Sciences; and\n(b) the report of the Company's statutory auditor, prepared in accordance with articles 7:180,\n7:191 and 7:193 of the Belgian Companies and Associations Code, in relation to the proposal\nto issue for the benefit of Exact Sciences 1,000,000 Exact Sciences Warrants, and to dis-apply,\nin the interest of the Company, the preferential subscription right of the Company's existing\nshareholders and, insofar as required, of the holders of subscription rights (share options) of\nthe Company, for the benefit of Exact Sciences.\n4. Proposal to issue 1,000,000 Exact Sciences Warrants\nProposed resolution: The general shareholders' meeting resolves to approve the issuance of 1,000,000 new\nsubscription rights for shares of the Company, called the \"Exact Sciences Warrants\", and to dis-apply, in the\ninterest of the Company, the preferential subscription right of the Company's existing shareholders and, insofar\nas required, of the holders of outstanding subscription rights (share options) of the Company, for the benefit of\nExact Sciences. To this end, the general shareholders' meeting resolves as follows:\n(a) Terms and conditions of the subscription rights: The terms and conditions of the Exact\nSciences Warrants will be in accordance with Annex A of the report of the board of directors\nreferred to in item 3.(a) of the agenda (for the purposes of this resolution, the \"Exact Sciences\nWarrants Terms and Conditions\"), a copy of which will remain attached to the minutes\nrecording the present resolution. The main terms and conditions of the Exact Sciences\nWarrants can, for information purposes, be summarised as follows:\n(i) Right to subscribe for one ordinary share: Each Exact Sciences Warrant entitles the\n3\nUnofficial English translation – For informational purposes only\nholder to subscribe for one (1) ordinary share of the Company to be issued by the\nCompany.\n(ii) Exercise price: The exercise price of the Exact Sciences Warrants (i.e., the price to\nbe paid in cash to subscribe for one new share in the Company when an Exact\nSciences Warrant is exercised) will be USD 5.265. The exercise price is subject to\npotential customary downward adjustments in the case of certain dilutive actions of\nthe Company.\n(iii) Term: The Exact Sciences Warrants will have a term starting as from their issuance\nand ending on (and including) August 22, 2028.\n(iv) Exercisability: The exercise of the Exact Sciences Warrants will be subject to the\nterms and conditions contained in the Exact Sciences Warrants Terms and\nConditions. The Exact Sciences Warrants may be exercised as from their issuance\nand until the end of their term, provided that a number of Exact Sciences Warrants\nwith an aggregate exercise price of at least USD 250,000 are exercised by the holder\nthereof.\n(v) Transferability: Except if the Company were to explicitly allow a transfer of the\nExact Sciences Warrants, the Exact Sciences Warrants cannot be transferred by the\nholder. Furthermore, the Exact Sciences Warrants will not be admitted to listing or\ntrading.\n(b) Underlying shares: Each Exact Sciences Warrant will entitle its holder to subscribe for one\nnew share to be issued by the Company. The new shares to be issued upon exercise of the\nExact Sciences Warrants shall have the same rights and benefits as, and rank pari passu in all\nrespects including as to entitlement to dividends and other distributions, with the existing and\noutstanding shares of the Company at the moment of their issuance and will be entitled to\ndividends and other distributions in respect of which the relevant record date or due date falls\non or after the date of their issuance.\n(c) Dis-application of the preferential subscription right for the benefit of Exact Sciences: The\ngeneral shareholders' meeting resolves, in accordance with articles 7:191 and 7:193 of the\nBelgian Companies and Associations Code, to dis-apply, in the interest of the Company, the\npreferential subscription right of existing shareholders of the Company and, insofar as\nrequired, of the holders of subscription rights (share options) of the Company, for the benefit\nof Exact Sciences, as explained in the report of the board of directors referred to in item 3.(a)\nof the agenda.\n(d) Conditional capital increase and issue of new shares: The general shareholders' meeting\nresolves, subject to and in the case of the exercise of the Exact Sciences Warrants, to increase\nthe share capital of the Company and to issue the appropriate number of new shares that may\nbe issued upon exercise of the Exact Sciences Warrants. Subject to, and in accordance with,\nthe respective provisions of the Exact Sciences Warrants Terms and Conditions, upon exercise\nof the Exact Sciences Warrants and the issuance of new shares, the aggregate amount of the\nexercise price of the Exact Sciences Warrants will be allocated to (as the case may be,\nfollowing conversion into the Company's share capital currency, on the basis of the relevant\nUSD/EUR exchange ratio as shall be published by the European Central Bank, as provided for\nin section 5.4 of the Exact Sciences Warrants Terms and Conditions) the share capital of the\nCompany. To the extent that the amount of the exercise price of the Exact Sciences Warrants,\nper share to be issued upon exercise of the Exact Sciences Warrants, exceeds the fractional\nvalue of the then existing shares of the Company existing immediately prior to the issue of the\nnew shares concerned, a part of the exercise price, per share to be issued upon exercise of the\nExact Sciences Warrants, equal to such fractional value shall be booked as share capital,\nwhereby the balance shall be booked as issue premium. Following the capital increase and\nissuance of new shares, each new and existing share shall represent the same fraction of the\nshare capital of the Company.\n4\nUnofficial English translation – For informational purposes only\n(e) Issue premium: Any issue premium that will be booked in connection with the Exact Sciences\nWarrants (whether upon exercise of the Exact Sciences Warrants, or otherwise) will be\naccounted for on a non-distributable account on the liabilities side of the Company's balance\nsheet under its net equity, and the account on which the issue premium will be booked shall,\nlike the share capital, serve as a guarantee for third parties and can only be reduced on the\nbasis of a lawful resolution of the general shareholders' meeting passed in the manner required\nfor an amendments to the Company's articles of association.\n(f) Powers of attorney: The board of directors is authorised to implement and execute the\nresolutions adopted by the general shareholders' meeting in connection with the Exact\nSciences Warrants, and to take all measures and carry out all formalities that will be required\npursuant to the Exact Sciences Warrants Terms and Conditions, the Company's articles of\nassociation and all applicable laws in order to issue or transfer the shares upon exercise of the\nExact Sciences Warrants. In addition, each director of the Company, Joe Sollee and Ron\nKalfus, each such person acting individually and with the possibility of sub-delegation and\npower of subrogation, shall have the power, upon exercise of the Exact Sciences Warrants, (i)\nto proceed with the recording of (A) the capital increase and the issue of new shares resulting\nfrom such exercise, (B) the allocation as share capital and (if applicable) as issue premium,\nand (C) the amendment of the Company's articles of association to reflect the new share\ncapital and number of shares outstanding following the exercise of the Exact Sciences\nWarrants (ii) to sign and deliver, on behalf of the Company, the relevant Euroclear,\nComputershare, Nasdaq and/or bank documentation, the share register and all other necessary\ndocuments in connection with the issuance and delivery of the shares to the beneficiary and\nthe admission to listing and trading of such shares, and (iii) to do whatever may be necessary\nor useful (including, but not limited to, the preparation and execution of all documents and\nforms) for the admission of the shares issued upon exercise of the Exact Sciences Warrants to\ntrading on Nasdaq (or any other market on which the Company's shares will then be traded).\n5. Submission of reports – OrbiMed Warrants\nSubmission of and discussion on:\n(a) the report of the board of directors of the Company, prepared in accordance with articles\n7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code, in relation to the\nproposal to issue, for the benefit of OrbiMed Royalty & Credit Opportunities IV, LP and\nOrbiMed Royalty & Credit Opportunities IV Offshore, LP (together referred to herein as\n\"OrbiMed\") 1,243,060 new subscription rights for shares of the Company (of those 1,243,060\nnew subscription rights for shares, 881,906 new subscription rights for shares to be issued for\nthe benefit of OrbiMed Royalty & Credit Opportunities IV, LP and 361,154 new subscription\nrights for shares to be issued for the benefit of OrbiMed Royalty & Credit Opportunities IV\nOffshore, LP), with a term of 5 years as from their issue date (the \"OrbiMed Warrants\"), and\nto dis-apply, in the interest of the Company, the preferential subscription right of the\nCompany's existing shareholders and, insofar as required, of the holders of subscription rights\n(share options) of the Company, for the benefit of OrbiMed; and\n(b) the report of the Company's statutory auditor, prepared in accordance with articles 7:180,\n7:191 and 7:193 of the Belgian Companies and Associations Code, in relation to the proposal\nto issue for the benefit of OrbiMed 1,243,060 OrbiMed Warrants, and to dis-apply, in the\ninterest of the Company, the preferential subscription right of the Company's existing\nshareholders and, insofar as required, of the holders of subscription rights (share options) of\nthe Company, for the benefit of OrbiMed.\n6. Proposal to issue 1,243,060 OrbiMed Warrants\nProposed resolution: The general shareholders' meeting resolves to approve the issuance of 1,243,060\nnew subscription rights for shares of the Company, with a term of 5 years as from their issue date,\ncalled the \"OrbiMed Warrants\", and to dis-apply, in the interest of the Company, the preferential\nsubscription right of the Company's existing shareholders and, insofar as required, of the holders of\nsubscription rights (share options) of the Company, for the benefit of each of OrbiMed Royalty &\n5\nUnofficial English translation – For informational purposes only\nCredit Opportunities IV, LP and OrbiMed Royalty & Credit Opportunities IV Offshore, LP. To this\nend, the general shareholders' meeting resolves as follows:\n(a) Terms and conditions of the subscription rights: The terms and conditions of the OrbiMed\nWarrants will be in accordance with Annex A of the report of the board of directors referred to\nin item 5.(a) of the agenda (for the purposes of this resolution, the \"OrbiMed Warrants\nTerms and Conditions\"), a copy of which will remain attached to the minutes recording the\npresent resolution. The main terms and conditions of the OrbiMed Warrants can, for\ninformation purposes, be summarised as follows:\n(i) Right to subscribe for one ordinary share: Each OrbiMed Warrant entitles its holder\nto subscribe for one (1) ordinary share of the Company to be issued by the Company.\n(ii) Exercise price: The exercise price of the OrbiMed Warrants (i.e., the price to be paid\nin cash to subscribe for one new share in the Company when an OrbiMed Warrant is\nexercised) will be USD 2.4134. The exercise price is subject to potential customary\ndownward adjustments in the case of certain dilutive actions of the Company.\n(iii) Subscription price: The subscription price for the 881,906 OrbiMed Warrants to be\nissued for the benefit of OrbiMed Royalty & Credit Opportunities IV, LP will be\nUSD 1,744,485.56, and the subscription price for the 361,154 OrbiMed Warrants to\nbe issued for the benefit of OrbiMed Royalty & Credit Opportunities IV Offshore, LP\nwill be USD 714,394.11. The subscription price shall be booked as issue premium (in\naccordance with what is stated in paragraph (d) below).\n(iv) Term: The OrbiMed Warrants will have a term of 5 years as from their issue date.\n(v) Exercisability: The exercise of the OrbiMed Warrants will be subject to the terms\nand conditions contained in the OrbiMed Warrants Terms and Conditions. The\nOrbiMed Warrants may be exercised as from their issuance and until the end of their\nterm.\n(vi) Transferability: The OrbiMed Warrants and all rights thereunder are transferable, in\nwhole or in part, by the relevant holder in accordance with the OrbiMed Warrants\nTerms and Conditions.\n(b) Underlying shares: Each OrbiMed Warrant will entitle its holder to subscribe for one new\nshare to be issued by the Company. The new shares to be issued upon exercise of the OrbiMed\nWarrants shall have the same rights and benefits as, and rank pari passu in all respects\nincluding as to entitlements to dividends and other distributions, with the existing and\noutstanding shares of the Company at the moment of their issuance and will be entitled to\ndividends and other distributions in respect of which the relevant record date or due date falls\non or after the date of their issuance.\n(c) Dis-application of the preferential subscription right for the benefit of OrbiMed: The general\nshareholders' meeting resolves, in accordance with articles 7:191 and 7:193 of the Belgian\nCompanies and Associations Code, to dis-apply, in the interest of the Company, the\npreferential subscription right of the existing shareholders of the Company and, insofar as\nrequired, of the holders of subscription rights (share options) of the Company, for the benefit\nof each of OrbiMed Royalty & Credit Opportunities IV, LP and OrbiMed Royalty & Credit\nOpportunities IV Offshore, LP, as explained in the report of the board of directors referred to\nin item 5.(a) of the agenda.\n(d) Conditional capital increase and issue of new shares: The general shareholders' meeting\nresolves, subject to and in the case of the exercise of the OrbiMed Warrants, to increase the\nshare capital of the Company and to issue the appropriate number of new shares that may be\nissued upon exercise of the OrbiMed Warrants. Subject to, and in accordance with, the\nrespective provisions of the OrbiMed Warrants Terms and Conditions, upon exercise of the\nOrbiMed Warrants and the issuance of new shares, the aggregate amount of the exercise price\nof the OrbiMed Warrants will be allocated to (as the case may be, following conversion into\n6\nUnofficial English translation – For informational purposes only\nthe Company's share capital currency, on the basis of the relevant USD/EUR exchange ratio as\nshall be published by the European Central Bank, as provided for in in section 4(b) of the\nOrbiMed Warrants Terms and Conditions) the share capital of the Company. To the extent\nthat the amount of the exercise price of the OrbiMed Warrants, per share to be issued upon\nexercise of the OrbiMed Warrants, exceeds the fractional value of the then existing shares of\nthe Company existing immediately prior to the issue of the new shares concerned, a part of the\nexercise price, per share to be issued upon exercise of the OrbiMed Warrants, equal to such\nfractional value shall be booked as share capital, whereby the balance shall be booked as issue\npremium. Following the capital increase and issuance of new shares, each new and existing\nshare shall represent the same fraction of the share capital of the Company.\n(e) Issue premium: Any issue premium that will be booked in connection with the OrbiMed\nWarrants (whether as subscription price, upon exercise of the OrbiMed Warrants, or\notherwise) will be accounted for on a non-distributable account on the liabilities side of the\nCompany's balance sheet under its net equity, and the account on which the issue premium\nwill be booked shall, like the share capital, serve as a guarantee for third parties and can only\nbe reduced on the basis of a lawful resolution of the general shareholders' meeting passed in\nthe manner required for an amendments to the Company's articles of association.\n(f) Powers of attorney: The board of directors is authorised to implement and execute the\nresolutions adopted by the general shareholders' meeting in connection with the OrbiMed\nWarrants, and to take all measures and carry out all formalities that will be required pursuant\nto the OrbiMed Warrants Terms and Conditions, the Company's articles of association and all\napplicable laws in order to issue or transfer the shares upon exercise of the OrbiMed Warrants.\nIn addition, each director of the Company, Joe Sollee and Ron Kalfus, each such person acting\nindividually and with the possibility of sub-delegation and power of subrogation, shall have\nthe power, upon exercise of the OrbiMed Warrants, (i) to proceed with the recording of (A)\nthe capital increase and the issue of new shares resulting from such exercise, (B) the allocation\nas share capital and (if applicable) as issue premium, and (C) the amendment of the\nCompany's articles of association to reflect the new share capital and number of shares\noutstanding following the exercise of the OrbiMed Warrants (ii) to sign and deliver, on behalf\nof the Company, the relevant Euroclear, Computershare, Nasdaq and/or bank documentation,\nthe share register and all other necessary documents in connection with the issuance and\ndelivery of the shares to the beneficiary and the admission to listing and trading of such\nshares, and (iii) to do whatever may be necessary or useful (including, but not limited to, the\npreparation and execution of all documents and forms) for the admission of the shares issued\nupon exercise of the OrbiMed Warrants to trading on Nasdaq (or any other market on which\nthe Company's shares will then be traded).\nQuorum: As this extraordinary general shareholders' meeting constitutes the second extraordinary general\nshareholders' meeting for the aforementioned agenda items, no quorum is required for the deliberation and\nvoting on the items referred to in the aforementioned agenda.\nVoting and majority: Subject to applicable legal provisions, each share shall have one vote. In accordance with\napplicable law, the proposed resolutions referred to in the aforementioned agenda of the extraordinary general\nshareholders' meeting shall be passed if they are approved by a majority of 75% of the votes validly cast by the\nshareholders. Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of\nsubscription rights have the right to participate to the extraordinary general shareholders' meeting, but only with\nan advisory vote.\nPARTICIPATION TO THE MEETING\nIntroduction: Holders of securities issued by the Company who wish to participate to the extraordinary general\nshareholders' meeting of the Company should take into account the formalities and procedures described below.\n7\nUnofficial English translation – For informational purposes only\nSince the completion, on 18 December 2023, of the Company's transition from a dual listing of the Company’s\nformer American Depositary Shares on Nasdaq and shares on Euronext Brussels to a sole listing of its shares on\nNasdaq, the Company's shares are comprised of:\n(a) shares that are reflected in the component of the Company's share register that is held in Belgium and\nwhich is managed by Euroclear Belgium (the \"Belgian Share Register\" and, the shares reflected in the\nBelgian Share Register, the \"European Shares\"), and that cannot be traded on Nasdaq until they have\nbeen repositioned into U.S. Shares (as defined below); and\n(b) shares that are reflected directly or indirectly in the component of the Company's share register that is\nheld in the United States and which is managed by Computershare (the \"U.S. Share Register\" and, the\nshares reflected in the U.S. Share Register, the \"U.S. Shares\"), and that can be traded on Nasdaq.\nFor further information and details regarding the transition to a single listing on Nasdaq and the repositioning\nprocess, please visit the dedicated web page on the Company’s website (see: https://mdxhealth.com/proposed-\ntransition-to-a-single-listing-on-nasdaq/).\nRegistration date: In accordance with article 32 of the Company's articles of association and article 7:134 of\nthe Belgian Companies and Associations Code, the Company's board of directors sets the registration date for\nthe extraordinary general shareholders' meeting on Monday, 17 June 2024, at midnight (12:00 a.m., Belgian\ntime) (the \"Registration Date\"). Only persons owning securities issued by the Company on Monday, 17 June\n2024, at midnight (12:00 a.m., Belgian time) shall be entitled to participate to, and, as the case may be, vote at\nthe extraordinary general shareholders' meeting. Only shareholders are entitled to vote. The holders of\nsubscription rights can participate to the extraordinary general shareholders' meeting, but only with an advisory\nvote. Shareholders, as well as holders of subscription rights must satisfy the formalities that are described under\n\"—Participation to the meeting\".\nParticipation to the meeting: In order to be able to participate to the extraordinary general meeting, a holder of\nsecurities issued by the Company must satisfy two conditions: (a) be registered as holder of such securities on\nthe Registration Date, and (b) notify the Company, as described below:\n(a) Registration: Firstly, the right for a holder of securities issued by the Company to participate to and, as\napplicable, to vote at the extraordinary general shareholders' meeting is only granted on the basis of the\nregistration of the securities concerned on the aforementioned Registration Date at midnight, as\nfollows:\n(i) Holders of registered European Shares and registered subscription rights issued by the\nCompany: The holders of registered European Shares and subscription rights in registered\nform issued by the Company may participate to the extraordinary general shareholders'\nmeeting only for the registered European Shares and registered subscription rights that are\nreflected in their name in the Belgian Share Register and relevant register of subscription\nrights, respectively, on the Registration Date.\n(ii) Holders of dematerialised European Shares: The holders of dematerialised European Shares\nthat want participate to the extraordinary general shareholders' meeting must request their\ncertified account holder or the central securities depositary for the shares concerned to issue a\ncertificate stating the number of dematerialised shares registered in the name of the\nshareholder in its books on the Registration Date, and to send it to the Company (by mail at its\nregistered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts,\nrue d'Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at\nagsm@mdxhealth.com) at the latest on the second business day prior to the extraordinary\ngeneral shareholders' meeting, i.e., on or before Tuesday, 18 June 2024 at the latest (the\n\"Notification Deadline\"). The Company shall determine the ownership of the relevant shares\nat the Registration Date solely on the basis of such certificates.\n(iii) Holders of U.S. Shares, reflected directly in the U.S. Share Register (not through DTCC): The\nholders of U.S. Shares reflected directly in the U.S. Share Register (not through DTCC) may\nonly be admitted to the extraordinary general shareholders' meeting if their ownership of U.S.\nShares is reflected in the U.S. Share Register on the Registration Date. The Company's U.S.\ntransfer agent will no later than the Notification Deadline provide the Company directly or\n8\nUnofficial English translation – For informational purposes only\nindirectly with a shareholder list at the Registration Date that contains all of the registered\nholders of the Company's U.S. Shares recorded in the U.S. Share Register directly (not\nthrough DTCC) on the Registration Date. The Company shall determine the ownership of the\nrelevant shares at the Registration Date solely on the basis of the aforementioned information.\n(iv) Holders of U.S. Shares reflected indirectly in the U.S. Share Register (through DTCC): The\nholders of U.S. Shares reflected indirectly in the U.S. Share Register, through CEDE & Co.,\nthe nominee holder of the U.S. Shares held for the beneficial owners through the DTCC\nsystem, may only be admitted to the extraordinary general shareholders' meeting if their\nownership of U.S. Shares is included in the information provided to the Company no later\nthan the Notification Deadline through the broker, financial institution or other intermediary\nof such shareholders. The Company shall determine the ownership of the relevant shares at the\nRegistration Date solely on the basis of the aforementioned information.\n(b) Notification: Secondly, in accordance with article 32 of the Company's articles of association and\narticle 7:134 of the Belgian Companies and Associations Code, the Company's board of directors sets\nthe deadline for holders of securities issued by the Company to notify their participation to the\nextraordinary general shareholders' meeting on the Notification Deadline. Therefore, in order to\nparticipate to the extraordinary general shareholders' meeting, holders of securities issued by the\nCompany must notify the Company whether they want to participate to the meeting, and the must do so\nprior to or at the latest on Tuesday, 18 June 2024. The holders of securities who wish to make such\nnotification can make use of the attendance form that can be obtained at the Company's registered\noffice and on the Company's website (http://www.mdxhealth.com). The notice must reach the\nCompany, by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des\nHauts-Sarts, rue d'Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at\nagsm@mdxhealth.com, at the latest on the Notification Deadline. Depending on the type securities it\nholds, a holder of securities issued by the Company must notify to the Company its participation to the\nextraordinary general shareholders' meeting as follows:\n(i) Holders of registered European Shares and registered subscription rights issued by the\nCompany: Holders of registered European Shares and subscription rights in registered form\nissued by the Company that wish to make such notification must make sure that the attendance\nform is duly signed and completed and reaches the Company no later than the Notification\nDeadline (pursuant to the instructions set out above).\n(ii) Holders of dematerialised European Shares: Holders of dematerialised European Shares that\nwish to make such notification must make sure that the attendance form is duly signed and\ncompleted and reaches the Company no later than the Notification Deadline (pursuant to the\ninstructions set out above). Furthermore, the notification must include a certificate confirming\nthe number of European Shares that have been registered in their name on the Registration\nDate. The certificate can be obtained by the holders of the dematerialised European Shares\nwith the certified account holder or the central securities depositary for the European Shares\nconcerned (see also under (ii) in paragraph (a) above).\n(iii) Holders of U.S. Shares, reflected directly in the U.S. Share Register (not through DTCC):\nHolders of U.S. Shares reflected directly in the U.S. Share Register (not through DTCC) that\nwish to make such notification must make sure that the attendance form included as part of\ntheir notice is duly completed and reaches the Company no later than the Notification\nDeadline (pursuant to the instructions set out above).\n(iv) Holders of U.S. Shares reflected indirectly in the U.S. Share Register (through DTCC):\nHolders of U.S. Shares reflected indirectly in the U.S. Share Register, through CEDE & Co.,\nthe nominee holder of the U.S. Shares held for the beneficial owners through the DTCC\nsystem, that wish to make such notification must make sure that the attendance form is duly\ncompleted and reaches the Company no later than the Notification Deadline (pursuant to the\ninstructions set out above). Furthermore, the notification must include a certificate from a\nbroker, financial institution or other intermediary indicating that such holder was the owner of\nsuch U.S. Shares on the Registration Date.\n9\nUnofficial English translation – For informational purposes only\nThe Company encourages shareholders to participate to the extraordinary general shareholders' meeting\nthrough a signed proxy or the U.S. proxy card (as further explained below under \"—Representation by\nproxy\") that will be provided or is made available to them and in accordance with the accompanying\ninstructions. If a shareholder attends to the extraordinary general shareholders' meeting in person, it\nmay revoke its signed proxy or U.S. proxy card until the Notification Deadline. Providing to the\nCompany a signed proxy or U.S. proxy card to the Company shall also qualify as a notification,\nprovided that the signed proxy or U.S. proxy card reaches the Company (by mail at its registered office\n(MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d'Abhooz 31, 4040\nHerstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com) no later than the\nNotification Deadline. For the shareholders referred to in (ii) and (iv) above, the signed proxy or U.S.\nproxy card must also include the certificates referred to in (ii) and (iv) above respectively.\nRepresentation by proxy: The holders of securities can participate to the meeting and vote, as applicable,\nthrough a written proxy. Written proxies must contain specific voting instructions for each proposed resolution.\nProxy forms can be obtained on the Company's website (http://www.mdxhealth.com). The proxy form must be\nsigned in writing or electronically. Holders of U.S Shares who want to appoint a proxy are strongly encouraged\nto use the U.S. proxy card that will be provided to them and according to the accompanying instructions. Signed\nproxies and U.S. proxy cards must reach the Company by mail at its registered office (MDxHealth SA, CAP\nBusiness Center, Zone Industrielle des Hauts-Sarts, rue d'Abhooz 31, 4040 Herstal, Belgium, Attention: Mr.\nRon Kalfus) or by e-mail at agsm@mdxhealth.com, at the latest on the Notification Deadline, i.e., on or before\nTuesday, 18 June 2024 at the latest. Holders of securities who wish to be represented by proxy must, in any case\ncomply with the formalities to participate to the meeting, as explained under \"—Participation to the meeting\".\nFor the shareholders referred to in (ii) and (iv) of paragraph (b) of \"—Participation to the meeting\", the signed\nproxy or U.S. proxy card must also include the certificates referred to in (ii) and (iv), respectively, of paragraph\n(b) of \"—Participation to the meeting\".\nAccess to the meeting room: The natural persons who attend the extraordinary general shareholders' meeting in\ntheir capacity as holder of securities, holder of proxies or representative of a legal entity must be able to provide\nevidence of their identity in order to be granted access to the meeting room (subject to what is shared above\nunder \"—General information\"). In addition, the representatives of legal entities must hand over the documents\nestablishing their capacity as corporate representative or attorney-in-fact. These documents will be verified\nimmediately before the start of the meeting.\nRecommendation to use e-mail: The Company recommends the holders of its securities to use e-mail for all\ncommunication with the Company regarding the general shareholders' meeting. The Company's e-mail address\nfor such communication is: agsm@mdxhealth.com. The Company also points at that, in addition to be\nphysically available at the Company's registered office and distributed by mail, all forms and other\ndocumentation in relation to the general shareholders' meeting will be available on the Company's website\n(http://www.mdxhealth.com). See also \"—Available documentation\".\nDATA PROTECTION\nThe Company is responsible for the processing of personal data it receives from, or collects about, holders of\nsecurities issued by the Company and proxy holders in the context of general shareholders' meeting. The\nprocessing of such data will be carried out for the purposes of the organisation and conduct of the relevant\ngeneral shareholders' meeting, including the convening notices, registrations, participation and voting, as well as\nfor maintaining lists or registers of security holders, and the analysis of the investor and security holder base of\nthe Company. The data include, amongst others, identification data, the number and nature of securities of a\nholder of securities issued by the Company, proxies and voting instructions. This data may also be transferred to\nthird parties for the purposes of assistance or services to the Company in connection with the foregoing. The\nprocessing of such data will be carried out, mutatis mutandis, in accordance with the Company's Privacy Policy,\navailable on the Company's website (https://mdxhealth.com/privacy-policy). The Company draws the attention\nof the holders of securities issued by the Company and proxy holders to the description of the rights they may\nhave as data subjects, such as, among others, the right to access, the right to rectify and the right to object to\nprocessing, which are outlined in the aforementioned Privacy Policy. All this does not affect the rules that apply\nin connection with the registration and participation to the general shareholders' meeting. To exercise rights as a\ndata subject and for all other information regarding the processing of personal data by or on behalf of the\nCompany, the Company can be contacted by e-mail at dataprotection@mdxhealth.com.\n10\nUnofficial English translation – For informational purposes only\nAVAILABLE DOCUMENTATION\nThe following documentation is available on the Company's website (http://www.mdxhealth.com): the notice\nconvening the extraordinary general shareholders' meeting, the documents to be submitted to the extraordinary\ngeneral shareholders' meeting as referred to in the agenda of the meeting, the attendance form, and the proxy\nform. Prior to the extraordinary general shareholders' meeting, holders of securities of the Company can also\nobtain at the registered office of the Company (CAP Business Center, Zone Industrielle des Hauts-Sarts, rue\nd'Abhooz 31, 4040 Herstal, Belgium), free of cost, a copy of this documentation.\nPlease address any correspondence on this matter to MDxHealth SA, Mr. Ron Kalfus CAP Business Center,\nZone Industrielle des Hauts-Sarts, rue d'Abhooz 31, 4040 Herstal, Belgium. The facsimile number is\n+32 (0)4 259 78 75 and the e-mail address is agsm@mdxhealth.com.\nOn behalf of the board of directors\nTHIS DOCUMENT IS NOT AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY\nSHARES OR OTHER SECURITIES OF MDXHEALTH SA.\n11"
        },
        {
          "title": "Attendance Form (EN)",
          "url": "https://mdxhealth.com/wp-content/uploads/2024/06/Attendance-Form-ENG.pdf",
          "content": "MDxHealth SA\nLimited Liability Company\n(société anonyme)\nCAP Business Center\nZone Industrielle des Hauts-Sarts\nRue d'Abhooz 31\n4040 Herstal, Belgium\nVAT BE 0479.292.440 (RLP Liège, division Liège)\nATTENDANCE FORM FOR SECURITY HOLDERS\nEXTRAORDINARY GENERAL MEETING\nto be held on Thursday, 20 June 2024, at 3:00 p.m. (Belgian time)\nThis attendance form should be used by holders of securities of MDxHealth SA (the \"Company\") who\nwant to attend the extraordinary general shareholders' meeting in person. More information regarding the\nrequirements for, and the modalities of, participation in the meeting can be found in the convening notice\nof the extraordinary general shareholders' meeting.\nThe signed and completed form must reach the Company at the latest on the second business day prior to\nthe extraordinary general shareholders' meeting, i.e., on or before Tuesday, 18 June 2024 at the latest, by\nmail to:\nMDxHealth SA\nAttention Mr. Ron Kalfus\nCompany Secretary\nCAP Business Center\nZone Industrielle des Hauts-Sarts\nRue d'Abhooz, 31\n4040 Herstal,\nBelgium\nor by e-mail to:\nagsm@mdxhealth.com\nThe use of e-mail is strongly encouraged.\nThe Company's shares are comprised of: (a) shares that are reflected in the component of the Company's\nshare register that is held in Belgium and which is managed by Euroclear Belgium (the \"Belgian Share\nRegister\" and, the shares reflected in the Belgian Share Register, the \"European Shares\"), and that cannot\nbe traded on Nasdaq until they have been repositioned into U.S. Shares (as defined below), and (b) shares\nthat are reflected directly or indirectly in the component of the Company's share register that is held in the\nUnited States and which is managed by Computershare (the \"U.S. Share Register\" and, the shares\nreflected in the U.S. Share Register, the \"U.S. Shares\"), and that can be traded on Nasdaq.\nHolders of dematerialised European Shares must attach to the present form a certificate issued by the\ncertified account holder or the central securities depositary for the shares concerned, confirming the\nnumber of dematerialised European Shares that have been registered in their name on the registration date\n(i.e., Monday, 17 June 2024, at midnight (12:00 a.m., Belgian time)) (the \"Registration Date\"), with\nwhich they want to participate to the extraordinary general shareholders' meeting.\nHolders of U.S. Shares reflected indirectly in the U.S. Share Register, through CEDE & Co., the nominee\nholder of the U.S. Shares held for the beneficial owners through the DTCC system, must attach to the\npresent form a certificate from a broker, financial institution or other intermediary confirming their\nownership of U.S. Shares on the Registration Date, with which they want to participate to the extraordinary\ngeneral shareholders' meeting.\nExtraordinary General Shareholders' Meeting of MDxHealth SA - Attendance form for security holders\nThe undersigned,\nFirst Name: …………………………………………………………………\nFamily Name: …………………………………………………………………\nAddress: …………………………………………………………………\nor\nCorporate name: …………………………………………………………………\nCorporate form: …………………………………………………………………\nRegistered office: …………………………………………………………………\n…………………………………………………………………\nRepresented by (first name, family name …………………………………………………………………\nand capacity): …………………………………………………………………\n…………………………………………………………………\n…………………………………………………………………\nowner of the following number of securities issued by MDxHealth SA, with registered office at CAP\nBusiness Center, Zone Industrielle des Hauts-Sarts, rue d'Abhooz 31, 4040 Herstal, Belgium:\n…………………………………….(1) registered European Shares\n…………………………….………(1) dematerialised European Shares\n……………………………………..(1) U.S. Shares reflected directly in the U.S.\nShare Register (not through DTCC)\n……………………………………..(1) U.S. Shares reflected indirectly in the U.S.\nShare Register (through DTCC)\n…………………………….…….…(1) subscription rights (2)\nNotes:\n(1) Number of relevant securities to be completed, when applicable.\n(2) Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of\nsubscription rights have the right to attend the shareholders' meeting, but only with an advisory\nvote.\nHereby notifies his/her/its intent to attend the extraordinary general shareholders' meeting of\nMDxhealth SA to be held on Thursday, 20 June 2024, at 3:00 p.m. (Belgian time) at the offices of the\nnotary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such other place\nindicated at that place at that time.\nThe undersigned agrees that the English translation of the present attendance form is a free translation and\nfor information purposes only, and that the French version shall prevail over the English translation.\nExtraordinary General Shareholders' Meeting of MDxHealth SA - Attendance form for security holders\nThe undersigned hereby confirms that the Company can send all confirmations and information required\nfor participation in the extraordinary general shareholders’ meeting to the following e-mail address of the\nundersigned:\n………………………………………………………………….\n(E-mail address of security holder)\nDone at ……………………………………., on ………………………………2024\nSignature……………………………\nExtraordinary General Shareholders' Meeting of MDxHealth SA - Attendance form for security holders"
        },
        {
          "title": "Proxy Form (ENG)",
          "url": "https://mdxhealth.com/wp-content/uploads/2024/06/Proxy-Form-FR-ENG.pdf",
          "content": "ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE DES EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING\nACTIONNAIRES 20 JUNE 2024\n20 JUIN 2024\nPROCURATION PROXY\nCette procuration doit être utilisée par les titulaires de titres de This proxy should be used by holders of securities of MDxHealth SA\nMDxHealth SA (la \"Société\") qui désirent être représentés par un (the \"Company\") who want to be represented by a proxy holder at the\nmandataire spécial à l'assemblée générale extraordinaire des actionnaires de extraordinary general shareholders' meeting of the Company to be held\nla Société à tenir le jeudi 20 juin 2024 à 15h00 (heure belge). Nonobstant ce on Thursday, 20 June 2024, at 3:00 p.m. (Belgian time).\nqui précède, les titulaires d'Actions Américaines (telles que définies ci- Notwithstanding the above, holders of U.S. Shares (as defined below)\ndessous) qui souhaitent désigner un mandataire sont vivement encouragés à who want to appoint a proxy are strongly encouraged to use the U.S.\nutiliser la carte de procuration américaine (U.S. proxy card) qui leur a été proxy card provided to them and according to the accompanying\nfournie et à suivre les instructions qui l'accompagnent. instructions.\nLes actions de la Société se composent : (a) d'actions inscrites dans la The Company's shares are comprised of: (a) shares that are reflected in\ncomposante du registre des actions de la Société qui est tenue en Belgique et the component of the Company's share register that is held in Belgium\nqui est maintenue par Euroclear Belgium (le \"Registre Belge des Actions\" and which is managed by Euroclear Belgium (the \"Belgian Share\net, les actions reflétées dans le Registre Belge des Actions, les \"Actions Register\" and, the shares reflected in the Belgian Share Register, the\nEuropéennes\"), et qui ne peuvent pas être négociées sur le Nasdaq tant \"European Shares\"), and that cannot be traded on Nasdaq until they\nqu'elles n'ont pas été repositionnées en Actions Américaines (telles que have been repositioned into U.S. Shares (as defined below), and (b)\ndéfinies ci-dessous), et (b) d'actions inscrites directement ou indirectement shares that are reflected directly or indirectly in the component of the\ndans la composante du registre des actions de la Société tenue aux États- Company's share register that is held in the United States and which is\nUnis et qui est maintenue par Computershare (le \"Registre Américain des managed by Computershare (the \"U.S. Share Register\" and, the shares\nActions\" et, les actions figurant dans le Registre Américain des Actions, les reflected in the U.S. Share Register, the \"U.S. Shares\"), and that can be\n\"Actions Américaines\"), et qui peuvent être négociées sur le Nasdaq. traded on Nasdaq.\nCette procuration ne constitue pas une sollicitation publique de procuration This proxy does not constitute a proxy solicitation in the sense of\nau sens des article 7:145 du Code des sociétés et des associations. article 7:145 of the Belgian Companies and Associations Code.\nLa procuration doit être signée de façon écrite ou électroniquement. The proxy must be signed in writing or electronically.\nLa procuration signée et complétée doit parvenir à la Société au plus tard le The signed and completed proxy must reach the Company at the latest\ndeuxième jour ouvrable qui précède l'assemblée générale extraordinaire des on the second business day prior to the extraordinary general\nactionnaires, soit le, ou avant le, mardi 18 juin 2024 shareholders' meeting, i.e. on or before Tuesday, 18 June 2024 (the\n(la \"Date limite de Notification\") au plus tard. Jusqu'à cette date, les \"Notification Deadline\") at the latest. Until the Notification Deadline,\nprocurations peuvent être envoyées à l'adresse suivante : proxies can be sent to the following address:\nMDxHealth SA\nMDxHealth SA\nAttention Mr. Ron Kalfus\nA l’attention de M. Ron Kalfus\nCompany Secretary\nSecrétaire de la Société\nCAP Business Center\nCAP Business Center\nZone Industrielle des Hauts-Sarts\nZone Industrielle des Hauts-Sarts\nRue d'Abhooz, 31\nRue d'Abhooz 31,\n4040 Herstal,\n4040 Herstal\nBelgium\nBelgique\nou par courrier électronique à : or by e-mail to:\nagsm@mdxhealth.com agsm@mdxhealth.com\nLes titulaires de titres de la Société qui désirent être représentés par Holders of securities of the Company who wish to be represented by\nprocuration doivent aussi s'enregistrer à l'assemblée générale extraordinaire proxy must also register for the extraordinary general shareholders'\ndes actionnaires, tel que décrit dans l'invitation à l'assemblée générale meeting, as described in the notice convening the extraordinary general\nextraordinaire des actionnaires. Les titulaires d'Actions Européennes shareholders' meeting. Holders of dematerialised European Shares must\ndématérialisés doivent joindre à ce formulaire un certificat délivré par le attach to the present form a certificate issued by the certified account\nteneur de compte agréé ou le dépositaire central de titres pour les actions holder or the central securities depositary for the shares concerned,\nconcernées, confirmant le nombre d'Actions Européennes dématérialisées confirming the number of dematerialised European Shares that have\nayant été enregistrés à leur nom à la date d'enregistrement (soit le lundi 17 been registered in their name on the registration date (i.e., Monday, 17\njuin 2024, à minuit (00h00, heure belge)) (la \"Date d'Enregistrement\") et June 2024, at midnight (12:00 a.m., Belgian time)) (the \"Registration\navec lesquelles ils veulent participer à l'assemblée générale extraordinaire Date\"), with which they want to participate to the extraordinary general\ndes actionnaires. Les titulaires d'Actions Américaines inscrites indirectement shareholders' meeting. Holders of U.S. Shares reflected indirectly in the\ndans le Registre Américain des Actions, par l'intermédiaire de CEDE & Co, U.S. Share Register, through CEDE & Co., the nominee holder of the\nle détenteur désigné des Actions Américaines détenues pour les bénéficiaires U.S. Shares held for the beneficial owners through the DTCC system,\neffectifs via le système DTCC, doivent joindre au présent formulaire un must attach to the present form a certificate from a broker, financial\ncertificat d'un courtier, d'une institution financière ou d'un autre institution or other intermediary confirming their ownership of U.S.\nintermédiaire confirmant leur propriété des Actions Américaines à la Date Shares on the Registration Date, with which they want to participate to\nd'Enregistrement, avec lesquelles ils souhaitent participer à l'assemblée the extraordinary general shareholders' meeting.\ngénérale extraordinaire des actionnaires.\nAssemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration\nExtraordinary General Shareholders' Meeting of MDxHealth SA - Proxy 1/11\nLa Société recommande d'utiliser le courrier électronique pour toute The Company recommends to use e-mail for all communication with\ncommunication avec la Société concernant l'assemblée générale des the Company regarding the general shareholders' meeting.\nactionnaires.\nLe/La soussigné(e), The undersigned,\nPrénom / First name: ……………………………………………………………………………………………………\nNom de famille / Family name: ……………………………………………………………………………………………………\nAdresse / Address: ……………………………………………………………………………………………………\nou / or\nDénomination / Corporate name: ……………………………………………………………………………………………………\nForme juridique / Corporate form: ……………………………………………………………………………………………………\nSiège / Registered office: ……………………………………………………………………………………………………\n……………………………………………………………………………………………………\nReprésenté par (prénom, nom de famille et ……………………………………………………………………………………………………\nqualité) / Represented by (first name, family ……………………………………………………………………………………………………\nname and capacity): ……………………………………………………………………………………………………\ntitulaire du (des) nombre(s) suivant(s) de titres émis par MDxHealth SA, owner of the following number of securities issued by MDxHealth SA,\nayant son siège au CAP Business Center, Zone Industrielle des Hauts-Sarts, with its registered office at CAP Business Center, Zone Industrielle des\nRue d'Abhooz 31, 4040 Herstal, Belgique, Hauts-Sarts, rue d'Abhooz 31, 4040 Herstal, Belgium,\nNombre d'Actions Européennes nominatives / Number of registered ……………….......\nEuropean Shares:\nNombre d'Actions Européennes dématérialisées / Number of ……………….......\ndematerialised European Shares:\nNombre d'Actions Américaines, inscrites directement dans le Registre ……………….......\nAméricain des Actions (pas par l'intermédiaire de DTCC) / Number of\nU.S. Shares reflected directly in the U.S. Share Register (not through\nDTCC):\nNombre d'Actions Américaines, inscrites indirectement dans le Registre ……………….......\nAméricain des Actions (par l'intermédiaire de DTCC) / Number of U.S.\nShares reflected indirectly in the U.S. Share Register (through DTCC):\nNombre de droits de souscription / Number of subscription rights:1 …………………..\nconstitue pour mandataire spécial, avec pouvoir de substitution: appoints as his/her/its proxy holder, with power of substitution:\n M./Mme / Mr./Ms. …………………………………………………………………………………………2\n Président du conseil d'administration / Chair of the board of directors3\n1 Conformément à l'article 7:135 du Code des sociétés et des associations, les 1 Pursuant to article 7:135 of the Belgian Companies and Associations Code, the\ntitulaires de droits de souscription ont le droit de participer à l'assemblée générale holders of subscription rights have the right to attend the shareholders' meeting,\ndes actionnaires mais seulement avec voix consultative. but only with an advisory vote.\n2 Veuillez compléter tel qu'approprié. Une absence d'instruction sera interprétée 2 Please complete as appropriate. An absence of instruction shall be tantamount\ncomme une nomination du président du conseil d'administration en tant que to an appointment of the chair of the board of directors as proxy holder.\nmandataire.\n3 Le président du conseil d'administration de la Société a le pouvoir de nommer un 3 The chair of the board of directors of the Company has the power to appoint\nautre administrateur, un employé ou remplaçant désigné de la Société comme another director, employee or substitute of the Company as a substitute\nsuppléant en vertu d'une sous-délégation si le président est empêché d'assister à pursuant to a sub delegation if the chair is hindered to attend the general\nl'assemblée générale des actionnaires. Le président ou son suppléant ne vote qu'en shareholders' meeting. The chair or his substitute may only vote in execution of\nexécution de la procuration, conformément aux instructions de vote spécifiques the proxy, in accordance with the specific voting instructions included in the\nfigurant dans la procuration. Voir également la note 2 ci-dessous. proxy. See also note 2 below.\nlequel accepte ainsi d'être nommé, et à qui le/la soussigné(e) donne les who agrees to be so appointed, and to whom the undersigned gives the\npouvoirs et instructions de vote spécifiques suivants:4 following powers and specific voting instructions:4\n4 Veuillez indiquer l'instruction de vote dans les cases appropriées pour les points à 4 Please indicate the voting instructions in the appropriate boxes of the agenda\nl'ordre du jour. En l'absence d'une instruction de vote pour un point de l'ordre du items. In the absence of voting instructions for any agenda item or in the event\njour, ou dans le cas où, pour quelque raison que ce soit, il y aurait un manque de that, for any reason whatsoever, any uncertainty would arise with regards to the\nclarté concernant les instructions de vote, le mandataire sera présumé avoir voté \"en voting instructions, the proxy holder will be presumed to have voted \"in favour\"\nAssemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration\nExtraordinary General Shareholders' Meeting of MDxHealth SA - Proxy 2/11\nfaveur\" des résolutions proposées soutenues par le conseil d'administration et cela of the proposed resolutions supported by the board of directors and that this will\nsera considéré comme une instruction de vote spécifique au sens de l'article 7:143 §4 be deemed to be a specific voting instruction in the sense of article 7:143 §4 2°\n2° du Code des sociétés et des associations. of the Belgian Companies and Associations Code.\nI. De représenter le/la soussigné(e) à l'assemblée générale extraordinaire des I. To represent the undersigned at the extraordinary general meeting of\nactionnaires à tenir le jeudi 20 juin 2024 à 15h00 (heure belge), dans les shareholders to be held on Thursday, 20 June 2024 at 3:00 p.m.\nbureaux de Maître Stijn Raes, notaire, à Kortrijksesteenweg 1147, 9051 (Belgian time), at the offices of the notary public Stijn Raes, at\nGand, Belgique, ou à tout autre endroit qui sera indiqué à cette occasion. Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such place as will\nbe indicated at that place at that time.\nORDRE DU JOUR AGENDA\nASSEMBLEE GENERALE EXTRAORDINAIRE EXTRAORDINARY GENERAL MEETING\n1. Communication des rapports - Plan d'Option sur Action de 2024 1. Submission of reports - 2024 Share Option Plan\nCommunication et discussion sur : Submission of and discussion on:\na) le rapport du conseil d'administration de la Société, préparé a) the report of the board of directors of the Company, prepared\nconformément aux articles 7:180 et 7:191 du Code des sociétés et in accordance with articles 7:180 and 7:191 of the Belgian\nassociations relatif à la proposition d'émettre 2.000.000 nouveaux Companies and Associations Code, in relation to the proposal\ndroits de souscription de la Société (les \"2024 Share Options\"), to issue 2,000,000 new subscription rights for shares of the\nen vertu d'un plan d'option sur action dénommé \"le Plan d'Option Company (the \"2024 Share Options\"), pursuant to a share\nsur Action de 2024\", et de supprimer, dans l'intérêt de la Société, option plan named \"the 2024 Share Option Plan\", and to\nle droit de préférence des actionnaires existants de la Société et, dis-apply, in the interest of the Company, the preferential\npour autant que de besoin, des détenteurs de droits de souscription subscription right of the existing shareholders of the\nen circulation (share options) de la Société, en faveur des membres Company and, insofar as required, of the holders of\ndu personnel de la Société et de ses filiales de temps à autre, au outstanding subscription rights (share options) of the\nsens de l'article 1:27 du Code des sociétés et des associations (les Company, for the benefit of the members of the personnel of\n\"Participants Sélectionnés\"); et the Company and its subsidiaries from time to time, within\nthe meaning of article 1:27 of the Belgian Companies and\nAssociations Code (the \"Selected Participant\"); and\nb) le rapport du commissaire de la Société, préparé conformément b) the report of the statutory auditor of the Company in\naux articles 7:180 et 7:191 du Code des sociétés et des accordance with articles 7:180 and 7:191 of the Belgian\nassociations, concernant la proposition d'émettre 2.000.000 2024 Companies and Associations Code in relation to the proposal\nShare Options et de supprimer, dans l'intérêt de la Société, le droit to issue 2,000,000 2024 Share Options, and to dis-apply, in\nde préférence des actionnaires existants de la Société et, pour the interest of the Company, the preferential subscription\nautant que de besoin, des détenteurs de droits de souscription en right of the existing shareholders of the Company and,\ncirculation (share options) de la Société, en faveur des Participant insofar as required, of the holders of outstanding subscription\nSélectionnés. rights (share options) or ADSs of the Company, to the benefit\nof the Selected Participants.\n2. Proposition d'émettre 2.000.000 2024 Share Options 2. Proposal to issue 2,000,000 2024 Share Options\n► Proposition de résolution : ►Proposed resolution:\nL'assemblée générale des actionnaires décide d'approuver l'émission de The general shareholders' meeting resolves to approve the issuance\n2.000.000 2024 Share Options, en vertu d'un plan d'option sur action of 2,000,000 2024 Share Options, pursuant to a share option plan\ndénommé \"le Plan d'Option sur Action de 2024\", et de supprimer, dans named the \"2024 Share Option Plan\", and to dis-apply, in the\nl'intérêt de la Société, le droit de préférence des actionnaires existants de interest of the Company, the preferential subscription right of the\nla Société et, pour autant que de besoin, des détenteurs de droits de existing shareholders of the Company and, insofar as required, of\nsouscription en circulation (share options) de la Société, en faveur des the holders of outstanding subscription rights (share options) of the\nParticipants Sélectionnés. En conséquence, le conseil d'administration Company, for the benefit of Selected Participant. In view thereof,\ndécide de ce qui suit : the general shareholders' meeting resolves as follows:\n(a) Termes et conditions des 2024 Share Options : Les termes et (a) Terms and conditions of the 2024 Share Options: The terms\nconditions des 2024 Share Options (inclus, mais sans s'y limiter, le and conditions of the 2024 Share Options (including, but not\nprix d'exercice des 2024 Share Options) seront tels que figurant limited to, the exercise price of the 2024 Share Options) shall\ndans l'annexe au rapport du conseil d'administration visé au point be as set out in the annex to the report of the board of\n1.(a) de l'ordre du jour (aux fins de la présente résolution, le directors referred to in item 1.(a) of the agenda (for the\n\"Plan\"), dont une copie restera jointe procès-verbal constatant la purpose of this resolution, the \"Plan\"), a copy of which shall\nprésente résolution. Les 2024 Share Options ont une durée de 10 remain attached to the minutes recording the present\nans à partir de leur date d'émission. resolution. The 2024 Share Options have a term of ten years\nas from their issue date.\n(b) Actions sous-jacentes : Chaque 2024 Share Option donne à son (b) Underlying shares: Each 2024 Share Option shall entitle the\ndétenteur le droit de souscrire à une nouvelle action qui sera émise holder thereof to subscribe for one new share to be issued by\npar la Société. Les nouvelles actions à émettre lors de l'exercice the Company. The new shares to be issued at the occasion of\ndes 2024 Share Options auront les mêmes droits et avantages, et the exercise of the 2024 Share Options shall have the same\nseront à tous égards pari passu, en ce compris en ce qui concerne rights and benefits as, and rank pari passu in all respects,\nAssemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration\nExtraordinary General Shareholders' Meeting of MDxHealth SA - Proxy 3/11\nles droits aux dividendes et autres distributions, avec les actions including as to entitlements to dividends and other\nexistantes et en circulation de la Société au moment de leur distributions, with the existing and outstanding shares of the\némission, et auront droit aux dividendes et autres distributions Company at the moment of their issuance, and will be\npour lesquelles la date d'enregistrement ou la date d'échéance entitled to dividends and other distributions in respect of\ntombe à, ou après la date d'émission des nouvelles actions. which the relevant record date or due date falls on or after the\ndate of issue of the new shares.\n(c) Suppression du droit de préférence en faveur des Participants (c) Dis-application of the preferential subscription right for the\nSélectionnés : L'assemblée générale des actionnaires décide, benefit of the Selected Participants: The general shareholders'\nconformément à l'article 7:191 du Code des sociétés et des meeting resolves, in accordance with article 7:191 of the\nassociations, de supprimer, dans l'intérêt de la Société, le droit de Belgian Companies and Associations Code, to dis-apply, in\npréférence des actionnaires existants de la Société et, pour autant the interest of the Company, the preferential subscription\nque de besoin, des détenteurs de droits de souscription en right of the existing shareholders of the Company and,\ncirculation (share options) de la Société, en faveur des Participants insofar as required, of the holders of outstanding subscription\nSélectionnés, et d'approuver la possibilité pour la Société rights (share options) of the Company, for the benefit of the\nd'octroyer les 2024 Share Options aux Participants Sélectionnés, Selected Participants, and to approve the possibility for the\ncomme expliqué plus en détail dans le rapport du conseil Company to grant the 2024 Share Options to the Selected\nd'administration visé au point 1.(a) de l'ordre du jour et dans les Participants, as further explained in the report of the board of\ntermes et conditions du Plan. directors referred to in item 1.(a) of the agenda and the terms\nand conditions of the Plan.\n(d) Confirmation de la souscription de 2024 Share Options par la (d) Confirmation of the subscription of 2024 Share Options by\nSociété : L'assemblée générale des actionnaires décide d'approuver the Company: The general shareholders' meeting resolves to\net de confirmer que la Société sera en mesure de souscrire aux approve and confirm that the Company will be able to\n2024 Share Options, en vue de créer un pool de 2024 Share subscribe for the 2024 Share Options, with a view to creating\nOptions disponible pour des octrois ultérieurs aux Participants a pool of outstanding 2024 Share Options available for\nSélectionnés. La Société ne peut cependant pas exercer les 2024 further grants to Selected Participants. The Company may\nShare Options pour son compte propre. not, however, exercise the 2024 Share Options for its own\naccount.\n(e) Augmentation de capital conditionnelle et émission de nouvelles (e) Conditional capital increase and issue of new shares: The\nactions : L'assemblée générale des actionnaires décide, sous general shareholders' meeting resolves, subject to, and to the\nréserve et dans la mesure de l'exercice des 2024 Share Options, extent of the exercise of the 2024 Share Options, to increase\nd'augmenter le capital de la Société et d'émettre le nombre the Company's share capital and to issue the relevant number\napproprié de nouvelles actions pouvant être émises lors de of new shares issuable upon the exercise of the 2024 Share\nl'exercice des 2024 Share Options. Sous réserve et conformément Options. Subject to, and in accordance with, the provisions of\naux dispositions du Plan, lors de l'exercice des 2024 Share Options the Plan, upon exercise of the 2024 Share Options and issue\net de l'émission de nouvelles actions, le montant total du prix of new shares, the aggregate amount of the exercise price of\nd'exercice des 2024 Share Options sera affecté (le cas échéant, the 2024 Share Options will be allocated to (as the case may\naprès conversion dans la devise du capital de la Société, sur la be, following conversion into the Company's share capital\nbase du taux de change USD/EUR publié par la Banque centrale currency, on the basis of the relevant USD/EUR exchange\neuropéenne, comme prévu à la section 5.2 du Plan) au capital de la ratio as shall be published by the European Central Bank, as\nSociété. Dans la mesure où le montant du prix d'exercice des 2024 provided for in section 5.2 of the Plan) the share capital of the\nShare Options, par action à émettre lors de l'exercice des 2024 Company. To the extent that the amount of the exercise price\nShare Options, excède le pair comptable des actions de la Société of the 2024 Share Options, per share to be issued upon\nexistantes alors immédiatement avant l'émission des nouvelles exercise of the 2024 Share Options, exceeds the fractional\nactions concernées, une partie du prix d'exercice, par action à value of the then existing shares of the Company existing\némettre lors de l'exercice des 2024 Share Options, égale à ce pair immediately prior to the issue of the new shares concerned, a\ncomptable sera comptabilisée en capital, le solde étant part of the exercise price, per share to be issued upon exercise\ncomptabilisé en prime d'émission. Suite à l'augmentation de of the 2024 Share Options, equal to such fractional value\ncapital et à l'émission de nouvelles actions, chaque action nouvelle shall be booked as share capital, whereby the balance shall be\net existante représentera la même fraction du capital de la Société. booked as issue premium. Following the capital increase and\nissuance of new shares, each new and existing share shall\nrepresent the same fraction of the share capital of the\nCompany.\n(f) Prime d'émission : Toute prime d'émission qui sera comptabilisée (f) Issue premium: Any issue premium that will be booked in\nen relation avec les 2024 Share Options sera comptabilisée sur un connection with the 2024 Share Options shall be accounted\ncompte indisponible au passif du bilan de la Société dans ses for on a non-distributable account on the liabilities side of the\ncapitaux propres, et le compte sur lequel la prime d'émission sera Company's balance sheet under its net equity, and the account\ncomptabilisée constituera, au même titre que le capital de la on which the issue premium will be booked shall, like the\nSociété, la garantie des tiers et, sauf possibilité de capitalisation de share capital, serve as a guarantee for third parties and can\nces réserves, ne pourra être réduit ou supprimé que par une only be reduced on the basis of a lawful resolution of the\ndécision de l'assemblée générale des actionnaires statuant dans les general shareholders' meeting passed in the manner required\nconditions requises pour la modification des statuts de la Société. for an amendments to the Company's articles of association.\n(g) Procurations : Le conseil d'administration est autorisé à mettre en (g) Powers of attorney: The board of directors is authorised to\nœuvre et à exécuter les résolution adoptées par l'assemblée implement and execute the resolutions passed by the general\ngénérale des actionnaires en rapport avec les 2024 Share Options, shareholders' meeting in connection with the 2024 Share\net à prendre toutes les mesures et à accomplir toutes les formalités Options, and to take all steps and carry out all formalities that\nAssemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration\nExtraordinary General Shareholders' Meeting of MDxHealth SA - Proxy 4/11\nrequises en vertu du Plan, des statuts de la Société et de la loi shall be required by virtue of the Plan, the Company's articles\napplicable afin d'émettre ou transférer les actions lors de l'exercice of association and applicable law in order to issue or transfer\ndes 2024 Share Options. En outre, chaque administrateur de la the shares upon exercise of the 2024 Share Options.\nSociété, Joe Sollee et Ron Kalfus, chacun agissant Furthermore, each of the Company's directors, Joe Sollee and\nindividuellement et avec possibilité de subdélégation et pouvoir de Ron Kalfus, each such person acting individually and with\nsubrogation, auront le pouvoir, lors de l'exercice des 2024 Share possibility of sub-delegation and the power of subrogation,\nOptions, (i) de procéder à la constatation (A) de l'augmentation de shall have the power, upon exercise of the 2024 Share\ncapital et de l'émission de nouvelles actions résultant de cet Options, (i) to proceed with the recording of (A) the capital\nexercice, (B) de l'allocation du capital et (le cas échéant) de la increase and issue of new shares resulting from such exercise,\nprime d'émission, et (C) de la modification des statuts de la (B) the allocation of the share capital and (as applicable) the\nSociété afin de refléter le nouveau capital et nombre d'actions en issue premium, and (C) the amendment of the Company's\ncirculation suite à l'exercice des 2024 Share Options, (ii) de signer articles of association in order to reflect the new share capital\net remettre, au nom de la Société, la documentation Euroclear, and number of outstanding shares following the exercise of\nComputershare, Nasdaq, bancaire et/ou autre pertinente, le registre the 2024 Share Options, (ii) to sign and deliver, on behalf of\ndes actions et tous les autres documents nécessaires en relation the Company, the relevant Euroclear, Computershare,\navec l'émission et la délivrance des actions aux Participant Nasdaq, bank and/or other documentation, the share register\nSélectionnés concernés et l'admission de ces actions à la cotation and all other necessary documents in connection with the\net à la négociation, et (iii) faire tout ce qui peut être nécessaire ou issuance and delivery of the shares to the Selected\nutile (y compris, mais sans s'y limiter, la préparation et l'exécution Participants concerned and the admission to listing and\nde tous les documents et formulaires) pour l'admission des actions trading of such shares, and (iii) to do whatever may be\némises lors de l'exercice des 2024 Share Options à la négociation necessary or useful (including but not limited to the\nsur Nasdaq (ou tout autre marché sur lequel les actions de la preparation and execution of all documents and forms) for the\nSociété seront négociées à ce moment). admission of the shares issued upon the exercise of the 2024\nShare Options to trading on Nasdaq (or such other markets on\nwhich the Company's shares will be trading at that time).\n► INSTRUCTION DE VOTE: ► VOTING INSTRUCTION:\n0 Pour / For 0 Contre / Against 0 Abstention\n3. Communication des rapports – Warrants d'Exact Sciences 3. Submission of reports – Exact Sciences Warrants\nCommunication et discussion sur : Submission of and discussion on:\n(a) le rapport du conseil d'administration de la Société, préparé (a) the report of the board of directors of the Company, prepared\nconformément aux articles 7:180, 7:191 et 7:193 du Code des in accordance with articles 7:180, 7:191 and 7:193 of the\nsociétés et associations, concernant la proposition d'émettre, en Belgian Companies and Associations Code, in relation to the\nfaveur de Genomic Health, Inc. (une filiale d'Exact Sciences proposal to issue, for the benefit of Genomic Health, Inc. (a\nCorporation dénommée ci-après \"Exact Sciences\") 1.000.000 de subsidiary of Exact Sciences Corporation referred to herein\nnouveaux droits de souscription pour actions de la Société as \"Exact Sciences\") 1,000,000 new subscription rights for\n(les \"Warrants d'Exact Sciences\"), et de supprimer, dans l'intérêt shares of the Company (the \"Exact Sciences Warrants\"),\nde la Société, le droit de préférence des actionnaires existants de la and to dis-apply, in the interest of the Company, the\nSociété et, pour autant que de besoin, des détenteurs de droits de preferential subscription right of the Company's existing\nsouscription en circulation (share options) de la Société, en faveur shareholders and, insofar as required, of the holders of\nd'Exact Sciences ; et subscription rights (share options) of the Company, for the\nbenefit of Exact Sciences; and\n(b) le rapport du commissaire de la Société, préparé conformément (b) the report of the Company's statutory auditor, prepared in\naux articles 7:180, 7:191 et 7:193 du Code des sociétés et des accordance with articles 7:180, 7:191 and 7:193 of the\nassociations, concernant la proposition d'émettre en faveur d'Exact Belgian Companies and Associations Code, in relation to the\nSciences 1.000.0000 de Warrants d'Exact Sciences, et de proposal to issue for the benefit of Exact Sciences 1,000,000\nsupprimer, dans l'intérêt de la Société, le droit de préférence des Exact Sciences Warrants, and to dis-apply, in the interest of\nactionnaires existants de la Société et, pour autant que de besoin, the Company, the preferential subscription right of the\ndes détenteurs de droits de souscription en circulation (share Company's existing shareholders and, insofar as required, of\noptions) de la Société, en faveur d'Exact Sciences. the holders of subscription rights (share options) of the\nCompany, for the benefit of Exact Sciences.\n4. Proposition d'émettre 1.000.000 de Warrants d'Exact Sciences 4. Proposal to issue 1,000,000 Exact Sciences Warrants\n► Proposition de résolution: ► Proposed resolution:\nL'assemblée générale des actionnaires décide d'approuver l'émission de The general shareholders' meeting resolves to approve the issuance\n1.000.000 de nouveaux droits de souscription pour actions de la Société, of 1,000,000 new subscription rights for shares of the Company,\ndénommé les \"Warrants d'Exact Sciences\", et de supprimer, dans called the \"Exact Sciences Warrants\", and to dis-apply, in the\nl'intérêt de la Société, le droit de préférence des actionnaires existants de interest of the Company, the preferential subscription right of the\nla Société et, pour autant que de besoin, des détenteurs de droits de Company's existing shareholders and, insofar as required, of the\nsouscription en circulation (share options) de la Société, en faveur des holders of outstanding subscription rights (share options) of the\nd'Exact Sciences. A cette fin, l'assemblée générale des actionnaires Company, for the benefit of Exact Sciences. To this end, the\ndécide de ce qui suit : general shareholders' meeting resolves as follows:\n(a) Termes et conditions des droits de souscription : Les termes et (a) Terms and conditions of the subscription rights: The terms\nconditions des Warrants d'Exact Sciences seront conformes à and conditions of the Exact Sciences Warrants will be in\nAssemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration\nExtraordinary General Shareholders' Meeting of MDxHealth SA - Proxy 5/11\nl'Annexe A du rapport du conseil d'administration visé au point accordance with Annex A of the report of the board of\n3.(a) de l'ordre du jour (aux fins de la présente résolution, le \"Les directors referred to in item 3.(a) of the agenda (for the\nTermes et Conditions des Warrants d'Exact Sciences\"), dont purposes of this resolution, the \"Exact Sciences Warrants\nune copie restera jointe au procès-verbal constatant la présente Terms and Conditions\"), a copy of which will remain\nrésolution. Les principaux termes et conditions des Warrants attached to the minutes recording the present resolution. The\nd'Exact Sciences peuvent, à titre d'information, être résumés main terms and conditions of the Exact Sciences Warrants\ncomme suit : can, for information purposes, be summarised as follows:\n(i) Droit de souscrire à une action ordinaire : Chaque Warrant (i) Right to subscribe for one ordinary share: Each Exact\nd'Exact Sciences permet à son détenteur de souscrire à une Sciences Warrant entitles the holder to subscribe for one\n(1) action ordinaire de la Société à émettre par la Société. (1) ordinary share of the Company to be issued by the\nCompany.\n(ii) Prix d'exercice : Le prix d'exercice des Warrants d'Exact (ii) Exercise price: The exercise price of the Exact Sciences\nSciences (c'est-à-dire le prix à payer en numéraire pour Warrants (i.e., the price to be paid in cash to subscribe\nsouscrire à une nouvelle action de la Société lorsqu'un for one new share in the Company when an Exact\nWarrant Exact Sciences est exercé) sera de USD 5,265. Le Sciences Warrant is exercised) will be USD 5.265. The\nprix d'exercice est sujet à d'éventuels ajustements habituels à exercise price is subject to potential customary\nla baisse en cas de certaines actions dilutives de la Société; downward adjustments in the case of certain dilutive\nactions of the Company.\n(iii) Durée : Les Warrants d'Exact Sciences auront une durée (iii) Term: The Exact Sciences Warrants will have a term\ncommençant à partir de leur émission et se terminant le 22 starting as from their issuance and ending on (and\naoût 2028 (inclus). including) August 22, 2028.\n(iv) Possibilité d'exercice : L'exercice des Warrants d'Exact (iv) Exercisability: The exercise of the Exact Sciences\nSciences sera soumis aux termes et conditions contenus dans Warrants will be subject to the terms and conditions\nles Termes et Conditions des Warrants d'Exact Sciences. Les contained in the Exact Sciences Warrants Terms and\nWarrants d'Exact Sciences peuvent être exercés à partir de Conditions. The Exact Sciences Warrants may be\nleur émission et jusqu'à la fin de leur durée, à condition qu'un exercised as from their issuance and until the end of\nnombre de Warrants d'Exact Sciences avec un prix d'exercice their term, provided that a number of Exact Sciences\nglobal d'au moins USD 250.000 soit exercé par leur Warrants with an aggregate exercise price of at least\ndétenteur. USD 250,000 are exercised by the holder thereof.\n(v) Cessibilité : A moins que la Société autorise explicitement la (v) Transferability: Except if the Company were to\ncession des Warrants d'Exact Sciences, les Warrants d'Exact explicitly allow a transfer of the Exact Sciences\nSciences ne peuvent pas être cédés par leur détenteur. En Warrants, the Exact Sciences Warrants cannot be\noutre, les Warrants d'Exact Sciences ne seront pas admis à la transferred by the holder. Furthermore, the Exact\ncotation ou à la négociation. Sciences Warrants will not be admitted to listing or\ntrading.\n(b) Actions sous-jacentes : Chaque Warrant d'Exact Sciences donnera (b) Underlying shares: Each Exact Sciences Warrant will entitle\nà son détenteur le droit de souscrire à une nouvelle action à its holder to subscribe for one new share to be issued by the\némettre par la Société. Les nouvelles actions à émettre lors de Company. The new shares to be issued upon exercise of the\nl'exercice des Warrants d'Exact Sciences auront les mêmes droits Exact Sciences Warrants shall have the same rights and\net avantages, et seront à tous égards pari passu, y compris en ce benefits as, and rank pari passu in all respects including as to\nqui concerne les droits aux dividendes et autres distributions, avec entitlement to dividends and other distributions, with the\nles actions existantes et en circulation de la Société au moment de existing and outstanding shares of the Company at the\nleur émission, et auront droit aux dividendes et autres distributions moment of their issuance and will be entitled to dividends\npour lesquelles la date d'enregistrement ou la date d'échéance and other distributions in respect of which the relevant record\ntombe à, ou après leur date d'émission. date or due date falls on or after the date of their issuance.\n(c) Suppression du droit de préférence en faveur d'Exact Sciences : (c) Dis-application of the preferential subscription right for the\nL'assemblée générale des actionnaires décide, conformément aux benefit of Exact Sciences: The general shareholders' meeting\narticles 7:191 et 7:193 du Code des sociétés et des associations, de resolves, in accordance with articles 7:191 and 7:193 of the\nsupprimer, dans l'intérêt de la Société, le droit de préférence des Belgian Companies and Associations Code, to dis-apply, in\nactionnaires existants de la Société et, pour autant que de besoin, the interest of the Company, the preferential subscription\ndes détenteurs actuels de droits de souscription (share options) de right of existing shareholders of the Company and, insofar as\nla Société, en faveur d'Exact Sciences, comme expliqué dans le required, of the holders of subscription rights (share options)\nrapport du conseil d'administration visé au point 3.(a) de l'ordre du of the Company, for the benefit of Exact Sciences, as\njour. explained in the report of the board of directors referred to in\nitem 3.(a) of the agenda.\n(d) Augmentation de capital conditionnelle et émission de nouvelles (d) Conditional capital increase and issue of new shares: The\nactions : L'assemblée générale des actionnaires décide, sous general shareholders' meeting resolves, subject to and in the\nréserve et dans la mesure de l'exercice des Warrants d'Exact case of the exercise of the Exact Sciences Warrants, to\nSciences, d'augmenter le capital de la Société et d'émettre le increase the share capital of the Company and to issue the\nnombre approprié de nouvelles actions pouvant être émises lors de appropriate number of new shares that may be issued upon\nl'exercice des Warrants d'Exact Sciences. Sous réserve et exercise of the Exact Sciences Warrants. Subject to, and in\nconformément aux dispositions des Termes et Conditions des accordance with, the respective provisions of the Exact\nAssemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration\nExtraordinary General Shareholders' Meeting of MDxHealth SA - Proxy 6/11\nWarrants d'Exact Sciences, lors de l'exercice des Warrants d'Exact Sciences Warrants Terms and Conditions, upon exercise of\nSciences et de l'émission de nouvelles actions, le prix d'exercice the Exact Sciences Warrants and the issuance of new shares,\nagrégé des Warrants d'Exact Sciences sera comptabilisé (le cas the aggregate amount of the exercise price of the Exact\néchéant, après conversion dans la devise du capital de la Société, Sciences Warrants will be allocated to (as the case may be,\nsur la base du taux de change USD/EUR publié par la Banque following conversion into the Company's share capital\ncentrale européenne, comme prévu à la section 5.4 des Termes et currency, on the basis of the relevant USD/EUR exchange\nConditions des Warrants d'Exact Sciences) en tant que capital de ratio as shall be published by the European Central Bank, as\nla Société. Dans la mesure où le montant du prix d'exercice des provided for in section 5.4 of the Exact Sciences Warrants\nWarrants d'Exact Sciences, par action à émettre lors de l'exercice Terms and Conditions) the share capital of the Company. To\ndes Warrants d'Exact Sciences, excède le pair comptable des the extent that the amount of the exercise price of the Exact\nactions de la Société existantes immédiatement avant l'émission Sciences Warrants, per share to be issued upon exercise of\ndes nouvelles actions concernées, une partie du prix d'exercice, the Exact Sciences Warrants, exceeds the fractional value of\npar action à émettre lors de l'exercice des Warrants d'Exact the then existing shares of the Company existing immediately\nSciences, égale à ce pair comptable sera comptabilisée en capital, prior to the issue of the new shares concerned, a part of the\nle solde étant comptabilisé en prime d'émission. Suite à exercise price, per share to be issued upon exercise of the\nl'augmentation de capital et à l'émission de nouvelles actions, Exact Sciences Warrants, equal to such fractional value shall\nchaque action nouvelle et existante représentera la même fraction be booked as share capital, whereby the balance shall be\ndu capital de la Société. booked as issue premium. Following the capital increase and\nissuance of new shares, each new and existing share shall\nrepresent the same fraction of the share capital of the\nCompany.\n(e) Prime d'émission : Toute prime d'émission qui sera comptabilisée (e) Issue premium: Any issue premium that will be booked in\nen rapport avec les Warrants d'Exact Sciences (sur exercice des connection with the Exact Sciences Warrants (whether upon\nWarrants d'Exact Sciences ou autrement) sera comptabilisée sur exercise of the Exact Sciences Warrants, or otherwise) will\nun compte indisponible au passif du bilan de la Société dans ses be accounted for on a non-distributable account on the\ncapitaux propres, et le compte sur lequel la prime d'émission sera liabilities side of the Company's balance sheet under its net\ncomptabilisée constituera, au même titre que le capital de la equity, and the account on which the issue premium will be\nSociété, la garantie des tiers et, sauf possibilité de capitalisation de booked shall, like the share capital, serve as a guarantee for\nces réserves, ne pourra être réduit ou supprimé que par une third parties and can only be reduced on the basis of a lawful\ndécision de l'assemblée générale des actionnaires statuant dans les resolution of the general shareholders' meeting passed in the\nconditions requises pour la modification des statuts de la Société. manner required for an amendments to the Company's\narticles of association.\n(f) Procurations : Le conseil d'administration est autorisé à mettre en (f) Powers of attorney: The board of directors is authorised to\nœuvre et à exécuter les résolutions adoptés par l'assemblée implement and execute the resolutions adopted by the general\ngénérale des actionnaires en rapport avec les Warrants d'Exact shareholders' meeting in connection with the Exact Sciences\nSciences, et à prendre toutes les mesures et à accomplir toutes les Warrants, and to take all measures and carry out all\nformalités qui seront requises en vertu des Termes et Conditions formalities that will be required pursuant to the Exact\ndes Warrants d'Exact Sciences, des statuts de la Société et des lois Sciences Warrants Terms and Conditions, the Company's\napplicables afin d'émettre ou transférer les actions lors de articles of association and all applicable laws in order to issue\nl'exercice des Warrants d'Exact Sciences. En outre, chaque or transfer the shares upon exercise of the Exact Sciences\nadministrateur de la Société, Joe Sollee et Ron Kalfus, chacun Warrants. In addition, each director of the Company, Joe\nagissant individuellement et avec possibilité de subdélégation et Sollee and Ron Kalfus, each such person acting individually\npouvoir de subrogation, auront le pouvoir, lors de l'exercice des and with the possibility of sub-delegation and power of\nWarrants d'Exact Sciences, (i) de procéder à la constatation (A) de subrogation, shall have the power, upon exercise of the Exact\nl'augmentation de capital et de l'émission de nouvelles actions Sciences Warrants, (i) to proceed with the recording of (A)\nrésultant de cet exercice, (B) de la comptabilisation en tant que the capital increase and the issue of new shares resulting from\ncapital et (le cas échéant) prime d'émission, et (C) de la such exercise, (B) the allocation as share capital and (if\nmodification des statuts de la Société afin de refléter le nouveau applicable) as issue premium, and (C) the amendment of the\ncapital et nombre d'actions en circulation suite à l'exercice des Company's articles of association to reflect the new share\nWarrants d'Exact Sciences, (ii) de signer et remettre, au nom de la capital and number of shares outstanding following the\nSociété, la documentation Euroclear, Computershare, Nasdaq, exercise of the Exact Sciences Warrants (ii) to sign and\nbancaire et/ou autre pertinente, le registre des actions et tous les deliver, on behalf of the Company, the relevant Euroclear,\nautres documents nécessaires en relation avec l'émission et la Computershare, Nasdaq and/or bank documentation, the\ndélivrance des actions au bénéficiaire et l'admission de ces actions share register and all other necessary documents in\nà la cotation et à la négociation, et (iii) faire tout ce qui peut être connection with the issuance and delivery of the shares to the\nnécessaire ou utile (y compris, mais sans s'y limiter, la préparation beneficiary and the admission to listing and trading of such\net l'exécution de tous les documents et formulaires) pour shares, and (iii) to do whatever may be necessary or useful\nl'admission des actions émises lors de l'exercice des Warrants (including, but not limited to, the preparation and execution\nd'Exact Sciences à la négociation sur le Nasdaq (ou tout autre of all documents and forms) for the admission of the shares\nmarché sur lequel les actions de la Société seront alors négociées à issued upon exercise of the Exact Sciences Warrants to\nce moment). trading on Nasdaq (or any other market on which the\nCompany's shares will then be traded).\n► INSTRUCTION DE VOTE: ► VOTING INSTRUCTION:\n0 Pour / For 0 Contre / Against 0 Abstention\n5. Communication des rapports – Warrants d'OrbiMed 5. Submission of reports – OrbiMed Warrants\nAssemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration\nExtraordinary General Shareholders' Meeting of MDxHealth SA - Proxy 7/11\nCommunication et discussion sur : Submission of and discussion on:\n(a) le rapport du conseil d'administration de la Société, préparé (a) the report of the board of directors of the Company, prepared\nconformément aux articles 7:180, 7:191 et 7:193 du Code des in accordance with articles 7:180, 7:191 and 7:193 of the\nsociétés et associations, concernant la proposition d'émettre, en Belgian Companies and Associations Code, in relation to the\nfaveur de OrbiMed Royalty & Credit Opportunities IV, LP et proposal to issue, for the benefit of OrbiMed Royalty &\nOrbiMed Royalty & Credit Opportunities IV Offshore, LP Credit Opportunities IV, LP and OrbiMed Royalty & Credit\n(ensemble dénommés ci-après \"OrbiMed\") 1.243.060 nouveaux Opportunities IV Offshore, LP (together referred to herein as\ndroits de souscription pour actions de la Société (de ces 1.243.060 \"OrbiMed\") 1,243,060 new subscription rights for shares of\nnouveaux droits de souscription pour actions, 881.906 nouveaux the Company (of those 1,243,060 new subscription rights for\ndroits de souscription pour actions à émettre en faveur d'OrbiMed shares, 881,906 new subscription rights for shares to be\nRoyalty & Credit Opportunities IV, LP et 361.154 nouveaux issued for the benefit of OrbiMed Royalty & Credit\ndroits de souscription pour actions à émettre en faveur d'OrbiMed Opportunities IV, LP and 361,154 new subscription rights for\nRoyalty & Credit Opportunities IV Offshore, LP), ayant une durée shares to be issued for the benefit of OrbiMed Royalty &\nde 5 ans à partir de leur date d'émission, (les \"Warrants Credit Opportunities IV Offshore, LP), with a term of 5 years\nd'OrbiMed\"), et de supprimer, dans l'intérêt de la Société, le droit as from their issue date (the \"OrbiMed Warrants\"), and to\nde préférence des actionnaires existants de la Société et, pour dis-apply, in the interest of the Company, the preferential\nautant que de besoin, des détenteurs de droits de souscription en subscription right of the Company's existing shareholders\ncirculation (share options) de la Société, en faveur d'OrbiMed ; et and, insofar as required, of the holders of subscription rights\n(share options) of the Company, for the benefit of OrbiMed;\nand\n(b) le rapport du commissaire de la Société, préparé conformément (b) the report of the Company's statutory auditor, prepared in\naux articles 7:180, 7:191 et 7:193 du Code des sociétés et des accordance with articles 7:180, 7:191 and 7:193 of the\nassociations, concernant la proposition d'émettre en faveur Belgian Companies and Associations Code, in relation to the\nd'OrbiMed 1.243.060 Warrants d'OrbiMed, et de supprimer, dans proposal to issue for the benefit of OrbiMed 1,243,060\nl'intérêt de la Société, le droit de préférence des actionnaires OrbiMed Warrants, and to dis-apply, in the interest of the\nexistants de la Société et, pour autant que de besoin, des détenteurs Company, the preferential subscription right of the\nde droits de souscription en circulation (share options) de la Company's existing shareholders and, insofar as required, of\nSociété, en faveur d'OrbiMed. the holders of subscription rights (share options) of the\nCompany, for the benefit of OrbiMed.\n6. Proposition d'émettre 1.243.060 Warrants d'OrbiMed 6. Proposal to issue 1,243,060 OrbiMed Warrants\n► Proposed resolution:\n► Proposition de résolution:\nL'assemblée générale des actionnaires décide d'approuver l'émission de The general shareholders' meeting resolves to approve the issuance\n1.243.060 nouveaux droits de souscription pour actions de la Société, of 1,243,060 new subscription rights for shares of the Company,\nayant une durée de 5 ans à partir de leur date d'émission, dénommés les with a term of 5 years as from their issue date, called the \"OrbiMed\n\"Warrants d'OrbiMed\", et de supprimer, dans l'intérêt de la Société, le Warrants\", and to dis-apply, in the interest of the Company, the\ndroit de préférence des actionnaires existants de la Société et, pour autant preferential subscription right of the Company's existing\nque de besoin, des détenteurs de droits de souscription en circulation shareholders and, insofar as required, of the holders of subscription\n(share options) de la Société, en faveur de chacun d'OrbiMed Royalty & rights (share options) of the Company, for the benefit of each of\nCredit Opportunities IV, LP et OrbiMed Royalty & Credit Opportunities OrbiMed Royalty & Credit Opportunities IV, LP and OrbiMed\nIV Offshore, LP. A cette fin, l'assemblée générale des actionnaires Royalty & Credit Opportunities IV Offshore, LP. To this end, the\ndécide de ce qui suit : general shareholders' meeting resolves as follows:\n(a) Termes et conditions des droits de souscription : Les termes et (a) Terms and conditions of the subscription rights: The terms\nconditions des Warrants d'OrbiMed seront conformes à l'annexe A and conditions of the OrbiMed Warrants will be in\ndu rapport du conseil d'administration visé au point 5.(a) de l'ordre accordance with Annex A of the report of the board of\ndu jour (aux fins de la présente résolution, le \"Les Termes et directors referred to in item 5.(a) of the agenda (for the\nConditions des Warrants d'OrbiMed\"), dont une copie restera purposes of this resolution, the \"OrbiMed Warrants Terms\njointe au procès-verbal constatant la présente résolution. Les and Conditions\"), a copy of which will remain attached to the\nprincipaux termes et conditions des Warrants d'OrbiMed peuvent, minutes recording the present resolution. The main terms and\nà titre d'information, être résumés comme suit : conditions of the OrbiMed Warrants can, for information\npurposes, be summarised as follows:\n(i) Droit de souscrire à une action ordinaire : Chaque Warrant (i) Right to subscribe for one ordinary share: Each\nd'OrbiMed permet à son détenteur de souscrire à une (1) OrbiMed Warrant entitles its holder to subscribe for one\naction ordinaire de la Société à émettre par la Société. (1) ordinary share of the Company to be issued by the\nCompany.\n(ii) Prix d'exercice : Le prix d'exercice des Warrants d'OrbiMed (ii) Exercise price: The exercise price of the OrbiMed\n(c'est-à-dire le prix à payer en numéraire pour souscrire à une Warrants (i.e., the price to be paid in cash to subscribe\nnouvelle action de la Société lorsqu'un Warrant d'OrbiMed for one new share in the Company when an OrbiMed\nest exercé) sera de USD 2,4134. Le prix d'exercice est sujet à Warrant is exercised) will be USD 2.4134. The exercise\nd'éventuels ajustements habituels à la baisse en cas de price is subject to potential customary downward\ncertaines actions dilutives de la Société. adjustments in the case of certain dilutive actions of the\nCompany.\nAssemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration\nExtraordinary General Shareholders' Meeting of MDxHealth SA - Proxy 8/11\n(iii) Prix de souscription : Le prix de souscription des 881.906 (iii) Subscription price: The subscription price for the\nWarrants d'OrbiMed à émettre en faveur d'OrbiMed Royalty 881,906 OrbiMed Warrants to be issued for the benefit\n& Credit Opportunities IV, LP sera de USD 1.744.485,56 et of OrbiMed Royalty & Credit Opportunities IV, LP will\nle prix de souscription des 361.154 Warrants d'OrbiMed à be USD 1,744,485.56, and the subscription price for the\némettre en faveur d'OrbiMed Royalty & Credit Opportunities 361,154 OrbiMed Warrants to be issued for the benefit\nIV Offshore, LP sera de USD 714.394,11. Le prix d'émission of OrbiMed Royalty & Credit Opportunities IV\ndoit être payé pour la souscription des Warrants d'OrbiMed Offshore, LP will be USD 714,394.11. The subscription\nrespectifs par OrbiMed Royalty & Credit Opportunities IV, price shall be booked as issue premium (in accordance\nLP et OrbiMed Royalty & Credit Opportunities IV Offshore, with what is stated in paragraph (d) below).\nLP, respectivement. Le prix de souscription sera comptabilisé\nen tant que prime d'émission (conformément ce qui est\nindiqué au paragraphe (d) ci-dessous).\n(iv) Durée : Les Warrants d'OrbiMed auront une durée de 5 ans à (iv) Term: The OrbiMed Warrants will have a term of 5\npartir de leur date d'émission. years as from their issue date.\n(v) Possibilité d'exercice : L'exercice des Warrants d'OrbiMed (v) Exercisability: The exercise of the OrbiMed Warrants\nsera soumis aux termes et conditions contenus dans les will be subject to the terms and conditions contained in\nTermes et Conditions des Warrants d'OrbiMed. Les Warrants the OrbiMed Warrants Terms and Conditions. The\nd'OrbiMed peuvent être exercés à partir de leur émission et OrbiMed Warrants may be exercised as from their\njusqu'à la fin de leur durée. issuance and until the end of their term.\n(vi) Cessibilité : Les Warrants OrbidMed et tous les droits qui en (vi) Transferability: The OrbiMed Warrants and all rights\ndécoulent sont cessibles, en tout ou en partie, par leur thereunder are transferable, in whole or in part, by the\ndétenteur concerné conformément aux Termes et Conditions relevant holder in accordance with the OrbiMed\ndes Warrants OrbidMed. Warrants Terms and Conditions.\n(b) Actions sous-jacentes : Chaque Warrant d'OrbiMed donnera à son (b) Underlying shares: Each OrbiMed Warrant will entitle its\ndétenteur le droit de souscrire à une nouvelle action à émettre par holder to subscribe for one new share to be issued by the\nla Société. Les nouvelles actions à émettre lors de l'exercice des Company. The new shares to be issued upon exercise of the\nWarrants d'OrbiMed auront les mêmes droits et avantages, et OrbiMed Warrants shall have the same rights and benefits as,\nseront à tous égards pari passu, y compris en ce qui concerne les and rank pari passu in all respects including as to entitlements\ndroits aux dividendes et autres distributions, avec les actions to dividends and other distributions, with the existing and\nexistantes et en circulation de la Société au moment de leur outstanding shares of the Company at the moment of their\némission, et auront droit aux dividendes et autres distributions issuance and will be entitled to dividends and other\npour lesquelles la date d'enregistrement ou la date d'échéance distributions in respect of which the relevant record date or\ntombe à, ou après leur date d'émission. due date falls on or after the date of their issuance.\n(c) Suppression du droit de préférence en faveur d'OrbiMed : (c) Dis-application of the preferential subscription right for the\nL'assemblée générale des actionnaires décide, conformément aux benefit of OrbiMed: The general shareholders' meeting\narticles 7:191 et 7:193 du Code des sociétés et des associations, de resolves, in accordance with articles 7:191 and 7:193 of the\nsupprimer, dans l'intérêt de la Société, le droit de préférence des Belgian Companies and Associations Code, to dis-apply, in\nactionnaires existants de la Société et, pour autant que de besoin, the interest of the Company, the preferential subscription\ndes détenteurs de droits de souscription (share options) de la right of the existing shareholders of the Company and,\nSociété, en faveur de chacun d'OrbiMed Royalty & Credit insofar as required, of the holders of subscription rights\nOpportunities IV, LP et OrbiMed Royalty & Credit Opportunities (share options) of the Company, for the benefit of each of\nIV Offshore, LP., comme expliqué dans le rapport du conseil OrbiMed Royalty & Credit Opportunities IV, LP and\nd'administration visé au point 5.(a) de l'ordre du jour. OrbiMed Royalty & Credit Opportunities IV Offshore, LP, as\nexplained in the report of the board of directors referred to in\nitem 5.(a) of the agenda.\n(d) Augmentation de capital conditionnelle et émission de nouvelles (d) Conditional capital increase and issue of new shares: The\nactions : L'assemblée générale des actionnaires décide, sous general shareholders' meeting resolves, subject to and in the\nréserve et dans la mesure de l'exercice des Warrants d'OrbiMed, case of the exercise of the OrbiMed Warrants, to increase the\nd'augmenter le capital de la Société et d'émettre le nombre share capital of the Company and to issue the appropriate\napproprié de nouvelles actions pouvant être émises lors de number of new shares that may be issued upon exercise of the\nl'exercice des Warrants d'OrbiMed. Sous réserve et conformément OrbiMed Warrants. Subject to, and in accordance with, the\naux dispositions des Termes et Conditions des Warrants respective provisions of the OrbiMed Warrants Terms and\nd'OrbiMed, lors de l'exercice des Warrants d'OrbiMed et de Conditions, upon exercise of the OrbiMed Warrants and the\nl'émission de nouvelles actions, le prix d'exercice agrégé des issuance of new shares, the aggregate amount of the exercise\nWarrants d'OrbiMed sera comptabilisé (le cas échéant, après price of the OrbiMed Warrants will be allocated to (as the\nconversion dans la devise du capital de la Société, sur la case may be, following conversion into the Company's share\nbase du taux de change USD/EUR publié par la Banque centrale capital currency, on the basis of the relevant USD/EUR\neuropéenne, comme prévu à la section 4(b) des Termes et exchange ratio as shall be published by the European Central\nConditions des Warrants d'OrbiMed) en tant que capital de la Bank, as provided for in in section 4(b) of the OrbiMed\nSociété. Dans la mesure où le montant du prix d'exercice des Warrants Terms and Conditions) the share capital of the\nWarrants d'OrbiMed, par action à émettre lors de l'exercice des Company. To the extent that the amount of the exercise price\nWarrants d'OrbiMed, excède le pair comptable des actions de la of the OrbiMed Warrants, per share to be issued upon\nSociété existantes immédiatement avant l'émission des nouvelles exercise of the OrbiMed Warrants, exceeds the fractional\nactions concernées, une partie du prix d'exercice, par action à value of the then existing shares of the Company existing\nAssemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration\nExtraordinary General Shareholders' Meeting of MDxHealth SA - Proxy 9/11\némettre lors de l'exercice des Warrants d'OrbiMed, égale à ce pair immediately prior to the issue of the new shares concerned, a\ncomptable sera comptabilisée en capital, le solde étant part of the exercise price, per share to be issued upon exercise\ncomptabilisé en prime d'émission. Suite à l'augmentation de of the OrbiMed Warrants, equal to such fractional value shall\ncapital et à l'émission de nouvelles actions, chaque action be booked as share capital, whereby the balance shall be\nnouvelle et existante représentera la même fraction du capital de la booked as issue premium. Following the capital increase and\nSociété. issuance of new shares, each new and existing share shall\nrepresent the same fraction of the share capital of the\nCompany.\n(e) Prime d'émission : Toute prime d'émission qui sera comptabilisée (e) Issue premium: Any issue premium that will be booked in\nen rapport avec les Warrants d'OrbiMed (sur exercice des connection with the OrbiMed Warrants (whether as\nWarrants d'OrbiMed ou autrement) sera comptabilisée sur un subscription price, upon exercise of the OrbiMed Warrants,\ncompte indisponible au passif du bilan de la Société dans ses or otherwise) will be accounted for on a non-distributable\ncapitaux propres, et le compte sur lequel la prime d'émission sera account on the liabilities side of the Company's balance sheet\ncomptabilisée constituera, au même titre que le capital de la under its net equity, and the account on which the issue\nSociété, la garantie des tiers et, sauf possibilité de capitalisation de premium will be booked shall, like the share capital, serve as\nces réserves, ne pourra être réduit ou supprimé que par une a guarantee for third parties and can only be reduced on the\ndécision de l'assemblée générale des actionnaires statuant dans les basis of a lawful resolution of the general shareholders'\nconditions requises pour la modification des statuts de la Société. meeting passed in the manner required for an amendments to\nthe Company's articles of association.\n(f) Procurations : Le conseil d'administration est autorisé à mettre en (f) Powers of attorney: The board of directors is authorised to\nœuvre et à exécuter les résolutions adoptées par l'assemblée implement and execute the resolutions adopted by the general\ngénérale des actionnaires en rapport avec les Warrants d'OrbiMed, shareholders' meeting in connection with the OrbiMed\net à prendre toutes les mesures et à accomplir toutes les formalités Warrants, and to take all measures and carry out all\nqui seront requises en vertu des Termes et Conditions des formalities that will be required pursuant to the OrbiMed\nWarrants d'OrbiMed, des statuts de la Société et des lois Warrants Terms and Conditions, the Company's articles of\napplicables afin d'émettre ou transférer les actions lors de association and all applicable laws in order to issue or\nl'exercice des Warrants d'OrbiMed. En outre, chaque transfer the shares upon exercise of the OrbiMed Warrants. In\nadministrateur de la Société, Joe Sollee et Ron Kalfus, chacun addition, each director of the Company, Joe Sollee and Ron\nagissant individuellement et avec possibilité de subdélégation et Kalfus, each such person acting individually and with the\npouvoir de subrogation, auront le pouvoir, lors de l'exercice des possibility of sub-delegation and power of subrogation, shall\nWarrants d'OrbiMed, (i) de procéder à la constatation (A) de have the power, upon exercise of the OrbiMed Warrants, (i)\nl'augmentation de capital et de l'émission de nouvelles actions to proceed with the recording of (A) the capital increase and\nrésultant de cet exercice, (B) de la comptabilisation en tant que the issue of new shares resulting from such exercise, (B) the\ncapital et (le cas échéant) prime d'émission, et (C) de la allocation as share capital and (if applicable) as issue\nmodification des statuts de la Société afin de refléter le nouveau premium, and (C) the amendment of the Company's articles\ncapital et nombre d'actions en circulation suite à l'exercice des of association to reflect the new share capital and number of\nWarrants d'OrbiMed, (ii) de signer et remettre, au nom de la shares outstanding following the exercise of the OrbiMed\nSociété, la documentation Euroclear, Computershare, Nasdaq, Warrants (ii) to sign and deliver, on behalf of the Company,\nbancaire et/ou autre pertinente, le registre des actions et tous les the relevant Euroclear, Computershare, Nasdaq and/or bank\nautres documents nécessaires en relation avec l'émission et la documentation, the share register and all other necessary\ndélivrance des actions au bénéficiaire et l'admission de ces actions documents in connection with the issuance and delivery of\nà la cotation et à la négociation, et (iii) faire tout ce qui peut être the shares to the beneficiary and the admission to listing and\nnécessaire ou utile (y compris, mais sans s'y limiter, la préparation trading of such shares, and (iii) to do whatever may be\net l'exécution de tous les documents et formulaires) pour necessary or useful (including, but not limited to, the\nl'admission des actions émises lors de l'exercice des Warrants preparation and execution of all documents and forms) for the\nd'OrbiMed à la négociation sur le Nasdaq (ou tout autre marché admission of the shares issued upon exercise of the OrbiMed\nsur lequel les actions de la Société seront alors négociées à ce Warrants to trading on Nasdaq (or any other market on which\nmoment). the Company's shares will then be traded).\n► INSTRUCTION DE VOTE: ► VOTING INSTRUCTION:\n0 Pour / For 0 Contre / Against 1 Abstention\nII. Si l'assemblée générale extraordinaire est ajournée ou suspendue, le II. In case the aforementioned extraordinary general shareholders'\nmandataire spécial aura les pouvoirs de représenter le soussigné à meeting would be postponed or suspended, the special proxy holder\nl'assemblée générale des actionnaires qui sera tenue avec le même ordre du shall have the power to represent the undersigned at the general\njour, le cas échéant: shareholders’ meeting that would be held having the same agenda, as\nrelevant:\n oui\n yes\n non  no\nVeuillez remplir la case appropriée. Une absence d'instruction ou si, pour quelque Please tick the appropriate box. In the absence of an instruction, or if, for\nraison, il y a une absence de clarté à propos de l'instruction donnée, le soussigné sera whatever reason, there is a lack of clarity with regard to the instruction given,\nsupposé avoir choisi \"oui\". Veuillez noter qu'aux fins de s'appliquer à telle assemblée the undersigned shall be deemed to have selected \"yes\". Please note that in order\nsubséquente, les titulaires de titres doivent s'enregistrer à nouveau pour cette to apply for such subsequent meeting, holders of securities must again register\nassemblée. for such meeting.\nSi, pendant l'assemblée, il y a des modifications à une proposition de In case of amendments during the meeting to a proposed resolution or a\nrésolution ou une nouvelle proposition de résolution:1 new proposed resolution:1\nAssemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration\nExtraordinary General Shareholders' Meeting of MDxHealth SA - Proxy 10/11\n le mandataire spécial votera contre la résolution modifiée ou  the proxy holder shall vote against the amended or new\nnouvelle resolution\n le mandataire spécial s'abstiendra de voter sur la résolution  the proxy holder shall abstain from the vote on the\nmodifiée ou nouvelle amended or new resolution\n le mandataire spécial votera sur la résolution modifiée ou  the proxy holder shall vote on the amended or new\nnouvelle selon la manière supportée ou recommandée par le resolution in the manner supported or recommended by the\nconseil d'administration de la Société board of directors of the Company\n1 Veuillez cocher tel qu'approprié. Une absence d'instruction sera interprétée comme 1 Please complete as appropriate. An absence of instruction shall be tantamount\nune instruction de voter pour la résolution modifiée ou nouvelle selon la manière to an instruction to vote for the amended or new resolution as will be supported\nsupportée ou recommandée par le conseil d'administration de la Société. or recommended by the board of directors of the Company.\nIII. Le mandataire spécial est autorisé, au nom et pour le compte du III. The special proxy holder has the power to, in the name of and on\nsoussigné, à signer toutes listes de présence et procès-verbaux, à participer à behalf of the undersigned, sign all attendance lists and minutes,\ntoutes les délibérations, à prendre part au vote sur toutes les décisions ou participate in all deliberations, vote with respect to all decisions or items\nsujets pouvant, conformément à cet ordre du jour, être soumis à l'assemblée. that can, pursuant to this agenda, be presented to said meeting.\nIV. Le mandataire spécial est autorisé, en général, à faire tout ce qui semble IV. In general, the special proxy holder has the power to do all that\nnécessaire et/ou utile pour exercer cette procuration. appears necessary and/or useful for the exercise of this proxy.\nLe/la soussigné(e) ratifie et approuve par la présente tous les actes accomplis The undersigned hereby ratifies and approves all acts carried out by the\npar le mandataire spécial susmentionné. Le mandataire spécial votera pour le aforementioned proxy holder. The special proxy holder will vote on\ncompte du/de la soussigné(s) conformément aux instructions spécifiques behalf of the undersigned in accordance with the specific instructions\ndonnées ci-dessus. given above.\nLa présente procuration vaut également notification conformément aux The present proxy shall also serve as notification in accordance with the\nformalités décrites dans l'invitation à l'assemblée générale extraordinaire des formalities described in the notice convening the extraordinary general\nactionnaires de la Société à tenir le jeudi 20 juin 2024, à condition qu'elle shareholders' meeting of the Company to be held on Thursday 20 June\nsoit dûment complétée par le soussigné et reçue par la Société au plus tard à 2024, provided it is duly completed by the undersigned and received by\nla Date limite de Notification. the Company at the latest on the Notification Deadline.\nLe soussigné confirme que la traduction anglaise de la présente procuration The undersigned confirms that the English translation of the present\nn'est qu'une traduction libre en anglais et à titre informatif uniquement, et proxy is a free English translation and for information purposes only,\nque la version française prévaut sur la version anglaise. and that the French version shall prevail over the English version.\nBON POUR PROCURATION GOOD FOR PROXY\n……………………………… 2024\n(date)\n……………………………………………………..\n(nom / name)\n……………………………………………………..\n(signature)\nAssemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration\nExtraordinary General Shareholders' Meeting of MDxHealth SA - Proxy 11/11"
        },
        {
          "title": "2024 Share Option Plan",
          "url": "https://mdxhealth.com/wp-content/uploads/2024/05/11EN-SO-Plan-2024-Plan-ENG.pdf",
          "content": "Free English translation - For information purposes only\nFree English translation\nThis English version of the 2024 Share Option Plan of MDxHealth SA is a free translation of the\noriginal French version. In case of discrepancies between the original French version and this English\nversion, the original French version shall prevail.\n2024 SHARE OPTION PLAN\nMDXHEALTH SA\nMDxHealth SA • Rue d'Abhooz 31 - CAP Business Center, 4040 Herstal, Belgium\nwww.mdxhealth.com • Tel (32) 4.257.70.21 • Fax (32) 4.259.78.75\nTVA BE 0479.292.440 RPM (Liège) • KBC Bank 736-0304341-19\n1\nFree English translation - For information purposes only\nARTICLE 1 – PURPOSE OF THE PLAN\nThis 2024 Share Option Plan (the \"Plan\") describes the general terms and conditions of the Share\nOptions that the Company may grant to the Selected Participants.\nThe aim of the Plan is to realise the following corporate and human resources goals:\n(i) encourage, motivate and retain the Selected Participants;\n(ii) enable the Company and its Subsidiaries to attract and retain Personnel with the required\nexperience and skills; and\n(iii) link the interests of the Selected Participants closer to the interests of the shareholders of the\nCompany by giving them the opportunity to share in the increase of the value of the\nCompany.\nARTICLE 2 – DEFINITIONS AND INTERPRETATION\nThe following terms shall have the following meaning for the purpose of the Plan:\nBelgian Companies and the Belgian Companies and Associations Code of 23 March 2019\nAssociations Code (as amended from time to time).\nBeneficiary With respect to a natural person, a person validly designated by\nthe Selected Participant, being either the Selected Participant's\nspouse, or the cohabiting partner, or legal heirs, in order to\nexercise the rights of the Selected Participant under the Plan after\nthe death of the Selected Participant. Designation, revocation and\nre-designation of a Beneficiary must be done in writing in\naccordance with the applicable law. In the absence of any valid\ndesignation, the heirs of the Selected Participant in accordance\nwith the applicable law of inheritance shall be deemed to be the\nBeneficiary. In the event that there are several heirs, all heirs\nacting jointly or one person designated by all heirs acting jointly\nshall be deemed to be the Beneficiary.\nBoard of Directors The board of directors of the Company.\nBusiness Day A day on which banks are open for business in Belgium and the\nUnited States of America, excluding Saturdays and Sundays.\nCompany MDxHealth SA, a company established under Belgian law,\nhaving its registered office at Rue d'Abhooz 31 - Cap Business\nCenter, 4040 Herstal, Belgium, registered with the register of\nlegal persons under number 0479.292.440.\nControl The possibility de facto or de jure to exercise a decisive influence\nover the appointment of the majority of the members of the Board\nof Directors or the general orientation of the Company's\ngovernance, as determined in articles 1:14 and following of the\nBelgian Companies and Associations Code.\n2\nFree English translation - For information purposes only\nDate of Grant The date on which the offer of the Share Options to a Selected\nParticipant is made.\nDate of Issuance The date on which the Share Options will be issued pursuant to a\nresolution of an extraordinary general shareholders' meeting held\non [] 2024.\nDate of Termination of the The effective date of termination of the Selected Participant's\nSelected Participant's Director's mandate, employment agreement, management\nDirector's mandate, agreement or similar agreement for whatever reason, with the\nemployment agreement, exception of a termination of a management agreement\nmanagement agreement or immediately followed by the signing of an employment\nsimilar agreement agreement, a new management agreement or a similar agreement\nwith the Company or a Subsidiary, a termination of an\nemployment agreement immediately followed by the signing of a\nnew employment agreement, management agreement or similar\nagreement with the Company or a Subsidiary, and the termination\nof a Director's mandate immediately followed by the re-\nappointment as Director.\nDirector A member of the board of directors of the Company or a\nSubsidiary.\nExercise Period The period during which the Selected Participant can exercise the\nShare Options granted to him/her, provided and to the extent that\nthe Share Options are exercisable in accordance with the\nconditions set forth in the Plan and in any other arrangement that\nmay exist between the Selected Participant and the Company.\nExercise Price The price, determined by the Board of Directors, or any other\ncommittee created or person appointed by the Board of Directors\nin accordance with article 4, at which each Share subject to a\nShare Option may be acquired/subscribed for upon the exercise of\nthat Share Option.\nNotification A written letter sent to the official domicile or registered office of\nthe addressee by means of (i) a courier with notice of receipt, (ii) a\nregistered letter or (iii) an e-mail sent to the addressee's e-mail\naddress. The date of the Notification is: (i) the date of signing for\nreceipt, or (ii), in the absence thereof, the postmarked date of the\nregistered letter, or (iii) the date of sending of the e-mail, provided\nthat the e-mail was sent to the correct e-mail address of the\naddressee.\nPersonnel An individual who is a member of the personnel of the Company or\na Subsidiary as defined under article 1:27 of the Belgian Companies\nand Associations Code.\nPlan The present 2024 Share Option Plan.\nSelected Participant(s) Any Personnel to whom Share Options will be granted pursuant\nto, or under, this Plan.\nShare A share of the Company, representing the share capital of the\n3\nFree English translation - For information purposes only\nCompany.\nShare Option A subscription right issued by the Company entitling the Selected\nParticipant to acquire/subscribe for one (1) Share pursuant to the\nPlan during a certain period at a certain price.\nShare Option Price The price, if any, which the Selected Participant owes to the\nCompany for the acquisition of the Share Option itself.\nSubsidiary Any company or organization which is directly or indirectly under\nthe Control of the Company.\nTransfer – Transferring Any transaction under living persons which has as its purpose the\nsale, acquisition, granting or accepting of options, exchange, waiver,\ncontribution to a company, transfer in any manner whether or not for\nconsideration, the giving of payment or pledge, or the acceptance of\npayment or pledge, or generally any agreement which has as its\nobject an immediate or future transfer of title.\nVested Share Options Share Options that have become definitely acquired by the\nSelected Participant in accordance with the conditions set forth in\nthe Plan, without prejudice to the possibility that the Share\nOptions become void in cases where they are not exercised or can\nno longer be exercised pursuant to Plan.\nExcept insofar as the context otherwise requires, (i) words denoting the singular shall include the\nplural and vice versa and (ii) words denoting the masculine gender shall include the feminine gender\nand vice versa.\nARTICLE 3 - TYPE AND NUMBER OF SHARE OPTIONS\nThe total number of Share Options issued under the Plan is of two million (2,000,000). All of such\nShare Options may be incentive stock options within the meaning of Section 422 of the U.S. Internal\nRevenue Code of 1986, as amended. Only Personnel who are employees subject to U.S. taxation as of\nthe applicable Date of Grant are eligible to receive such incentive stock options.\nEach Share Option shall entitle a Selected Participant to acquire one (1) Share.\nThe new Shares to be issued at the occasion of the exercise of the Share Options shall have the same\nrights and benefits as, and rank pari passu in all respects, including with respect to entitlements to\ndistributions and dividends, with the existing and outstanding Shares of the Company at the time of\ntheir issuance. They will be entitled to dividends and other distributions in respect of which the\nrelevant record date or due date falls on or after the date of issue of the new Shares.\nA new Share shall represent the same fraction of the capital of the Company as the other outstanding\nShares of the Company at that moment.\nARTICLE 4 - ADMINISTRATION\nThe Board of Directors shall administer the Plan. The Board of Directors shall have the possibility to\ndelegate its powers or certain of its powers to certain persons of the management and/or to certain\ncommittees that may be established by the Board of Directors, in compliance with the Belgian\n4\nFree English translation - For information purposes only\nCompanies and Associations Code and the Company's internal governance rules.\nSubject to the provisions of the Plan and in as far as the decisions are in line with the purpose of the\nPlan, the Board of Directors, or any other committee created or person appointed by the Board of\nDirectors, is entitled to determine, define and interpret all rules, regulations or other measures\nrequired or desirable for the administration of the Plan. The Board of Directors may terminate the\nPlan at any time. Share Options granted prior to such termination shall remain valid and exercisable in\naccordance with the Plan.\nARTICLE 5 - CONDITIONS OF THE SHARE OPTIONS\n5.1 Share Option Price\nExcept where the Board of Directors, or any other committee created or person appointed by the\nBoard of Directors in accordance with article 4, decides otherwise, on a one to one basis, the Selected\nParticipant shall owe no Share Option Price to the Company upon subscription for, or acceptance of,\nthe Share Options.\nShould a Share Option Price be due, it would be recorded as an issue premium. This issue premium\nwould be booked as a liability on the Company's balance sheet under its equity, and the account to\nwhich the issue premium would be booked would serve, in the same way as the share capital, as a\nguarantee for third parties, and may only be reduced on the basis of a valid resolution of the general\nshareholders' meeting passed in the manner required for an amendment to the Company's articles of\nassociation.\n5.2 Exercise Price\nThe Exercise Price of a Share Option shall be determined by the Board of Directors, or any other\ncommittee created or person appointed by the Board of Directors in accordance with article 4, on the\nDate of the Grant thereof. Unless determined otherwise by the Board of Directors, or any other\ncommittee created or person appointed by the Board of Directors in accordance with article 4, prior\nto, at, or after the Date of Grant, the Exercise Price shall not be lower than the lower of (i) the price of\nthe Shares on the stock market on which the Shares are listed and traded on the day prior to the Date\nof Grant (should the Shares or securities be listed on the Nasdaq, the Nasdaq must be used as market\nof reference), and (ii) the average price of the Shares on the relevant stock market on which the Shares\nare listed and traded during the period of 30 days preceding the Date of Grant of the relevant Share\nOption (should the Shares or securities be listed on the Nasdaq, the Nasdaq must be used as market of\nreference).\nUpon exercise of Share Options and issue of new shares, the aggregate amount of the Exercise Price\nof the Share Options will be allocated the share capital of the Company. To the extent that the amount\nof the Exercise Price of the Share Option, per Share to be issued upon exercise of the Share Option,\nwould exceed the fractional value of the then existing shares of the Company existing immediately\nprior to the issue of the new Shares concerned, a part of the Exercise Price, per Share to be issued\nupon exercise of the Share Option equal to such fractional value shall be booked as share capital,\nwhereby the balance shall be booked as issue premium. In accordance with article 7:178 of the\nBelgian Companies and Associations Code, following the capital increase and issuance of new\nShares, each new and existing Share shall represent the same fraction of the share capital of the\nCompany.\nUpon exercise of Share Options:\n• should the Company's share capital be expressed in euro currency and the aggregate amount\n5\nFree English translation - For information purposes only\nof the Exercise Price of such Share Options exercise be paid by the relevant Selected\nParticipant (or its Beneficiary, as the case may be) in US dollars, the amount equal to the\nrelevant aggregate Exercise Price for such Share Options exercise shall be converted into euro\non the basis of the relevant USD/EUR exchange ratio as shall be published by the European\nCentral Bank (\"ECB\") on\nhttps://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/\nhtml/index.en.html (or such other relevant website of the ECB) (the \"Exchange Rate\") on the\nsecond Business Day preceding the date of the relevant notarial deed in which the issuance of\nthe relevant new Shares and the corresponding capital increase are established, and whereby\nthe final amount in euro will be rounded down to the nearest two decimals; and\n• should the Company's share capital be expressed in US dollar currency and the aggregate\namount of the Exercise Price of such Share Options exercise be paid by the relevant Selected\nParticipant (or its Beneficiary, as the case may be) in euro, the amount equal to the relevant\naggregate Exercise Price for such Share Options exercise shall be converted into US dollar on\nthe basis of the relevant USD/EUR exchange ratio as shall be published by the ECB on\nhttps://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/\nhtml/index.en.html (or such other relevant website of the ECB) (the \"Exchange Rate\") on the\nsecond Business Day preceding the date of the relevant notarial deed in which the issuance of\nthe relevant new Shares and the corresponding capital increase are established, and whereby\nthe final amount in US dollar will be rounded down to the nearest two decimals.\n5.3 Term (duration) of the Share Options\nThe duration of a Share Option shall be ten (10) years as of their Date of Issuance. However, the\nBoard of Directors, or any other committee created or person appointed by the Board of Directors in\naccordance with article 4, shall have the right to shorten this term. Unless a shorter term is provided\nby the Board of Directors, or any other committee created or person appointed by the Board of\nDirectors in accordance with article 4, a Share Option is therefore (in any event) automatically null,\nvoid and of no value at 24:00 (midnight) CET on the tenth (10th) anniversary date of the Date of\nIssuance.\n5.4 Registered nature\nThe Share Options are and shall remain registered, and shall be entered in the register of subscription\nright holders that shall be held at the registered office of the Company. The Company shall deliver to\neach Selected Participant and Beneficiary, free of charge, a certificate confirming that the Participant\nor Beneficiary is duly registered in the register of subscription right holders as owner of the Share\nOptions.\n5.5 Rights as a shareholder\nThe Selected Participant (in the Selected Participant's capacity as holder of a Share Option) is not a\nshareholder of the Company, nor shall the Selected Participant have any rights or privileges, which as\na rule belong to a shareholder of the Company, as long as the Share Options held by the Selected\nParticipant have not been exercised.\nARTICLE 6 – TRANSFER OF THE SHARE OPTIONS\n6.1 Decease\nIn case the holder of a Share Option is a natural person, the following will apply: in the event of the\ndecease of a Selected Participant, all Share Options (including the Vested Share Options at the time of\n6\nFree English translation - For information purposes only\ndecease) shall be transferred to the Beneficiary of the Selected Participant and shall be (or remain as\nfar as the Vested Share Options are concerned) exercisable at the time and under the terms established\nin this Plan.\n6.2 Transferability of the Share Options\nExcept for the transfer contemplated under article 6.1 above and except if the Board of Directors, or\nany other committee created or person appointed by the Board of Directors in accordance with article\n4, were to allow a Transfer of the Share Options, the Share Options cannot be Transferred by a\nSelected Participant once they have been granted to a Selected Participant.\nARTICLE 7 - EXERCISE OF THE SHARE OPTIONS\nShare Options can only be exercised during an Exercise Period (as specified in article 7.2 below)\nprovided and to the extent that they have become Vested Share Options and have become exercisable\n(in accordance with article 7.1 below) prior to or during a certain Exercise Period.\n7.1 Vesting and exercisability of the Share Options\nThe vesting schedule of a Share Option, i.e. the dates and conditions upon which it shall become a\nVested Share Option, shall be as set forth in this Plan, except where, for Share Options granted to\nSelected Participants in any capacity other than the capacity of non-executive director of the\nCompany, the Board of Directors, or any other committee created or person appointed by the Board of\nDirectors in accordance with article 4, determines otherwise and, for Share Options granted to\nSelected Participants in their capacity of non-executive director of the Company, the general\nshareholders' meeting determines otherwise. The vesting schedule and the period before a Share\nOption can become exercisable can therefore be shorter than the periods as referred to below in this\narticle 7.1.\n7.1.1 General vesting mechanism of the Share Options\nUnless otherwise determined by the Board of Directors, or any other committee created or person\nappointed by the Board of Directors in accordance with article 4, the Share Options subscribed for by\na Selected Participant in any capacity other than the capacity of non-executive director of the\nCompany shall vest, i.e. become Vested Share Options, in installments of twenty-five percent (25%)\nper year during a period of four (4) years as of the Date of Grant, as follows:\n• on the first anniversary date of the Date of Grant: 25%;\n• during the second year from the Date of Grant: maximum 25%, i.e. maximum 50% in total\nover the first two years after the Date of Grant;\n• during the third year from the Date of Grant: maximum 25%, i.e. maximum 75% in total over\nthe first three years after the Date of Grant;\n• as from the fourth year from the Date of Grant: 25%, i.e. maximum 100% in total over the\nfirst four years after the Date of Grant.\nDuring the second, the third, and the fourth years after the Date of Grant, the Share Options\nsubscribed for by a Selected Participant in any capacity other than the capacity of non-executive\ndirector of the Company shall vest pro rata temporis on a quarterly basis, i.e. for a number that bears\nthe same proportion to the maximum number of Share Options that can vest during that period as the\nnumber of (full) quarters that have passed during said given period bears to the total number of\n7\nFree English translation - For information purposes only\nquarters of that period. For example, one year and seven months after the Date of Grant, a maximum\nof 37.5% of the Share Options granted to a Selected Participant could be Vested Share Options.\nThe Share Options granted to a non-executive director of the Company shall all vest, i.e. become\nVested Share Options, on the date of the ordinary shareholders' meeting that takes place in the\ncalendar year following the calendar year where the Share Options were granted, provided that on the\ndate preceding the date of the former ordinary shareholders' meeting the mandate of such non-\nexecutive director of the Company has not terminated (without prejudice to section 7.1.3 of the Plan).\nNotwithstanding the foregoing, all Share Options subscribed for by a Selected Participant shall\nautomatically vest (if not yet vested) and become Vested Share Options in the event of a change of\nControl over the Company. A change of Control shall be deemed to have occurred if (i) any “person”\nor “group” (within the meaning of Rule 13d-5 of the U.S. Securities Exchange Act of 1934, as\namended), shall own, directly or indirectly, beneficially or of record, determined on a fully diluted\nbasis, more than 35% of the securities or interests of any class or kind ordinarily having the power to\nvote for the election of Directors of the Company, (ii) a majority of the mandates (other than vacant\nmandates) on the Board of Directors of the Company shall be taken by persons whose nomination as\nDirector (A) was not proposed to the general shareholders’ meeting of the Company by (a majority\nof) the Board of Directors of the Company, or (B) was not supported or approved by (a majority of)\nthe Board of Directors of the Company, or (iii) any person acquires (or has acquired during the twelve\n(12) month period ending on the date of the most recent acquisition by such person) assets from the\nCompany that have a total gross fair market value equal to or more than fifty percent (50%) of the\ntotal gross fair market value of all of the assets of the Company immediately prior to such acquisition\nor acquisitions; provided, however, that the following will not constitute a change in the ownership of\na substantial portion of the Company’s assets: (A) a transfer of assets to an entity that is directly or\nindirectly controlled by the Company’s shareholders immediately after the transfer, or (B) a transfer\nof assets by the Company to: (1) a shareholder of the Company (immediately before the asset transfer)\nin exchange for or with respect to the Company’s shares, (2) an entity, fifty percent (50%) or more of\nthe total value or voting power of which is owned, directly or indirectly, by the Company, or (3) a\nperson that owns, directly or indirectly, fifty percent (50%) or more of the total value or voting power\nof all the outstanding shares of the Company. For purposes of the foregoing, gross fair market value\nmeans the value of the assets of the Company, or the value of the assets being disposed of, determined\nwithout regard to any liabilities associated with such assets.\n7.1.2 Exercisability of the Share Options\nThe Selected Participants are allowed to exercise any Vested Share Options during any Exercise\nPeriod as of and from the moment where such Share Options became Vested Share Options. The rules\nset forth in section 7.1.3. below however prevail over the rules set forth in this section 7.1.2.\n7.1.3 Consequences of termination of a Director's mandate, employment agreement,\nmanagement agreement or similar agreement\nWithout prejudice to the provisions of the following paragraphs and unless otherwise determined by\nthe Board of Directors, or any other committee created or person appointed by the Board of Directors\nin accordance with article 4, when (i) the Director's mandate of a Selected Participant is terminated for\nother reasons than for breach of his/her duties as a Director, (ii) the employment agreement of a\nSelected Participant is terminated for other reason than for serious cause, or (iii) management or\nsimilar agreement of the Selected Participant is terminated for other reasons than breach of said\nagreement, in each such case the Selected Participant may exercise all his/her Share Options that have\nbecome Vested Share Options at the Date of Termination of the Selected Participant's Director's\nmandate, employment agreement, management agreement or similar agreement, as relevant, at the\ntime and in accordance with the conditions set forth in the Plan, within a period of one year as from\nthe Date of Termination of the Director's mandate, employment agreement, management agreement or\n8\nFree English translation - For information purposes only\nsimilar agreement.\nUnless otherwise determined by the Board of Directors, or any other committee created or person\nappointed by the Board of Directors in accordance with article 4, the Vested Share Options that are\nnot exercised within the period referred to in the previous paragraph shall automatically lapse and\nbecome null and void. The Share Options that have not become Vested Share Options at the Date of\nTermination of the Selected Participant's Director's mandate, employment agreement, management\nagreement or similar agreement, as relevant, automatically lapse and become null and void.\nUpon termination of (i) the Director's mandate of the Selected Participant for breach of his/her duties\nas a Director, (ii) the employment agreement of the Selected Participant for serious cause, or (iii)\nmanagement or similar agreement of the Selected Participant for breach of said agreement, all Share\nOptions granted to the Selected Participant shall, unless determined otherwise by the Board of\nDirectors, or any other committee created or person appointed by the Board of Directors in\naccordance with article 4, whether vested or not, automatically become definitely non-exercisable as\nfrom the Date of Termination of the Selected Participant's Director's mandate, employment\nagreement, management agreement or similar agreement, as relevant.\n7.1.4 Consequences of legal retirement, disability or serious disease\nIn case the holder of a Share Option is a natural person, the following will apply: in the event of\ntermination of the Director's mandate, employment agreement, management agreement or similar\nagreement of the Selected Participant, as relevant, as a consequence of legal retirement, disability or\nserious disease, the (at that time) Vested Share Options shall remain exercisable for the remaining\nterm of the Share Options pursuant to the terms and conditions set forth in the Plan.\n7.2 Exercise Period\nVested Share Options can only be exercised during the following periods: during the term of the\nShare Options, between 1 March and 31 March, and between 1 September and 30 September. Each\nExercise Period shall close on the last Business Day of the particular Exercise Period.\nThe Board of Directors, or any other committee created or person appointed by the Board of Directors\nin accordance with article 4, may, however, in its absolute discretion, provide for additional Exercise\nPeriods and do so for instance in case of a change of Control over the Company (e.g. in case all Share\nOptions automatically vest in accordance with 7.1.1 in fine above).\n7.3 Partial exercise\nA Selected Participant may exercise all or part of his/her Vested Share Options. However, it is not\npossible to exercise a Share Option with respect to fractions of Shares.\n7.4 Exercise procedure\nA Share Option shall be deemed to have been exercised upon receipt by the Company, at the latest on\nthe last Business Day of the Exercise Period, of:\n(i) a Notification signed by the Selected Participant and stating that a Share Option or a specified\nnumber of Share Options is exercised;\n(ii) evidence of complete payment of the Exercise Price, within thirty (30) calendar days\nfollowing the last Business Day of the Exercise Period in which the Share Options were\nexercised, for the number of Shares as indicated in the Notification provided sub (i), by bank\ntransfer to a blocked account of the Company whose number is communicated by the\nCompany;\n9\nFree English translation - For information purposes only\n(iii) in the event that a Share Option is exercised by a person or persons other than the Selected\nParticipant, suitable proof of the right of this person or these persons to exercise the Share\nOption; and\n(iv) Any and all statements and documents, which the Board of Directors, or any other committee\ncreated or person appointed by the Board of Directors in accordance with article 4, deems\ndesirable or necessary in order to comply with all applicable legal and regulatory provisions,\nand the submission of which the Board of Directors, or any other committee created or person\nappointed by the Board of Directors in accordance with article 4, consequently requests.\n7.5 Conditions for the issuance of Shares\n7.5.1 The Company shall only be obliged to issue the Shares as a result of the exercise of the Share\nOptions, by registration in the Company's share register or any other manner prescribed by the\nBelgian Companies and Associations Code, after all of the preceding conditions set forth in\narticle 7.4 have been fulfilled and following the completion of the capital increase mentioned\nbelow.\n7.5.2 The Board of Directors, or one member thereof or any other person specifically delegated for\nsuch purpose, shall, in accordance with article 7:187 of the Belgian Companies and\nAssociations Code (or any other provision having the same purport), have the capital increase\nresulting from the exercise of the Share Options, and the fully paid in Shares thus subscribed\nfor, recorded before a notary public within sixty (60) days after the closing of the Exercise\nPeriod in which the Share Options were exercised.\n7.5.3 If, at the time of exercise of the Share Options, the Shares are admitted to listing and/or\ntrading on the Nasdaq, another stock market or another trading platform, the Company shall\nuse reasonable efforts in order to take such actions and make such filings as shall be\nnecessary to have the Shares that are issued upon exercise of the relevant Share Options\nadmitted to listing and/or trading on the Nasdaq, such other stock market or such other trading\nplatform under the timeline as shall be decided by the Board of Directors.\n7.5.4. The Company may at its discretion postpone the delivery of the Shares, if this is necessary in\norder to comply with the applicable regulations or provisions of whatever nature, including\nbut not limited to public offer, registration and other obligations with respect to the Shares of\nthe Company, as the Company deems appropriate.\nARTICLE 8 – CHANGE IN THE CAPITAL STRUCTURE OF THE COMPANY –\nEXERCISE OF THE SHARE OPTIONS BY VIRTUE OF LAW\n8.1 Change in the capital structure of the Company\nContrary to article 7:71 of the Belgian Companies and Associations Code, the Company explicitly\nreserves the right to take all possible decisions and to enter into all possible transactions that may have\nan impact on its capital, on the distribution of profits or on the distribution of liquidation proceeds or\nthat may otherwise affect the rights of the Selected Participants.\nShould the rights of the Selected Participant be affected by such decision or transaction, then the\nSelected Participant shall not be entitled to a change of the Exercise Price, a change of the exercise\nconditions or any other form of (financial or other) compensation, unless such a decision or\ntransaction would have as its main purpose to prejudice the rights of the holders of the Share Options.\n10\nFree English translation - For information purposes only\nIn case of a merger, de-merger or share split of the Company, the rights attached to the outstanding\nShare Options and/or Exercise Price of the Share Options, shall be adapted in accordance with the\nconversion ratios applied at the occasion of the merger, de-merger or share split to the other\nshareholders.\n8.2 Exercise of the Share Options by virtue of law\nIf a Share Option which is not exercisable or which cannot be exercised pursuant to the issuance\nconditions (as determined in this Plan) becomes prematurely exercisable on the basis of article 7:71 of\nthe Belgian Companies and Associations Code and is also exercised pursuant to said article, the\nShares obtained by exercising the Share Option shall not be transferable, unless explicitly agreed upon\nby the Board of Directors, or any other committee created or person appointed by the Board of\nDirectors in accordance with article 4, until the time the underlying Share Options would have\nbecome exercisable in accordance with the Plan.\nARTICLE 9 – MISCELLANEOUS\n9.1 Taxes and social security\nThe Company or a Subsidiary shall be entitled, in accordance with the applicable law or practice, to\nwithhold from any cash payment made to a Selected Participant, and/or the Selected Participant shall\nbe obliged to pay to the Company or to a Subsidiary (if requested for by the Company or a\nSubsidiary), the amount of any tax and/or social security contributions, if any, attributable to or\npayable in connection with the grant, vesting or exercise of any Share Options or attributable to or\npayable in connection with the delivery of the Shares.\nThe Company or a Subsidiary shall also be entitled, in accordance with the applicable law or practice,\nto make the necessary reporting, required as a result of the grant of Share Options, their vesting, their\nexercisability or the delivery of the Shares.\n9.2 Costs\nStamp duties and other similar duties or taxes levied upon exercise of the Share Options and/or the\ndelivery of the new Shares shall be borne by the Selected Participant.\nCosts related to the capital increase that shall take place upon the exercise of the Share Options shall\nbe borne by the Company.\n9.3 Applicable law and competent courts\nBelgian law governs the Plan. Disputes shall fall under the exclusive jurisdiction of the courts and\ntribunal of the jurisdiction where the Company has its registered office.\nShare Options subscribed for in the framework of this Plan shall be governed by and construed in\naccordance with the laws of Belgium.\n9.4 Notifications\nEach Notification to a Selected Participant shall be made to the address mentioned in the register of\nsubscription rights holders or the relevant notice details as set out in the agreement between the\nCompany and the Selected Participant pursuant to which the Share Options were granted. Each\nNotification to the Company, a Subsidiary or the Board of Directors, or any other committee created\nor person appointed by the Board of Directors in accordance with article 4, shall be validly made to\n11\nFree English translation - For information purposes only\nthe address of the registered office of the Company. Address changes must be communicated in\naccordance with this provision.\n9.5 Relation to Selected Participant's agreement\nNotwithstanding any provision of the plan, the rights and obligations of a Selected Participant as\ndetermined under the terms of the Selected Participant's employment agreement or management\nagreement or similar agreement with the Company or any Subsidiary shall not be affected by the\nSelected Participant's participation in the Plan or by any right that the Selected Participant may have\nto participate therein. A Selected Participant who subscribes for Share Options pursuant to the Plan\nshall have no rights to compensation or damages in consequence of the termination of the Selected\nParticipant's employment agreement, or management agreement or similar agreement with the\nCompany or a Subsidiary for any reason whatsoever, insofar as those rights arise or may arise from\nthe termination of the rights which the Selected Participant would have or of the claims which the\nSelected Participant could make relating to the exercise of the Share Options under the Plan as a result\nof the termination of such Selected Participant's employment agreement, or management agreement or\nsimilar agreement, or from the loss or reduction in value of the rights or advantages.\n12"
        },
        {
          "title": "Insider Trading Policy (June 2023)",
          "url": "https://mdxhealth.com/wp-content/uploads/2024/01/MDXH-Insider-Trading-Policy-FINAL-2023-12-15.pdf",
          "content": "Insider Trading Policy\nDecember 15, 2023\nMDxHealth S.A. (the “Company”) has adopted this Insider Trading Policy (as it may be in effect from time to time,\nthis “Policy”) to promote compliance with federal and international securities laws by directors, officers, employees\nand consultants of the Company and its affiliates, as well as any immediate family members sharing the household\nof any of the foregoing, and any entities controlled by any of the foregoing persons, including corporations,\npartnerships or trusts (collectively, “Company Personnel”). This Policy also is designed to protect an important\ncorporate asset: the Company’s reputation for integrity and ethical conduct. This Policy governs transactions in\nsecurities of the Company or any other issuer where conflicts of interest could arise. As a result of applicable\nsecurities laws and this Policy, Company Personnel may, from time to time, have to forego or delay a desired\nsecurities transaction, and may suffer economic loss or forego anticipated profit as a result.\nPOLICY\nNo Company Personnel may trade in the Company’s securities unless certain that he or she does not possess\nmaterial inside information. No Company Personnel may disclose, or “tip,” such information to others who might\nuse it for trading, might pass it along to others who might trade, or might use it for any other improper purpose.\nSimilarly, Company Personnel may not purchase or sell, offer to purchase or sell, or otherwise trade in securities\nof any other company unless they are certain that they do not possess any material inside information about that\ncompany which they obtained in the course of their employment or consulting relationship with the Company,\nsuch as information about a major contract or merger being negotiated. No Company Personnel may “tip” such\ninformation to others who might use it for trading or might pass it along to others who might trade, or otherwise\npotentially use it for any improper purpose.\nCovered Persons (as defined below) must “pre-clear” all trading in Company securities in accordance with the\nprocedures set forth below in the section entitled “Pre-Clearance of Securities Transactions.”\nInside information relating to the Company is the property of the Company, and the unauthorized disclosure of\nsuch information is prohibited.\nThe Company’s General Counsel (or his/her designee) shall have the authority to administer and interpret this\nPolicy.\nAll Company Personnel will be required to undergo periodic training regarding this Policy, and to certify that they\nhave read, understand, and will abide by the terms of this Policy as it may be in effect from time to time.\nDEFINITIONS\n“Covered Persons” include (1) all members of the Company’s Board of Directors, (2) all personnel at the level of\nVice President or above, (3) all executive officers, (4) any other Company Personnel as determined from time to\ntime by the General Counsel and notified in writing (including via email), and (5) any immediate family members\nsharing the household of any of the foregoing.\n“non-public information” or “inside information”, means information that has not yet become publicly available or\ndisseminated to the public. The test of whether information is non-public is fact-based and depends on the specific\ncircumstances involved. For example, the fact that information has been disclosed to a few members of the public\ndoes not make it public for insider trading purposes. Release of information to the media does not immediately\nfree Company Personnel to trade. To be “public” the information must have been disseminated in a manner\ndesigned to reach investors generally. Further, information that has been released may not mean that the\ninformation is “non-public.” Company Personnel should refrain from trading until the market has had an\nopportunity to absorb and evaluate the information. If the information has been widely disseminated, it is usually\nsufficient to wait at least 24 hours after publication before trading. If you are not sure whether information is\nconsidered public, you should either consult with the General Counsel or assume that the information is non-\npublic and treat it as confidential.\n“securities” include any type of stock, share, limited partnership interest, or bond, debt or other fixed income\ninstrument issued by a business, organization or government agency or instrumentality. It also includes buying,\nselling or writing an option or some other instrument that derives its value from another security, such as put and\ncall options and convertible debentures or preferred stock, as well as debt securities such as bonds and notes.\n“trading” includes buying or selling or any other transaction involving publicly-traded securities (such as “shorting”\na stock). It does not include purchasing stock under an employee option or making a gift that does not satisfy a\nlegal obligation. It does not include previously created 10b5-1 plans, for example, as discussed below.\n“material information” is any information relating to a company, its business operations or securities, the public\ndissemination of which would be likely to affect the market price of any of its securities, or which would be likely\nto be considered important by a reasonable investor in determining whether to buy, sell or hold such securities.\nWhile it is not possible to list all types of information which might be considered material under particular\ncircumstances, information concerning the following subjects are particularly likely to be found material:\n• earnings;\n• unexpected financial results;\n• major new discoveries or advances in research;\n• acquisitions, including mergers and tender offers;\n• sales of substantial assets;\n• financings or restructurings;\n• an extraordinary item for accounting purposes, including:\no changes in debt ratings;\no significant write-downs of assets;\no additions to reserves for bad debts or contingent liabilities;\no liquidity problems;\n• extraordinary management developments;\n• dividends;\n• public or private offerings of securities;\n• major price or marketing changes for products;\n• labor negotiations;\n• threatened or actual significant litigation or investigations by government authorities, cybersecurity\nattacks, breaches or similar events;\n• awards or losses of significant contracts; and\n• receipt or denial of licenses or regulatory approvals of products or rates.\nThe information may be positive or negative. Material information is not limited to historical facts but may also\ninclude projections and forecasts. The public, the media, and the courts may use hindsight in judging what is\nmaterial. When in doubt about whether particular inside information is material, you should presume it is material\nand consult with the General Counsel.\nADDITIONAL PROHIBITIONS AND GUIDANCE\nShort Sales and Derivatives.\nShort sales of the Company’s securities (a sale of securities which are not then owned), including a “sale against\nthe box” (a sale with delayed delivery) are prohibited.\n2\nM dxh ver 202312\nNo Company Personnel may ever engage in transactions in publicly traded options, such as puts, calls and other\nderivative securities, relating to the Company. This prohibition also extends to various forms of hedging\ntransactions or monetization transactions, such as zero-cost collars and forward sale contracts, as they involve\nthe establishment of a short position in the Company’s securities. This prohibition does not prevent employees\nfrom exercising company-issued options, subject to the other restrictions of this Policy.\nStanding Orders\nStanding orders (except standing orders under approved Rule 10b5-1 plans, see below) should be used only for\na brief period of time. The problem with purchases or sales resulting from standing instructions to a broker is that\nthere is no control over the timing of the transaction. The broker could execute a transaction when you are in\npossession of material inside information.\nMargin Accounts and Pledges\nSecurities held in a margin account may be sold by the broker without the customer’s consent if the customer fails\nto meet a margin call. Similarly, securities pledged as collateral for a loan may be sold in foreclosure if the borrower\ndefaults on the loan or, in many instances, if the value of the collateral declines. Because a margin sale or\nforeclosure sale may occur at a time when the pledgor is aware of material inside information regarding the\nCompany, Company Personnel are prohibited from holding securities of the Company in a margin account or\npledging such securities as collateral for a loan. An exception to this prohibition may be permitted in certain limited\ncircumstances with the advance written approval of the Company’s General Counsel (or his/her designee).\n10b5-1 Plans\nRule 10b5-1 provides a defense from insider trading liability under SEC Rule 10b-5. To be eligible for this defense,\nCompany Personnel may enter into a “10b5-1 plan” for trading in the Company’s stock. If the plan meets the\nrequirements of Rule 10b5-1, the Company’s stock may be purchased or sold without regard to certain insider\ntrading restrictions.\nTo comply with this Policy, a 10b5-1 plan must be approved by the General Counsel (or his/her designee) and\nmeet the requirements of Rule 10b5-1.\nIn general, a 10b5-1 plan must be entered into at a time when there is no undisclosed material information. Once\nthe plan is adopted, Company Personnel must not exercise any influence over the amount of securities to be\ntraded, the price at which they are to be traded or the date of the trade. The plan must either specify the amount,\npricing and timing of transactions in advance or delegate discretion on these matters to an independent third party.\nInternet and Social Media\nBecause of the potential for abuse of the prohibition on “tipping,” Company Personnel are prohibited from posting\nany information on Internet chat rooms, social media or other types of public forums where the Company or the\nCompany’s securities are a topic.\nBLACKOUT POLICY\nAs part of this Policy, the Company has adopted a blackout policy that prohibits trading in the Company’s securities\nby officers, directors and certain employees and/or consultants, beginning on the day that is seven (7) calendar\ndays prior to the last day of each fiscal quarter and ending 48 hours after earnings for such quarter are publicly\nreleased.\nWho is covered by this blackout policy?\n• All Company Personnel.\n3\nM dxh ver 202312\nWhat transactions are prohibited during a blackout period?\n• Open market purchase or sale of the Company’s securities;\n• Purchase or sale of the Company’s securities through a broker; and\n• Exercise of stock options where all or a portion of the acquired stock is sold during the blackout\nperiod.\nWhat transactions are allowed during a blackout period?\n• Exercise of stock options where no Company stock is sold in the market to fund the option exercise;\n• Gifts of Company stock;\n• Transfers of Company stock to or from a trust; and\n• Transactions pursuant to Rule 10b5-1 plans approved by the General Counsel (or his/her designee)\nin accordance with this Policy.\nIn addition to the standard end-of-quarter blackout periods, the Company may, from time to time, impose other\nblackout periods upon notice to those persons who are affected. The scope of persons affected may be broader\nthan, or different from, the persons described above.\nAs an aid to implementation of this Policy, during blackout periods the Company may utilize available procedures\nto restrict prohibited actions on any equity award administration website made available to employees.\nPRE-CLEARANCE OF SECURITIES TRANSACTIONS\nAll Covered Persons are obligated to pre-clear transactions in the Company’s securities. These transactions\ninclude all transactions noted above as being prohibited during a blackout period. Pre-clearance is not required\nfor the trading of securities under an approved 10b5-1 plan.\nWho authorizes the pre-clearance?\n• The General Counsel (or his/her designee); or\n• The Chief Financial Officer, in the event the General Counsel is seeking pre-clearance.\nHow does a Covered Person request pre-clearance?\n• The General Counsel (or his/her designee) will implement and maintain processes for requesting\npre-clearance\n• A Covered Person requesting pre-clearance may be required to certify that he or she is not in\npossession of material nonpublic information\nPre-clearance authorization generally is good for up to five (5) days, unless you come into contact with material\ninside information during that time or if the authorization is designated for a shorter period. If the transaction does\nnot occur during such authorization period, pre-clearance of the transaction must be re-requested. The pre-\nclearance authorization decision, whether approved or denied, shall be final and shall be kept confidential by the\nrequestor.\nPOST-TERMINATION TRANSACTIONS\nApplicable securities laws continue to apply to transactions in Company securities even after service with the\nCompany has ended. Company Personnel in possession of material non-public information at the time of their\ntermination, may not purchase or sell Company securities until that information has become public or is no longer\nmaterial.\n4\nM dxh ver 202312\nSECTION 16 REPORTS\nSome officers and all of the Company’s directors may be obligated to file Section 16 reports when they engage in\ntransactions in the Company’s securities. Although the General Counsel’s office may assist reporting persons in\npreparing and filing the required reports, the reporting persons retain responsibility for the reports.\nWho may be obligated to file Section 16 reports?\n• the Company’s directors; and\n• the Company’s officers designated as “executive officers” for SEC reporting purposes by the Board\nof Directors.\nFORM 144 REPORTS\nThe Company’s directors and certain officers designated by the Board of Directors are required to file Form 144\nbefore making an open market sale of the Company’s securities. Form 144 notifies the SEC of your intent to sell\nthe Company’s securities. This form is generally prepared and filed by your broker and is in addition to the Section\n16 reports that may be filed on your behalf by the Company.\nINDIVIDUAL RESPONSIBILITY\nEach individual is responsible for making sure that he or she complies with this Policy, and that any family member,\nhousehold member or entity whose transactions are subject to this Policy also complies with this Policy. In all\ncases, the responsibility for determining whether an individual is in possession of material inside information rests\nwith that individual, and any action on the part of the Company, the General Counsel (or his/her designee) or any\nother Company employee or service provider pursuant to this Policy (or otherwise) does not in any way constitute\nlegal advice or insulate an individual from liability under applicable securities laws. Trading in the Company’s\nsecurities during the trading window should not be considered a “safe harbor,” and all Company Personnel should\nuse good judgment at all times.\nPENALTIES FOR NON-COMPLIANCE\nPenalties under the SEC for violations of insider trading laws, which prohibit trading on material inside information,\napply to both the individuals involved in such unlawful conduct and their employers and supervisors, and include:\n(1) imprisonment, (2) criminal fines, (3) civil penalties, (4) prejudgment interest, and (5) private party damages. In\naddition, violation of this Policy could result in termination or other disciplinary action. Given the severity of the\npotential penalties, compliance with this Policy is absolutely mandatory. If you have questions regarding any of\nthe provisions of this Policy, please contact the General Counsel.\nCERTIFICATION\nFrom time to time, all Company Personnel will be required to certify that they have received and read a copy of\nthis Policy and to certify compliance with it. In the event that an individual fails to make such a certification, the\nCompany, in its discretion, may request information or documentation, including records relating to securities\ntrading, or take such other action as it may deem appropriate to assure compliance with this Policy.\n5\nM dxh ver 202312\nMDxHealth S.A.\nAcknowledgement Regarding Insider Trading Policy\nThe undersigned director, officer, employee, contractor or consultant of MDxHealth S.A. (“Mdxhealth”)\nor its affiliate hereby acknowledges that the undersigned:\n1. Has received and reviewed a copy of Mdxhealth’s Insider Trading Policy (the “Policy”), and\nunderstands the Policy and the responsibilities of the undersigned thereunder; and\n2. Will comply at all times with the Policy, as it may be in effect from time to time, in connection\nwith (i) all trading in Mdxhealth securities by the undersigned, or in which the undersigned\nparticipates or provides assistance (whether or not for the account of the undersigned) and (ii)\nthe confidentiality of inside information.\nDate:\nSignature\nTyped or Printed Name"
        },
        {
          "title": "Convening Notice (FR)",
          "url": "https://mdxhealth.com/wp-content/uploads/2024/06/Invitation-FR.pdf",
          "content": "MDxHealth SA\nSociété anonyme\nCAP Business Center\nZone Industrielle des Hauts-Sarts\nRue d'Abhooz 31\n4040 Herstal, Belgique\nTVA BE 0479.292.440 (RPM Liège, division Liège)\nINVITATION\nASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE\nà tenir le jeudi 20 Juin 2024 à 15h00\nLe quorum pour la délibération et le vote sur les points à l'ordre du jour de l'assemblée générale\nextraordinaire de MDxHealth SA (la \"Société\") tenue le 30 mai 2024 n'ayant pas été atteint, les\ndétenteurs de titres de la Société sont invités à assister à une deuxième assemblée générale\nextraordinaire des actionnaires de la Société devant le notaire.\nINFORMATION GÉNÉRALE\nDate, heure et lieu : L'assemblée générale extraordinaire des actionnaires se tiendra le jeudi 20\njuin 2024 à 15 heures dans les bureaux de Maître Stijn Raes, notaire, à Kortrijksesteenweg 1147, 9051\nGand, Belgique, ou à tout autre endroit indiqué à cette occasion.\nOuverture des portes : Afin de faciliter la tenue de la liste de présence le jour de l'assemblée générale\nextraordinaire, les détenteurs de titres et leurs représentants sont invités à s'inscrire à partir de 14h15.\nASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE\nOrdre du jour et propositions de résolution : L'ordre du jour et les propositions de résolution de\nl'assemblée générale extraordinaire des actionnaires de la Société qui, le cas échéant, peuvent être\nmodifiés lors de l'assemblée au nom du conseil d'administration, sont les suivants :\n1. Communication des rapports – Plan d'Option sur Action de 2024\nCommunication et discussion sur :\n(a) le rapport du conseil d'administration de la Société, préparé conformément aux\narticles 7:180 et 7:191 du Code des sociétés et associations relatif à la proposition\nd'émettre 2.000.000 nouveaux droits de souscription de la Société (les \"2024 Share\nOptions\"), en vertu d'un plan d'option sur action dénommé \"le Plan d'Option sur\nAction de 2024\", et de supprimer, dans l'intérêt de la Société, le droit de préférence\ndes actionnaires existants de la Société et, pour autant que de besoin, des détenteurs\nde droits de souscription en circulation (share options) de la Société, en faveur des\nmembres du personnel de la Société et de ses filiales de temps à autre, au sens de\nl'article 1:27 du Code des sociétés et des associations (les \"Participants\nSélectionnés\"); et\n(b) le rapport du commissaire de la Société, préparé conformément aux articles 7:180 et\n7:191 du Code des sociétés et des associations, concernant la proposition d'émettre\n2.000.000 2024 Share Options et de supprimer, dans l'intérêt de la Société, le droit de\npréférence des actionnaires existants de la Société et, pour autant que de besoin, des\ndétenteurs de droits de souscription en circulation (share options) de la Société, en\nfaveur des Participant Sélectionnés.\n2. Proposition d'émettre 2.000.000 2024 Share Options\nProposition de résolution : L'assemblée générale des actionnaires décide d'approuver\nl'émission de 2.000.000 2024 Share Options, en vertu d'un plan d'option sur action dénommé\n\"le Plan d'Option sur Action de 2024\", et de supprimer, dans l'intérêt de la Société, le droit de\n1/12\npréférence des actionnaires existants de la Société et, pour autant que de besoin, des détenteurs\nde droits de souscription en circulation (share options) de la Société, en faveur des Participants\nSélectionnés. En conséquence, le conseil d'administration décide de ce qui suit:\n(a) Termes et conditions des 2024 Share Options : Les termes et conditions des 2024\nShare Options (inclus, mais sans s'y limiter, le prix d'exercice des 2024 Share\nOptions) seront tels que figurant dans l'annexe au rapport du conseil d'administration\nvisé au point 1.(a) de l'ordre du jour (aux fins de la présente résolution, le \"Plan\"),\ndont une copie restera jointe procès-verbal constatant la présente résolution. Les 2024\nShare Options ont une durée de 10 ans à partir de leur date d'émission.\n(b) Actions sous-jacentes : Chaque 2024 Share Option donne à son détenteur le droit de\nsouscrire à une nouvelle action qui sera émise par la Société. Les nouvelles actions à\némettre lors de l'exercice des 2024 Share Options auront les mêmes droits et\navantages, et seront à tous égards pari passu, en ce compris en ce qui concerne les\ndroits aux dividendes et autres distributions, avec les actions existantes et en\ncirculation de la Société au moment de leur émission, et auront droit aux dividendes\net autres distributions pour lesquelles la date d'enregistrement ou la date d'échéance\ntombe à, ou après la date d'émission des nouvelles actions.\n(c) Suppression du droit de préférence en faveur des Participants Sélectionnés :\nL'assemblée générale des actionnaires décide, conformément à l'article 7:191 du\nCode des sociétés et des associations, de supprimer, dans l'intérêt de la Société, le\ndroit de préférence des actionnaires existants de la Société et, pour autant que de\nbesoin, des détenteurs de droits de souscription en circulation (share options) de la\nSociété, en faveur des Participants Sélectionnés, et d'approuver la possibilité pour la\nSociété d'octroyer les 2024 Share Options aux Participants Sélectionnés, comme\nexpliqué plus en détail dans le rapport du conseil d'administration visé au point 1.(a)\nde l'ordre du jour et dans les termes et conditions du Plan.\n(d) Confirmation de la souscription de 2024 Share Options par la Société : L'assemblée\ngénérale des actionnaires décide d'approuver et de confirmer que la Société sera en\nmesure de souscrire aux 2024 Share Options, en vue de créer un pool de 2024 Share\nOptions disponible pour des octrois ultérieurs aux Participants Sélectionnés. La\nSociété ne peut cependant pas exercer les 2024 Share Options pour son compte\npropre.\n(e) Augmentation de capital conditionnelle et émission de nouvelles actions :\nL'assemblée générale des actionnaires décide, sous réserve et dans la mesure de\nl'exercice des 2024 Share Options, d'augmenter le capital de la Société et d'émettre le\nnombre approprié de nouvelles actions pouvant être émises lors de l'exercice des\n2024 Share Options. Sous réserve et conformément aux dispositions du Plan, lors de\nl'exercice des 2024 Share Options et de l'émission de nouvelles actions, le montant\ntotal du prix d'exercice des 2024 Share Options sera affecté (le cas échéant, après\nconversion dans la devise du capital de la Société, sur la base du taux de change\nUSD/EUR publié par la Banque centrale européenne, comme prévu à la section 5.2\ndu Plan) au capital de la Société. Dans la mesure où le montant du prix d'exercice des\n2024 Share Options, par action à émettre lors de l'exercice des 2024 Share Options,\nexcède le pair comptable des actions de la Société existantes alors immédiatement\navant l'émission des nouvelles actions concernées, une partie du prix d'exercice, par\naction à émettre lors de l'exercice des 2024 Share Options, égale à ce pair comptable\nsera comptabilisée en capital, le solde étant comptabilisé en prime d'émission. Suite à\nl'augmentation de capital et à l'émission de nouvelles actions, chaque action nouvelle\net existante représentera la même fraction du capital de la Société.\n(f) Prime d'émission : Toute prime d'émission qui sera comptabilisée en relation avec les\n2024 Share Options sera comptabilisée sur un compte indisponible au passif du bilan\nde la Société dans ses capitaux propres, et le compte sur lequel la prime d'émission\nsera comptabilisée constituera, au même titre que le capital de la Société, la garantie\ndes tiers et, sauf possibilité de capitalisation de ces réserves, ne pourra être réduit ou\nsupprimé que par une décision de l'assemblée générale des actionnaires statuant dans\nles conditions requises pour la modification des statuts de la Société.\n2/12\n(g) Procurations : Le conseil d'administration est autorisé à mettre en œuvre et à exécuter\nles résolution adoptées par l'assemblée générale des actionnaires en rapport avec les\n2024 Share Options, et à prendre toutes les mesures et à accomplir toutes les\nformalités requises en vertu du Plan, des statuts de la Société et de la loi applicable\nafin d'émettre ou transférer les actions lors de l'exercice des 2024 Share Options. En\noutre, chaque administrateur de la Société, Joe Sollee et Ron Kalfus, chacun agissant\nindividuellement et avec possibilité de subdélégation et pouvoir de subrogation,\nauront le pouvoir, lors de l'exercice des 2024 Share Options, (i) de procéder à la\nconstatation (A) de l'augmentation de capital et de l'émission de nouvelles actions\nrésultant de cet exercice, (B) de l'allocation du capital et (le cas échéant) de la prime\nd'émission, et (C) de la modification des statuts de la Société afin de refléter le\nnouveau capital et nombre d'actions en circulation suite à l'exercice des 2024 Share\nOptions, (ii) de signer et remettre, au nom de la Société, la documentation Euroclear,\nComputershare, Nasdaq, bancaire et/ou autre pertinente, le registre des actions et tous\nles autres documents nécessaires en relation avec l'émission et la délivrance des\nactions aux Participant Sélectionnés concernés et l'admission de ces actions à la\ncotation et à la négociation, et (iii) faire tout ce qui peut être nécessaire ou utile (y\ncompris, mais sans s'y limiter, la préparation et l'exécution de tous les documents et\nformulaires) pour l'admission des actions émises lors de l'exercice des 2024 Share\nOptions à la négociation sur Nasdaq (ou tout autre marché sur lequel les actions de la\nSociété seront négociées à ce moment).\n3. Communication des rapports – Warrants d'Exact Sciences\nCommunication et discussion sur :\n(a) le rapport du conseil d'administration de la Société, préparé conformément aux\narticles 7:180, 7:191 et 7:193 du Code des sociétés et associations, concernant la\nproposition d'émettre, en faveur de Genomic Health, Inc. (une filiale d'Exact Sciences\nCorporation dénommée ci-après \"Exact Sciences\") 1.000.000 de nouveaux droits de\nsouscription pour actions de la Société (les \"Warrants d'Exact Sciences\"), et de\nsupprimer, dans l'intérêt de la Société, le droit de préférence des actionnaires\nexistants de la Société et, pour autant que de besoin, des détenteurs de droits de\nsouscription en circulation (share options) de la Société, en faveur d'Exact Sciences;\net\n(b) le rapport du commissaire de la Société, préparé conformément aux articles 7:180,\n7:191 et 7:193 du Code des sociétés et des associations, concernant la proposition\nd'émettre en faveur d'Exact Sciences 1.000.0000 de Warrants d'Exact Sciences, et de\nsupprimer, dans l'intérêt de la Société, le droit de préférence des actionnaires\nexistants de la Société et, pour autant que de besoin, des détenteurs de droits de\nsouscription en circulation (share options) de la Société, en faveur d'Exact Sciences.\n4. Proposition d'émettre 1.000.000 de Warrants d'Exact Sciences\nProposition de résolution : L'assemblée générale des actionnaires décide d'approuver\nl'émission de 1.000.000 de nouveaux droits de souscription pour actions de la Société,\ndénommé les \"Warrants d'Exact Sciences\", et de supprimer, dans l'intérêt de la Société, le\ndroit de préférence des actionnaires existants de la Société et, pour autant que de besoin, des\ndétenteurs de droits de souscription en circulation (share options) de la Société, en faveur des\nd'Exact Sciences. A cette fin, l'assemblée générale des actionnaires décide de ce qui suit:\n(a) Termes et conditions des droits de souscription : Les termes et conditions des\nWarrants d'Exact Sciences seront conformes à l'Annexe A du rapport du conseil\nd'administration visé au point 3.(a) de l'ordre du jour (aux fins de la présente\nrésolution, le \"Les Termes et Conditions des Warrants d'Exact Sciences\"), dont\nune copie restera jointe au procès-verbal constatant la présente résolution. Les\nprincipaux termes et conditions des Warrants d'Exact Sciences peuvent, à titre\nd'information, être résumés comme suit :\n3/12\n(i) Droit de souscrire à une action ordinaire : Chaque Warrant d'Exact\nSciences permet à son détenteur de souscrire à une (1) action ordinaire de la\nSociété à émettre par la Société.\n(ii) Prix d'exercice : Le prix d'exercice des Warrants d'Exact Sciences (c'est-à-\ndire le prix à payer en numéraire pour souscrire à une nouvelle action de la\nSociété lorsqu'un Warrant Exact Sciences est exercé) sera de USD 5,265. Le\nprix d'exercice est sujet à d'éventuels ajustements habituels à la baisse en cas\nde certaines actions dilutives de la Société;\n(iii) Durée : Les Warrants d'Exact Sciences auront une durée commençant à\npartir de leur émission et se terminant le 22 août 2028 (inclus).\n(iv) Possibilité d'exercice : L'exercice des Warrants d'Exact Sciences sera\nsoumis aux termes et conditions contenus dans les Termes et Conditions des\nWarrants d'Exact Sciences. Les Warrants d'Exact Sciences peuvent être\nexercés à partir de leur émission et jusqu'à la fin de leur durée, à condition\nqu'un nombre de Warrants d'Exact Sciences avec un prix d'exercice global\nd'au moins USD 250.000 soit exercé par leur détenteur.\n(v) Cessibilité : A moins que la Société autorise explicitement la cession des\nWarrants d'Exact Sciences, les Warrants d'Exact Sciences ne peuvent pas\nêtre cédés par leur détenteur. En outre, les Warrants d'Exact Sciences ne\nseront pas admis à la cotation ou à la négociation.\n(b) Actions sous-jacentes : Chaque Warrant d'Exact Sciences donnera à son détenteur le\ndroit de souscrire à une nouvelle action à émettre par la Société. Les nouvelles\nactions à émettre lors de l'exercice des Warrants d'Exact Sciences auront les mêmes\ndroits et avantages, et seront à tous égards pari passu, y compris en ce qui concerne\nles droits aux dividendes et autres distributions, avec les actions existantes et en\ncirculation de la Société au moment de leur émission, et auront droit aux dividendes\net autres distributions pour lesquelles la date d'enregistrement ou la date d'échéance\ntombe à, ou après leur date d'émission.\n(c) Suppression du droit de préférence en faveur d'Exact Sciences : L'assemblée générale\ndes actionnaires décide, conformément aux articles 7:191 et 7:193 du Code des\nsociétés et des associations, de supprimer, dans l'intérêt de la Société, le droit de\npréférence des actionnaires existants de la Société et, pour autant que de besoin, des\ndétenteurs actuels de droits de souscription (share options) de la Société, en faveur\nd'Exact Sciences, comme expliqué dans le rapport du conseil d'administration visé au\npoint 3.(a) de l'ordre du jour.\n(d) Augmentation de capital conditionnelle et émission de nouvelles actions :\nL'assemblée générale des actionnaires décide, sous réserve et dans la mesure de\nl'exercice des Warrants d'Exact Sciences, d'augmenter le capital de la Société et\nd'émettre le nombre approprié de nouvelles actions pouvant être émises lors de\nl'exercice des Warrants d'Exact Sciences. Sous réserve et conformément aux\ndispositions des Termes et Conditions des Warrants d'Exact Sciences, lors de\nl'exercice des Warrants d'Exact Sciences et de l'émission de nouvelles actions, le prix\nd'exercice agrégé des Warrants d'Exact Sciences sera comptabilisé (le cas échéant,\naprès conversion dans la devise du capital de la Société, sur la base du taux de change\nUSD/EUR publié par la Banque centrale européenne, comme prévu à la section 5.4\ndes Termes et Conditions des Warrants d'Exact Sciences) en tant que capital de la\nSociété. Dans la mesure où le montant du prix d'exercice des Warrants d'Exact\nSciences, par action à émettre lors de l'exercice des Warrants d'Exact Sciences,\nexcède le pair comptable des actions de la Société existantes immédiatement avant\nl'émission des nouvelles actions concernées, une partie du prix d'exercice, par action\nà émettre lors de l'exercice des Warrants d'Exact Sciences, égale à ce pair comptable\nsera comptabilisée en capital, le solde étant comptabilisé en prime d'émission. Suite à\nl'augmentation de capital et à l'émission de nouvelles actions, chaque action nouvelle\net existante représentera la même fraction du capital de la Société.\n4/12\n(e) Prime d'émission : Toute prime d'émission qui sera comptabilisée en rapport avec les\nWarrants d'Exact Sciences (sur exercice des Warrants d'Exact Sciences ou autrement)\nsera comptabilisée sur un compte indisponible au passif du bilan de la Société dans\nses capitaux propres, et le compte sur lequel la prime d'émission sera comptabilisée\nconstituera, au même titre que le capital de la Société, la garantie des tiers et, sauf\npossibilité de capitalisation de ces réserves, ne pourra être réduit ou supprimé que par\nune décision de l'assemblée générale des actionnaires statuant dans les conditions\nrequises pour la modification des statuts de la Société.\n(f) Procurations : Le conseil d'administration est autorisé à mettre en œuvre et à exécuter\nles résolutions adoptés par l'assemblée générale des actionnaires en rapport avec les\nWarrants d'Exact Sciences, et à prendre toutes les mesures et à accomplir toutes les\nformalités qui seront requises en vertu des Termes et Conditions des Warrants\nd'Exact Sciences, des statuts de la Société et des lois applicables afin d'émettre ou\ntransférer les actions lors de l'exercice des Warrants d'Exact Sciences. En outre,\nchaque administrateur de la Société, Joe Sollee et Ron Kalfus, chacun agissant\nindividuellement et avec possibilité de subdélégation et pouvoir de subrogation,\nauront le pouvoir, lors de l'exercice des Warrants d'Exact Sciences, (i) de procéder à\nla constatation (A) de l'augmentation de capital et de l'émission de nouvelles actions\nrésultant de cet exercice, (B) de la comptabilisation en tant que capital et (le cas\néchéant) prime d'émission, et (C) de la modification des statuts de la Société afin de\nrefléter le nouveau capital et nombre d'actions en circulation suite à l'exercice des\nWarrants d'Exact Sciences, (ii) de signer et remettre, au nom de la Société, la\ndocumentation Euroclear, Computershare, Nasdaq, bancaire et/ou autre pertinente, le\nregistre des actions et tous les autres documents nécessaires en relation avec\nl'émission et la délivrance des actions au bénéficiaire et l'admission de ces actions à\nla cotation et à la négociation, et (iii) faire tout ce qui peut être nécessaire ou utile (y\ncompris, mais sans s'y limiter, la préparation et l'exécution de tous les documents et\nformulaires) pour l'admission des actions émises lors de l'exercice des Warrants\nd'Exact Sciences à la négociation sur le Nasdaq (ou tout autre marché sur lequel les\nactions de la Société seront alors négociées à ce moment).\n5. Communication des rapports – Warrants d'OrbiMed\nCommunication et discussion sur :\n(a) le rapport du conseil d'administration de la Société, préparé conformément aux\narticles 7:180, 7:191 et 7:193 du Code des sociétés et associations, concernant la\nproposition d'émettre, en faveur de OrbiMed Royalty & Credit Opportunities IV, LP\net OrbiMed Royalty & Credit Opportunities IV Offshore, LP (ensemble dénommés\nci-après \"OrbiMed\") 1.243.060 nouveaux droits de souscription pour actions de la\nSociété (de ces 1.243.060 nouveaux droits de souscription pour actions, 881.906\nnouveaux droits de souscription pour actions à émettre en faveur d'OrbiMed Royalty\n& Credit Opportunities IV, LP et 361.154 nouveaux droits de souscription pour\nactions à émettre en faveur d'OrbiMed Royalty & Credit Opportunities IV Offshore,\nLP), ayant une durée de 5 ans à partir de leur date d'émission, (les \"Warrants\nd'OrbiMed\"), et de supprimer, dans l'intérêt de la Société, le droit de préférence des\nactionnaires existants de la Société et, pour autant que de besoin, des détenteurs de\ndroits de souscription en circulation (share options) de la Société, en faveur\nd'OrbiMed ; et\n(b) le rapport du commissaire de la Société, préparé conformément aux articles 7:180,\n7:191 et 7:193 du Code des sociétés et des associations, concernant la proposition\nd'émettre en faveur d'OrbiMed 1.243.060 Warrants d'OrbiMed, et de supprimer, dans\nl'intérêt de la Société, le droit de préférence des actionnaires existants de la Société\net, pour autant que de besoin, des détenteurs de droits de souscription en circulation\n(share options) de la Société, en faveur d'OrbiMed.\n6. Proposition d'émettre 1.243.060 Warrants d'OrbiMed\nProposition de résolution : L'assemblée générale des actionnaires décide d'approuver\nl'émission de 1.243.060 nouveaux droits de souscription pour actions de la Société, ayant une\n5/12\ndurée de 5 ans à partir de leur date d'émission, dénommés les \"Warrants d'OrbiMed\", et de\nsupprimer, dans l'intérêt de la Société, le droit de préférence des actionnaires existants de la\nSociété et, pour autant que de besoin, des détenteurs de droits de souscription en circulation\n(share options) de la Société, en faveur de chacun d'OrbiMed Royalty & Credit Opportunities\nIV, LP et OrbiMed Royalty & Credit Opportunities IV Offshore, LP. A cette fin, l'assemblée\ngénérale des actionnaires décide de ce qui suit :\n(a) Termes et conditions des droits de souscription : Les termes et conditions des\nWarrants d'OrbiMed seront conformes à l'annexe A du rapport du conseil\nd'administration visé au point 5.(a) de l'ordre du jour (aux fins de la présente\nrésolution, le \"Les Termes et Conditions des Warrants d'OrbiMed\"), dont une\ncopie restera jointe au procès-verbal constatant la présente résolution. Les principaux\ntermes et conditions des Warrants d'OrbiMed peuvent, à titre d'information, être\nrésumés comme suit :\n(i) Droit de souscrire à une action ordinaire : Chaque Warrant d'OrbiMed\npermet à son détenteur de souscrire à une (1) action ordinaire de la Société à\némettre par la Société.\n(ii) Prix d'exercice : Le prix d'exercice des Warrants d'OrbiMed (c'est-à-dire le\nprix à payer en numéraire pour souscrire à une nouvelle action de la Société\nlorsqu'un Warrant d'OrbiMed est exercé) sera de USD 2,4134. Le prix\nd'exercice est sujet à d'éventuels ajustements habituels à la baisse en cas de\ncertaines actions dilutives de la Société.\n(iii) Prix de souscription : Le prix de souscription des 881.906 Warrants\nd'OrbiMed à émettre en faveur d'OrbiMed Royalty & Credit Opportunities\nIV, LP sera de USD 1.744.485,56 et le prix de souscription des 361.154\nWarrants d'OrbiMed à émettre en faveur d'OrbiMed Royalty & Credit\nOpportunities IV Offshore, LP sera de USD 714.394,11. Le prix d'émission\ndoit être payé pour la souscription des Warrants d'OrbiMed respectifs par\nOrbiMed Royalty & Credit Opportunities IV, LP et OrbiMed Royalty &\nCredit Opportunities IV Offshore, LP, respectivement. Le prix de\nsouscription sera comptabilisé en tant que prime d'émission (conformément\nce qui est indiqué au paragraphe (d) ci-dessous).\n(iv) Durée : Les Warrants d'OrbiMed auront une durée de 5 ans à partir de leur\ndate d'émission.\n(v) Possibilité d'exercice : L'exercice des Warrants d'OrbiMed sera soumis aux\ntermes et conditions contenus dans les Termes et Conditions des Warrants\nd'OrbiMed. Les Warrants d'OrbiMed peuvent être exercés à partir de leur\némission et jusqu'à la fin de leur durée.\n(vi) Cessibilité : Les Warrants OrbidMed et tous les droits qui en découlent sont\ncessibles, en tout ou en partie, par leur détenteur concerné conformément\naux Termes et Conditions des Warrants OrbidMed.\n(b) Actions sous-jacentes : Chaque Warrant d'OrbiMed donnera à son détenteur le droit\nde souscrire à une nouvelle action à émettre par la Société. Les nouvelles actions à\némettre lors de l'exercice des Warrants d'OrbiMed auront les mêmes droits et\navantages, et seront à tous égards pari passu, y compris en ce qui concerne les droits\naux dividendes et autres distributions, avec les actions existantes et en circulation de\nla Société au moment de leur émission, et auront droit aux dividendes et autres\ndistributions pour lesquelles la date d'enregistrement ou la date d'échéance tombe à,\nou après leur date d'émission.\n(c) Suppression du droit de préférence en faveur d'OrbiMed : L'assemblée générale des\nactionnaires décide, conformément aux articles 7:191 et 7:193 du Code des sociétés\net des associations, de supprimer, dans l'intérêt de la Société, le droit de préférence\ndes actionnaires existants de la Société et, pour autant que de besoin, des détenteurs\n6/12\nde droits de souscription (share options) de la Société, en faveur de chacun\nd'OrbiMed Royalty & Credit Opportunities IV, LP et OrbiMed Royalty & Credit\nOpportunities IV Offshore, LP., comme expliqué dans le rapport du conseil\nd'administration visé au point 5.(a) de l'ordre du jour.\n(d) Augmentation de capital conditionnelle et émission de nouvelles actions :\nL'assemblée générale des actionnaires décide, sous réserve et dans la mesure de\nl'exercice des Warrants d'OrbiMed, d'augmenter le capital de la Société et d'émettre\nle nombre approprié de nouvelles actions pouvant être émises lors de l'exercice des\nWarrants d'OrbiMed. Sous réserve et conformément aux dispositions des Termes et\nConditions des Warrants d'OrbiMed, lors de l'exercice des Warrants d'OrbiMed et de\nl'émission de nouvelles actions, le prix d'exercice agrégé des Warrants d'OrbiMed\nsera comptabilisé (le cas échéant, après conversion dans la devise du capital de la\nSociété, sur la base du taux de change USD/EUR publié par la Banque centrale\neuropéenne, comme prévu à la section 4(b) des Termes et Conditions des Warrants\nd'OrbiMed) en tant que capital de la Société. Dans la mesure où le montant du prix\nd'exercice des Warrants d'OrbiMed, par action à émettre lors de l'exercice des\nWarrants d'OrbiMed, excède le pair comptable des actions de la Société existantes\nimmédiatement avant l'émission des nouvelles actions concernées, une partie du prix\nd'exercice, par action à émettre lors de l'exercice des Warrants d'OrbiMed, égale à ce\npair comptable sera comptabilisée en capital, le solde étant comptabilisé en prime\nd'émission. Suite à l'augmentation de capital et à l'émission de nouvelles actions,\nchaque action nouvelle et existante représentera la même fraction du capital de la\nSociété.\n(e) Prime d'émission : Toute prime d'émission qui sera comptabilisée en rapport avec les\nWarrants d'OrbiMed (sur exercice des Warrants d'OrbiMed ou autrement) sera\ncomptabilisée sur un compte indisponible au passif du bilan de la Société dans ses\ncapitaux propres, et le compte sur lequel la prime d'émission sera comptabilisée\nconstituera, au même titre que le capital de la Société, la garantie des tiers et, sauf\npossibilité de capitalisation de ces réserves, ne pourra être réduit ou supprimé que par\nune décision de l'assemblée générale des actionnaires statuant dans les conditions\nrequises pour la modification des statuts de la Société.\n(f) Procurations : Le conseil d'administration est autorisé à mettre en œuvre et à exécuter\nles résolutions adoptées par l'assemblée générale des actionnaires en rapport avec les\nWarrants d'OrbiMed, et à prendre toutes les mesures et à accomplir toutes les\nformalités qui seront requises en vertu des Termes et Conditions des Warrants\nd'OrbiMed, des statuts de la Société et des lois applicables afin d'émettre ou\ntransférer les actions lors de l'exercice des Warrants d'OrbiMed. En outre, chaque\nadministrateur de la Société, Joe Sollee et Ron Kalfus, chacun agissant\nindividuellement et avec possibilité de subdélégation et pouvoir de subrogation,\nauront le pouvoir, lors de l'exercice des Warrants d'OrbiMed, (i) de procéder à la\nconstatation (A) de l'augmentation de capital et de l'émission de nouvelles actions\nrésultant de cet exercice, (B) de la comptabilisation en tant que capital et (le cas\néchéant) prime d'émission, et (C) de la modification des statuts de la Société afin de\nrefléter le nouveau capital et nombre d'actions en circulation suite à l'exercice des\nWarrants d'OrbiMed, (ii) de signer et remettre, au nom de la Société, la\ndocumentation Euroclear, Computershare, Nasdaq, bancaire et/ou autre pertinente, le\nregistre des actions et tous les autres documents nécessaires en relation avec\nl'émission et la délivrance des actions au bénéficiaire et l'admission de ces actions à\nla cotation et à la négociation, et (iii) faire tout ce qui peut être nécessaire ou utile (y\ncompris, mais sans s'y limiter, la préparation et l'exécution de tous les documents et\nformulaires) pour l'admission des actions émises lors de l'exercice des Warrants\nd'OrbiMed à la négociation sur le Nasdaq (ou tout autre marché sur lequel les actions\nde la Société seront alors négociées à ce moment).\nQuorum : La présente assemblée générale extraordinaire des actionnaires constituant la deuxième\nassemblée générale extraordinaire des actionnaires pour les points de l'ordre du jour susmentionnés,\naucun quorum n'est requis pour la délibération et le vote sur les points mentionnés dans l'ordre du jour\nsusmentionné.\n7/12\nVote et majorité : Sous réserve des dispositions légales applicables, chaque action a un vote.\nConformément au droit applicable, les résolutions proposées auxquelles il est fait référence dans l'ordre\ndu jour susmentionné de l'assemblée générale extraordinaire des actionnaires seront adoptées si elles\nsont approuvées par une majorité de 75% des voix valablement émises par les actionnaires.\nConformément à l'article 7:135 du Code des sociétés et des associations, les détenteurs de droits de\nsouscription ont le droit de participer à l'assemblée générale des actionnaires mais seulement avec voix\nconsultative.\nPARTICIPATION A L'ASSEMBLEE\nIntroduction : Les détenteurs de titres émis par la Société qui souhaitent participer à l'assemblée\ngénérale extraordinaire des actionnaires de la Société doivent prendre en compte les formalités et\nprocédures décrites ci-dessous.\nDepuis la réalisation, le 18 décembre 2023, de la transition de la Société d'une double cotation des\nanciennes American Depositary Shares de la Société sur le Nasdaq et des actions de la Société sur\nEuronext Brussels à une cotation unique de ses actions sur le Nasdaq, les actions de la Société sont\ncomposées :\n(a) d'actions inscrites dans la composante du registre des actions de la Société qui est tenue en\nBelgique et qui est maintenue par Euroclear Belgium (le \"Registre Belge des Actions \" et, les\nactions reflétées dans le Registre Belge des Actions, les \"Actions Européennes\"), et qui ne\npeuvent pas être négociées sur le Nasdaq tant qu'elles n'ont pas été repositionnées en Actions\nAméricaines (telles que définies ci-dessous) ; et\n(b) d'actions inscrites directement ou indirectement dans la composante du registre des actions de\nla Société tenue aux États-Unis et qui est maintenue par Computershare (le \"Registre\nAméricain des Actions \" et, les actions figurant dans le Registre Américain des Actions, les\n\"Actions Américaines\"), et qui peuvent être négociées sur le Nasdaq.\nPour plus d'informations et de détails concernant la transition à une cotation unique sur Nasdaq et le\nprocessus de repositionnement, veuillez consulter la page web dédiée sur le site web de la Société\n(voir: https://mdxhealth.com/proposed-transition-to-a-single-listing-on-nasdaq/).\nDate d'enregistrement : Conformément à l'article 32 des statuts de la Société et à l'article 7:134 du\nCode des sociétés et associations, le conseil d'administration de la Société fixe la date d'enregistrement\npour l'assemblée générale extraordinaire des actionnaires au lundi 17 juin 2024 à minuit (00h00, heure\nbelge) (la \"Date d'Enregistrement\"). Seules les personnes détenant des titres émis par la Société le\nlundi 17 juin 2024 à minuit (00h00, heure belge) seront en droit de participer et, le cas échéant, de voter\nà l'assemblée générale extraordinaire des actionnaires. Seuls les actionnaires ont le droit de voter. Les\ndétenteurs de droits de souscription peuvent participer à l'assemblée générale extraordinaire des\nactionnaires, mais seulement avec voix consultative. Les actionnaires et les détenteurs de droits de\nsouscriptions doivent satisfaire aux formalités qui sont décrites sous \"—Participation à l'assemblée\".\nParticipation à l'assemblée : Pour être autorisé à participer à l'assemblée générale extraordinaire, un\ndétenteur de titres émis par la Société doit satisfaire deux conditions : (a) être enregistré en tant que\ndétenteur de tels titres à la Date d'Enregistrement et (b) notifier la Société, tel que décrit ci-dessous:\n(a) Enregistrement : Premièrement, le droit d'un détenteur de titres émis par la Société de\nparticiper et, le cas échéant, de voter à l'assemblée générale extraordinaire est uniquement\naccordé sur base de l'enregistrement des titres concernés à la Date d'Enregistrement\nsusmentionnée à minuit, comme suit :\n(i) Détenteurs d'Actions Européennes nominatives et de droits de souscription\nnominatifs émis par la Société : Les détenteurs d'Actions Européennes nominatives et\nde droits de souscription émis sous forme nominative par la Société ne peuvent\nparticiper à l'assemblée générale extraordinaire des actionnaires que pour les Actions\nEuropéennes nominatives et les droits de souscription nominatifs qui sont inscrits\nrespectivement à leur nom dans le Registre Belge des Actions et dans le registre des\ndroits de souscription correspondant, à la Date d'Enregistrement.\n8/12\n(ii) Détenteurs d'Actions Européennes dématérialisées : Les détenteurs d'Actions\nEuropéennes dématérialisées qui souhaitent participer à l'assemblée générale\nextraordinaire des actionnaires doivent demander à leur teneur de compte agréé ou au\ndépositaire central de titres pour les actions concernées d'émettre un certificat\nindiquant le nombre d'actions dématérialisées inscrites au nom de l'actionnaire dans\nses livres à la Date d'Enregistrement de l'envoyer à la Société (par courrier à son\nsiège (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue\nd'Abhooz 31, 4040 Herstal, Belgique, à l'attention de : M. Ron Kalfus) ou par e-mail\nà l'adresse agsm@mdxhealth.com) au plus tard le deuxième jour ouvrable précédant\nl'assemblée générale extraordinaire des actionnaires, c'est-à-dire au plus tard le mardi\n18 juin 2024 (la \"Date Limite de Notification\"). La Société déterminera la propriété\ndes actions concernées à la Date d'Enregistrement uniquement sur la base de ces\ncertificats.\n(iii) Détenteurs d'Actions Américaines, inscrits directement dans le Registre Américain\ndes Actions (et non par l'intermédiaire de DTCC) : Les détenteurs d'Actions\nAméricaines inscrits directement dans le Registre Américain des Actions (et non par\nl'intermédiaire de DTCC) ne peuvent être admis à l'assemblée générale extraordinaire\ndes actionnaires que si la propriété de leurs Actions Américaines est reflétée dans le\nRegistre Américain des Actions à la Date d'Enregistrement. L'agent de transfert\naméricain de la Société fournira à la Société, au plus tard à la Date Limite de\nNotification, directement ou indirectement, une liste d'actionnaires à la Date\nd'Enregistrement qui contient tous les détenteurs d'Actions Américaines nominatives\nde la Société inscrits directement dans le Registre Américain des Actions (et non par\nl'intermédiaire de DTCC) à la Date d'Enregistrement. La Société déterminera la\npropriété des actions concernées à la Date d'Enregistrement uniquement sur la base\ndes informations susmentionnées.\n(iv) Détenteurs d'Actions Américaines inscrits indirectement dans le Registre Américain\ndes Actions (par l'intermédiaire de DTCC) : Les détenteurs d'Actions Américaines\ninscrits indirectement dans le Registre Américain des Actions, par l'intermédiaire de\nCEDE & Co, le détenteur désigné des Actions Américaines détenues pour les\nbénéficiaires effectifs via le système DTCC, ne peuvent être admis à l'assemblée\ngénérale extraordinaire des actionnaires que si la propriété de leurs Actions\nAméricaines est incluse dans les informations fournies à la Société au plus tard à la\nDate Limite de Notification, par le courtier, l'institution financière ou tout autre\nintermédiaire de ces actionnaires. La Société déterminera la propriété des actions\nconcernées à la Date d'Enregistrement uniquement sur la base des informations\nsusmentionnées.\n(b) Notification : Deuxièmement, conformément à l'article 32 des statuts de la Société et à l'article\n7:134 du Code des sociétés et associations, le conseil d'administration de la Société fixe la\ndate limite à laquelle les détenteurs de titres émis par la Société doivent notifier leur\nparticipation à l'assemblée générale extraordinaire des actionnaires à la Date limite de\nNotification. Par conséquent, afin de participer à l'assemblée générale extraordinaire des\nactionnaires, les détenteurs de titres émis par la Société doivent notifier à la Société leur\nintention de participer à l'assemblée et doivent le faire avant ou au plus tard le mardi 18 juin\n2024. Les détenteurs de titres qui souhaitent faire une telle notification peuvent utiliser le\nformulaire de participation qui peut être obtenu au siège de la Société et sur le site web de la\nSociété (http://www.mdxhealth.com). La notification doit parvenir à la Société par courrier, à\nson siège (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue\nd'Abhooz 31, 4040 Herstal, Belgique, à l'attention de : M. Ron Kalfus) ou par courrier\nélectronique à agsm@mdxhealth.com au plus tard à la Date Limite de Notification. Selon le\ntype de titres qu'il détient, un détenteur de titres émis par la Société doit notifier à la Société sa\nparticipation à l'assemblée générale extraordinaire des actionnaires de la manière suivante :\n(i) Détenteurs d'Actions Européennes nominatives et de droits de souscription\nnominatifs émis par la Société : Les détenteurs d'Actions Européennes nominatives et\nde droits de souscription émis sous forme nominative par la Société qui souhaitent\nfaire une telle notification doivent s'assurer que le formulaire de participation est\n9/12\ndûment signé et complété et qu'il parvient à la Société au plus tard à la Date Limite\nde Notification (conformément aux instructions données ci-dessus).\n(ii) Détenteurs d'Actions Européennes dématérialisées : Les détenteurs d'Actions\nEuropéennes dématérialisées qui souhaitent faire une telle notification doivent\ns'assurer que le formulaire de participation est dûment signé et complété et qu'il\nparvient à la Société au plus tard à la Date Limite de Notification (conformément aux\ninstructions mentionnées ci-dessus). En outre, la notification doit être accompagnée\nd'un certificat confirmant le nombre d'Actions Européennes qui ont été enregistrées à\nleur nom à la Date d'Enregistrement. Le certificat peut être obtenu par les détenteurs\nd'Actions Européennes dématérialisées auprès du teneur de compte agréé ou du\ndépositaire central de titres pour les Actions Européennes concernées (voir également\nle point (ii) du paragraphe (a) ci-dessus).\n(iii) Détenteurs d'Actions Américaines inscrits directement dans le Registre Américain\ndes Actions (et non par l'intermédiaire de DTCC) : Les détenteurs d'Actions\nAméricaines inscrits directement dans le Registre Américain des Actions (et non par\nl'intermédiaire de DTCC) qui souhaitent faire une telle notification doivent s'assurer\nque le formulaire de participation joint à leur convocation est dûment complété et\nqu'il parvient à la Société au plus tard à la Date Limite de Notification\n(conformément aux instructions mentionnées ci-dessus).\n(iv) Détenteurs d'Actions Américaines inscrits indirectement dans le Registre Américain\ndes Actions (par l'intermédiaire de DTCC) : Les détenteurs d'Actions Américaines\ninscrits indirectement dans le Registre Américain des Actions, par l'intermédiaire de\nCEDE & Co, le détenteur désigné des Actions Américaines détenues pour les\nbénéficiaires effectifs via le système DTCC, qui souhaitent faire une telle notification\ndoivent s'assurer que le formulaire de participation est dûment complété et qu'il\nparvient à la Société au plus tard à la Date Limite de Notification (conformément aux\ninstructions mentionnées ci-dessus). En outre, la notification doit inclure un certificat\nd'un courtier, d'une institution financière ou d'un autre intermédiaire indiquant que ce\ndétenteur était le propriétaire de ces actions américaines à la Date d'Enregistrement.\nLa Société encourage les actionnaires à participer à l'assemblée générale extraordinaire des\nactionnaires par le biais d'une procuration signée ou de la carte de procuration américaine\n(U.S. proxy card) (tel que décrit sous \"—Représentation par procuration\") qui leur sera fournie\nou leur est mis à disposition et conformément aux instructions les accompagnant. Si un\nactionnaire assiste en personne à l'assemblée générale extraordinaire des actionnaires, il peut\nrévoquer sa procuration signée ou sa carte de procuration américaine (U.S. proxy card) signée\njusqu'à la Date Limite de Notification. La remise d'une procuration signée à la Société ou\nd'une carte de procuration américaine (U.S. proxy card) signée à la Société sera également\nconsidérée comme une notification, à condition que la procuration signée ou la carte de\nprocuration américaine (U.S. proxy card) signée parvienne à la Société (par courrier, à son\nsiège (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d'Abhooz\n31, 4040 Herstal, Belgique, à l'attention de : M. Ron Kalfus) ou par courrier électronique à\nagsm@mdxhealth.com) au plus tard à la Date Limite de Notification. Pour les actionnaires\nvisés aux points (ii) et (iv) ci-dessus, la procuration signée ou la carte de procuration\naméricaine (U.S. proxy card) signée doit également inclure les certificats visés respectivement\naux points (ii) et (iv) ci-dessus.\nReprésentation par procuration: Les détenteurs de titres peuvent participer à l'assemblée et voter, le\ncas échéant, par le biais d'une procuration écrite. Les procurations écrites doivent contenir des\ninstructions de vote spécifiques pour chaque résolution proposée. Le formulaire de procuration peut\nêtre obtenu sur le site web de la société (http://www.mdxhealth.com). Le formulaire de procuration doit\nêtre signé par écrit ou électroniquement. Les détenteurs d'Actions Américaines qui souhaitent désigner\nun mandataire sont vivement encouragés à utiliser la carte de procuration américaine (U.S. proxy card)\nqui leur sera fournie et à suivre les instructions qui l'accompagnent. Les procurations signées et les\ncartes de procuration américaines (U.S. proxy card) signées doivent parvenir à la Société par courrier à\nson siège (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d'Abhooz 31,\n4040 Herstal, Belgique, à l'attention de: M. Ron Kalfus) ou par courrier électronique à\nagsm@mdxhealth.com, au plus tard à la Date Limite de Notification, c'est-à-dire au plus tard le, ou\navant le, mardi 18 juin 2024. Les détenteurs de titres qui souhaitent se faire représenter par un\n10/12\nmandataire doivent, en tout état de cause, remplir les formalités de participation à l'assemblée, tel que\ndécrit sous \"—Participation à l'assemblée\". Pour les actionnaires visés aux points (ii) et (iv) du\nparagraphe (b) sous \"—Participation à l'assemblée\", la procuration signée ou la carte de procuration\naméricaine (U.S. proxy card) signée doit également inclure les certificats visés respectivement aux\npoints (ii) et (iv) du paragraphe (b) sous \"—Participation à l'assemblée\".\nAccès à la salle de réunion : Les personnes physiques qui assistent à l'assemblée générale\nextraordinaire des actionnaires en qualité de détenteur de titres, de mandataire ou de représentant d'une\npersonne morale doivent être en mesure de justifier de leur identité pour pouvoir accéder à la salle de\nréunion (sous réserve de ce qui est exposé ci-dessus sous \"—Information générale\"). En outre, les\nreprésentants des personnes morales doivent remettre les documents établissant leur qualité de\nreprésentant ou de mandataire de la société. Ces documents seront vérifiés immédiatement avant le\ndébut de l'assemblée.\nRecommandation d'utiliser le courrier électronique: La Société recommande aux détenteurs de ses\ntitres d'utiliser le courrier électronique pour toute communication avec la Société concernant\nl'assemblée générale des actionnaires. L'adresse électronique de la Société pour ce type de\ncommunication est : agsm@mdxhealth.com. La Société souligne également que, en plus d'être\nphysiquement disponibles au siège de la Société et distribués par courrier, tous les formulaires (mis à\njour) et autres documents relatifs à l'assemblée générale des actionnaires seront disponibles sur le site\nweb de la société (http://www.mdxhealth.com). Voir aussi \"—Documents disponibles\".\nPROTECTION DES DONNÉES\nLa Société est responsable du traitement des données personnelles qu'elle reçoit ou recueille des\ndétenteurs de titres émis par la Société et des mandataires dans le cadre de l'assemblée générale des\nactionnaires. Le traitement de ces données sera effectué aux fins de l'organisation et du déroulement de\nl'assemblée générale des actionnaires concernée, y compris la convocation, les inscriptions, la\nparticipation et le vote, ainsi que pour la tenue des listes ou registres des détenteurs de titres et l'analyse\ndes investisseurs et des détenteurs de titres de la Société. Ces données comprennent, entre autres, des\ndonnées d'identification, le nombre et la nature des titres d'un porteur de titres émis par la Société, les\nprocurations et les instructions de vote. Ces données peuvent également être transférées à des tiers à\ndes fins d'assistance ou de services à la Société dans le cadre de ce qui précède. Le traitement de ces\ndonnées sera effectué, mutatis mutandis, conformément à la Privacy Policy de la Société, disponible\nsur le site internet de la Société (https://mdxhealth.com/privacy-policy). La Société attire l'attention des\ndétenteurs de titres émis par la Société et des mandataires sur la description des droits qu'ils peuvent\navoir en tant que personnes concernées, tels que, entre autres, le droit d'accès, le droit de rectification et\nle droit de s'opposer au traitement, qui sont décrits dans ladite Privacy Policy. Tout ceci n'affecte pas\nles règles applicables en matière d'inscription et de participation à l'assemblée générale des\nactionnaires. Pour exercer ses droits en tant que personne concernée et pour toute autre information\nconcernant le traitement des données personnelles par ou au nom de la Société, la Société peut être\ncontactée par courrier électronique à dataprotection@mdxhealth.com.\nDOCUMENTS DISPONIBLES\nLes documents suivants sont disponibles sur le site internet de la Société (www.mdxhealth.com): l'avis\nde convocation à l'assemblée générale extraordinaire des actionnaires, le formulaire de participation, les\ndocuments à soumettre à l'assemblée générale extraordinaire des actionnaires qui sont visés à l'ordre du\njour de l'assemblée, et le formulaire de procuration. Avant l'assemblée générale extraordinaire des\nactionnaires, les détenteurs de titres de la Société peuvent également obtenir gratuitement au siège de la\nSociété (CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d'Abhooz 31, 4040 Herstal,\nBelgique) une copie de cette documentation.\nVeuillez adresser toute correspondance à ce sujet à MDxHealth SA, M. Ron Kalfus, CAP Business\nCenter, Zone Industrielle des Hauts-Sarts, rue d'Abhooz 31, 4040 Herstal, Belgique. Le numéro de fax\nest le +32 (0)4 259 78 75 et l'adresse email est la suivante : agsm@mdxhealth.com.\n11/12\nPour le conseil d'administration\nCE DOCUMENT NE CONSTITUE PAS UNE OFFRE DE VENTE OU UNE SOLLICITATION\nD'OFFRE D'ACHAT D'ACTIONS OU AUTRES TITRES DE MDXHEALTH SA.\n12/12"
        },
        {
          "title": "Board Report 2024 Share Option Plan",
          "url": "https://mdxhealth.com/wp-content/uploads/2024/05/9EN-Board-Report-SO-Plan-2024-ENG.pdf",
          "content": "English translation - For information purposes only\nMDXHEALTH\nLimited Liability Company\nCAP Business Center\nZone Industrielle des Hauts-Sarts\nRue d'Abhooz 31\n4040 Herstal\nBelgium\nRegistered with the Register of Legal Persons\nVAT BE 0479.292.440 (RLP Liège, division Liège)\n____________________________________________________\nREPORT OF THE BOARD OF DIRECTORS\nIN ACCORDANCE WITH ARTICLES 7:180 AND 7:191\nOF THE BELGIAN COMPANIES AND ASSOCIATIONS CODE\n____________________________________________________\n1. INTRODUCTION\nThis report has been prepared by the board of directors of MDxHealth SA (the \"Company\") in\naccordance with articles 7:180 and 7:191 of the Belgian Companies and Associations Code (as\namended from time to time) (the \"Belgian Companies and Associations Code\"). It relates to\nthe proposal of the board of directors to issue a total number of 2,000,000 share options in the\nform of subscription rights (the \"2024 Share Options\") in order to enable the Company to grant\nthem to certain members of the personnel of the Company and its subsidiaries from time to\ntime, within the meaning of article 1:27 of the Belgian Companies and Associations Code (the\n\"Selected Participants\"), in the framework of a share option plan, called the \"2024 Share\nOption Plan\", and the proposal of the board of directors to dis-apply, in the interest of the\nCompany, the statutory preferential subscription right of the Company's existing shareholders\nand, insofar as required, of the Company's existing holders of subscription rights (share\noptions), for the benefit of the Selected Participants. The proposals will be submitted to an\nextraordinary general shareholders' meeting to be held before a notary public (the \"EGM\").\nIn accordance with article 7:180 of the Belgian Companies and Associations Code, the board\nof directors provides in this report a justification of the proposed issuance of 2024 Share\nOptions, with notably a justification of the proposed exercise price of the 2024 Share Options\nand a description of the consequences of the proposed issuance of 2024 Share Options for the\nfinancial and shareholder rights of the shareholders of the Company.\nIn accordance with article 7:191 of the Belgian Companies and Associations Code, the board\nof directors also provides in this report a justification of the proposed dis-application of the\nstatutory preferential subscription right of the existing shareholders and, insofar as required, of\nthe existing holders of subscription rights (share options), for the benefit of the Selected\nParticipants in connection with the proposed issuance of 2024 Share Options and a description\nof the consequences thereof for the financial and shareholder rights of the shareholders.\nThis report must be read together with the report prepared in accordance with articles 7:180 and\n7:191 of the Belgian Companies and Associations Code by the Company's statutory auditor,\nBDO Réviseurs d'Entreprises SRL, a limited liability company organised and existing under\nthe laws of Belgium, with registered office at Da Vincilaan 9 E.6, 1930 Zaventem, Belgium,\nrepresented by Mr. Bert Kegels.\n1\nEnglish translation - For information purposes only\n2. PROPOSED ISSUANCE OF THE 2024 SHARE OPTIONS\nThe board of directors proposes to issue a total number of 2,000,000 2024 Share Options to the\nSelected Participants in order to achieve the following goals:\n(a) encourage, motivate and retain the Selected Participants;\n(b) enable the Company and its subsidiaries to attract and retain Members of the Personnel\nwith the required experience and skills; and\n(c) link the interests of the Selected Participants closer to the interests of the shareholders\nof the Company by giving them the opportunity to share in the increase of the value of\nthe Company.\nThe Company has used share options in the past as a form of incentive and compensation for\nmembers of the personnel. For an overview of the outstanding share option plans, see also\nbelow in section 6.1(d). As the available headroom under the currently outstanding plans is no\nlonger sufficient, the board of directors proposes to create the 2024 Share Options. In order to\nenable the Company to grant the 2024 Share Options to the Selected Participants in accordance\nwith the proposed terms and conditions of the 2024 Share Option Plan attached hereto as\nAnnex A, the board of directors proposes to dis-apply, in the interest of the Company, the\nstatutory preferential subscription right of the Company's existing shareholders and, insofar as\nrequired, of the Company's existing holders of subscription rights (share options), for the\nbenefit of the Selected Participants. The issuance of the 2024 Share Options and the resolution\non the dis-application of the preferential subscription right shall be submitted to the EGM.\nThe main terms governing the 2024 Share Options can be summarized as follows:\n(a) Term of the 2024 Share Options: The duration of a 2024 Share Option shall be ten (10)\nyears as of the date on which they are issued. The board of directors, or any other\ncommittee created or person appointed by the board of directors in accordance with the\n2024 Share Option Plan, shall, however, have the right to shorten such term.\n(b) Form of the 2024 Share Options: The 2024 Share Options shall be issued as\nsubscription rights in registered form.\n(c) Underlying shares: Each 2024 Share Option shall entitle the holder thereof to subscribe\nfor one new share to be issued by the Company. The new shares to be issued at the\noccasion of the exercise of the 2024 Share Options shall have the same rights and\nbenefits as, and rank pari passu in all respects, including as to entitlements to dividends\nand other distributions, with the existing and outstanding shares of the Company at the\nmoment of their issuance, and will be entitled to dividends and other distributions in\nrespect of which the relevant record date or due date falls on or after the date of issue\nof the new shares.\n(d) Dis-application of the statutory preferential subscription right: The board of directors\nproposes to dis-apply, in the interest of the Company, the statutory preferential\nsubscription right of the Company's existing shareholders and, insofar as required, of\nthe Company's existing holders of subscription rights (share options), for the benefit of\nthe Selected Participants in accordance with article 7:191 of the Belgian Companies\nand Associations Code.\n(e) Confirmation of the subscription to the 2024 Share Options by the Company: Subject\nto the dis-application of the statutory preferential subscription right of the Company's\nexisting shareholders and, insofar as required, of the Company's existing holders of\nsubscription rights (share options), for the benefit of the Selected Participants in\n2\nEnglish translation - For information purposes only\naccordance with article 7:191 of the Belgian Companies and Associations Code, the\nCompany shall be able to subscribe for the 2024 Share Options, with a view to creating\na pool of outstanding 2024 Share Options available for further grants to Selected\nParticipants. The Company may not, however, exercise the 2024 Share Options for its\nown account.\n(f) Issuance price of the 2024 Share Options: The 2024 Share Options will be granted free\nof charge.\n(g) Exercise price of the 2024 Share Options: The exercise price of a 2024 Share Option\nshall be determined by the board of directors, or any other committee created or person\nappointed by the board of directors in accordance with the 2024 Share Option Plan, of\nthe Company on the date of the grant thereof.\nUnless determined otherwise by the board of directors, or any other committee created\nor person appointed by the board of directors in accordance with the 2024 Share Option\nPlan, prior to, at, or after the date of grant, the exercise price shall not be lower than the\nlower of (i) the price of the shares on the relevant stock market on which the shares are\nlisted and traded on the day prior to the date of grant of the relevant 2024 Share Option\n(should the shares be listed on Nasdaq, Nasdaq must be used as market of reference),\nand (ii) the average price of the shares on the relevant stock market on which the shares\nare listed and traded during the period of 30 days preceding the date of grant of the\nrelevant 2024 Share Option (should the shares be listed on Nasdaq, Nasdaq must be\nused as market of reference).\n(h) Vesting policy: Unless determined otherwise by the board of directors, or any other\ncommittee created or person appointed by the board of directors in accordance with the\n2024 Share Option Plan, the 2024 Share Options to be granted to a Selected Participant\nin a capacity other than the capacity of non-executive director of the Company shall\nvest in instalments of twenty-five percent (25%) per year during a period of four (4)\nyears as of the date of grant of the relevant 2024 Share Options, as follows:\n(i) on the first anniversary date of the date of grant: 25%;\n(ii) during the second year from the date of grant: maximum 25%, i.e., maximum\n50% in total over the first two years after the date of grant;\n(iii) during the third year from the date of grant: maximum 25%, i.e., maximum\n75% in total over the first three years after the date of grant; and\n(iv) as from the fourth year from the date of grant: 25%, i.e., maximum 100% in\ntotal over the first four years after the date of grant.\nDuring the second, third, and fourth years after the date of grant, the 2024 Share\nOptions granted to a Selected Participant in any capacity other than the capacity of non-\nexecutive director of the Company shall vest pro rata temporis on a quarterly basis.\nThe 2024 Share Options granted to a non-executive director of the Company shall all\nvest on the date of the ordinary general shareholders' meeting that takes place in the\ncalendar year following the calendar year in which the 2024 Share Options were\ngranted, provided that on the date preceding the date of the former ordinary general\nshareholders' meeting the mandate of such non-executive director of the Company has\nnot terminated (without prejudice to section 7.1.3 of the 2024 Share Option Plan).\n3\nEnglish translation - For information purposes only\n(i) Exercisability: Provided that section 7.1.3 of the 2024 Share Option Plan is not\napplicable, all vested 2024 Share Options shall be exercisable during any exercise\nperiod as of and from the moment where such 2024 Share Options became vested 2024\nShare Options. A Selected Participant is allowed to exercise any vested 2024 Share\nOptions during any exercise period following the exercisability date.\n(j) Transferability of the 2024 Share Options: The 2024 Share Options granted to the\nSelected Participants will generally not be transferable (except in case of decease in the\nevent of 2024 Share Options granted to a natural person and except if the board of\ndirectors, or any other committee created or person appointed by the board of directors\nin accordance with the 2024 Share Option Plan, decides otherwise).\n(k) Exercise of the 2024 Share Options: Each of the 2024 Share Options may be exercised\nstarting as from the date of issuance until ten (10) years as of the date on which they\nare issued, at the times and in the manner specified in the 2024 Share Option Plan.\n(l) Increase of the share capital of the Company: Upon exercise of 2024 Share Options\nand issue of new shares, the aggregate amount of the exercise price of the 2024 Share\nOptions will be allocated to (as the case may be, following conversion into the\nCompany's share capital currency, on the basis of the relevant USD/EUR exchange\nratio as shall be published by the European Central Bank (\"ECB\"), as provided in\nsection 5.2 of the 2024 Share Option Plan) the share capital of the Company. To the\nextent that the amount of the exercise price of the 2024 Share Options, per share to be\nissued upon exercise of the 2024 Share Options, exceeds the fractional value of the\nthen existing shares of the Company existing immediately prior to the issue of the new\nshares concerned, a part of the exercise price, per share to be issued upon exercise of\nthe 2024 Share Options, equal to such fractional value shall be booked as share capital,\nwhereby the balance shall be booked as issue premium. Following the capital increase\nand issuance of new shares, each new and existing share shall represent the same\nfraction of the share capital of the Company.\n(m) Issue premium: Any issue premium that will be booked in connection with the 2024\nShare Option Plan shall be accounted for on a non-distributable account on the\nliabilities side of the Company's balance sheet under its net equity, and the account on\nwhich the issue premium will be booked shall, like the share capital, serve as a\nguarantee for third parties and can only be reduced on the basis of a lawful resolution\nof the general shareholders' meeting passed in the manner required for an amendments\nto the Company's articles of association.\n3. JUSTIFICATION OF THE PROPOSED ISSUANCE OF 2024 SHARE OPTIONS\nThe board of directors of the Company deems the proposed issuance of the 2024 Share Options\nto be in the Company's interest because, on the one hand, it enables the Company to receive\nnew financial resources if and when the 2024 Share Options are exercised and, on the other\nhand, it enables the Company to offer to the Selected Participants a (potential) participation in\nthe Company's share capital, which, according to the board of directors, can be considered an\nappropriate tool to value the loyalty and motivation of the Selected Participants and to\nencourage such loyalty and motivation.\nFurthermore, the ability to remunerate Selected Participants with the 2024 Share Options allows\nthe Company to limit the portion of remuneration in cash that the Company would otherwise\nneed to pay to attract or retain renowned experts with the most relevant skills, knowledge and\nexpertise. For the surplus, the board of directors is of the opinion that such remuneration\n4\nEnglish translation - For information purposes only\npackage is adapted and customary for companies in the biotech and life sciences industry that\nare still in a development phase\nFor a more detailed description of the purpose and the objective of the proposed issuance of the\n2024 Share Options, reference is made to section 1 of the 2024 Share Option Plan attached\nhereto as Annex A.\nFinally, the proposed issuance of the 2024 Share Options is also in line with the remuneration\npolicy that, upon recommendation of the nomination and remuneration committee, was\napproved by the Company's ordinary general shareholders' meeting held on May 27, 2021.\nFor all of the above reasons, the board of directors believes that the proposed issuance of the\n2024 Share Options is in the interest of the Company, its shareholders, and other stakeholders.\n4. JUSTIFICATION OF THE PROPOSED ISSUANCE PRICE AND EXERCISE PRICE\nOF THE 2024 SHARE OPTIONS\nPursuant to the terms and conditions of the 2024 Share Option Plan, the 2024 Share Options\nwill be granted to the Selected Participants without any further consideration.\nThe exercise price of the 2024 Share Options shall be determined as summarised in section 2(g)\nof this report. For a detailed overview of the conditions concerning the issuance price and\nexercise price of the 2024 Share Options, reference is made to sections 5.1 and 5.2 of the 2024\nShare Option Plan attached hereto as Annex A.\nThe board of directors considers the fall-back mechanism for the proposed exercise price of the\n2024 Share Options to be justified, since (amongst other things) it limits the potential financial\ndilution to a certain extent and it enables the Company to obtain additional cash resources as\nmentioned above and further described below. In any event, the terms and conditions of the\n2024 Share Options also allow for a different mechanism. This will allow the Company to set\nthe exercise price in such a manner and with reference to such price points as shall be\nappropriate in order to take into account the tax and social security situation of the relevant\nSelected Participants and the ultimate goals of the 2024 Share Options Plan.\nWhether or not a 2024 Share Option will be exercised depends on the (sole) decision of the\nholder of the 2024 Share Option. Such decision will depend on the price of the share of the\nCompany at the moment of the decision whether or not to exercise as compared with the\nexercise price of the 2024 Share Option, since essentially, the holder can realise a capital gain\nat the exercise of the 2024 Share Option if the price of the share of the Company at that moment\nis higher than the exercise price of the 2024 Share Option (not taking into account the possible\ntax related costs and assuming that the holder of the 2024 Share Option can sell the underlying\nshare at such price on the market).\nUpon exercise of the 2024 Share Options, the exercise price shall be booked as share capital\nand issue premium as further described in section 6.2 of this report.\nHence, in view of all of the foregoing, the board of directors believes that the proposed issue\nprice and exercise price of the 2024 Share Options can be sufficiently justified and are without\nprejudice to existing shareholders and holders of outstanding subscription rights (share options)\nof the Company.\n5\nEnglish translation - For information purposes only\n5. JUSTIFICATION OF THE DIS-APPLICATION OF THE PREFERENTIAL\nSUBSCRIPTION RIGHT\nThe board of directors proposes to issue a total number of 2,000,000 2024 Share Options, to be\noffered to the Selected Participants, in accordance with the terms and conditions of the 2024\nShare Option Plan.\nEach 2024 Share Option shall entitle the Selected Participant to acquire one (1) share of the\nCompany, to which the same rights and benefits as the outstanding shares of the Company are\nattached. All 2024 Share Options together entitle the holders thereof to subscribe for an\naggregate 2,000,000 new shares of the Company, which equals to approximately 7.33% of the\nexisting shares representing the share capital of the Company immediately prior to the issuance\nof the 2024 Share Options (assuming all the granted 2024 Share Options are fully exercisable\nand exercised under the terms and conditions of the 2024 Share Option Plan).\nIn order to be able to offer the 2024 Share Options to the Selected Participants in accordance\nwith the proposed terms and conditions of the 2024 Share Option Plan, the board of directors\nproposes to dis-apply the statutory preferential subscription right of the Company's existing\nshareholders and, insofar as required, of the Company's existing holders of subscription rights\n(share options), for the benefit of the Selected Participants in accordance with article 7:191 of\nthe Belgian Companies and Associations Code.\nFor all of the above reasons, the board of directors is of the opinion that the proposed issuance\nof 2024 Share Options, with the proposed dis-application of the statutory preferential\nsubscription right for the benefit of the Selected Participants, and notwithstanding the dilution\nfollowing therefrom for the shareholders and the holders of subscription rights (share options),\nis in the interest of both the Company and the existing shareholders and holders of subscription\nrights (share options).\n6. CERTAIN FINANCIAL CONSEQUENCES\n6.1. Introductory comments\nThe following paragraphs provide an overview of certain financial consequences of the\nproposed issuance and exercise of 2024 Share Options. For further information with regard to\nthe financial consequences of the proposed issuance and exercise of 2024 Share Options,\nreference is also made to the report prepared in accordance with articles 7:180 and 7:191 of the\nBelgian Companies and Associations Code by the statutory auditor of the Company, BDO\nRéviseurs d'Entreprises SRL.\nThe actual financial consequences resulting from the proposed issuance and exercise of 2024\nShare Options cannot yet be determined with certainty, as the final exercise price of the\nrespective 2024 Share Options is still to be determined and will depend on the price of the\nCompany's shares on the relevant stock market or trading platform prior to the date of the grant\nof the 2024 Share Options. In addition, whether or not certain financial consequences will\nmaterialise will depend on whether the 2024 Share Options will be granted to Selected\nParticipants, and whether these 2024 Share Options will ultimately be exercised. The decision\nto exercise the 2024 Share Options is a decision that solely rests with the holder of the 2024\nShare Options, and will likely be in function of the market price of the shares of the Company\nat the moment of exercise compared to the exercise price of the relevant 2024 Share Options\n(see also below).\n6\nEnglish translation - For information purposes only\nLikewise, the actual financial consequences resulting from the exercise or conversion for shares\nof the other outstanding and proposed new dilutive instruments of the Company cannot yet be\ndetermined with certainty.\nAccordingly, the discussion herein of the financial consequences of the proposed issuance\nand exercise of the 2024 Share Options for existing shareholders is purely illustrative and\nhypothetical, and is based on purely indicative financial parameters (where relevant). The\nactual number of shares to be issued upon exercise of the 2024 Share Options and their\nissuance and exercise price may vary significantly from the hypothetical values used in this\nreport.\nSubject to the foregoing reservations, for the purposes of the illustration of some of the financial\nconsequences of the exercise of the 2024 Share Options and notably the dilution for the\nshareholders, the following parameters and assumptions were used:\n1\n(a) Exchange Rate : For the purpose of the simulations and illustrations below, the\nfollowing exchange rate is used: USD 1.0743 for 1 EUR, which is the exchange rate as\npublished by the ECB on\nhttps://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchang\ne_rates/html/index.en.html on May 8, 2024( the \"Exchange Rate\").\n(b) Hypothetical exercise price: The hypothetical exercise price of the 2024 Share Options\nto be issued (to be determined as set out in paragraph 2(g) of this report) will be:\n(i) EUR 2.3736 per 2024 Share Option (or USD 2.5500, representing a discount\nof 15% against the closing price of the Company's shares on Nasdaq on\nMay 8, 2024 (i.e., USD 3.00));\n(ii) EUR 2.5133 per 2024 Share Option (or USD 2.7000, representing a discount\nof 10% against the closing price of the Company's shares on Nasdaq on\nMay 8, 2024 (i.e., USD 3.00)); and\n(iii) EUR 2.9321 per 2024 Share Option (or USD 3.1500, representing a premium\nof 5% against the closing price of the Company's shares on Nasdaq on\nMay 8, 2024 (i.e., USD 3.00)).\n(c) Current share capital: At the date of this report, the share capital of the Company\namounts to EUR 164,302,752.89 represented by 27,288,093 shares without nominal\nvalue, each representing the same fraction of the share capital, i.e., (rounded)\nEUR 6.0210. The share capital is entirely and unconditionally subscribed for and is\nfully paid-up.\n(d) Share Options: Furthermore, the following 18,388,230 subscription rights issued by the\nCompany are still outstanding at the date of this report (the \"Share Options\"):\n(i) 522,500 outstanding share options issued under the form of subscription rights\non June 23, 2014 (\"2014 Share Options\") (of which 68,500 share options have\n2\nnot yet been granted) ;\n1\nThe Company's shares are listed on Nasdaq, where they are traded in USD. However, the Company's share capital\nis currently expressed in EUR. In view of the current difference between the Company's shares trading currency and\nthe Company's share capital currency, except for amounts in the financial dilution simulations in paragraph 6.4\nbelow, all amount in USD used in the simulations herein are converted in EUR on the basis of the Exchange Rate.\n2\nAll 2014 Share Options that are not exercised by June 23, 2024 will automatically lapse and become null and void.\n7\nEnglish translation - For information purposes only\n(ii) 1,866,000 outstanding share options issued under the form of subscription\nrights on June 19, 2017 (\"2017 Share Options\") (which have all been\ngranted);\n(iii) 2,632,860 outstanding share options issued under the form of subscription\nrights on June 21, 2019 (\"2019 Share Options\") (of which 1,500 share options\nhave not yet been granted);\n(iv) 3,525,000 outstanding share options issued under the form of subscription\nrights on May 27, 2021 (\"2021 Share Options\") (which have all been granted);\n(v) 4,851,870 outstanding share options issued under the form of subscription\nrights on May 25, 2022 (\"2022 Share Options\") (of which 2,500 share options\nhave not yet been granted); and\n(vi) 4,990,000 outstanding share options issued under the form of subscription\nrights on June 30, 2023 (\"2023 Share Options\") (of which 1,960,000 share\noptions have not yet been granted).\nEach of the aforementioned Share Options entitles the holders thereof to subscribe for\none new share of the Company upon exercise of the relevant Share Option. For the\npurpose of the full-dilution scenario calculations further below, it is assumed that all of\nthe 18,388,230 outstanding Share Options (including the 68,500 outstanding 2014\nShare Options, the 1,500 outstanding 2019 Share Options, the 2,500 outstanding 2022\nShare Options and the 1,960,000 outstanding 2023 Share Options that can still be\ngranted) have been effectively granted, have vested and are exercisable. On that basis,\nif all 18,388,230 Share Options were exercised, 1,838,823 new shares would need to\nbe issued by the Company.\n(e) Exact Sciences Earn-Out Consideration: On August 2, 2022, the Company entered into\nan asset purchase agreement with Genomic Health, Inc. (a subsidiary of Exact Sciences\nCorporation referred to herein as \"Exact Sciences\"), pursuant to which, among other\nthings and subject to the terms and conditions included in the asset purchase agreement,\nExact Sciences agreed to sell and assign, and the Company agreed to purchase and\nassume, the business of developing, marketing and performing the Oncotype DX\nGenomic Prostate Score test (the \"GPS Test Business\") for an aggregate purchase\nprice of up to USD 100,000,000.00 to be paid as follows: (i) an amount of\nUSD 24,999,999.64, which was paid on the date of the asset purchase agreement, (ii)\nan amount of USD 5,000,000.36, which was contributed in kind by Exact Sciences to\nthe Company on August 11, 2022, within the context of a capital increase by the\nCompany within the framework of the authorised capital of the Company against the\nissuance by the Company of 6,911,710 new shares, and (iii) an additional aggregate\nearn-out amount of up to USD 70,000,000.00. On August 23, 2023, the Company and\nExact Sciences entered into an amendment to the asset purchase agreement (as further\namended on October 9, 2023), pursuant to which they agreed to defer the payment of\nthe up to USD 70,000,000.00 earn-out amount, in consideration of (i) the increase and\nreplacement of the up to USD 70,000,000.00 earn-out amount by an aggregate earn-\nout amount of up to USD 82,500,000.00 to be paid by the Company to Exact Sciences\nupon achievement of certain revenue milestones related to fiscal years 2023 through\n2025, with the maximum earn-out payable in relation to 2023 and 2024 not to exceed\nUSD 30,000,000.00 plus USD 10,000,000.00 (or such lesser amount if the maximum\nearn-out amount required to be paid exceeds USD 82,500,000.00 in the aggregate) and\nUSD 40,000,000.00, respectively (the \"Exact Sciences Earn-Out Consideration\"),\n(ii) the payment of an additional cash consideration of USD 250,000 (paid on August\n23, 2023), (iii) the contribution in kind (completed on October 20, 2023) of an amount\n8\nEnglish translation - For information purposes only\nof USD 877,500.00, within the context of a capital increase by the Company within the\nframework of the authorised capital of the Company against the issuance by the\nCompany of 2,500,000 new shares, and (iv) the commitment by the Company to issue\nto the benefit of Exact Sciences the Exact Sciences Warrants (as defined below). At the\noption of the Company, amounts reflecting the Exact Sciences Earn-Out Consideration\ncan be settled in cash or through the issuance of additional shares of the Company by\ncontribution in kind of the relevant receivables due by the Company (at an issue price\nper share valued in function of a volume weighted average trading price of the\nCompany's shares at the end of the relevant earn-out period) to be delivered to Exact\nSciences, provided that the aggregate number of shares held by Exact Sciences shall\nnot exceed more than 7.5% of the outstanding shares of the Company.\nFor the purpose of the full-dilution scenario calculations further below, it is assumed\nthat the full Exact Sciences Earn-Out Consideration amount of USD 82,500,000.00 is\nconverted, by applying the Exchange Rate (see paragraph 6.1(a)), into\nEUR 76,794,191.56 and is fully paid in kind by the Company to Exact Sciences by the\nissuance of new shares of the Company at the hypothetical issue prices (see paragraph\n(6.1(b)) in consideration of the settlement through a contribution in kind of receivables\ndue by the Company to Exact Sciences up to the Earn-Out Consideration. To reflect\nmaximum dilution, the maximum 7.5% shareholding cap (as described above) is not\ntaken into account in the simulations below. Should this 7.5% shareholding cap be\napplied, only 3,678,875 shares could be issued to Exact Sciences on a fully diluted\nbasis, taking into account the most dilutive parameters used herein.\n(f) Exact Sciences Warrants: In the context of the amendment to the asset purchase\nagreement with Exact Sciences (as described in paragraph 6.1(e) above), the Company\nhas committed to issue to the benefit of Exact Sciences, 1,000,000 new subscription\nrights for new shares of the Company (each exercisable for 1 new share of the Company\nat an exercise price per new share of USD 5.265) with a term until August 22, 2028\n(the \"Exact Sciences Warrants\"). The proposed issuance of the Exact Sciences\nWarrants will be submitted for approval by the same extraordinary general\nshareholders' meeting of the Company as the one that will need to decide on the\nissuance of the 2024 Share Options and the OrbiMed Warrants (as defined below).\nFor the purpose of the full dilution scenario calculations further below, it is assumed\nthat the 1,000,000 Exact Sciences Warrants are issued and all exercised, for a total of\n1,000,000 newly issued shares at an issue price of USD 5.265 per new shares, resulting\nin a total issue price of USD 5,265,000, or, applying the Exchange Rate, at an issue\nprice of EUR 4.900 per new shares, resulting in a total issue price of EUR 4,900,000\n(including issue premium, if any).\n(g) ATM Facility: On April 30, 2024, the Company entered into a sales agreement with\nTD Securities (USA) LLC (\"TD Cowen\") with respect to an equity offering program\nunder which the Company may offer and place new shares, via TD Cowen and through\nvarious placements from time to time in an “at the market offering”, as defined in Rule\n415 promulgated under the Securities Act of 1933, as amended, and the rules and\nregulations thereunder, for an aggregate maximum offering amount of USD 50,000,000\n(the \"ATM Facility\"). The actual number of new shares to be issued in the framework\nof the ATM Facility will vary depending on the effective placements of new shares and\non the price for each such placements. However the number of new shares to be issued\nin the framework of the ATM Facility shall not exceed 100,000,000 shares. Such new\nshares will be placed at a final subscription price per new share in function of the then\ncurrent USD market prices on Nasdaq at the time of the relevant placements, while\nsuch issue price cannot be lower than USD 0.50.\n9\nEnglish translation - For information purposes only\nFor the purpose of the full-dilution scenario calculations further below, it is assumed\nthat (i) new shares are issued under the ATM Facility for the full amount of\nUSD 50,000,000.00, and (ii) all such new shares issued under the ATM Facility are\nissued at an issue price per share of USD 3.00 (i.e., the closing price of the Company's\nshares on Nasdaq on May 8, 2024). On that basis, applying the Exchange Rate,\nEUR 46,541,934.28 would be raised by the Company against the issuance 16,681,696\nnew shares of the Company at an issue price of EUR 2.79 per share.\n(h) OrbiMed Warrants: On May 1, 2024, the Company entered into a credit agreement, as\nguarantor, with MDxHealth, Inc., a wholly-owned subsidiary of the Company, as\nborrower, and ORC SPV LLC (\"OrbiMed\"), as lender and administrative agent,\npursuant to which OrbiMed agreed to provide a five-year senior secured credit facility\nin an aggregate principal amount of up to USD 100 million, of which (i) USD 55\nmillion was advanced on the date of closing, (ii) USD 25 million will be made\navailable, at MDxHealth, Inc.’s discretion, on or prior to March 31, 2025, subject to\ncertain net revenue requirements and other customary conditions, and, and (iii) USD\n20 million will be made available, at MDxHealth, Inc.’s discretion, on or prior to March\n31, 2026, subject to certain net revenue requirements and other customary conditions.\nFurthermore, pursuant to the credit agreement, the Company has committed to issue to\nthe benefit of affiliates of OrbiMed, 1,243,060 new subscription rights for new shares\nof the Company (each exercisable for 1 new share of the Company at an exercise price\nper new share of USD 2.4134) with a 5 years term as from their issue date (the\n\"OrbiMed Warrants\"). The proposed issuance of the OrbiMed Warrants will be\nsubmitted for approval by the same extraordinary general shareholders' meeting of the\nCompany as the one that will need to decide on the issuance of the 2024 Share Options\nand the Exact Sciences Warrants.\nFor the purpose of the full dilution scenario calculations further below, it is assumed\nthat the 1,243,060 OrbiMed Warrants are issued and all exercised, for a total of\n1,243,060 newly issued shares at an issue price of USD 2.41 (rounded) per new shares,\nresulting in a total issue price of USD 2,995,774.60, or, applying the Exchange Rate,\nat an issue price of EUR 2.24 (rounded) per new shares, resulting in a total issue price\nof EUR 2,784,454.40 (including issue premium, if any). It is also assumed that the\naggregate subscription price for the OrbiMed Warrants is paid in full upon issuance\nand subscription of the OrbiMed Warrants.\n(i) Allocation of the issue price of the outstanding dilutive instruments: Upon the issuance\nof new shares upon exercise of the OrbiMed Warrants (should their issuance be\napproved by an extraordinary general shareholders' meeting of the Company), and/or\nthe full placement of the ATM Facility, and/or the contribution of the Exact Sciences\nEarn-Out Consideration, and/or the exercise of the Share Options, and/or the exercise\nof the Exact Sciences Warrants (should their issuance be approved by an extraordinary\ngeneral shareholders' meeting of the Company), the amount of the issue price of the\nrelevant new shares will be booked as equity (in the form of share capital and share\npremium, as the case may be). The amount that shall be booked as share capital shall,\non a per share basis, be equal to the amount of the applicable fractional value of the\nCompany's shares at the relevant time. The balance, as the case may be, shall be booked\nas issue premium.\n10\nEnglish translation - For information purposes only\nIn this report, when reference is made to \"outstanding dilutive instruments\", it refers,\nrespectively, to the issuance of new shares upon exercise of the OrbiMed Warrants (assuming\ntheir issuance will be approved by an extraordinary general shareholders' meeting of the\nCompany), the full placement of the ATM Facility, the contribution of the Exact Sciences Earn-\nOut Consideration, exercise of the outstanding Share Options and exercise of the Exact\nSciences Warrants (assuming their issuance will be approved by an extraordinary general\nshareholders' meeting of the Company).\nWhether the outstanding Share Options, the OrbiMed Warrants (assuming their issuance will\nbe approved by an extraordinary general shareholders' meeting of the Company) or the Exact\nSciences Warrants (assuming their issuance will be approved by an extraordinary general\nshareholders' meeting of the Company) will be effectively exercised will ultimately depend on\nthe decision of the respective holders thereof. Such decision will likely be in function of the\nmarket price of the shares of the Company at the moment of exercise, compared to their\nrespective exercise prices. The respective holders will likely not exercise if the market price of\nthe shares of the Company is less than the relevant exercise price.\nWhether the Exact Sciences Earn-Out Consideration amount is due and converted into shares\nof the Company will depend on the fulfilment (or not) of the respective conditions provided by\nthe asset purchase agreement, as amended from time to time. Furthermore, should an Exact\nSciences Earn-Out Consideration amount be due by the Company to Exact Sciences, the\nCompany can also ultimately opt to pay such Exact Sciences Earn-Out Consideration amount\nin cash rather than in shares.\nWhether the full USD 50,000,000 amount is placed by the Company under the ATM Facility,\nthe applicable issue prices for such placements and the total number of new shares issued under\nthe ATM Facility will depend on the ultimate decision of the Company to proceed with such\nplacements, the terms at which such placements are made (including the relevant USD market\nprices on Nasdaq used as reference to determine the relevant issue prices) and whether such\nplacements are successful or not.\nIn order to reflect the maximum dilution below, it is assumed that none of the existing\nshareholders, holders of Share Options, OrbiMed or Exact Sciences will be granted with and\nwill exercise any of the 2024 Share Options.\n6.2. Evolution of the share capital, voting power, participation in the results and other\nshareholder rights\nEach share in the Company currently represents an equal part of the share capital of the\nCompany and provides for one vote in function of the part of the capital it represents. The\nissuance of the new shares upon exercise of the 2024 Share Options will lead to a dilution of\nthe existing shareholders of the Company and of the relative voting power of each share in the\nCompany.\nThe dilution relating to the voting right also applies, mutatis mutandis, to the participation of\neach share in the profit and liquidation proceeds and other rights attached to the shares of the\nCompany, such as the statutory preferential subscription right in case of a capital increase in\ncash through the issuance of new shares or in case of the issuance of new subscription rights or\nconvertible bonds.\nSpecifically, prior to the issuance of new shares upon exercise of the 2024 Share Options (and\nprior to the issuance of new shares pursuant the other outstanding dilutive instruments), each\nshare of the Company participates equally in the profit and liquidation proceeds of the Company\nand each shareholder has a statutory preferential subscription right in case of a capital increase\nin cash or in case of the issuance of new subscription rights or convertible bonds. Upon the\nissuance of new shares upon exercise of the 2024 Share Options, the new shares to be issued\n11\nEnglish translation - For information purposes only\nwill have the same rights and benefits as, and rank pari passu in all respects with, the existing\nand outstanding shares of the Company at the moment of their issuance and delivery, and will\nbe entitled to dividends and other distributions in respect of which the relevant record date or\ndue date falls on or after the date of issuance and delivery of the new shares. As a result (and\nto the extent the new shares will be issued and subscribed for pursuant to the exercise of the\n2024 Share Options), the participation by the existing shareholders in the profit and liquidation\nproceeds of the Company and their holders' statutory preferential subscription right in case of\na capital increase in cash, shall be diluted accordingly.\nA similar dilution occurs upon exercise or conversion of the other outstanding dilutive\ninstruments.\nFurthermore, should the final exercise price of the new shares be below the fractional value of\nthe existing shares of the Company (i.e., currently rounded EUR 6.0210), to some extent, the\nissuance of the new shares might have had a reduced voting right, a reduced participation in the\nprofit and liquidation proceeds, and a reduced preferential subscription right. However, all of\nthe new shares to be issued will have to have the same rights and benefits as, and rank pari\npassu in all respects with, the existing and outstanding shares of the Company. Therefore, in\naccordance with article 7:178 of the Belgian Companies and Associations Code, after the\ncompletion of the issuance of the new shares upon exercise of the 2024 Share Options, all of\nthe Company's outstanding shares will have the same (as the case may be adjusted) fractional\nvalue. This would entail that, at least conceptually, there would be a dilution of the voting right,\nthe right to participate in the profit and liquidation proceeds, and the preferential subscription\nright of the existing shares of the Company to the benefit of the new shares.\nSubject to the methodological reservations noted in paragraph 6.1, the evolution of the share\ncapital and the number of shares, with voting rights attached thereto, of the Company as a result\nof the proposed issuance and exercise of all 2,000,000 2024 Share Options (and the subsequent\nissuance of 2,000,000 new shares resulting from it) is simulated below in a scenario before\ndilution due to outstanding dilutive instruments, as well as in a scenario after dilution due to\noutstanding dilutive instruments.\nEvolution of the number of outstanding shares\nExercise price\nEUR 2.3736 EUR 2.5133 EUR 2.9321\nEquivalent to Equivalent to Equivalent to\nUSD 2.5500 USD 2.7000 USD 3.1500\nAfter exercise of the 2024 Share Options\nbut before dilution due to outstanding\ndilutive instruments\n(A) Outstanding shares ........................... 27,288,093 27,288,093 27,288,093\n(B) New shares to be issued upon\nexercise of the 2024 Share Options ........ 2,000,000 2,000,000 2,000,000\n(C) Total number of shares outstanding\nafter (B) ................................................... 29,288,093 29,288,093 29,288,093\n(D) Dilution ............................................ 6.83% 6.83% 6.83%\nAfter dilution due to outstanding dilutive\ninstruments but before the exercise of the\n2024 Share Options\n(A) Outstanding shares ........................... 27,288,093 27,288,093 27,288,093\n12\nEnglish translation - For information purposes only\nExercise price\nEUR 2.3736 EUR 2.5133 EUR 2.9321\nEquivalent to Equivalent to Equivalent to\nUSD 2.5500 USD 2.7000 USD 3.1500\n(B) New shares to be issued upon\nexercise of all outstanding Share Option 1,838,823 1,838,823 1,838,823\n(C) New shares to be issued upon\ncontribution of the Exact Sciences Earn-\nOut Consideration ................................... 32,352,941 30,555,555 26,190,476\n(D) New shares to be issued upon\nexercise of all Exact Sciences Warrants . 1,000,000 1,000,000 1,000,000\n(E) New shares to be issued upon\nexercise of all OrbiMed Warrants ........... 1,243,060 1,243,060 1,243,060\n(F) New shares to be issued upon full\nplacement of the ATM Facility ............... 16,681,696 16,681,696 16,681,696\n(G) Total number of new shares to be\nissued under (B), (C), (D), (E) and (F) ... 53,116,520 51,319,134 46,954,055\n(H) Total number of shares outstanding\nafter (B), (C), (D), (E) and (F) ................ 80,404,613 78,607,227 74,242,148\nAfter the exercise of the 2024 Share\nOptions and after dilution due to\noutstanding dilutive instruments\n(A) Outstanding shares after dilution due\nto outstanding dilutive instruments ......... 80,404,613 78,607,227 74,242,148\n(B) New shares to be issued upon\nexercise of the 2024 Share Options ........ 2,000,000 2,000,000 2,000,000\n(C) Total number of shares outstanding\nafter (B) ................................................... 82,404,613 80,607,227 76,242,148\n(D) Dilution ............................................ 2.43% 2.48% 2.62%\nSubject to the methodological reservations noted in paragraph 6.1, the table below reflects the\nevolution of the share capital, assuming the exercise of all 2,000,000 2024 Share Options and\nthe subsequent issuance of 2,000,000 new shares resulting from it. The maximum amount of\nshare capital increase (excluding issue premium) is computed by multiplying the number of\nnew shares to be issued (i.e., 2,000,000) with the applicable issue price (as the relevant price is\nin each case lower than the fractional value of the shares of the Company (i.e., currently rounded\nEUR 6.0210 per share)).\nEvolution of the share capital(1)\nExercise price\nEUR 2.3736 EUR 2.5133 EUR 2.9321\nEquivalent to Equivalent to Equivalent to\nUSD 2.5500 USD 2.7000 USD 3.1500\nBefore the exercise of the 2024 Share\nOptions\n(A) Share capital (in EUR) ..............\n164,302,752.89 164,302,752.89 164,302,752.89\n(B) Outstanding shares .................... 27,288,093 27,288,093 27,288,093\n13\nEnglish translation - For information purposes only\nExercise price\nEUR 2.3736 EUR 2.5133 EUR 2.9321\nEquivalent to Equivalent to Equivalent to\nUSD 2.5500 USD 2.7000 USD 3.1500\n(C) Fractional value (in EUR)\n(rounded) ......................................... 6.0210 6.0210 6.0210\nExercise of the 2024 Share Options\n(A) Increase of share capital (in\nEUR) ................................................ 4,747,277.30 5,026,528.90 5,864,283.72\n(B) New shares to be issued upon\nexercise of the 2024 Share Options.. 2,000,000 2,000,000 2,000,000\nAfter the exercise of the 2024 Share\nOptions\n(A) Share capital (in EUR) .............. 169,050,030.19 169,329,281.79 170,167,036.61\n(B) Outstanding shares .................... 29,288,093 29,288,093 29,288,093\n(C) Fractional value (in EUR)\n(rounded) ......................................... 5.7720 (2) 5.7815 (2) 5.8101(2)\n____________\nNotes:\n(1) This simulation does not take into account the exercise or conversion of outstanding dilutive instruments.\n(2) In such simulations, the respective exercise price would be below the fractional value of the existing shares\nof the Company (i.e., rounded EUR 6.0210). Therefore, in accordance with article 7:178 of the Belgian\nCompanies and Associations Code, after the exercise of the 2024 Share Options, all of the Company's\noutstanding shares will have the same fractional value, i.e., rounded EUR 5.7720, EUR 5.7815 and\nEUR 5.8101.\n6.3. Participation in the consolidated accounting net equity\nThe evolution of the consolidated accounting net equity of the Company as a result of the\nexercise of the 2024 Share Options is simulated below.\nThe simulation is based on the audited consolidated annual financial statements of the Company\nfor the financial year ended on December 31, 2023 (which have been prepared in accordance\nwith the International Financial Reporting Standards, as adopted by the European Union\n(\"IFRS\") and which have been submitted to the Company's annual shareholders' meeting for\napproval). The consolidated accounting net equity of the Company as at December 31, 2023\namounted to EUR 6,709 ('000) (rounded) (i.e., USD 7,208 ('000) (rounded)), on the basis of the\nExchange Rate) or EUR 0.2459 (rounded) per share (based on 27,288,093 outstanding shares\nas at December 31, 2023). The simulation does not take into account any changes in the\nconsolidated accounting net equity since December 31, 2023.\nFor further information on the Company's net equity position on December 31, 2023, reference\nis made to the financial statements of the Company, which are available on the Company's\nwebsite.\nBased on the assumptions set out above, as a result of the exercise of 2024 Share Options,\nwithout taking into account the other outstanding dilutive instruments, the Company's\naccounting net equity on a consolidated basis, would be increased as indicated below:\n14\nEnglish translation - For information purposes only\nEvolution of the consolidated accounting net equity\nExercise price\nEUR 2.3736 EUR 2.5133 EUR 2.9321\nEquivalent to Equivalent to Equivalent to\nUSD 2.5500 USD 2.7000 USD 3.1500\nConsolidated net equity for FY\n2023\n(A) Net equity (in EUR '000)\n(rounded) .................................. 6,709 6,709 6,709\n(B) Outstanding shares ............. 27,288,093 27,288,093 27,288,093\n(C) Net equity per share (in\nEUR) (rounded) ........................ 0.2459 0.2459 0.2459\nExercise of the 2024 Share\nOptions\n(A) Increase of net equity (in\nEUR '000) (rounded) (1) ............ 4,747 5,027 5,864\n(B) New shares to be issued\nupon exercise of the 2024 Share\nOptions ..................................... 2,000,000 2,000,000 2,000,000\nAfter exercise of the 2024 Share\nOptions\n(A) Net equity (in EUR '000)\n(rounded) .................................. 11,456 11,736 12,573\n(B) Outstanding shares ............. 29,288,093 29,288,093 29,288,093\n(C) Net equity per share (in\nEUR) (rounded) ........................ 0.3912 0.4007 0.4293\n____________\nNotes:\n(1) Consisting of the amount of the capital increase and the amount of the increase of issue premium, as the\ncase may be, but not reflecting that the accounting of this amount may be subject to further adjustments\npursuant to IFRS.\nThe table above demonstrates that the issuance of the 2,000,000 2024 Share Options and the\nsubsequent exercise of all 2024 Share Options will, from a pure accounting point of view, lead\nto an increase of the amount represented by each share in the consolidated accounting net equity\nof the Company.\n6.4. Financial dilution\nThe evolution of the market capitalisation as a result of the exercise of the 2024 Share Options\nis simulated below.\nSubject to the methodological reservations noted in paragraph 6.1, the table below reflects the\nimpact of the exercise of the 2024 Share Options, without taking into account the other\noutstanding dilutive instruments, on the market capitalisation and the resulting financial\ndilution at various price levels, assuming the exercise of all 2,000,000 2024 Share Options and\nthe subsequent issuance of 2,000,000 new shares resulting from it.\nAfter close of trading on Nasdaq on May 8, 2024, the Company's market capitalisation was\nUSD 81,864,279.00, on the basis of a closing price of USD 3.0000 per share. Assuming that,\nfollowing the exercise of the 2024 Share Options, without taking into account the other\n15\nEnglish translation - For information purposes only\noutstanding dilutive instruments, the market capitalisation increases exclusively with the funds\nraised on the basis of the parameters set out above, the new market capitalisation would then\nbe rounded, respectively, to USD 2.9693, USD 2.9795 and USD 3.0102 per share. This would\nrepresent a (theoretical) financial dilution of 1.02% and 0.68% and a (theoretical) financial\naccretion of 0.34% per share, respectively.\nEvolution of the market capitalisation and financial dilution\nExercise price\nEUR 2.3736 EUR 2.5133 EUR 2.9321\nEquivalent to Equivalent to Equivalent to\nUSD 2.5500 USD 2.7000 USD 3.1500\nBefore the exercise of the 2024\nShare Options(1)\n(A) Market capitalisation (in\nUSD) ....................................... 81,864,279.00 81,864,279.00 81,864,279.00\n(B) Outstanding shares ............ 27,288,093 27,288,093 27,288,093\n(C) Market capitalisation per\nshare (in USD) ........................ 3.0000 3.0000 3.0000\nExercise of the 2024 Share\nOptions\n(A) Funds raised (in USD) ...... 5,100,000.00 5,400,000.00 6,300,000.00\n(B) New shares to be issued\nupon exercise of the 2024 Share\nOptions .................................... 2,000,000 2,000,000 2,000,000\nAfter the exercise of the 2024\nShare Options\n(A) Market capitalisation (in\nUSD) ....................................... 86,964,279.00 87,264,279.00 88,164,279.00\n(B) Outstanding shares ............ 29,288,093 29,288,093 29,288,093\n(C) Market capitalisation per\nshare (in USD) (rounded) ........ 2.9693 2.9795 3.0102\nDilution/Accretion ...................... -1.02% -0.68% 0.34%\n____________\nNotes:\n(1) At the date of this report and not taking into account the potential issuance of new shares pursuant to the\nexercise of other outstanding dilutive instruments.\n6.5. Other financial consequences\nIt is expected that, in the context of the Company's consolidated financial statements in\naccordance with the IFRS, the 2024 Share Options will be accounted for in accordance with\n(among others) IFRS 2 (\"Share-based payment\"). The actual application of the reporting\nstandard, the timing of initial recognition and the valuation of the 2024 Share Options are still\nto be determined and assessed. The actual amount will ultimately depend on the actual exercise\nprice of the relevant 2024 Share Options.\nFor a further discussion on the financial consequences of the proposed issuance of the 2024\nShare Options and their subsequent exercise, the board of directors refers to the report prepared\nin connection therewith by the statutory auditor of the Company.\n16\nEnglish translation - For information purposes only\n* * *\n[signature page follows]\nDone on May 13, 2024.\n17\nEnglish translation - For information purposes only\nOn behalf of the board of directors,\n[SIGNED] [SIGNED]\nBy: _______________________ By: ________________________\nDirector Director\n18\nEnglish translation - For information purposes only\nANNEX A\n2024 SHARE OPTION PLAN\n19"
        },
        {
          "title": "Board Report Exact Sciences Warrants (EN)",
          "url": "https://mdxhealth.com/wp-content/uploads/2024/05/12EN-Board-Report-Exact-Sciences-Warrants-2024-ENG.pdf",
          "content": "English translation - For information purposes only\nMDXHEALTH\nLimited Liability Company\nCAP Business Center\nZone Industrielle des Hauts-Sarts\nRue d'Abhooz 31\n4040 Herstal\nBelgium\nRegistered with the Register of Legal Persons\nVAT BE 0479.292.440 (RLP Liège, division Liège)\n____________________________________________________\nREPORT OF THE BOARD OF DIRECTORS\nIN ACCORDANCE WITH ARTICLES 7:180, 7:191 AND 7:193 OF THE BELGIAN\nCOMPANIES AND ASSOCIATIONS CODE\n____________________________________________________\n1. INTRODUCTION\nOn August 2, 2022, MDxHealth SA (the \"Company\") entered into an asset purchase agreement\n(the \"Asset Purchase Agreement\") with Genomic Health, Inc. (a subsidiary of Exact Sciences\nCorporation referred to herein as \"Exact Sciences\"), pursuant to which among other things and\nsubject to the terms and conditions included in the Asset Purchase Agreement, Exact Sciences\nagreed to sell and assign, and the Company agreed to purchase and assume, the business of\ndeveloping, marketing and performing the Oncotype DX Genomic Prostate Score test (the\n\"GPS Test Business\"), in consideration of (i) a cash consideration of USD 24,999,999.64, (ii)\nthe Initial Earn-Out Consideration (as defined below), and (iii) the First Closing Equity\nConsideration (as defined below).\nOn August 23, 2023, the Company and Exact Sciences entered into an amendment to the Asset\nPurchase Agreement (as further amended on October 9, 2023, the \"Amendment\"), pursuant to\nwhich they agreed to defer the payment of the Initial Earn-Out Consideration, in consideration\nof (i) the increase and replacement of the Initial Earn-Out Consideration by the Amended Earn-\nOut Consideration (as defined below), (ii) a cash consideration of USD 250,000, (iii) the\nSecond Closing Equity Consideration (as defined below) and (iv) the commitment by the\nCompany to issue to the benefit of Exact Sciences 1,000,000 new subscription rights for new\nshares of the Company (each exercisable for 1 new share of the Company) with a term until\nAugust 22, 2028, (the \"Exact Sciences Warrants\").\nIn this context, the board of directors submits to the extraordinary general shareholders' meeting\nof the Company convened on May 30, 2024 (or at any other subsequent date, should the legally\nrequired attendance quorum not be met at such meeting) (the \"EGM\") the proposal to issue\n1,000,000 Exact Sciences Warrants under the conditions described below in this report, and to\ndis-apply, in the interest of the Company, the statutory preferential subscription right of the\nexisting shareholders of the Company and, to the extent necessary, of the Company's existing\nholders of subscription rights (share options), to the benefit of Exact Sciences, as provided for\nin the Amendment (the proposed issuance of the Exact Sciences Warrants, the \"Transaction\").\nShareholders should note that the Exact Sciences Warrants are complex instruments and that\nExact Sciences could benefit from a significant discount when subscribing for new shares by\nvirtue of the potential exercise of the Exact Sciences Warrants, as described below.\n1\nEnglish translation - For information purposes only\nThe Exact Sciences Warrants are subscription rights within the meaning of articles 7:67 et seq.\nof the Belgian Companies and Associations Code of 23 March 2019 (as amended from time to\ntime) (the \"Belgian Companies and Associations Code\").\nFor the purposes of the Transaction, this report has been prepared by the board of directors of\nthe Company, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies\nand Associations Code, in connection with the proposal of the board of directors to issue the\nExact Sciences Warrants and to dis-apply, in the interest of the Company, the statutory\npreferential subscription right of the existing shareholders of the Company and, to the extent\nnecessary, of the Company's existing holders of subscription rights (share options), to the\nbenefit of Exact Sciences.\nIn accordance with article 7:180 of the Belgian Companies and Associations Code, the board\nof directors provides in this report a justification of the proposed Transaction, including a\njustification of the proposed exercise price of the Exact Sciences Warrants, and a description\nof the consequences of the proposed Transaction for the financial and shareholder rights of the\nshareholders of the Company.\nIn accordance with article 7:191 of the Belgian Companies and Associations Code, the board\nof directors also provides in this report a justification of the proposal to dis-apply, in the interest\nof the Company, the statutory preferential subscription right of the existing shareholders of the\nCompany and, to the extent necessary, of the Company's existing holders of subscription rights\n(share options) in connection with the capital increase proposed in the Transaction and a\ndescription of the consequences thereof for the financial and shareholder rights of the\nshareholders of the Company.\nIn accordance with article 7:193 of the Belgian Companies and Associations Code, the\njustification of the proposed Transaction and the proposed exercise price of the Exact Sciences\nWarrants shall take into account in particular the financial situation of the Company, the identity\nof Exact Sciences and the nature and size of Exact Sciences' contribution.\nThis report must be read together with the report prepared in accordance with articles 7:180,\n7:191 and 7:193 of the Belgian Companies and Associations Code by the Company's statutory\nauditor, BDO Réviseurs d'Entreprises SRL, a limited liability company organised and existing\nunder the laws of Belgium, with registered office at Da Vincilaan 9, 1930 Zaventem, Belgium,\nrepresented by Mr. Bert Kegels.\n2. CONTEXT\n2.1. Asset Purchase Agreement and Amendment\nFounded in February 1995, Exact Sciences is a leading, global, advanced cancer diagnostics\ncompany, listed on Nasdaq, which has developed some of the most impactful tests in cancer\ndiagnostics.\nOn August 2, 2022, the Company and Exact Sciences entered into the Asset Purchase\nAgreement, pursuant to which, subject to its terms and conditions, Exact Sciences agreed to\nsell and assign, and the Company agreed to purchase and assume, the GPS Test Business for\nan aggregate purchase price of up to USD 100,000,000.00. Pursuant to the Asset Purchase\nAgreement, the aggregate purchase price was (to be) paid as follows:\n(a) Cash consideration: An amount of USD 24,999,999.64 was paid on the date of the\nAsset Purchase Agreement.\n(b) First Closing Equity Consideration: An amount of USD 5,000,000.36, which remained\noutstanding as a payable (without accruing interest) due by the Company as from the\n2\nEnglish translation - For information purposes only\ndate of the Asset Purchase Agreement, was contributed in kind on August 11, 2022, by\nExact Sciences to the Company within the context of a capital increase by the Company\nwithin the framework of the authorised capital of the Company against the issuance by\nthe Company of 6,911,710 new shares at an issue price of EUR 0.7056 (the \"First\nClosing Equity Consideration\"). The aggregate number of Company's shares held by\nExact Sciences was not to exceed more than 5% of the outstanding shares of the\nCompany.\n(c) Initial Earn-Out Consideration: Following the signing of the Asset Purchase\nAgreement, an additional aggregate earn-out amount of up to USD 70,000,000.00 was\nto be paid by the Company to Exact Sciences upon achievement of certain revenue\nmilestones related to fiscal years 2023 through 2025, with the maximum earn-out\npayable in relation to 2023 and 2024 not to exceed USD 30,000,000.00 and\nUSD 40,000,000.00, respectively (the \"Initial Earn-Out Consideration\"). At the\noption of the Company, amounts reflecting the Initial Earn-Out Consideration could be\nsettled in cash or through the issuance of additional shares of the Company by\ncontribution in kind (at an issue price per share valued in function of a volume weighted\naverage trading price of the Company's shares at the end of the relevant earn-out\nperiod), provided that the aggregate number of shares held by Exact Sciences was not\nto exceed more than 5% of the outstanding shares of the Company.\nSubsequently, in order to defer the payment of the Initial Earn-Out Consideration, On August\n23, 2023, the Company and Exact Sciences entered into the Amendment, the main terms of\nwhich can be summarised as follows:\n(a) Deferment of payments under the earn-out consideration provided by the Asset\nPurchase Agreement: Pursuant to the Amendment, and subject to its terms and\nconditions, Exact Sciences agreed to defer the payment of the Initial Earn-Out\nConsideration due by the Company under the Asset Purchase Agreement by 3 years,\nfrom 2024 to 2027.\n(b) Consideration of payments deferment: In consideration of such payments deferment,\nthe Company agreed to the following:\n(i) Cash consideration: An amount of USD 250,000.00 was paid by the Company\non the date of the Amendment.\n(ii) Second Closing Equity Consideration: An amount of USD 877,500.00 which\nremained outstanding as a payable (without accruing interest) due by the\nCompany as from the date of the Amendment, was contributed in kind on\nOctober 20, 2023, by Exact Sciences to the Company within the context of a\ncapital increase by the Company within the framework of the authorised capital\nof the Company against the issuance by the Company of 2,500,000 new shares\nat an issue price of EUR 0.3324 (the \"Second Closing Equity\nConsideration\"). It was also agreed that the aggregate number of Company's\nshares held by Exact Sciences shall not exceed more than 7.5% of the\noutstanding shares of the Company (compared to 5% previously, under the\nAsset Purchase Agreement).\n(iii) Amended Earn-Out Consideration: The Initial Earn-out Consideration was\nincreased and replaced by an additional aggregate earn-out amount of up to\nUSD 82,500,000.00 to be paid by the Company to Exact Sciences upon\nachievement of certain revenue milestones related to fiscal years 2023 through\n2025, with the maximum earn-out payable in relation to 2023 and 2024 not to\nexceed USD 30,000,000.00 plus USD 10,000,000 (or such lesser amount if the\n3\nEnglish translation - For information purposes only\nmaximum earn-out amount required to be paid exceeds USD 82,500,000.00 in\nthe aggregate) and USD 40,000,000.00, respectively (the \"Amended Earn-\nOut Consideration\"). At the option of the Company, amounts reflecting the\nAmended Earn-Out Consideration can be settled in cash or through the\nissuance of additional shares of the Company by contribution in kind (at an\nissue price per share valued in function of a volume weighted average trading\nprice of the Company's shares at the end of the relevant earn-out period) to be\ndelivered to Exact Sciences, provided that the aggregate number of shares held\nby Exact Sciences shall not exceed more than 7.5% of the outstanding shares\nof the Company (compared to 5% previously, under the Asset Purchase\nAgreement).\n(iv) Exact Sciences Warrants: Pursuant to the Amendment, the Company has\ncommitted to issue, to the benefit of Exact Sciences, 1,000,000 new\nsubscription rights for new shares of the Company (each exercisable for 1 new\nshare of the Company) with a term until August 22, 2028, such issuance having\nto be submitted for approval by an extraordinary general shareholders' meeting\nof the Company to be convened (which is the reason why the present report\nhas been prepared). The principal terms and conditions of the Exact Sciences\nWarrants are summarized in paragraph 3.1 below.\n2.2. Proposed issuance of the Exact Sciences Warrants\nAs indicated above, in the context of the Amendment, the Company has undertaken to Exact\nSciences to issue the Exact Sciences Warrants to the benefit of Exact Sciences. In view hereof,\nthe board of directors of the Company has undertaken to propose to the shareholders of the\nCompany, in the context of the EGM, to approve the issuance by the Company, to the benefit\nof Exact Sciences, of the Exact Sciences Warrants.\nThe Company and Exact Sciences have agreed that the issuance of the Exact Sciences Warrants\nto Exact Sciences was essential for Exact Sciences to agree to the deferment of the payment of\nthe Initial Earn-Out Consideration. Furthermore, in the event that the EGM does not approve\nthe proposed issuance of the Exact Sciences Warrants, the Company may be in breach of its\nobligations under the Amendment.\n3. PROPOSED TRANSACTION\n3.1. Terms and Conditions of the Exact Sciences Warrants\nThe draft terms and conditions of the Exact Sciences Warrants are set out in Annex A to this\nreport of the board of directors (the \"Exact Sciences Warrants Terms and Conditions\"). The\nprincipal terms and conditions of the Exact Sciences Warrants can, for information purposes,\nbe summarised as follows:\n• Issuer: The Company (MDxHealth SA).\n• Right to subscribe for one ordinary share: Each subscription right entitles the holder\nto subscribe for one (1) ordinary share to be issued by the Company.\n• Exercise price: The exercise price of the Exact Sciences Warrants (i.e., the price to be\npaid in cash to subscribe for one new share in the Company when an Exact Sciences\nWarrant is exercised) will be USD 5.265.\n• Term: The Exact Sciences Warrants will have a term starting as from their issuance and\nending on (and including) August 22, 2028.\n4\nEnglish translation - For information purposes only\n• Exercisability: The exercise of the Exact Sciences Warrants will be subject to the terms\nand conditions contained in the Exact Sciences Warrants Terms and Conditions. The\nExact Sciences Warrants may be exercised as from their issuance and until the end of\ntheir term, provided that a number of Exact Sciences Warrants with an aggregate\nexercise price of at least USD 250,000 are exercised by the holder thereof.\n• Nature of the shares issued upon exercise: Each Exact Sciences Warrant will entitle its\nholder to subscribe for one new share to be issued by the Company. The new shares to\nbe issued upon exercise of the Exact Sciences Warrants shall have the same rights and\nbenefits as, and rank pari passu in all respects including as to entitlement to dividends\nand other distributions, with the existing and outstanding shares of the Company at the\nmoment of their issuance and will be entitled to dividends and other distributions in\nrespect of which the relevant record date or due date falls on or after the date of their\nissuance.\n• Increase of the share capital and allocation of the exercise price: Upon exercise of\nExact Sciences Warrant and issue of new shares, the aggregate amount of the exercise\nprice of the Exact Sciences Warrants will be allocated to (as the case may be, following\nconversion into the Company's share capital currency, on the basis of the relevant\nUSD/EUR exchange ratio as shall be published by the European Central Bank\n(\"ECB\"), as provided for in in section 5.4 of the Exact Sciences Warrants Terms and\nConditions) the share capital of the Company. To the extent that the amount of the\nexercise price of the Exact Sciences Warrants, per share to be issued upon exercise of\nthe Exact Sciences Warrants, exceeds the fractional value of the then existing shares\nof the Company existing immediately prior to the issue of the new shares concerned,\na part of the exercise price, per share to be issued upon exercise of the Exact Sciences\nWarrants, equal to such fractional value shall be booked as share capital, whereby the\nbalance shall be booked as issue premium. Following the capital increase and issuance\nof new shares, each new and existing share shall represent the same fraction of the\nshare capital of the Company.\n• Admission to listing and trading of the underlying shares: The new shares to be issued\nfollowing the exercise of the Exact Sciences Warrants will be admitted to listing and\ntrading on any principal stock exchange or other trading platform on which the\nCompany's other shares are then admitted to listing and trading. To this end, the\nCompany will make the necessary filings and applications.\n• Transferability: Except if the Company were to explicitly allow a transfer of the Exact\nSciences Warrants, the Exact Sciences Warrants cannot be transferred by the holder.\nFurthermore, the Exact Sciences Warrants will not be admitted to listing or trading.\n• Form: The Exact Sciences Warrants will be issued in registered form and cannot be\ndematerialised.\n3.2. Dis-application of the statutory preferential subscription right of existing shareholders\nIn the context of the proposed Transaction, the board of directors proposes to the EGM to dis-\napply the statutory preferential subscription right of the Company's existing shareholders and,\nto the extent necessary, of the Company's existing holders of subscription rights (share options),\nin accordance with article 7:193 of the Belgian Companies and Associations Code, to the\nbenefit of Exact Sciences\n5\nEnglish translation - For information purposes only\nExact Sciences is not a member of the Company's personnel within the meaning of article 1:27\nof the Belgian Companies and Associations Code.\nThe dis-application of the statutory preferential subscription right of the existing shareholders\nand, to the extent necessary, of the Company's existing holders of subscription rights (share\noptions), is necessary in order to allow the Company to issue the Exact Sciences Warrants, as\nagreed in the Amendment.\n3.3. Exercise price\nAs indicated above, the Exact Sciences Warrants, may be exercised at an exercise price of\nUSD 5.265 per new share. Subject to and in accordance with the respective provisions of the\nExact Sciences Warrants Terms and Conditions, upon exercise of the Exact Sciences Warrants\nand the issuance of new shares, the exercise price of the Exact Sciences Warrants will be\nallocated to (as the case may be, following conversion into the Company's share capital\ncurrency, on the basis of the relevant USD/EUR exchange ratio as shall be published by the\nECB, as provided for in in section 5.4 of the Exact Sciences Warrants Terms and Conditions)\nthe share capital of the Company. To the extent that the amount of the exercise price of the\nExact Sciences Warrants, per share to be issued upon exercise of the Exact Sciences Warrants,\nexceeds the fractional value of the then existing shares of the Company existing immediately\nprior to the issue of the new shares concerned, a part of the exercise price, per share to be issued\nupon exercise of the Exact Sciences Warrants, equal to such fractional value shall be booked\nas share capital, whereby the balance shall be booked as issue premium. Following the capital\nincrease and issuance of new shares, each new and existing share shall represent the same\nfraction of the share capital of the Company. Any issue premium will be accounted for on a\nnon-distributable account on the liabilities side of the Company's balance sheet under its net\nequity, and the account on which the issue premium will be booked shall, like the share capital,\nserve as a guarantee for third parties and can only be reduced on the basis of a lawful resolution\nof the general shareholders' meeting passed in the manner required for an amendments to the\nCompany's articles of association.\n3.4. Rights attached to the new shares to be issued upon exercise of the Exact Sciences\nWarrants\nAs mentioned above, the new shares to be issued upon exercise of the Exact Sciences Warrants\nshall have the same rights and benefits as, and rank pari passu in all respects including as to\nentitlement to dividends and other distributions, with the existing and outstanding shares at the\nmoment of their issue and will be entitled to dividends and other distributions in respect of\nwhich the relevant record date or due date falls on or after the date of their issue.\n4. JUSTIFICATION OF THE PROPOSED TRANSACTION\nThe board of directors believes that the Transaction is in the interest of the Company because,\nfirst and foremost, the Amendment, of which the Transaction is a part, allowed the Company\nto defer and amend payments in cash of milestones under the Initial Earn-Out Consideration,\nwhich in turn enabled the Company to preserve its cash resources for other general corporate\nand working capital purposes. If the Exact Sciences Warrants are not issued to Exact Sciences,\nas provided for in the Amendment, the Company could be in breach of its undertakings pursuant\nto the Amendment.\nIn addition, although there can be no guarantee that the Exact Sciences Warrants will ultimately\nbe exercised, the exercise of the Exact Sciences Warrants and the payment of the corresponding\nexercise price of the Exact Sciences Warrants as the case may be, will provide the Company\nwith additional cash, which can be used to further finance the Company's activities and\nstrengthen its balance sheet.\n6\nEnglish translation - For information purposes only\nThe board of directors is aware that the issue of the Exact Sciences Warrants may result in\nadditional dilution for shareholders. However, the dilution will depend on the actual exercise\nof the Exact Sciences Warrants. In any event, the board of directors believes this potential\ndilution does not outweigh a scenario in which the Company would have not entered into the\nAmendment and would have not obtained a deferment and amendment of payments in cash of\nmilestones under the Initial Earn-Out Consideration.\nFor all of the above reasons, the board of directors believes that the proposed Transaction is in\nthe interest of the Company, its shareholders, and other stakeholders. The board of directors\ntherefore recommends that the EGM approves the issuance of the Exact Sciences Warrants.\n5. JUSTIFICATION OF THE ISSUANCE PRICE AND EXERCISE PRICE OF THE\nEXACT SCIENCES WARRANTS\nPursuant to the Exact Sciences Terms and Conditions, the Exact Sciences Warrants will be\ngranted to Exact Sciences without any further consideration.\nThe exercise price of the Exact Sciences Warrants of USD 5.265 (representing the share capital\nof the Company for the amount equal to the fractional value and the issue premium for the\namount in excess of the fractional value), was determined by the board of directors following\nnegotiations with Exact Sciences. The negotiation process was conducted objectively and\nindependently. The exercise price represented a premium of circa 45% compared to the trading\nprice of the Company's American depositary shares that were traded on Nasdaq on August 23,\n2023, i.e. the day on which the Amendment was signed.\nWhether or not an Exact Sciences Warrant will be exercised depends on the (sole) decision of\nExact Sciences. Such decision will depend on the price of the Company's shares at the moment\nof the decision whether or not to exercise as compared with the exercise price of the Exact\nSciences Warrants, since essentially, Exact Sciences can realise a capital gain at the exercise of\nthe Exact Sciences Warrants if the price of the Company's shares at that moment is higher than\nthe exercise price of the Exact Sciences Warrants (not taking into account the possible tax\nrelated costs and assuming that Exact Sciences can sell the underlying share at such price on\nthe market).\nTherefore, taking into account all of the above, the board of directors is of the opinion that the\nexercise price of the Exact Sciences Warrants is not unreasonable and can be sufficiently\njustified, and that it is in the interest of the Company, the existing shareholders, the existing\nholders of subscription rights (share options) of the Company, and other stakeholders.\n6. JUSTIFICATION OF THE DIS-APPLICATION OF THE STATUTORY\nPREFERENTIAL SUBSCRIPTION RIGHT\nIn the context of the envisaged Transaction as described above, the board of directors proposes\nto the EGM to dis-apply the statutory preferential subscription right of the existing shareholders\nof the Company and, to the extent necessary, of the existing holders of subscription rights (share\noptions) of the Company in accordance with articles 7:191 and 7:193 of the Belgian Companies\nand Associations Code, to the benefit of Exact Sciences.\nThe dis-application of the statutory preferential subscription right of the existing shareholders\nand, to the extent necessary, of the existing holders of subscription rights (share options), is\nnecessary to enable the Company to issue the Exact Sciences Warrants in accordance with the\nAmendment.\nThe Company's undertaking to submit the issuance of the Exact Sciences Warrants to the EGM\nwas one of the key elements that allowed the Company to enter into the Amendment and to\ndefer and amend the payments in cash of milestones under the Initial Earn-Out Consideration\n7\nEnglish translation - For information purposes only\nThis enabled the Company to preserve its cash resources to further finance its activities, as set\nout in paragraph 4 above.\nIf the Exact Sciences Warrants are not issued to Exact Sciences, as provided for in the\nAmendment, the Company could be in breach of its undertakings pursuant to the Amendment.\nFor all the above reasons, the board of directors is of the opinion that the proposed issuance of\nthe Exact Sciences Warrants, with dis-application of the statutory preferential subscription right\nto the benefit of Exact Sciences and notwithstanding the dilution resulting from the potential\nexercise of the Exact Sciences Warrants for the shareholders and, as the case may be, the\nholders of subscription rights (share options), is in the interest of both the Company and existing\nshareholders and holders of subscription rights (share options), and other stakeholders, since it\nallowed the Company to defer and amend payments in cash of milestones under the Initial Earn-\nOut Consideration.\n7. CERTAIN FINANCIAL CONSEQUENCES\n7.1. Introductory comments\nThe following paragraphs provide an overview of certain financial consequences of the\npotential exercise of the Exact Sciences Warrants. For further information with regard to the\nfinancial consequences of the potential exercise of the Exact Sciences Warrants, reference is\nalso made to the report prepared in accordance with articles 7:180, 7:191 and 7:193 of the\nBelgian Companies and Associations Code by the statutory auditor of the Company, BDO\nRéviseurs d'Entreprises SRL.\nWhether or not new shares are issued pursuant to the exercise of the Exact Sciences Warrants\nwill depend on whether or not the Exact Sciences Warrants are exercised by Exact Sciences.\nLikewise, the actual financial consequences resulting from the exercise or conversion for shares\nof the other outstanding and proposed new dilutive instruments of the Company cannot yet be\ndetermined with certainty.\nAccordingly, the discussion herein of the financial consequences of the proposed issuance\nand exercise of the Exact Sciences Warrants for existing shareholders is purely illustrative\nand hypothetical, and is based on purely indicative financial parameters (where relevant)\nSubject to the foregoing reservations, for the purposes of the illustration of some of the financial\nconsequences of the exercise of the Exact Sciences Warrants and notably the dilution for the\nshareholders, the following parameters and assumptions were used:\n1\n(a) Exchange Rate : For the purpose of the simulations and illustrations below, the\nfollowing exchange rate is used: USD 1.0743 for 1 EUR, which is the exchange rate as\npublished by the ECB on\nhttps://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchang\ne_rates/html/index.en.html on May 8, 2024 (the \"Exchange Rate\").\n(b) Current share capital: At the date of this report, the share capital of the Company\namounts to EUR 164,302,752.89 represented by 27,288,093 shares without nominal\nvalue, each representing the same fraction of the share capital, i.e., (rounded)\n1\nThe Company's shares are listed on Nasdaq, where they are traded in USD. However, the Company's share capital\nis currently expressed in EUR. In view of the current difference between the Company's shares trading currency and\nthe Company's share capital currency, except for amounts in the financial dilution simulations in paragraph 7.4\nbelow, all amounts in USD used in the simulations herein are converted in EUR on the basis of the Exchange Rate.\n8\nEnglish translation - For information purposes only\nEUR 6.0210. The share capital is entirely and unconditionally subscribed for and is\nfully paid-up.\n(c) The Transaction: In order to illustrate the maximum potential dilutive effects of the\nTransaction below, it is assumed that the 1,000,000 Exact Sciences Warrants are issued\nand all exercised, for a total of 1,000,000 newly issued shares at an issue price of\nUSD 5.265 per new shares, resulting in a total issue price of USD 5,265,000, or,\napplying the Exchange Rate, at an issue price of EUR 4.900 per new shares, resulting\nin a total issue price of EUR 4,900,000 (including issue premium, if any). To reflect\nmaximum dilution, the maximum 7.5% shareholding cap (as described above) is not\ntaken into account in the simulations below. Should this 7.5% shareholding cap be\napplied, only 3,528,875 shares could be issued to Exact Sciences on a fully diluted\nbasis, taking into account the most dilutive parameters used herein.\n(d) Share Options: Furthermore, the following 18,388,230 subscription rights issued by the\nCompany are still outstanding at the date of this report (the \"Share Options\"):\n(i) 522,500 outstanding share options issued under the form of subscription rights\non June 23, 2014 (\"2014 Share Options\") (of which 68,500 share options have\n2\nnot yet been granted) ;\n(ii) 1,866,000 outstanding share options issued under the form of subscription\nrights on June 19, 2017 (\"2017 Share Options\") (which have all been\ngranted);\n(iii) 2,632,860 outstanding share options issued under the form of subscription\nrights on June 21, 2019 (\"2019 Share Options\") (of which 1,500 share options\nhave not yet been granted);\n(iv) 3,525,000 outstanding share options issued under the form of subscription\nrights on May 27, 2021 (\"2021 Share Options\") (which have all been granted);\n(v) 4,851,870 outstanding share options issued under the form of subscription\nrights on May 25, 2022 (\"2022 Share Options\") (of which 2,500 share options\nhave not yet been granted); and\n(vi) 4,990,000 outstanding share options issued under the form of subscription\nrights on June 30, 2023 (\"2023 Share Options\") (of which 1,960,000 share\noptions have not yet been granted).\nEach of the aforementioned Share Options entitles the holders thereof to subscribe for\none new share of the Company upon exercise of the relevant Share Option. For the\npurpose of the full-dilution scenario calculations further below, it is assumed that all of\nthe 18,388,230 outstanding Share Options (including the 68,500 outstanding 2014\nShare Options, the 1,500 outstanding 2019 Share Options, the 2,500 outstanding 2022\nShare Options and the 1,960,000 outstanding 2023 Share Options that can still be\ngranted) have been effectively granted, have vested and are exercisable. On that basis,\nif all 18,388,230 Share Options were exercised, 1,838,823 new shares would need to\nbe issued by the Company.\n(e) Amended Earn-Out Consideration: For the purpose of the full-dilution scenario\ncalculations further below, it is assumed that the full Amended Earn-Out Consideration\n2\nAll 2014 Share Options that are not exercised by June 23, 2024 will automatically lapse and become null and void.\n9\nEnglish translation - For information purposes only\namount of USD 82,500,000.00 is converted, by applying the Exchange Rate (see\nparagraph 7.1(a)), into EUR 76,794,191.56 and is fully paid in kind by the Company\nto Exact Sciences by the issuance of new shares of the Company, at an issue price per\nshare of USD 3.00 (i.e., the closing price of the Company's shares on Nasdaq on\nMay 8, 2024) or, applying the Exchange Rate, at an issue price per share of EUR 2.79,\nin consideration of the settlement through a contribution in kind of receivables due by\nthe Company to Exact Sciences up to the Amended Earn-Out Consideration. To reflect\nmaximum dilution, the maximum 7.5% shareholding cap (as described above) is not\ntaken into account in the simulations below. Should this 7.5% shareholding cap be\napplied, only 3,528,875 shares could be issued to Exact Sciences on a fully diluted\nbasis, taking into account the most dilutive parameters used herein.\n(f) ATM Facility: On April 30, 2024, the Company entered into a sales agreement with\nTD Securities (USA) LLC (\"TD Cowen\") with respect to an equity offering program\nunder which the Company may offer and place new shares, via TD Cowen and through\nvarious placements from time to time in an “at the market offering”, as defined in Rule\n415 promulgated under the Securities Act of 1933, as amended, and the rules and\nregulations thereunder, for an aggregate maximum offering amount of USD 50,000,000\n(the \"ATM Facility\"). The actual number of new shares to be issued in the framework\nof the ATM Facility will vary depending on the effective placements of new shares and\non the price for each such placements. However the number of new shares to be issued\nin the framework of the ATM Facility shall not exceed 100,000,000 shares. Such new\nshares will be placed at a final subscription price per new share in function of the then\ncurrent USD market prices on Nasdaq at the time of the relevant placements, while\nsuch issue price cannot be lower than USD 0.50.\nFor the purpose of the full-dilution scenario calculations further below, it is assumed\nthat (i) new shares are issued under the ATM Facility for the full amount of\nUSD 50,000,000.00, and (ii) all such new shares issued under the ATM Facility are\nissued at an issue price per share of USD 3.00 (i.e., the closing price of the Company's\nshares on Nasdaq on May 8, 2024). On that basis, applying the Exchange Rate,\nEUR 46,541,934.28 would be raised by the Company against the issuance 16,681,696\nnew shares of the Company at an issue price of EUR 2.79 per share.\n(g) OrbiMed Warrants: On May 1, 2024, the Company entered into a credit agreement, as\nguarantor, with MDxHealth, Inc., a wholly-owned subsidiary of the Company, as\nborrower, and ORC SPV LLC (\"OrbiMed\"), as lender and administrative agent,\npursuant to which OrbiMed agreed to provide a five-year senior secured credit facility\nin an aggregate principal amount of up to USD 100 million, of which (i) USD 55\nmillion was advanced on the date of closing, (ii) USD 25 million will be made\navailable, at MDxHealth, Inc.’s discretion, on or prior to March 31, 2025, subject to\ncertain net revenue requirements and other customary conditions, and, and (iii) USD\n20 million will be made available, at MDxHealth, Inc.’s discretion, on or prior to March\n31, 2026, subject to certain net revenue requirements and other customary conditions.\nFurthermore, pursuant to the credit agreement, the Company has committed to issue to\nthe benefit of affiliates of OrbiMed, 1,243,060 new subscription rights for new shares\nof the Company (each exercisable for 1 new share of the Company at an exercise price\nper new share of USD 2.4134) with a 5 years term as from their issue date (the\n\"OrbiMed Warrants\"). The proposed issuance of the OrbiMed Warrants will be\nsubmitted for approval by the same extraordinary general shareholders' meeting of the\nCompany as the one that will need to decide on the issuance of the Exact Sciences\nWarrants.\nFor the purpose of the full dilution scenario calculations further below, it is assumed\nthat the 1,243,060 OrbiMed Warrants are issued and all exercised, for a total of\n10\nEnglish translation - For information purposes only\n1,243,060 newly issued shares at an issue price of USD 2.41 (rounded) per new shares,\nresulting in a total issue price of USD 2,995,774.60, or, applying the Exchange Rate,\nat an issue price of EUR 2.24 (rounded) per new shares, resulting in a total issue price\nof EUR 2,784,454.40 (including issue premium, if any). It is also assumed that the\naggregate subscription price for the OrbiMed Warrants is paid in full upon issuance\nand subscription of the OrbiMed Warrants.\n(h) Allocation of the issue price of the outstanding dilutive instruments: Upon the issuance\nof new shares upon exercise of the OrbiMed Warrants (should their issuance be\napproved by an extraordinary general shareholders' meeting of the Company), and/or\nthe full placement of the ATM Facility, and/or the contribution of the Amended Earn-\nOut Consideration, and/or the exercise of the Share Options, the amount of the issue\nprice of the relevant new shares will be booked as equity (in the form of share capital\nand share premium, as the case may be). The amount that shall be booked as share\ncapital shall, on a per share basis, be equal to the amount of the applicable fractional\nvalue of the Company's shares at the relevant time. The balance, as the case may be,\nshall be booked as issue premium.\nIn this report, when reference is made to \"outstanding dilutive instruments\", it refers,\nrespectively, to the issuance of new shares upon exercise of the OrbiMed Warrants, the full\nplacement of the ATM Facility, the contribution of the Amended Earn-Out Consideration and\nthe exercise of the outstanding Share Options.\nWhether the Exact Sciences Warrants (assuming their issuance will be approved by an\nextraordinary general shareholders' meeting of the Company), the outstanding Share Options\nor OrbiMed Warrants (assuming their issuance will be approved by an extraordinary general\nshareholders' meeting of the Company) will be effectively exercised will ultimately depend on\nthe decision of the respective holders thereof. Such decision will likely be in function of the\nmarket price of the shares of the Company at the moment of exercise or conversion, compared\nto their respective exercise prices. The respective holders will likely not exercise if the market\nprice of the shares of the Company is less than the relevant exercise price.\nWhether the Amended Earn-Out Consideration amount is due and converted into shares of the\nCompany will depend on the fulfilment (or not) of the respective conditions provided by the\nAsset Purchase Agreement, as amended from time to time. Furthermore, should an Amended\nEarn-Out Consideration amount be due by the Company to Exact Sciences, the Company can\nalso ultimately opt to pay such Amended Earn-Out Consideration amount in cash rather than in\nshares.\nWhether the full USD 50,000,000 amount is placed by the Company under the ATM Facility,\nthe applicable issue prices for such placements and the total number of new shares issued under\nthe ATM Facility will depend on the ultimate decision of the Company to proceed with such\nplacements, the terms at which such placements are made (including the relevant USD market\nprices on Nasdaq used as reference to determine the relevant issue prices) and whether such\nplacements are successful or not.\n7.2. Evolution of the share capital, voting power, participation in the results and other\nshareholder rights\nEach share in the Company currently represents an equal part of the share capital of the\nCompany and provides for one vote in function of the part of the capital it represents. The\nissuance of the new shares upon exercise of the Exact Sciences Warrants (provided that the\nExact Sciences Warrants are issued to the benefit of Exact Sciences) will lead to a dilution of\nthe existing shareholders of the Company and of the relative voting power of each share in the\nCompany.\n11\nEnglish translation - For information purposes only\nThe dilution relating to the voting right also applies, mutatis mutandis, to the participation of\neach share in the profit and liquidation proceeds and other rights attached to the shares of the\nCompany, such as the statutory preferential subscription right in case of a capital increase in\ncash through the issuance of new shares or in case of the issuance of new subscription rights or\nconvertible bonds.\nSpecifically, prior to the issuance of new shares upon exercise of the Exact Sciences Warrants\n(and prior to the issuance of new shares pursuant the other outstanding dilutive instruments),\neach share of the Company participates equally in the profit and liquidation proceeds of the\nCompany and each shareholder has a statutory preferential subscription right in case of a capital\nincrease in cash or in case of the issuance of new subscription rights or convertible bonds. In\ncase of the issuance of the new shares upon exercise of the Exact Sciences Warrants (provided\nthat the Exact Sciences Warrants are issued to the benefit of Exact Sciences), the new shares to\nbe issued will have the same rights and benefits as, and rank pari passu in all respects with, the\nexisting and outstanding shares of the Company at the moment of their issuance and delivery,\nand will be entitled to dividends and other distributions in respect of which the relevant record\ndate or due date falls on or after the date of issuance and delivery of the new shares. As a result\n(and to the extent the new shares will be issued and subscribed for pursuant to the exercise of\nthe Exact Sciences Warrants), the participation by the existing shareholders in the profit and\nliquidation proceeds of the Company and their holders' statutory preferential subscription right\nin case of a capital increase in cash, shall be diluted accordingly.\nA similar dilution occurs upon exercise or conversion of the other outstanding dilutive\ninstruments.\nFurthermore, in accordance with article 7:178 of the Belgian Companies and Associations\nCode, after the completion of the issuance of the new shares upon exercise of the Exact Sciences\nWarrants, all of the Company's outstanding shares will have the same (as the case may be\nadjusted) fractional value.\nSubject to the methodological reservations noted in paragraph 7.1, the evolution of the share\ncapital and the number of shares, with voting rights attached thereto, of the Company as a result\nof the proposed issuance and exercise of all 1,000,000 Exact Sciences Warrants (and the\nsubsequent issuance of 1,000,000 new shares resulting from it) is simulated below in a scenario\nbefore dilution due to outstanding dilutive instruments, as well as in a scenario after dilution\ndue to outstanding dilutive instruments.\nEvolution of the number of outstanding shares\nAfter the exercise of the Exact Sciences Warrants but before dilution\ndue to outstanding dilutive instruments\n(A) Outstanding shares .............................................................................. 27,288,093\n(B) New shares to be issued upon exercise of the Exact Sciences 1,000,000\nWarrants ....................................................................................................\n(C) Total number of shares outstanding after (B) .................................... 28,288,093\n(D) Dilution ............................................................................................... 3.54%\nAfter dilution due to outstanding dilutive instruments but before the\nexercise of the Exact Sciences Warrants\n(A) Outstanding shares .............................................................................. 27,288,093\n(B) New shares to be issued upon exercise of all outstanding Share\nOptions ...................................................................................................... 1,838,823\n(C) New shares to be issued upon contribution of the Amended Earn-Out\nConsideration ............................................................................................ 27,499,999\n12\nEnglish translation - For information purposes only\n(D) New shares to be issued upon exercise of all OrbiMed Warrants ...... 1,243,060\n(E) New shares to be issued upon full placement of the ATM Facility .... 16,681,696\n(F) Total number of new shares to be issued under (B), (C), (D) and (E) 47,263,578\n(G) Total number of shares outstanding after (B), (C), (D) and (E) ......... 74,551,671\nAfter the exercise of the Exact Sciences Warrants and after dilution\ndue to outstanding dilutive instruments\n(A) Outstanding shares after dilution due to outstanding dilutive\ninstruments ................................................................................................ 74,551,671\n(B) New shares to be issued upon exercise of the Exact Sciences\nWarrants .................................................................................................... 1,000,000\n(C) Total number of shares outstanding after (B) ..................................... 75,551,671\n(D) Dilution ............................................................................................... 1.32%\nSubject to the methodological reservations noted in paragraph 7.1, the table below reflects the\nevolution of the share capital, assuming the exercise of all 1,000,000 Exact Sciences Warrants\nand the subsequent issuance of 1,000,000 new shares resulting from it. The maximum amount\nof share capital increase (excluding issue premium) is computed by multiplying the number of\nnew shares to be issued (i.e., 1,000,000) with the fractional value (i.e., currently rounded\nEUR 6.0210 per share).\nEvolution of the share capital(1)\nBefore the exercise of the Exact Sciences Warrants\n(A) Share capital (in EUR) ........................................................................ 164,302,752.89\n(B) Outstanding shares .............................................................................. 27,288,093\n(C) Fractional value (in EUR) (rounded) .................................................. 6.0210\nExercise of the Exact Sciences Warrants\n(A) Increase of share capital (in EUR) ...................................................... 4,900,000.00\n(B) New shares to be issued upon exercise of the Exact Sciences\nWarrants.. 1,000,000\nAfter the exercise of the Exact Sciences Warrants\n(A) Share capital (in EUR) ........................................................................ 169,202,752.89\n(B) Outstanding shares .............................................................................. 28,288,093\n(C) Fractional value (in EUR) (rounded) ................................................. 5.9814(2)\n___________\nNotes:\n(1) This simulation does not take into account the exercise or conversion of outstanding dilutive instruments.\n(2) The issue price is lower than the fractional value of the existing shares of the Company (i.e., currently\nrounded EUR 6.0210). Therefore, in accordance with Article 7:178 of the Belgian Companies and\nAssociations Code, after the exercise of the Exact Sciences Warrants, all outstanding shares of the\nCompany will have the same fractional value, i.e. rounded to EUR 5.9814.\n7.3. Participation in the consolidated accounting net equity\nThe evolution of the consolidated accounting net equity of the Company as a result of the\nexercise of the Exact Sciences Warrants is simulated below.\nThe simulation is based on the audited consolidated annual financial statements of the Company\nfor the financial year ended on December 31, 2023 (which have been prepared in accordance\nwith the International Financial Reporting Standards, as adopted by the European Union\n13\nEnglish translation - For information purposes only\n(\"IFRS\") and which have been submitted to the Company's annual shareholders' meeting for\napproval). The consolidated accounting net equity of the Company as at December 31, 2023\namounted to EUR 6,709 ('000) (rounded) (i.e., USD 7,208 ('000) (rounded)), on the basis of the\nExchange Rate) or EUR 0.2459 (rounded) per share (based on 27,288,093 outstanding shares\nas at December 31, 2023). The simulation does not take into account any changes in the\nconsolidated accounting net equity since December 31, 2023.\nFor further information on the Company's net equity position on December 31, 2023, reference\nis made to the financial statements of the Company, which are available on the Company's\nwebsite.\nBased on the assumptions set out above, as a result of the exercise of the Exact Sciences\nWarrants, without taking into account the other outstanding dilutive instruments, the\nCompany's accounting net equity on a consolidated basis, would be increased as indicated\nbelow:\nEvolution of the consolidated accounting net equity\nConsolidated net equity for FY 2023\n(A) Net equity (in EUR '000) (rounded) ....................................................... 6,709\n(B) Outstanding shares .................................................................................. 27,288,093\n(C) Net equity per share (in EUR) (rounded) ............................................... 0.2459\nExercise of the Exact Sciences Warrants\n(A) Increase of net equity (in EUR '000) (rounded) (1) .................................. 4,900\n(B) New shares to be issued upon exercise of the Exact Sciences Warrants 1,000,000\nAfter exercise of the Exact Sciences Warrants\n(A) Net equity (in EUR '000) (rounded) ...................................................... 11,609\n(B) Outstanding shares .................................................................................. 28,288,093\n(C) Net equity per share (in EUR) (rounded) ............................................... 0.4104\nThe table above demonstrates that the issuance of the Exact Sciences Warrants and the\nsubsequent exercise of all the Exact Sciences Warrants will would, from a pure accounting\npoint of view, lead to an increase of the amount represented by each share in the consolidated\naccounting net equity of the Company.\n7.4. Financial dilution\nThe evolution of the market capitalisation as a result of the exercise of the Exact Sciences\nWarrants is simulated below.\nSubject to the methodological reservations noted in paragraph 7.1, the table below reflects the\nimpact of the exercise of the Exact Sciences Warrants, without taking into account the other\noutstanding dilutive instruments, on the market capitalisation and the resulting financial\ndilution.\nAfter close of trading on Nasdaq on May 8, 2024, the Company's market capitalisation was\nUSD 81,864,279.00, on the basis of a closing price of USD 3.0000 per share. Assuming that,\nfollowing the exercise of the Exact Sciences Warrants, without taking into account the other\noutstanding dilutive instruments, the market capitalisation increases exclusively with the funds\nraised based on the parameters described hereabove, the new market capitalisation would then\n14\nEnglish translation - For information purposes only\nbe rounded to USD 3.0801 per share. This would represent a (theoretical) financial accretion\nof 2.67% per share.\nEvolution of the market capitalisation and financial dilution\nBefore the exercise of the Exact Sciences Warrants (1)\n(A) Market capitalisation (in USD) ................................................................. 81,864,279.00\n(B) Outstanding shares .................................................................................... 27,288,093\n(C) Market capitalisation per share (in USD) ................................................. 3.0000\nExercise of the Exact Sciences Warrants\n(A) Funds raised (in USD) .............................................................................. 5,265,000.00\n(B) New shares to be issued upon exercise of the Exact Sciences Warrants .. 1,000,000\nAfter the exercise of the Exact Sciences Warrants (1)\n(A) Market capitalisation (in USD) ................................................................. 87,129,279.00\n(B) Outstanding shares .................................................................................... 28,288,093\n(C) Market capitalisation per share (in USD) (rounded) ................................. 3.0801\nDilution/Accretion ......................................................................................... 2.67%\n___________\nNotes:\n(1) At the date of this report and not taking into account the potential issuance of new shares pursuant to the\nexercise or conversion of other outstanding dilutive instruments.\n7.5. Other financial consequences\nFor a further discussion on the financial consequences of the proposed issuance of the Exact\nSciences Warrants and their subsequent exercise, the board of directors refers to the report\nprepared in connection therewith by the statutory auditor of the Company.\n* * *\nDone on May 13, 2024.\n15\nEnglish translation - For information purposes only\nOn behalf of the board of directors,\n[Signed] [Signed]\nBy: _______________________ By: ________________________\n16\nEnglish translation - For information purposes only\nANNEX A\nEXACT SCIENCES WARRANTS TERMS AND CONDITIONS\n17\nEnglish translation - For information purposes only\nANNEX B\nREPORT OF THE STATUTORY AUDITOR PREPARED IN ACCORDANCE WITH\nARTICLES 7:180, 7:191 AND 7:193 OF THE BELGIAN COMPANIES AND ASSOCIATIONS\nCODE\n18"
        },
        {
          "title": "Board Report Exact Sciences Warrants (FR)",
          "url": "https://mdxhealth.com/wp-content/uploads/2024/05/12FR-Rapport-du-Conseil-dAdministration-sur-les-Warrants-dExact-Sciences-FR.pdf",
          "content": "MDXHEALTH\nSociété anonyme\nCAP Business Center\nZone Industrielle des Hauts-Sarts\nRue d'Abhooz 31\n4040 Herstal\nBelgique\nEnregistrée au Registre des Personnes Morales\nTVA BE 0479.292.440 (RPM Liège, division Liège)\n____________________________________________________\nRAPPORT DU CONSEIL D'ADMINISTRATION\nCONFORMEMENT AUX ARTICLES 7:180, 7:191 ET 7:193 DU CODE DES SOCIETES ET\nDES ASSOCIATIONS\n____________________________________________________\n1. INTRODUCTION\nLe 2 août 2022, MDxHealth SA (la \"Société\") a conclu une convention de cession d'actif (la\n\"Convention de Cession d'Actif\") avec Genomic Health, Inc. (une filiale d'Exact Sciences\nCorporation, ci-après dénommée \"Exact Sciences\"), en vertu de laquelle, entre autres choses\net sous réserve des termes et conditions inclus dans la Convention de Cession d'Actif, Exact\nSciences a accepté de vendre et de céder, et la Société a accepté d'acheter et d'assumer l'activité\nde développement, de commercialisation et de mise en œuvre du test Oncotype DX Genomic\nProstate Score (l'\"Activité GPS Test\"), en contrepartie (i) d'une contrepartie en numéraire de\nUSD 24.999.999,64, (ii) d'un Complément de Prix Initial (tel que défini ci-dessous) et (iii) de\nla Première Contrepartie de Clôture en Actions (tel que défini ci-dessous).\nLe 23 août 2023, la Société et Exact Sciences ont conclu un amendement à la Convention de\nCession d'Actif (tel que modifié ultérieurement le 9 octobre 2023, l'\"Amendement\"), en vertu\nde laquelle ils ont accepté de reporter le paiement du Complément de Prix Initial, en\ncontrepartie (i) de l'augmentation et du remplacement du Complément de Prix Initial par le\nComplément de Prix Amendé (tel que défini ci-dessous), (ii) d'une contrepartie en numéraire\nde USD 250.000, (iii) la Seconde Contrepartie de Clôture en Actions (telle que définie ci-\ndessous) et (iv) l'engagement de la Société d'émettre en faveur d'Exact Sciences 1.000.000\nnouveaux droits de souscription pour nouvelles actions de la Société (chacun exerçable pour 1\nnouvelle action de la Société) avec une durée allant jusqu'au 22 août 2028 (les \"Warrants\nd'Exact Sciences\").\nDans ce contexte, le conseil d'administration soumet à l'assemblée générale extraordinaire des\nactionnaires de la Société convoquée le 30 mai 2024 (ou à toute autre date ultérieure, si le\nquorum de présence légalement requis n'est pas atteint lors de cette assemblée) (l'\"AGE\") la\nproposition d'émettre 1.000.000 de Warrants d'Exact Sciences dans les conditions décrites ci-\ndessous dans le présent rapport, et de supprimer, dans l'intérêt de la Société, le droit de\npréférence des actionnaires existants de la Société et, pour autant que de besoin, des détenteurs\nactuels de droits de souscription (share options) de la Société, en faveur d'Exact Sciences,\ncomme prévu dans l'Amendement (l'émission proposée des Warrants d'Exact Sciences,\nl'\"Opération\").\nLes actionnaires doivent noter que les Warrants d'Exact Sciences sont des instruments\ncomplexes et qu'Exact Sciences pourrait bénéficier d'une décote significative lors de la\nsouscription de nouvelles actions en vertu de l'exercice potentiel des Warrants d'Exact Sciences,\ntel que décrit ci-dessous.\n1\nLes Warrants d'Exact Sciences sont des droits de souscription au sens des articles 7:67 et\nsuivants du Code des sociétés et des associations du 23 mars 2019 (tel que modifié de temps à\nautre) (le \"Code des Sociétés et des Associations\").\nAux fins de l'Opération, ce rapport a été préparé par le conseil d'administration de la Société,\nconformément aux articles 7:180, 7:191 et 7:193 du Code des Sociétés et des Associations, en\nrelation avec la proposition du conseil d'administration d'émettre les Warrants d'Exact Sciences\net de supprimer, dans l'intérêt de la Société, le droit de préférence des actionnaires existants de\nla Société et, pour autant que de besoin, des détenteurs actuels de droits de souscription (share\noptions) de la Société, en faveur d'Exact Sciences.\nConformément à l'article 7:180 du Code des Sociétés et des Associations, le conseil\nd'administration fournit dans ce rapport une justification de l'Opération proposée, incluant une\njustification du prix d'exercice proposé des Warrants d'Exact Sciences et une description des\nconséquences de l'Opération proposée pour les droits patrimoniaux et les droits sociaux des\nactionnaires de la Société.\nConformément à l'article 7:191 du Code des Sociétés et des Associations, le conseil\nd'administration fournit également dans ce rapport une justification de la proposition de\nsupprimer, dans l'intérêt de la Société, le droit de préférence des actionnaires existants de la\nSociété et, pour autant que de besoin, des détenteurs actuels de droits de souscription (share\noptions) en rapport avec l'augmentation de capital proposée dans le cadre de l'Opération, et une\ndescription de ses conséquences sur les droits patrimoniaux et les droits des actionnaires de la\nSociété.\nConformément à l'article 7:193 du Code des Sociétés et des Associations, la justification de\nl'Opération proposée et du prix d'exercice proposé des Warrants d'Exact Sciences doivent tenir\ncompte en particulier de la situation financière de la Société, de l'identité d'Exact Sciences et\nde la nature et de l'importance de l'apport d'Exact Sciences.\nCe présent rapport doit être lu conjointement avec le rapport préparé en conformité avec les\narticles 7:180, 7:191 et 7:193 du Code des Sociétés et des Associations par le commissaire de\nla Société, BDO Réviseurs d'entreprises SRL, une société à responsabilité limitée, ayant son\nsiège à Da Vincilaan 9, 1930 Zaventem, Belgique, représentée par Monsieur Bert Kegels.\n2. CONTEXTE\n2.1. Convention de Cession d'Actif et Amendement\nConstituée en février 1995, Exact Sciences est une société mondiale de premier plan dans le\ndomaine du diagnostic avancé du cancer, cotée sur le Nasdaq, qui a développé certains des tests\nles plus impactant dans le domaine du diagnostic du cancer.\nLe 2 août 2022, la Société et Exact Sciences ont conclu la Convention de Cession d'Actif, en\nvertu de laquelle et sous réserve de ses termes et conditions, Exact Sciences a accepté de vendre\net de céder, et la Société a accepté d'acheter et d'assumer, l'Activité GPS Test pour un prix\nd'achat total maximum de USD 100.000.000,00. En vertu de la Convention de Cession d'Actif,\nle prix d'achat total devait être payé comme suit :\n(a) Contrepartie en numéraire : Un montant de USD 24.999.999,64 a été payé à la date de\nla Convention de Cession d'Actif.\n(b) Première Contrepartie de Clôture en Actions : Un montant de USD 5.000.000,36,\nlequel restait impayé en tant que dette (sans intérêt) due par la Société à la date de la\nConvention de Cession d'Actif, a été apporté en nature le 11 août 2022 par Exact\nSciences à la Société dans le cadre d'une augmentation de capital par la Société dans le\n2\ncadre du capital autorisé de la Société contre l'émission par la Société de 6.911.710\nnouvelles actions à un prix d'émission de EUR 0,7056 (la \"Première Contrepartie de\nClôture en Actions\"). Le nombre total d'actions de la Société détenues par Exact\nSciences ne devait pas dépasser plus de 5% des actions en circulation de la Société.\n(c) Complément de Prix Initial : A la suite de la signature de la Convention de Cession\nd'Actif, un complément de prix additionnel d'un montant total de de USD\n70.000.000,00 devait être payé par la Société à Exact Sciences lors de la réalisation de\ncertains objectifs de revenus liés aux exercices 2023 à 2025, le complément de prix\nmaximum payable pour 2023 et 2024 ne devant pas dépasser USD 30.000.000,00 et\nUSD 40.000.000,00, respectivement (le \"Complément de Prix Initial\"). Au choix de\nla Société, les montants reflétant le Complément de Prix Initial pouvaient être réglés\nen numéraire ou par l'émission d'actions supplémentaires de la Société par apport en\nnature (à un prix d'émission par action évalué sur la base d'un cours moyen pondéré en\nfonction du volume des actions de la Société à la fin de la période de complétion de\nprix concernée), à condition que le nombre total d'actions détenues par Exact Sciences\nne dépasse pas plus de 5% des actions en circulation de la Société.\nPar la suite, afin de reporter le paiement du Complément de Prix Initial, la Société et Exact\nSciences ont conclu l'Amendement en date du 23 août 2023, dont les principaux termes peuvent\nêtre résumés comme suit :\n(a) Report de paiements dans le cadre du complément de prix prévu par la Convention de\nCession d'Actif : En vertu de l'Amendement, et sous réserve de ses termes et conditions,\nExact Sciences a accepté de reporter le paiement du Complément de Prix Initial du par\nla Société en vertu de la Convention de Cession d'Actif de 3 ans, de 2024 à 2027.\n(b) Contrepartie pour le report de paiements : En contrepartie de ce report de paiements, la\nSociété a accepté ce qui suit :\n(i) Contrepartie en numéraire : Un montant de USD 250.000,00 a été payé par la\nSociété à la date de l'Amendement.\n(ii) Seconde Contrepartie de Clôture en Actions : Un montant de USD 877.500,00\nqui est resté impayé en tant que dette (sans intérêt) due par la Société à la date\nde la Convention de Cession d'Actif a été apportée en nature le 20 octobre 2023\npar Exact Sciences à la Société dans le cadre d'une augmentation de capital par\nla Société dans le cadre du capital autorisé de la Société contre l'émission par\nla Société de 2.500.000 nouvelles actions au prix d'émission de EUR 0,3324\n(la \"Seconde Contrepartie de Clôture en Actions\"). Il a également été\nconvenu que le nombre total d'actions de la Société détenues par Exact\nSciences ne doit pas dépasser plus de 7.5% des actions en circulation de la\nSociété (comparé aux 5% précédemment, sous la Convention de Cession\nd'Actif).\n(iii) Complément de Prix Amendé : Le Complément de Prix Initial a été augmenté\net remplacé par un complément de prix additionnel d'un montant total\nmaximum de USD 82.500.000,00 à payer par la Société à Exact Sciences lors\nde la réalisation de certains objectifs de revenus liés aux exercices 2023 à 2025,\nle complément de prix maximum payable pour 2023 et 2024 ne devant pas\ndépasser USD 30.000.000,00 plus USD 10.000.000,00 (ou tout autre montant\ninférieur si le complément de prix maximum requis à payer excède USD\n82.500.000,00 au total) et USD 40.000.000,00, respectivement\n(le \"Complément de Prix Amendé\"). Au choix de la Société, les montants\n3\nreflétant le Complément de Prix Amendé peuvent être réglés en numéraire ou\npar l'émission d'actions supplémentaires de la Société par apport en nature (à\nun prix d'émission par action évalué sur la base d'un cours moyen pondéré en\nfonction du volume des actions de la Société à la fin de la période de\ncomplément de prix concernée) à délivrer à Exact Sciences, à condition que le\nnombre total d'actions détenues par Exact Sciences ne dépasse pas plus de\n7,5% des actions en circulation de la Société (comparé aux 5% précédemment\nstipulés dans la Convention de Cession d'Actif).\n(iv) Warrants d'Exact Sciences : Conformément à l'Amendement, la Société s'est\nengagée à émettre, en faveur d'Exact Sciences, 1.000.000 de nouveaux droits\nde souscription pour nouvelles actions de la Société (chacun pouvant être\nexercé pour 1 nouvelle action de la Société) avec une durée allant jusqu'au 22\naoût 2023, cette émission devant être soumise à l'approbation d'une assemblée\ngénérale extraordinaire des actionnaires de la Société à convoquer (raison pour\nlaquelle le présent rapport a été préparé). Les principaux termes et conditions\ndes Warrants d'Exact Sciences sont résumés au paragraphe 3.3 ci-dessous.\n2.2. Emission proposée des Warrants d'Exact Sciences\nComme indiqué ci-dessus, dans le contexte de l'Amendement, la Société s'est engagée envers\nExact Sciences à émettre les Warrants d'Exact Sciences en faveur d'Exact Sciences. A cette fin,\nle conseil d'administration de la Société s'est engagé à proposer aux actionnaires de la Société,\ndans le cadre de l'AGE, d'approuver l'émission par la Société, en faveur d'Exact Sciences, des\nWarrants d'Exact Sciences.\nLa Société et Exact Sciences ont convenu que l'émission des Warrants d'Exact Sciences à Exact\nSciences était essentielle pour qu'Exact Sciences accepte le report du paiement du Complément\nde Prix Initial. En outre, dans l'éventualité où l'AGE n'approuverait pas l'émission proposée des\nWarrants d'Exact Sciences, la Société pourrait se trouver en violation de ses obligations en vertu\nde l'Amendement.\n3. OPERATION PROPOSEE\n3.1. Termes et Conditions d'Warrants d'Exact Sciences\nLe projet de termes et conditions des Warrants d'Exact Sciences figure à l'Annexe A du présent\nrapport du conseil d'administration (les \"Termes et conditions des Warrants d'Exact\nSciences\"). Les principaux termes et conditions des Warrants d'Exact Sciences peuvent, à titre\nd'information, être résumés comme suit :\n• Emetteur : La Société (MDxHealth SA).\n• Droit de souscrire à une action ordinaire : Chaque droit de souscription permet à son\ndétenteur de souscrire une (1) action ordinaire à émettre par la Société.\n• Prix d'exercice : Le prix d'exercice des Warrants d'Exact Sciences (c'est-à-dire le prix\nà payer en numéraire pour souscrire à une nouvelle action de la Société lorsqu'un\nWarrant Exact Sciences est exercé) sera de USD 5,265.\n• Durée : Les Warrants d'Exact Sciences auront une durée commençant à partir de leur\némission et se terminant le 22 août 2028 (inclus).\n• Possibilité d'exercice : L'exercice des Warrants d'Exact Sciences sera soumis aux\ntermes et conditions contenus dans les Termes et Conditions des Warrants d'Exact\n4\nSciences. Les Warrants d'Exact Sciences peuvent être exercés à partir de leur émission\net jusqu'à la fin de leur durée, à condition qu'un nombre de Warrants d'Exact Sciences\navec un prix d'exercice global d'au moins USD 250.000 soit exercé par leur détenteur.\n• Nature des actions émises lors de l'exercice : Chaque Warrant d'Exact Sciences\ndonnera à son détenteur le droit de souscrire à une nouvelle action à émettre par la\nSociété. Les nouvelles actions à émettre lors de l'exercice des Warrants d'Exact\nSciences auront les mêmes droits et avantages, et seront à tous égards pari passu, y\ncompris en ce qui concerne les droits aux dividendes et autres distributions, avec les\nactions existantes et en circulation de la Société au moment de leur émission, et auront\ndroit aux dividendes et autres distributions pour lesquelles la date d'enregistrement ou\nla date d'échéance tombe à, ou après leur date d'émission.\n• Augmentation du capital et comptabilisation du prix d'exercice : Lors de l'exercice des\nWarrants d'Exact Sciences et de l'émission de nouvelles actions, le montant total du\nprix d'exercice des Warrants d'Exact Sciences sera comptabilisé (le cas échéant, après\nconversion dans la devise du capital de la Société, sur la base du taux de change\nUSD/EUR publié par la Banque Centrale Européenne (\"BCE\"), comme prévu à la\nsection 5.4 des Termes et Conditions des Warrants d'Exact Sciences) en tant que capital\nde la Société. Dans la mesure où le montant du prix d'exercice des Warrants d'Exact\nSciences, par action à émettre lors de l'exercice des Warrants d'Exact Sciences, excède\nle pair comptable des actions de la Société existantes immédiatement avant l'émission\ndes nouvelles actions concernées, une partie du prix d'exercice, par action à émettre\nlors de l'exercice des Warrants d'Exact Sciences, égale à ce pair comptable sera\ncomptabilisée en capital, le solde étant comptabilisé en prime d'émission. Suite à\nl'augmentation de capital et à l'émission de nouvelles actions, chaque action nouvelle\net existante représentera la même fraction du capital de la Société.\n• Admission à la cotation et à la négociation des actions sous-jacentes : Les nouvelles\nactions à émettre lors de l'exercice des Warrants d'Exact Sciences seront admises à la\ncotation et à la négociation sur toute bourse principale ou autre plateforme de\nnégociation sur laquelle les autres actions de la Société sont alors admises à la cotation\net à la négociation. A cette fin, la Société effectuera les dépôts et demandes nécessaires.\n• Cessibilité : A moins que la Société autorise explicitement la cession des Warrants\nd'Exact Sciences, les Warrants d'Exact Sciences ne peuvent pas être cédés par leur\ndétenteur. En outre, les Warrants d'Exact Sciences ne seront pas admis à la cotation ou\nà la négociation.\n• Forme : Les Warrants d'Exact Sciences seront émis sous forme nominative et ne\npourront pas être dématérialisés.\n3.2. Suppression du droit de préférence des actionnaires existants\nDans le cadre de l'Opération proposée, le conseil d'administration propose à l'AGE de\nsupprimer le droit de préférence des actionnaires existants de la Société et, pour autant que de\nbesoin, des détenteurs actuels de droits de souscription (share options) de la Société,\nconformément à l'article 7:193 du Code des Sociétés et des Associations, en faveur d'Exact\nSciences.\nExact Sciences n'est pas un membre du personnel de la Société au sens de l'article 1:27 du Code\ndes Sociétés et des Associations.\nLa suppression du droit de préférence des actionnaires existants et, dans la mesure nécessaire,\ndes détenteurs existants de droits de souscription (share options), est nécessaire pour permettre\n5\nà la Société d'émettre les Warrants d'Exact Sciences, comme convenu dans l'Amendement.\n3.3. Prix d'exercice\nComme indiqué ci-dessus, les Warrants d'Exact Sciences peuvent être exercés au prix d'exercice\nde USD 5,265 par nouvelle action. Sous réserve et conformément aux dispositions respectives\ndes Termes et Conditions des Warrants d'Exact Sciences, lors de l'exercice des Warrants d'Exact\nSciences et de l'émission de nouvelles actions, le prix d'exercice des Warrants d'Exact Sciences\nsera comptabilisé (le cas échéant, après conversion dans la devise du capital de la Société, sur\nla base du taux de change USD/EUR publié par la BCE, comme prévu à la section 5.4 des\nTermes et Conditions des Warrants d'Exact Sciences) en tant que capital de la Société. Dans la\nmesure où le montant du prix d'exercice des Warrants d'Exact Sciences, par action à émettre\nlors de l'exercice des Warrants d'Exact Sciences, excède le pair comptable des actions de la\nSociété existantes immédiatement avant l'émission des nouvelles actions concernées, une partie\ndu prix d'exercice, par action à émettre lors de l'exercice des Warrants d'Exact Sciences, égale\nà ce pair comptable sera comptabilisée en capital, le solde étant comptabilisé en prime\nd'émission. Suite à l'augmentation de capital et à l'émission de nouvelles actions, chaque action\nnouvelle et existante représentera la même fraction du capital de la Société. Toute prime\nd'émission sera comptabilisée sur un compte indisponible au passif du bilan de la Société, dans\nles capitaux propres, et le compte sur lequel la prime d'émission sera comptabilisée servira,\ncomme le capital, de garantie pour les tiers et ne pourra être réduit que sur la base d'une décision\nrégulière de l'assemblée générale des actionnaires adoptée de la manière requise pour une\nmodification des statuts de la Société.\n3.4. Droits attachés aux nouvelles actions à émettre lors de l'exercice des Warrants d'Exact\nSciences\nComme mentionné ci-dessus, les nouvelles actions à émettre lors de l'exercice des Warrants\nd'Exact Sciences auront les mêmes droits et avantages, et seront à tous égards pari passu, y\ncompris en ce qui concerne les droits aux dividendes et autres distributions, avec les actions\nexistantes et en circulation de la Société au moment de leur émission, et auront droit aux\ndividendes et autres distributions pour lesquelles la date d'enregistrement ou la date d'échéance\ntombe à, ou après leur date d'émission.\n4. JUSTIFICATION DE L'OPÉRATION PROPOSÉE\nLe conseil d'administration estime que l'Opération est dans l'intérêt de la Société car avant tout,\nl'Amendement, dont l'Opération fait partie, a permis à la Société de reporter et de modifier les\npaiements en numéraire de milestones dans le cadre du Complément de Prix Initial, ce qui a\npermis à la Société de préserver ses moyens financiers pour d'autres fins générales et pour son\nfonds de roulement. Si les Warrants d'Exact Sciences ne sont pas émis en faveur d'Exact\nSciences, comme le prévoit l'Amendement, la Société pourrait être en violation de ses\nengagements en vertu de l'Amendement.\nEn outre, bien qu'il n'y ait aucune garantie que les Warrants d'Exact Sciences seront finalement\nexercés, l'exercice des Warrants d'Exact Sciences et le paiement du prix d'exercice\ncorrespondant aux Warrants d'Exact Sciences, le cas échéant, fourniront à la Société des\nliquidités supplémentaires, qui pourront être utilisées pour financer davantage les activités de\nla Société et renforcer son bilan.\nLe conseil d'administration est également conscient que l'émission des Warrants d'Exact\nSciences peut entraîner une dilution supplémentaire pour les actionnaires. Cependant, la\ndilution dépendra de l'exercice effectif des Warrants d'Exact Sciences. En tout état de cause, le\nconseil d'administration et d'avois que cette dilution potentielle ne l'emporte pas sur un scénario\ndans lequel la Société n'aurait pas conclu l'Amendement et n'aurait pas obtenu un report et une\n6\nmodification des paiements en numéraire de milestones dans le cadre du Complément de Prix\nInitial.\nPour toutes les raisons susmentionnées, le conseil d'administration estime que l'Opération\nproposée est dans l'intérêt de la Société, de ses actionnaires, et des autres parties prenantes. Le\nconseil d'administration recommande donc à l'AGE d'approuver l'émission des Warrants\nd'Exact Sciences.\n5. JUSTIFICATION DU PRIX D'ÉMISSION ET DU PRIX D'EXERCICE DES\nWARRANTS D'EXACT SCIENCES\nConformément aux Termes et Conditions d'Exact Sciences, les Warrants d'Exact Sciences\nseront attribués à Exact Sciences sans aucune autre contrepartie.\nLe prix d'exercice des Warrants d'Exact Sciences de USD 5,265 (représentant le capital de la\nSociété pour le montant égal au pair comptable et la prime d'émission pour le montant excédant\nle pair comptable), a été déterminé par le conseil d'administration à la suite de négociations\navec Exact Sciences. Le processus de négociation a été mené de manière objective et\nindépendante. Le prix d'exercice représentait une prime d'environ 45 % par rapport au cours\ndes American Depositary Shares de la Société négociées sur le Nasdaq le 23 août 2023, soit le\njour de la signature de l'Amendement.\nL'exercice ou non d'un Warrant d'Exact Sciences dépend de la (seule) décision d'Exact\nSciences. Cette décision dépendra du cours des actions de la Société au moment de la décision\nd'exercer ou non par rapport au prix d'exercice des Warrants d'Exact Sciences, puisque\nessentiellement, Exact Sciences peut réaliser une plus-value lors de l'exercice des Warrants\nd'Exact Sciences si le cours des actions de la Société à ce moment est plus élevé que le prix\nd'exercice des Warrants d'Exact Sciences (sans tenir compte des coûts fiscaux éventuels et en\nsupposant qu'Exact Sciences puisse vendre l'action sous-jacente à ce prix sur le marché).\nPar conséquent, compte tenu de tout ce qui précède, le conseil d'administration est d'avis que\nle prix d'exercice des Warrants d'Exact Sciences n'est pas déraisonnable et peut être\nsuffisamment justifié, et qu'il est dans l'intérêt de la Société, des actionnaires existants, des\ndétenteurs actuels de droits de souscription (share option) de la société et des autres\nstakeholders.\n6. JUSTIFICATION DE LA SUPPRESSION DU DROIT DE PRÉFÉRENCE\nDans le cadre de l'Opération envisagée telle décrite ci-dessus, le conseil d'administration\npropose à l'AGE de supprimer le droit de préférence des actionnaires existants de la Société et,\npour autant que de besoin, des détenteurs actuels de droits de souscription (share options) de la\nSociété conformément aux articles 7:191 et 7:193 du Code des Sociétés et des Associations, en\nfaveur d'Exact Sciences.\nLa suppression du droit de préférence des actionnaires existants de la Société et, pour autant\nque de besoin, des détenteurs actuels de droits de souscription (share options), est nécessaire\npour permettre à la Société d'émettre les Warrants d'Exact Sciences conformément à\nl'Amendement.\nL'engagement de la Société de soumettre l'émission des Warrants d'Exact Sciences à l'AGE a\nété un des éléments clés qui ont permis à la Société de conclure l'Amendement et de reporter et\nmodifier les paiement en numéraires de milestones dans le cadre du Complément de Prix Initial,\nce qui a permis à la Société de préserver sa trésorerie pour continuer à financer ses activités,\ncomme indiqué au paragraphe 4 ci-dessus.\n7\nSi les Warrants d'Exact Sciences ne sont pas émis en faveur d'Exact Sciences, comme prévu\ndans l'Amendement, la Société pourrait être en violation de ses engagements en vertu de\nl'Amendement.\nPour toutes les raisons susmentionnées, le conseil d'administration est d'avis que l'émission\nproposée des Warrants d'Exact Sciences, avec suppression du droit de préférence en faveur\nd'Exact Sciences et nonobstant la dilution résultant de l'exercice potentiel des Warrants d'Exact\nSciences pour les actionnaires et, le cas échéant, les détenteurs de droits de souscription (share\noptions), est dans l'intérêt de la société, des actionnaires existants et des détenteurs de droits de\nsouscription (share options), ainsi que des autres stakeholders, puisqu'elle a permis à la société\nde différer et de modifier les paiements en numéraire des milestones dans le cadre du\nComplément de Prix Initial.\n7. CERTAINES CONSÉQUENCES FINANCIÈRES\n7.1. Commentaire introductif\nLes paragraphes suivants donnent un aperçu de certaines conséquences financières de l'exercice\npotentiel des Warrants d'Exact Sciences. Pour de plus amples informations concernant les\nconséquences financières de l'exercice potentiel des Warrants d'Exact Sciences, il est également\nfait référence au rapport préparé conformément aux articles 7:180, 7:191 et 7:193 du Code des\nSociétés et des Associations par le commissaire de la Société, BDO Réviseurs d'Entreprises\nSRL.\nL'émission ou non de nouvelles actions suite à l'exercice des Warrants d'Exact Sciences\ndépendra de l'exercice ou non des Warrants d'Exact Sciences par Exact Sciences.\nDe même, les conséquences financières réelles liées à l'exercice ou la conversion en actions des\nautres instruments dilutifs en circulation et des nouveaux instruments dilutifs proposés par la\nSociété ne peuvent pas encore être déterminées avec certitude.\nPar conséquent, la discussion des conséquences financières de la proposition d'émettre et de\nl'exercice des Warrants d'Exact Sciences pour les actionnaires existants est purement\nillustrative et hypothétique, et est basée sur des paramètres financiers purement indicatifs\n(lorsqu'approprié).\nSous réserve de ce qui précède, pour illustrer certaines des conséquences financières de\nl'exercice des Warrants d'Exact Sciences et notamment la dilution pour les actionnaires, les\nparamètres et hypothèses suivants ont été utilisés :\n(a) Taux de Change1: Aux fins des simulations et illustrations ci-dessous, le taux de change\nsuivant est utilisé: USD 1,0743 pour 1 EUR, lequel est le taux de change publié par la\nBCE sur\nhttps://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchang\ne_rates/html/index.fr.html le 8 mai 2024 (le \"Taux de Change\").\n(b) Capital actuel : A la date du présent rapport, le montant du capital de la Société s'élève\nà EUR 164.302.752,89 représenté par 27.288.093 actions ordinaires sans valeur\nnominale, représentant chacune la même fraction du capital de la Société, soit arrondi\n1\nLes actions de la Société sont cotées sur le Nasdaq, où elles sont négociées en USD. Cependant le capital de la\nSociété est actuellement exprimé en EUR. Compte tenu de la différence actuelle entre la devise de négociation des\nactions de la Société et la devise du capital de la Société, à l'exception des montants dans les simulations de dilution\nfinancière au paragraphe 7.4 ci-dessous, tous les montants en USD utilisés dans les simulations ci-dessous sont\nconvertis en EUR sur la base du Taux de Change.\n8\nà EUR 6,0210. Le montant du capital est entièrement et inconditionnellement souscrit\net entièrement libéré.\n(c) L'Opération : Afin d'illustrer les effets dilutifs potentiels maximums de l'Opération ci-\ndessous, il est supposé que les 1.000.000 de Warrants d'Exact Sciences sont émis et\ntous exercés, pour un total de 1.000.000 de actions nouvellement émises à un prix\nd'émission de USD 5,265 par nouvelle action, résultant en un prix d'émission total de\nUSD 5.265.000, ou, en appliquant le Taux de Change, à un prix d'émission de\nEUR 4,900 par nouvelle action, résultant en un prix d'émission total de EUR 4.900.000\n(prime d'émission incluse, le cas échéant). Afin de refléter la dilution maximale, le\nplafond actionnarial de 7,5% (tel que décrit ci-dessus) n'est pas pris en compte dans les\nsimulations ci-dessous. Si ce plafond actionnarial de 7,5 % était appliqué, seules\n3.528.875 actions pourraient être émises en faveur d'Exact Sciences sur une base\nentièrement diluée, en tenant compte des paramètres les plus dilutifs utilisés ici.\n(d) Share Options : En outre, les 18.388.230 droits de souscription suivants émis par la\nSociété sont toujours en circulation à la date du présent rapport (les \"Share Options\"):\n(i) 522.500 share options en circulation émis sous la forme de droits de\nsouscription le 23 juin 2014 (\"Share Options 2014\") (desquels 68.500 share\noptions n'ont pas encore été octroyés)2;\n(ii) 1.866.000 share options en circulation émis sous forme de droits de\nsouscription le 19 juin 2017 (\"Share Options 2017\") (lesquels ont tous été\noctroyés);\n(iii) 2.632.860 share options en circulation émis sous forme de droits de\nsouscription le 21 juin 2019 (\"Share Options 2019\") (desquels 1.500 share\noptions n'ont pas encore été octroyés) ;\n(iv) 3.525.000 share options en circulation émis sous forme de droits de\nsouscription le 27 mai 2021 (\"Share Options 2021\")\n(qui ont tous été octroyés) ;\n(v) 4.851.870 share options en circulation émis sous forme de droits de\nsouscription le 25 mai 2022 (\"Share Options 2022\") (desquels 2.500 share\noptions n'ont pas encore été octroyés) ; et\n(vi) 4.990.000 share options en circulation émis sous forme de droits de\nsouscription le 30 juin 2023 (\"Share Options 2023\") (desquels 1.960.000\nshare options n'ont pas encore été octroyés).\nChacun des Share Options susmentionnés permet aux détenteurs de celui-ci de\nsouscrire à une nouvelle action de la Société suite à l'exercice du Share Option\nconcerné. Pour les besoins du calcul du scénario de dilution totale ci-après, il est\nprésumé que tous les 18.388.230 Share Options en circulation (y compris les 68.500\nShare Options 2014 en circulation, les 1.500 Share Options 2019 en circulation, les\n2.500 Share Options 2022 en circulation et les 1.960.000 Share Options 2023 en\ncirculation qui peuvent encore être octroyés) ont été effectivement octroyés,\ndéfinitivement acquis et sont exerçables. Sur cette base, si tous les 18.388.230 Share\n2\nTous les Share Options 2014 qui n'auront pas été exercées avant le 23 juin 2024 deviendront automatiquement\ncaduques et non avenues.\n9\nOptions étaient exercés, 1.838.823 nouvelles actions devraient être émises par la\nSociété.\n(e) Complément de Prix Amendé : Pour les besoins des calculs du scénario de dilution\ntotale ci-dessous, il est supposé que le montant total du Complément de Prix Amendé\nmodifié de USD 82.500.000,00 est converti, en appliquant le Taux de Change (voir\nparagraphe (a)), en EUR 76.794.191,56 et est entièrement payé en nature par la Société\nà Exact Sciences par l'émission de nouvelles actions de la Société, à un prix d'émission\npar action de USD 3,00 (soit le prix de clôture des actions de la Société sur le Nasdaq\nle 8 mai 2024) ou, en appliquant le Taux de Change, à un prix d'émission par action de\nEUR 2,79, en contrepartie du règlement par un apport en nature des créances dues par\nla Société à Exact Sciences jusqu'à concurrence du Complément de Prix Amendé. Afin\nde refléter la dilution maximale, le plafond actionnarial de 7,5% (tel que décrit ci-\ndessus) n'est pas pris en compte dans les simulations ci-dessous. Si ce plafond\nactionnarial de 7,5 % était appliqué, seules 3.528.875 actions pourraient être émises en\nfaveur d'Exact Sciences sur une base entièrement diluée, en tenant compte des\nparamètres les plus dilutifs utilisés ici.\n(f) Facilité ATM : Le 30 avril 2024, la Société a conclu une convention de ventes avec TD\nSecurities (USA) LLC (\"TD Cowen\") concernant un programme d'offre d'actions dans\nle cadre duquel la Société peut offrir et placer de nouvelles actions, par l'intermédiaire\nde TD Cowen et par divers placements de temps à autre dans des offres\n\"at the market\", tel que défini dans la Rule 415(a)(4) promulguée en vertu de la loi\naméricaine sur les valeurs mobilières de 1933, telle que modifiée, et les règles et\nrèglements qui en découlent, pour un montant d'offre maximum global de\nUSD 50.000.000 (la \"Facilité ATM\"). Le nombre actuel de nouvelles actions à émettre\ndans le cadre de la Facilité ATM variera en fonction des placements effectifs de\nnouvelles actions et du prix de chacun de ces placements. Toutefois, le nombre de\nnouvelles actions à émettre dans le cadre de la Facilité ATM ne dépassera pas\n100.000.000 actions. Ces nouvelles actions seront placées à un prix de souscription\nfinal par nouvelle action en fonction des cours en USD sur le Nasdaq au moment des\nplacements concernés, le prix d'émission ne pouvant être inférieur à USD 0,50.\nPour les besoins des calculs du scénario de dilution totale ci-dessous, il est supposé que\n(i) des nouvelles actions sont émises dans le cadre de la Facilité ATM pour le montant\ntotal de USD 50.000.000,00, et (ii) toutes ces nouvelles actions émises dans le cadre de\nla Facilité ATM sont émises à un prix d'émission par action de USD 3,00 (soit le cours\nde clôture des actions de la Société sur le Nasdaq le 8 mai 2024). Sur cette base, en\nappliquant le Taux de Change, EUR 46.541.934,28 seraient levés par la Société contre\nl'émission de 16.681.696 nouvelles actions de la Société à un prix d'émission de EUR\n2,79 par action.\n(g) Warrants d'OrbiMed : Le 1er mai 2024, la Société a conclu une convention de crédit,\nen tant que garant, avec MDxHealth, Inc, une filiale détenue à 100 % par la Société, en\ntant qu'emprunteur, et ORC SPV LLC (\"OrbiMed\"), en tant que prêteur et agent\nadministratif, en vertu de laquelle OrbiMed a accepté de fournir une facilité de crédit\ngarantie de premier rang d'une durée de cinq ans pour un montant total en principal de\nUSD 100 millions, dont (i) USD 55 millions ont été avancés à la date de closing, (ii)\nUSD 25 millions seront mis à disposition, à la discrétion de MDxHealth, Inc., au plus\ntard le 31 mars 2025, sous réserve de certaines exigences en matière de revenus nets et\nd'autres conditions habituelles, et (iii) USD 20 millions seront mis à disposition, à la\ndiscrétion de MDxHealth, Inc., au plus tard le 31 mars 2026, sous réserve de certaines\nexigences en matière de revenus nets et d'autres conditions habituelles. En outre,\nconformément à la convention de crédit, la Société s'est engagée à émettre en faveur de\n10\nsociétés liées à OrbiMed, 1.243.060 nouveaux droits de souscription pour nouvelles\nactions de la Société (chacun pouvant être exercé pour une nouvelle action de la Société\nà un prix d'exercice par nouvelle action de USD 2,4134) avec une durée de 5 ans à\ncompter de leur date d'émission (les \"Warrants d'OrbiMed\"). L'émission proposée\ndes Warrants d'OrbiMed sera soumise à l'approbation de la même assemblée générale\nextraordinaire des actionnaires de la Société que celle qui devra décider de l'émission\ndes Warrants d'Exact Sciences.\nPour les besoins des calculs du scénario de dilution totale ci-dessous, il est supposé que\nles 1.243.060 Warrants d'OrbiMed sont émis et tous exercés, pour un total de 1.243.060\nactions nouvellement émises à un prix d'émission de USD 2,41 (arrondi) par nouvelle\naction, résultant en un prix d'émission total de USD 2.995.774,60, ou, en appliquant le\nTaux de Change, à un prix d'émission de EUR 2,24 (arrondi) par nouvelle action,\nrésultant en un prix d'émission total de EUR 2.784.454,40 (y compris la prime\nd'émission, le cas échéant). Il est également supposé que le prix de souscription global\ndes Warrants d'OrbiMed est payé intégralement lors de l'émission et de la souscription\ndes Warrants d'OrbiMed.\n(h) Comptabilisation du prix d'émission des instruments dilutifs en circulation : Lors de\nl'émission de nouvelles actions suite à l'exercice des Warrants d'OrbiMed (si leur\némission est approuvée par une assemblée générale extraordinaire des actionnaires de\nla Société), et/ou le placement intégral de la Facilité ATM, et/ou l'apport du\nComplément de Prix Amendé, et/ou l'exercice des Share Options, le montant du prix\nd'émission des nouvelles actions concernées sera comptabilisé en tant que capitaux\npropres (en tant que capital et de prime d'émission, le cas échéant). Le montant qui sera\ncomptabilisé en tant que capital sera, sur une base par action, égal au montant du pair\ncomptable applicable des actions de la Société au moment concerné. Le solde sera\ncomptabilisé en tant que prime d'émission.\nDans le présent rapport, lorsqu'il est fait référence aux \"instruments dilutifs en circulation\", il\ns'agit respectivement de l'émission de nouvelles actions lors de l'exercice des Warrants\nd'OrbiMed en supposant que leur émission soit approuvée par une assemblée générale\nextraordinaire des actionnaires de la Société), du placement intégral de la Facilité ATM, de\nl'apport du Complément de Prix Amendé, de l'exercice des Share Options en circulation.\nLe fait que les Share Options en circulation, les Warrants d'OrbiMed (en supposant que leur\némission soit approuvée par une assemblée générale extraordinaire des actionnaires de la\nSociété) ou les Warrants Exact Sciences (en supposant que leur émission soit approuvée par\nune assemblée générale extraordinaire des actionnaires de la Société) soient effectivement\nexercés dépendra en fin de compte de la décision de leurs détenteurs respectifs. Cette décision\nsera probablement fonction du cours des actions de la Société au moment de l'exercice, par\nrapport à leurs prix d'exercice respectifs. Les détenteurs respectifs n'exerceront probablement\npas si le cours des actions de la Société est inférieur au prix d'exercice concerné.\nLe fait que le montant du Complément de Prix d'Exact Amendé soit dû et converti en actions\nde la Société dépendra de la réalisation (ou non) des conditions respectives prévues par la\nConvention de Cession d'Actif, telle qu'amendée de temps à autre. En outre, si un montant d'un\nComplément de Prix Amendé est dû par la Société à Exact Sciences, la Société peut également\nchoisir de payer ce montant de Complément de Prix Amendé en numéraire plutôt qu'en actions.\nLe fait que le montant total de USD 50.000.000 soit placé par la Société dans le cadre de la\nFacilité ATM, les prix d'émission applicables pour ces placements et le nombre total de\nnouvelles actions émises dans le cadre de la Facilité ATM dépendront de la décision finale de\nla Société de procéder à de tels placements, des conditions auxquelles ces placements sont\n11\neffectués (y compris les cours en USD pertinents sur le Nasdaq utilisés comme référence pour\ndéterminer les prix d'émission pertinents) et de la réussite ou non de ces placements.\n7.2. Évolution du capital, droit de vote, participation aux résultats et autres droits des\nactionnaires\nChaque action dans la Société représente actuellement une portion égale du capital de la Société\net donne droit à un vote en fonction de la portion du capital qu'elle représente. L'émission des\nnouvelles actions lors de l'exercice des Warrants d'Exact Sciences (à condition que les Warrants\nd'Exact Sciences soient émis en faveur d'Exact Sciences) aboutira à une dilution des\nactionnaires existants de la Société et du pouvoir de vote afférent à chaque action dans la\nSociété.\nLa dilution concernant le droit de vote s'applique également, mutatis mutandis, à la participation\nde chaque action dans le bénéfice et les produits de liquidation et les autres droits attachés aux\nactions de la Société tel que le droit de préférence en cas d'augmentation de capital en numéraire\npar l'émission de nouvelles actions ou en cas d'émission de nouveaux droits de souscription ou\nd'obligations convertibles.\nEn particulier, avant l'émission de nouvelles actions lors de l'exercice des Warrants d'Exact\nSciences (et avant l'émission de nouvelles actions en vertu des instruments dilutifs en\ncirculation), chaque action de la Société participera de manière égale aux bénéfices de la Société\net aux produits de liquidation de la Société et chaque actionnaire dispose d'un droit de\npréférence en cas d'une augmentation du capital en numéraire ou en cas d'émission de nouveaux\ndroits de souscription ou d'obligations convertibles. Lors de l'émission de nouvelles actions en\nvertu de l'exercice des Warrants d'Exact Sciences (à condition que les Warrants d'Exact\nSciences soient émis en faveur d'Exact Sciences), les nouvelles actions à émettre auront les\nmêmes droits et bénéfices que, et seront à tous égards pari passu avec, les actions existantes et\nen circulation de la Société au moment de leur émission et de leur délivrance et auront droit\naux dividendes et autres distributions pour lesquelles la date d'enregistrement ou d'échéance\ntombe à ou après la date d'émission et de délivrance des nouvelles actions. Par conséquent, (et\ndans la mesure où les nouvelles actions seront émises et souscrites) la participation des\nactionnaires existants aux bénéfices et au produit de liquidation de la Société et le droit de\npréférence de leurs détenteurs en cas d'augmentation de capital en numéraire, seront dilués\nproportionnellement.\nUne dilution similaire se produit lors de l'exercice ou de la conversion des autres instruments\ndilutifs en circulation.\nEn outre, conformément à l'article 7:178 du Code des Sociétés et des Associations, après la\nréalisation de l'émission des nouvelles actions, suite à l'exercice des Warrants Exact Sciences\ntoutes les actions en circulation de la Société auront le même pair comptable (ajusté, le cas\néchéant).\nSous réserve des réserves méthodologiques mentionnées au paragraphe 7.1, l'évolution du\ncapital et du nombre d'actions, avec droits de vote attachés, de la Société suite à l'émission et\nl'exercice proposés de l'ensemble des 1.000.000 de Warrants d'Exact Sciences (et de l'émission\nsubséquente de 1.000.000 nouvelles actions en résultant) est simulée ci-dessous dans un\nscénario avant dilution due aux instruments dilutifs en circulation, ainsi que dans un scénario\naprès dilution due aux instruments dilutifs en circulation.\n12\nÉvolution du nombre d'actions en circulation\nAprès l'exercice des Warrants d'Exact Sciences mais avant la\ndilution due aux instruments dilutifs en circulation\n(A) Actions en circulation ......................................................................... 27.288.093\n(B) Nouvelles actions à émettre lors de l'exercice des Warrants d'Exact\nSciences ..................................................................................................... 1.000.000\n(C) Nombre total d'actions en circulation après (B) ................................. 28.288.093\n(D) Dilution ............................................................................................... 3,54%\nAprès la dilution due aux instruments dilutifs en circulation mais\navant l'exercice des Warrants d'Exact Sciences\n(A) Actions en circulation ......................................................................... 27.288.093\n(B) Nouvelles actions à émettre lors de l'exercice de tous les Share\nOptions en circulation ............................................................................... 1.838.823\n(C) Nouvelles actions à émettre sur apport du Complément de Prix\nAmendé ..................................................................................................... 27.499.999\n(D) Nouvelles actions à émettre lors de l'exercice de tous les Warrants\nd'OrbiMed ................................................................................................. 1.243.060\n(E) Nouvelles actions à émettre sur placement intégral de la Facilité ATM 16.681.696\n(F) Nombre total de nouvelles actions à émettre en vertu de (B), (C), (D)\net (E) .......................................................................................................... 47.263.578\n(G) Nombre total d'actions en circulation après (B), (C), (D) et (E).. ....... 74.551.671\nAprès l'exercice des Warrants d'Exact Sciences et après la dilution\ndue aux instruments dilutifs en circulation\n(A) Actions en circulation après la dilution due aux instruments dilutifs\nen circulation ............................................................................................. 74.551.671\n(B) Nouvelles actions à émettre lors de l'exercice des Warrants d'Exact\nSciences ..................................................................................................... 1.000.000\n(C) Nombre total d'actions en circulation après (B) .................................. 75.551.671\n(D) Dilution ............................................................................................... 1,32%\nSous réserves des réserves méthodologiques reprises au paragraphe 7.1, le tableau ci-dessous\nreflète sur l'évolution du capital, en supposant l'exercice de l'ensemble des 1.000.000 de\nWarrants d'Exact Sciences et l'émission subséquente de 1.000.000 de nouvelles actions en\nrésultant. Le montant maximum de l'augmentation de capital (hors prime d'émission) est calculé\nen multipliant le nombre de nouvelles actions à émettre (c'est-à-dire 1.000.000) par le prix\nd'émission applicable (étant donné que le prix d'émission est inférieur au pair comptable des\nactions de la Société (soit actuellement arrondi à EUR 6,0210 par action)).\nÉvolution du capital(1)\nAvant l'exercice des Warrants d'Exact Sciences\n(A) Capital (en EUR) .................................................................................. 164.302.752,89\n(B) Actions en circulation ........................................................................... 27.288.093\n(C) Pair comptable (en EUR) ..................................................................... 6,0210\nExercice des Warrants d'Exact Sciences\n(A) Augmentation de capital (en EUR) ...................................................... 4.900.000,00\n(B) Nouvelles actions à émettre lors de l'exercice des Warrants d'Exact\nSciences ...................................................................................................... 1.000.000\n13\nAprès l'exercice des Warrants d'Exact Sciences\n(A) Capital (en EUR) .................................................................................. 169.202.752,89\n(B) Actions en circulation ........................................................................... 28.288.093\n(C) Pair comptable (en EUR) (arrondi) ...................................................... 5,9814(2)\n____________\nNotes:\n(1) Cette simulation ne tient pas compte de l'exercice ou de la conversion des instruments dilutifs en\ncirculation.\n(2) Le prix d'exercice est inférieur au pair comptable des actions existantes de la Société (soit, actuellement\narrondi à EUR 6,0210). Par conséquent, conformément à l'article 7:178 du Code des Sociétés et des\nAssociations, après l'exercice des Warrants d'Exact Sciences, toutes les actions en circulation de la Société\nauront le même pair comptable, soit arrondi à EUR 5,9814.\n7.3. Participation dans les capitaux propres nets comptables consolidés\nL'évolution des capitaux propres nets comptables consolidés de la Société suite à l'exercice des\nWarrants d'Exact Sciences est simulée ci-après.\nLa simulation est basée sur les comptes annuels consolidés de la Société pour l'exercice social\nclôturés le 31 décembre 2023 (qui ont été préparés conformément aux normes internationales\nd'information financière, adoptés par l'Union européenne (\"IFRS\") et qui ont été soumises à\nl'approbation de l'assemblée générale des actionnaires de la Société). Les capitaux propres nets\ncomptables consolidés de la Société au 31 décembre 2023 s'élevaient à EUR 6.709 ('000)\n(arrondi) (soit, USD 7.208 ('000) (arrondi) sur la base du Taux de Change) ou EUR 0,2459\n(arrondi) par action (basé sur 27.288.093 actions en circulation au 31 décembre 2023). La\nsimulation ne tient pas compte des changements intervenus dans les capitaux propres nets\ncomptables consolidés depuis le 31 décembre 2023.\nPour plus d'informations sur la situation des capitaux propres nets de la Société au 31 décembre\n2023, il est fait référence au comptes annuels, lesquels sont disponibles sur le site web de la\nSociété.\nSur base de l'hypothèse établie ci-dessus, il résulterait de l'exercice des Warrants d'Exact\nSciences, sans tenir compte des autres instruments dilutifs en circulation, que les capitaux\npropres nets comptables consolidés de la Société seraient augmentés comme indiqué ci-\ndessous:\nEvolution des capitaux propres nets comptables consolidés\nCapitaux propres nets consolidés pour FY 2023\n(A) Capitaux propres nets (en EUR '000) (arrondi) ......................................... 6.709\n(B) Actions en circulation ................................................................................ 27.288.093\n(C) Capitaux propres nets par action (en EUR) (arrondi) ................................ 0,2459\nExercice des Warrants d'Exact Sciences\n(A) Augmentation des capitaux propres nets (en EUR '000) (arrondi) ........... 4.900\n(B) Nouvelles actions à émettre lors de l'exercice des Warrants d'Exact\nSciences ............................................................................................................ 1.000.000\nAprès l'Exercice des Warrants d'Exact Sciences\n(A) Capitaux propres nets (en EUR '000) (arrondi) ......................................... 11.609\n(B) Actions en circulation ................................................................................ 28.288.093\n(C) Capitaux propres nets par action (en EUR) (arrondi) ................................ 0,4104\n14\nLe tableau ci-dessus démontre que l'émission des Warrants d'Exact Sciences et l'exercice\nsubséquent de tous les Warrants d'Exact Sciences conduira, d'un point de vue purement\ncomptable, en une augmentation du montant représenté par chaque action dans les capitaux\npropres nets comptables consolidés de la Société.\n7.4. Dilution financière\nL'évolution de la capitalisation boursière résultant de l'exercice des Warrants d'Exact Sciences\nest simulée ci-dessous.\nSous réserve des réserves méthodologiques reprises au paragraphe 7.1, le tableau ci-dessous\nreflète l'impact de l'exercice des Warrants d'Exact Sciences, sans tenir compte des autres\ninstruments dilutifs en circulation, sur la capitalisation boursière et la dilution financière qui en\nrésulte à différents niveaux de prix.\nAprès la clôture du marché sur le Nasdaq le 8 mai 2024, la capitalisation boursière de la Société\nétait de USD 81.864.279,00, sur la base d'un cours de clôture de USD 3,0000 par action. Partant\ndu principe qu'après l'exercice des Warrants d'Exact Sciences, sans prendre en compte les autres\ninstruments dilutifs en circulation, la capitalisation boursière augmente exclusivement avec les\nfonds levés sur base des paramètres décrits ci-dessus, la nouvelle capitalisation boursière serait\narrondie après à USD 3,0801 par action. Ceci représenterait une accrétion financière (théorique)\nde, 2,67% par action.\nÉvolution de la capitalisation boursière et dilution financière\nAvant l'exercice des Warrants d'Exact Sciences (1)\n(A) Capitalisation boursière (en USD) ............................................................ 81.864.279,00\n(B) Actions en circulation ............................................................................... 27.288.093\n(C) Capitalisation boursière par action (en USD) ........................................... 3,0000\nExercice des Warrants d'Exact Sciences\n(A) Fonds levés (en USD) ............................................................................... 5.265.000,00\n(B) Nouvelles actions à émettre lors de l'exercice des Warrants d'Exact\nSciences ........................................................................................................... 1.000.000\nAprès l'exercice des Warrants d'Exact Sciences (1)\n(A) Capitalisation boursière (en USD) ............................................................ 87.129.279,00\n(B) Actions en circulation ............................................................................... 28.288.093\n(C) Capitalisation boursière par action (en USD) (arrondi) ............................ 3,0801\nAccrétion ........................................................................................................ 2,67%\n___________\nNotes:\n(1) A la date du présent rapport et sans tenir comptes de l'exercice ou de la conversion des autres instruments\ndilutifs en circulation.\n7.5. Autres conséquences financières\nPour une discussion complémentaire sur les conséquences financières de la proposition\nd'émission des Warrants d'Exact Sciences et leur exercice subséquent, le conseil\nd'administration renvoie au rapport préparé en relation avec celui-ci par le commissaire de la\nSociété.\n* * *\nFait le 13 mai 2024.\n15\nPour le conseil d'administration,\nPar: __________________ Par: _______________\nAdministrateur Administrateur\nANNEXE A\nTERMES ET CONDITIONS DES WARRANTS D'EXACT SCIENCES\n17"
        },
        {
          "title": "Shareholder Meeting Minutes June 20, 2024",
          "url": "https://mdxhealth.com/wp-content/uploads/2024/07/MDxHealth-Deed-EGM-2-2024-EXEC-conformed.pdf",
          "content": ""
        },
        {
          "title": "Shareholder Meeting Minutes May 30, 2024 (EN)",
          "url": "https://mdxhealth.com/wp-content/uploads/2024/06/MDxHealth-AGM-minutes-FR-Conformed.pdf",
          "content": "MDxHealth SA\nSociété anonyme\nCAP Business Center\nZone Industrielle des Hauts-Sarts\nRue d'Abhooz 31\n4040 Herstal, Belgique\nTVA BE 0479.292.440 (RPM Liège, division Liège)\nPROCES-VERBAL DE\nL'ASSEMBLEE GENERALE ORDINAIRE\ntenue le jeudi 30 mai 2024 à 15h00\nLe 30 mai 2024, l'assemblée générale ordinaire des actionnaires de MDxHealth SA (la \"Société\") est tenue dans\nles bureaux de Maître Stijn Raes, notaire, à Kortrijksesteenweg 1147, 9051 Gand, Belgique.\nOUVERTURE DE LA REUNION\nL'assemblée générale ordinaire des actionnaires est ouverte à 15h00 par Ahok BV, représentée par M. Koen\nHoffman, administrateur et président du conseil d'administration (le \"Président\").\nLe Président note que, conformément au droit applicable, le français est la langue de travail applicable pour la\nréunion.\nCOMPOSITION DU BUREAU\nConformément aux statuts de la Société, le Président désigne Loore De Weirt en qualité de secrétaire.\nAu vu du nombre limité de personnes présentes à la réunion, aucun scrutateur n'est désigné.\nLe Président constitue, ensemble avec le secrétaire, le bureau de l'assemblée générale des actionnaires.\nDÉCLARATIONS DU PRÉSIDENT\nLe Président fait les déclarations suivantes à propos de la convocation et de la composition de l'assemblée.\nOrdre du jour\nLe Président expose que la présente assemblée a été convoquée avec l'ordre du jour et les propositions de\nrésolutions suivantes:\n1. Rapport sur les comptes annuels statutaires et sur les comptes annuels consolidés\nCommunication et discussion (a) du rapport annuel combiné du conseil d'administration sur les\ncomptes annuels consolidés et statutaires (non consolidés) de la Société pour l'exercice social clôturé\nau 31 décembre 2023, (b) du rapport du commissaire sur les comptes annuels statutaires (non\nconsolidés) de la Société pour l'exercice social clôturé au 31 décembre 2023, et (c) du rapport du\ncommissaire sur les comptes annuels consolidés de la Société pour l'exercice social clôturé au 31\ndécembre 2023.\n2. Approbation des comptes annuels statutaires (non consolidés)\nCommunication, discussion et approbation des comptes annuels statutaires (non consolidés) pour\nl'exercice social clôturé au 31 décembre 2023 et approbation de l'affectation du résultat tel que proposé\npar le conseil d'administration.\n1\nProposition de résolution : L'assemblée générale des actionnaires décide d'approuver les comptes\nannuels statutaires (non consolidés) de la Société pour l'exercice social clôturé le 31 décembre 2023 et\nd'approuver l'affectation du résultat annuel tel que proposé par le conseil d'administration.\n3. Comptes annuels consolidés\nCommunication et discussion des comptes annuels consolidés de la Société pour l'exercice social\nclôturé le 31 décembre 2023.\n4. Décharge de responsabilité des administrateurs\nDécharge de responsabilité des administrateurs pour l'exercice de leur mandat au cours de l'exercice\nsocial clôturé le 31 décembre 2023.\nProposition de résolution : L'assemblée générale des actionnaires décide d'accorder la décharge à\nchacun des administrateurs qui était en fonction au cours de l'exercice social clôturé le 31 décembre\n2023 pour l'exercice de son mandat au cours de cet exercice social.\n5. Décharge de responsabilité du commissaire\nDécharge de responsabilité du commissaire pour l'exercice de son mandat au cours de l'exercice social\nclôturé le 31 décembre 2023.\nProposition de résolution : L'assemblée générale des actionnaires décide d'accorder la décharge au\ncommissaire qui était en fonction au cours de l'exercice social clôturé le 31 décembre 2023 pour\nl'exercice de son mandat au cours de cet exercice social.\n6. Renouvellement de mandats d'administrateurs\nLe conseil d'administration recommande que (a) Ahok BV, représentée par Koen Hoffman en tant que\nreprésentant permanent, et (b) Qaly-Co BV, représentée par Lieve Verplancke en tant que représentante\npermanente, soient renouvelés en tant qu'administrateurs de la Société, chacune pour une durée de deux\nans.\nPropositions de résolutions :\n(a) L'assemblée générale des actionnaires décide de renouveler le mandat de Ahok BV,\nreprésentée par Koen Hoffman en tant que représentant permanent, en tant qu'administrateur\nde la Société, pour une durée de deux ans, s'étendant jusqu'à, et y compris, la clôture de\nl'assemblée générale ordinaire des actionnaires à tenir en 2026 qui statuera sur les comptes\nannuels de l'exercice social clôturé le 31 décembre 2025. Le mandat de l'administrateur est\nrémunéré, cette rémunération étant telle que décidée par l'assemblée générale des actionnaires\nde temps à autre.\n(b) L'assemblée générale des actionnaires décide de renouveler le mandat de Qaly-Co BV,\nreprésentée par Lieve Verplancke en tant que représentante permanente, en tant\nqu'administrateur de la Société, pour une durée de deux ans, s'étendant jusqu'à, et y compris,\nla clôture de l'assemblée générale ordinaire des actionnaires à tenir en 2026 qui statuera sur les\ncomptes annuels de l'exercice social clôturé le 31 décembre 2025. Le mandat de\nl'administrateur est rémunéré, cette rémunération étant telle que décidée par l'assemblée\ngénérale des actionnaires de temps à autre.\nNote: Si la résolution proposée au point 6 est approuvée par l'assemblée générale des actionnaires, le\nconseil d'administration de la Société sera composé de (1) Michael K. McGarrity, Chief Executive\nOfficer (CEO), administrateur et administrateur délégué (jusqu'en 2026), (2) Ahok BV, représentée par\nKoen Hoffman, administrateur et président du conseil d'administration (jusqu'en 2026), (3) Hilde\nWindels BV, représentée par Hilde Windels, administrateur (jusqu'en 2025), (4) Qaly-Co BV,\nreprésentée par Lieve Verplancke, administrateur (jusqu'en 2026), (5) Donnie M. Hardison Jr.,\nadministrateur (jusqu'en 2025), (6) Regine Slagmulder BV, représentée par Regine Slagmulder,\nadministrateur (jusqu'en 2025), et (7) Eric Bednarski, administrateur (jusqu'en 2025).\n2\n7. Rémunération des administrateurs\nEn tenant compte de la recommandation du Comité de Rémunération du conseil d'administration, le\nconseil d'administration propose que la rémunération des membres du conseil d'administration soit\nmodifiée comme indiqué dans la proposition de résolution.\nProposition de résolution : L'assemblée générale des actionnaires décide que la rémunération des\nmembres du conseil d'administration de la Société sera la suivante :\n(a) Le mandat des administrateurs de la Société est rémunéré comme suit :\n(i) Chaque administrateur a droit à une rémunération fixe annuelle maximale de USD\n40.000,00 (environ EUR 37.120,00).\n(ii) Le président du conseil d'administration a droit à une rémunération fixe annuelle\nmaximale supplémentaire de USD 64.400,00 (environ EUR 59.762,00).\n(iii) Le président du Comité d'Audit a droit à une rémunération fixe annuelle maximale\nsupplémentaire de EUR 19.000,00 (environ EUR 17.632,00), et les autres membres\ndu Comité d'Audit (autres que le président de ce comité) ont droit à une rémunération\nfixe annuelle maximale supplémentaire de USD 9.500,00 (environ EUR 8.816,00).\n(iv) Le président du Comité de Gouvernance d'Entreprise et de Nomination a droit à une\nrémunération fixe annuelle maximale supplémentaire de USD 10.000,00 (environ\nEUR 9.280,00), et les autres membres du Comité de Gouvernance d'Entreprise et de\nNomination (autres que le président de ce comité) ont droit à une rémunération fixe\nannuelle maximale supplémentaire de USD 5.000,00 (environ EUR 4.640,00).\n(v) Le président du Comité de Rémunération a droit à une rémunération fixe annuelle\nmaximale supplémentaire de USD 13.500,00 (environ EUR 12.528,00), et les autres\nmembres du Comité de Rémunération (autres que le président de ce comité) ont droit\nà une rémunération fixe annuelle maximale supplémentaire de USD 6.800,00\n(environ EUR 6.310,00).\n(vi) Les rémunérations prévues aux paragraphes (ii), (iii), (iv) et (v) s'ajoutent à la\nrémunération prévue au paragraphe (i) et peuvent être combinées, selon que les\ncritères d'éligibilité énoncés dans ces paragraphes ont été remplis ou non. La\nrémunération peut être réduite pro rata temporis en fonction de la durée du mandat ou\nde la présidence d'un administrateur ou de son appartenance à un comité au cours\nd'une année donnée. Tous les montants s'entendent hors TVA et autres charges\nsimilaires.\n(b) Nonobstant ce qui précède, les administrateurs qui, conformément aux règles et\nréglementations de la législation américaine et/ou du Nasdaq, peuvent être ou ont été qualifié\nd'administrateurs indépendants, ont chacun le droit (i) de recevoir, le 15 juin 2024, une\nattribution unique de droits de souscription (share options) pour 30.000 actions de la Société,\net (ii) chaque année suivante, à compter de l'assemblée générale ordinaire des actionnaires qui\nse tiendra en 2025 et qui aura statué sur les comptes annuels de l'exercice social clôturé le 31\ndécembre 2024, de recevoir des droits de souscription (share options) pour un maximum de\n10.000 actions de la Société.\n(c) Les règles énoncées au paragraphe (a) s'appliquent à partir du 1 juillet 2024, la rémunération\npour la période allant du 1 juillet 2024 au 31 décembre 2024 étant égale à 50 % de la\nrémunération visée au paragraphe (a).\nPar souci d'exhaustivité, la rémunération des administrateurs décrite ci-dessus remplace, à partir du 1\njuillet 2024, toutes les autres décisions concernant la rémunération des administrateurs approuvées dans\nle passé par l'assemblée générale des actionnaires, y compris la politique de rémunération approuvée\npar l'assemblée générale ordinaire des actionnaires tenue le 27 mai 2021.\n3\nConvocations\nLe Président déclare que, conformément à l'article 7:127 du Code des sociétés et des associations, les\nconvocations pour la présente assemblée générale des actionnaires, reprenant entre autres l'ordre du jour, les\nrésolutions proposées et d'autres informations requises par le Code des sociétés et des associations, ont été\npubliées quinze (15) jours calendrier avant cette assemblée dans :\n- le Moniteur belge du 15 mai 2024 ; et\n- l'Echo du 15 mai 2024.\nDes copies des publications sont présentées au bureau et paraphées par les membres du bureau. Celles-ci seront\nconservées dans les livres de la Société avec le procès-verbal de cette assemblée.\nLe Président déclare que, conformément aux articles 7:127 et 7:132 du Code des sociétés et des associations, les\nconvocations de l'assemblée générale ordinaire des actionnaires ont également été envoyés par courrier et (le cas\néchéant) par courrier électronique au moins quinze (15) jours calendrier avant la tenue de l'assemblée aux\nadministrateurs de la Société, au commissaire de la Société, aux titulaires d'actions nominatives émis par la\nSociété et aux titulaires de droits de souscription.\nLes pièces afférentes à ces convocations sont, à titre de preuve, présentées à l'assemblée pour consultation. Ces\npièces seront annexées au présent procès-verbal en Annexe A et conservées avec le procès-verbal de cette\nassemblée dans les livres de la Société.\nEn outre, à partir du 15 mai 2024, la documentation suivante a été mise à la disposition du public et des titulaires\nde titres émis par la Société sur le site web de la Société (www.mdxhealth.com) (en plus de toute documentation\nrelative à l'assemblée générale extraordinaire des actionnaires qui se tiendra également le 30 mai 2024):\n- la convocation à l'assemblée générale ordinaire ;\n- les documents à soumettre à l'assemblée générale ordinaire des actionnaires auxquels il est fait\nréférence dans l'ordre du jour ;\n- un formulaire de participation pour les titulaires de titres émis par la Société ; et\n- un formulaire de procuration pour permettre aux titulaires de titres émis par la Société d'être\nreprésentés à l'assemblée générale ordinaire des actionnaires à travers un mandataire.\nLes preuves seront conservées dans les livres de la Société avec le procès-verbal de cette assemblée.\nParticipation à l'assemblée générale\nLes détenteurs de titres émis par la Société qui souhaitaient participer à l'assemblé générale ordinaire des\nactionnaires de la Société devaient prendre en compte les formalités et procédures décrites dans la convocation à\nl'assemblée générale ordinaire des actionnaires.\nDepuis la réalisation, le 18 décembre 2023, de la transition de la Société d'une double cotation des anciennes\nAmerican Depositary Shares de la Société sur le Nasdaq et des actions de la Société sur Euronext Brussels à une\ncotation unique de ses actions sur le Nasdaq, les actions de la Société sont composées :\n- d'actions inscrites dans la composante du registre des actions de la Société qui est tenue en Belgique et\nqui est maintenue par Euroclear Belgium (le \"Registre Belge des Actions \" et, les actions reflétées\ndans le Registre Belge des Actions, les \"Actions Européennes\"), et qui ne peuvent pas être négociées\nsur le Nasdaq tant qu'elles n'ont pas été repositionnées en Actions Américaines (telles que définies ci-\ndessous) ; et\n- d'actions inscrites directement ou indirectement dans la composante du registre des actions de la\nSociété tenue aux États-Unis et qui est maintenue par Computershare (le \"Registre Américain des\nActions \" et, les actions figurant dans le Registre Américain des Actions, les \"Actions Américaines\"),\net qui peuvent être négociées sur le Nasdaq.\n4\nRegistre et liste de présence\nLa date d'enregistrement pour l'assemblée générale ordinaire des actionnaires était le vendredi 24 mai 2024 à\nminuit (00h00, heure belge) (la \"Date d'Enregistrement\") comme indiqué dans la convocation à l'assemblée\ngénérale des actionnaires conformément à l'article 32 des statuts de la Société et à l'article 7:134 du Code des\nsociétés et des associations.\nUn registre a été préparé dans lequel, pour chaque actionnaire ayant notifié son intention de participer à\nl'assemblée, les informations suivantes ont été mentionnées: (i) l'identité de l'actionnaire et son domicile ou\nsiège, (ii) le nombre d'actions détenues à la Date d'Enregistrement, et (iii) une description des documents qui\nindiquent la détention d'actions à la Date d'Enregistrement. Ce registre est annexé au présent procès-verbal en\nAnnexe B.\nEn outre, une liste de présence a aussi été établie, avec mention de (i) l'identité des actionnaires présents ou\nreprésentés à l'assemblée, (ii) le domiciles ou siège de ces actionnaires, (iii) le cas échéant, l'identité du\nmandataire de ces actionnaires, et (iv) le nombre d'actions que ces actionnaires détenaient à la Date\nd'Enregistrement et avec lesquelles ils prennent part au vote. La liste de présence indique également les\nadministrateurs et le commissaire présents ou représentés à l'assemblée, ainsi que les titulaires des droits de\nsouscription émis précédemment par la Société, présents ou représentés à l'assemblée. La liste de présence a été\nsignée par le mandataire, ou (le cas échéant) le Président pour le compte, des actionnaires, des administrateurs,\ndu commissaire et des titulaires de droits de souscription représentés à l'assemblée. La liste de présence est\nannexée au présent procès-verbal en Annexe C. Les procurations y afférentes seront également conservées avec\nla liste de présence et le procès-verbal de cette assemblée dans les livres de la Société.\nLa liste susmentionnée et le registre sont présentés au bureau et sont par la suite arrêtés, paraphés et signés par\nles membres du bureau. La liste ainsi que le registre seront conservés dans les livres de la Société avec le\nprocès-verbal de cette assemblée.\nTous les titulaires de titres émis par la Société présents ou représentés à l'assemblée repris dans le registre et la\nliste susmentionnée ont respecté les formalités afin d'être admis à l'assemblée générale ordinaire des actionnaires\nconformément aux statuts de la Société, au Code des sociétés et des associations et tel qu'indiqué dans la\nconvocation.\nLes documents suivants seront conservés dans les livres de la Société avec le procès-verbal de cette assemblée :\n(i) les notifications et les formulaires de participation soumis pour les Actions Européennes nominatives ; (ii) les\nnotifications, les formulaires de participation et les certificats soumis pour les Actions Européennes\ndématérialisées ; (iii) les notifications et les formulaires de participation relatifs aux Actions Américaines\ninscrites directement (et non par l'intermédiaire de DTCC) dans le Registre Américain des actions; (iv) les\nnotifications, les formulaires de participation et les certificats relatifs aux Actions Américaines inscrites\nindirectement dans le Registre Américain des actions, par l'intermédiaire de CEDE &Co ; et (v) les procurations\nqui ont été soumises par les détenteurs de titres.\nParticipation\nLe Président expose que le capital de la Société s'élève à EUR 164.302.752,89 et est représenté par 27.288.093\nactions, sans valeur nominale, chacune représentant la même fraction du capital de la Société. Sur base de la\nliste de présence susmentionnée et de la vérification de l'admission à l'assemblée générale ordinaire des\nactionnaires, il apparait que 13.183.136 actions au total ou 48,31% des actions émises et existantes sont\nprésentes ou représentées à l'assemblée.\nDroits de vote\nActions\nLe Président expose que, conformément à l'article 7:83 du Code des sociétés et des associations, nul ne peut\nprendre part au vote d'une assemblée générale des actionnaires pour un nombre de titres dématérialisés\noctroyant le droit de vote supérieur ou égal à 25 % du total des droits de vote à la date de la présente assemblée\nsi un tel titulaire de titres n'a pas fait les déclarations requises aux paragraphe 1 de l'article 7:83 du Code des\nsociétés et des associations.\n5\nPour l'ensemble des actionnaires présents ou représentés, il est établi que ceux-ci prennent part au vote avec\ntoutes les actions qu'ils ont présentées au vote.\nDroits de souscription\nLe Président expose que, conformément à l'article 7:135 du Code des sociétés et des associations, les titulaires\nde droits de souscription peuvent participer à la présente assemblée mais avec voix consultative seulement.\nQuorum et vote\nConformément au Code des sociétés et des associations, il n'y a pas d'exigence de quorum pour le vote sur les\nsujets repris à l'ordre du jour de l'assemblée générale ordinaire des actionnaires.\nChacune des propositions de résolution sous les sujets repris à l'ordre du jour susmentionné sera adoptée si elle\nest approuvée à une majorité simple des voix valablement émises.\nChaque action donne droit à une voix.\nTiers admis à l'assemblée\nUn certain nombre de personnes participent à l'assemblée, telles que des tiers engagés par la Société pour\nfournir des services en rapport avec l'assemblée générale des actionnaires. Sur proposition du Président,\nl'assemblée admet ces personnes. Les personnes susmentionnées ont signé la liste de présence concernant les\npersonnes qui ne sont pas actionnaires ou qui le sont mais qui n'ont pas rempli les formalités pour être admises à\nl'assemblée.\nVÉRIFICATION DE LA CONVOCATION ET DE LA COMPOSITION DE L'ASSEMBLÉE\nLes déclarations susmentionnées du Président sont vérifiées et approuvées par tous les membres de l'assemblée\ngénérale ordinaire des actionnaires. Ensuite, l'assemblée générale ordinaire des actionnaires détermine et\nconfirme qu'elle a été valablement convoquée et est valablement constituée et est autorisée à délibérer et voter\nsur les sujets repris à l'ordre du jour de l'assemblée.\nDÉLIBÉRATION ET RÉSOLUTIONS\nSur proposition du Président, l'assemblée entame l'examen des sujets à l'ordre du jour.\nPrésentation des documents\nLe Président résume les sujets à l'ordre du jour de l'assemblée.\nLe Président présente à l'assemblée la documentation suivante qui a été mentionnée dans les premiers sujets de\nl'ordre du jour de l'assemblée :\n- le rapport annuel combiné du conseil d'administration sur les comptes annuels consolidés et statutaires\n(non consolidés) de la Société pour l'exercice social clôturé au 31 décembre 2023 ;\n- le rapport du commissaire sur les comptes annuels statutaires (non consolidés) de la Société pour\nl'exercice social clôturé au 31 décembre 2023 ;\n- le rapport du commissaire sur les comptes annuels consolidés de la Société pour l'exercice social\nclôturé au 31 décembre 2023 ;\n- les comptes annuels statutaires (non consolidés) pour l'exercice social clôturé au 31 décembre 2023 ; et\n- les comptes annuels consolidés de la Société pour l'exercice social clôturé le 31 décembre 2023.\nLe Président déclare que ces documents ont été mis à la disposition des administrateurs, du commissaire et des\ntitulaires de titres émis par la Société conformément aux statuts de la Société et au Code des sociétés et des\nassociations. Le Président indique également que ces documents ont été mis à la disposition des titulaires de\n6\ntitres émis par la Société et du public via le site web de la Société. Les documents concernés seront conservés\ndans les livres de la Société avec le procès-verbal de cette assemblée.\nL'assemblée acte que la documentation a été présentée. L'assemblée décharge le Président de la lecture de la\ndocumentation qui a été présentée.\nQuestions\nChaque titulaire de titres émis par la Société avait le droit de poser des questions aux administrateurs et au\ncommissaire sur les points à l'ordre du jour de l'assemblée générale des actionnaires. Le Président informe\nl'assemblée qu'aucun titulaire de titres n'a soumis de questions écrites au préalable à la réunion conformément à\nl'article 7:139 du Code des sociétés et des associations.\nPar la suite, après la discussion, aucune question n'est posée par l'assemblée conformément à l'article 7:139 du\nCode des sociétés et des associations, relativement aux documents présentés à l'assemblée et aux sujets repris à\nl'ordre du jour de l'assemblée.\nDélibération et votes\nEnsuite, sur proposition du Président, l'assemblée générale procède à la délibération et aux votes relatifs à\nchaque sujet repris à l'ordre du jour.\nLes sujets à l'ordre du jour sont traités individuellement.\n1. Rapport sur les comptes annuels statutaires et sur les comptes annuels consolidés\nCe point à l'ordre du jour concerne la communication et discussion (a) du rapport annuel combiné du\nconseil d'administration sur les comptes annuels consolidés et statutaires (non consolidés) de la Société\npour l'exercice social clôturé au 31 décembre 2023, (b) du rapport du commissaire sur les comptes\nannuels statutaires (non consolidés) de la Société pour l'exercice social clôturé au 31 décembre 2023, et\n(c) du rapport du commissaire sur les comptes annuels consolidés de la Société pour l'exercice social\nclôturé au 31 décembre 2023.\nLe Président ordonne qu'une copie de ces documents soit annexée au présent procès-verbal en\nAnnexe D.\nCe point à l'ordre du jour ne requiert pas de résolution.\n2. Approbation des comptes annuels statutaires (non consolidés)\nCe point à l'ordre du jour concerne la communication, discussion et approbation des comptes annuels\nstatutaires (non consolidés) pour l'exercice social clôturé au 31 décembre 2023 et approbation de\nl'affectation du résultat tel que proposé par le conseil d'administration.\nLe Président ordonne qu'une copie de ce document soit annexée au présent procès-verbal en Annexe E.\nAprès délibération, la résolution suivante est adoptée à la majorité de 99,78% :\nL'assemblée générale des actionnaires décide d'approuver les comptes annuels statutaires\n(non consolidés) de la Société pour l'exercice social clôturé le 31 décembre 2023 et\nd'approuver l'affectation du résultat annuel tel que proposé par le conseil d'administration.\nVote: Cette résolution est adoptée comme suit :\n(a) Votes prononcés valides : 13.183.136 sur un total de 27.288.093 actions, soit 48,31% du\ncapital.\n(b) Votes pour ladite résolution : 13.154.174\n(c) Votes contre ladite résolution : 24.307\n(d) Abstentions : 4.655\n7\n3. Comptes annuels consolidés\nCe point à l'ordre du jour concerne la communication et discussion des comptes annuels consolidés de\nla Société pour l'exercice social clôturé le 31 décembre 2023.\nLe Président ordonne qu'une copie de ce document soit annexée au présent procès-verbal en Annexe F.\nCe point à l'ordre du jour ne requiert pas de résolution.\n4. Décharge de responsabilité des administrateurs\nCe point à l'ordre du jour concerne la décharge de responsabilité des administrateurs pour l'exercice de\nleur mandat au cours de l'exercice social clôturé le 31 décembre 2023.\nAprès délibération, la résolution suivante est adoptée à la majorité de 98,60% :\nL'assemblée générale des actionnaires décide d'accorder la décharge à chacun des\nadministrateurs qui était en fonction au cours de l'exercice social clôturé le 31 décembre 2023\npour l'exercice de son mandat au cours de cet exercice social.\nVote: Cette résolution est adoptée comme suit:\n(a) Votes prononcés valides : 13.183.136 sur un total de 27.288.093 actions, soit 48,31% du\ncapital.\n(b) Votes pour ladite résolution : 12.999.060\n(c) Votes contre ladite résolution : 64.514\n(d) Abstentions : 119.562\n5. Décharge de responsabilité du commissaire\nCe point à l'ordre du jour concerne la décharge de responsabilité du commissaire pour l'exercice de son\nmandat au cours de l'exercice social clôturé le 31 décembre 2023.\nAprès délibération, la résolution suivante est adoptée à la majorité de 98,61% :\nL'assemblée générale des actionnaires décide d'accorder la décharge au commissaire qui\nétait en fonction au cours de l'exercice social clôturé le 31 décembre 2023 pour l'exercice de\nson mandat au cours de cet exercice social.\nVote: Cette résolution est adoptée comme suit:\n(a) Votes prononcés valides : 13.183.136 sur un total de 27.288.093 actions, soit 48,31% du\ncapital.\n(b) Votes pour ladite résolution : 12.999.260\n(c) Votes contre ladite résolution : 64.439\n(d) Abstentions : 119.437\n6. Renouvellement de mandats d'administrateurs\nCe point à l'ordre du jour concerne le renouvellement de mandats d'administrateurs.\nLe conseil d'administration recommande que (a) Ahok BV, représentée par Koen Hoffman en tant que\nreprésentant permanent, et (b) Qaly-Co BV, représentée par Lieve Verplancke en tant que représentante\npermanente, soient renouvelés en tant qu'administrateurs de la Société, chacune pour une durée de deux\nans.\nAprès délibération, les résolutions suivantes sont adoptées:\n(a) L'assemblée générale des actionnaires décide de renouveler le mandat de Ahok BV,\nreprésentée par Koen Hoffman en tant que représentant permanent, en tant qu'administrateur\n8\nde la Société, pour une durée de deux ans, s'étendant jusqu'à, et y compris, la clôture de\nl'assemblée générale ordinaire des actionnaires à tenir en 2026 qui statuera sur les comptes\nannuels de l'exercice social clôturé le 31 décembre 2025. Le mandat de l'administrateur est\nrémunéré, cette rémunération étant telle que décidée par l'assemblée générale des\nactionnaires de temps à autre.\nVote: Cette résolution est adoptée à la majorité de 87,97% comme suit:\n(a) Votes prononcés valides : 13.183.136 sur un total de 27.288.093 actions, soit 48,31% du\ncapital.\n(b) Votes pour ladite résolution : 11.596.880\n(c) Votes contre ladite résolution : 343.685\n(d) Abstentions : 1.242.571\n(b) L'assemblée générale des actionnaires décide de renouveler le mandat de Qaly-Co BV,\nreprésentée par Lieve Verplancke en tant que représentante permanente, en tant\nqu'administrateur de la Société, pour une durée de deux ans, s'étendant jusqu'à, et y compris,\nla clôture de l'assemblée générale ordinaire des actionnaires à tenir en 2026 qui statuera sur\nles comptes annuels de l'exercice social clôturé le 31 décembre 2025. Le mandat de\nl'administrateur est rémunéré, cette rémunération étant telle que décidée par l'assemblée\ngénérale des actionnaires de temps à autre.\nVote: Cette résolution est adoptée à la majorité de 90,37% comme suit:\n(a) Votes prononcés valides : 13.183.136 sur un total de 27.288.093 actions, soit 48,31% du\ncapital.\n(b) Votes pour ladite résolution : 11.913.931\n(c) Votes contre ladite résolution : 26.634\n(d) Abstentions : 1.242.571\nSuite à l'approbation des résolutions indiquées au point 6, le conseil d'administration de la Société est\nmaintenant composé de (1) Michael K. McGarrity, Chief Executive Officer (CEO), administrateur et\nadministrateur délégué (jusqu'en 2026), (2) Ahok BV, représentée par Koen Hoffman, administrateur et\nprésident du conseil d'administration (jusqu'en 2026), (3) Hilde Windels BV, représentée par Hilde\nWindels, administrateur (jusqu'en 2025), (4) Qaly-Co BV, représentée par Lieve Verplancke,\nadministrateur (jusqu'en 2026), (5) Donnie M. Hardison Jr., administrateur (jusqu'en 2025), (6) Regine\nSlagmulder BV, représentée par Regine Slagmulder, administrateur (jusqu'en 2025), et (7) Eric\nBednarski, administrateur (jusqu'en 2025).\n7. Rémunération des administrateurs\nCe point à l'ordre du jour concerne la rémunération des administrateurs.\nEn tenant compte de la recommandation du Comité de Rémunération du conseil d'administration, le\nconseil d'administration propose que la rémunération des membres du conseil d'administration soit\nmodifiée comme indiqué dans la proposition de résolution.\nAprès délibération, la résolution suivante est adoptée à la majorité de 90,05% :\nL'assemblée générale des actionnaires décide que la rémunération des membres du conseil\nd'administration de la Société sera la suivante :\n(a) Le mandat des administrateurs de la Société est rémunéré comme suit :\n(i) Chaque administrateur a droit à une rémunération fixe annuelle maximale de USD\n40.000,00 (environ EUR 37.120,00).\n(ii) Le président du conseil d'administration a droit à une rémunération fixe annuelle\nmaximale supplémentaire de USD 64.400,00 (environ EUR 59.762,00).\n9\n(iii) Le président du Comité d'Audit a droit à une rémunération fixe annuelle maximale\nsupplémentaire de EUR 19.000,00 (environ EUR 17.632,00), et les autres membres\ndu Comité d'Audit (autres que le président de ce comité) ont droit à une\nrémunération fixe annuelle maximale supplémentaire de USD 9.500,00 (environ\nEUR 8.816,00).\n(iv) Le président du Comité de Gouvernance d'Entreprise et de Nomination a droit à une\nrémunération fixe annuelle maximale supplémentaire de USD 10.000,00 (environ\nEUR 9.280,00), et les autres membres du Comité de Gouvernance d'Entreprise et de\nNomination (autres que le président de ce comité) ont droit à une rémunération fixe\nannuelle maximale supplémentaire de USD 5.000,00 (environ EUR 4.640,00).\n(v) Le président du Comité de Rémunération a droit à une rémunération fixe annuelle\nmaximale supplémentaire de USD 13.500,00 (environ EUR 12.528,00), et les autres\nmembres du Comité de Rémunération (autres que le président de ce comité) ont droit\nà une rémunération fixe annuelle maximale supplémentaire de USD 6.800,00\n(environ EUR 6.310,00).\n(vi) Les rémunérations prévues aux paragraphes (ii), (iii), (iv) et (v) s'ajoutent à la\nrémunération prévue au paragraphe (i) et peuvent être combinées, selon que les\ncritères d'éligibilité énoncés dans ces paragraphes ont été remplis ou non. La\nrémunération peut être réduite pro rata temporis en fonction de la durée du mandat\nou de la présidence d'un administrateur ou de son appartenance à un comité au\ncours d'une année donnée. Tous les montants s'entendent hors TVA et autres charges\nsimilaires.\n(b) Nonobstant ce qui précède, les administrateurs qui, conformément aux règles et\nréglementations de la législation américaine et/ou du Nasdaq, peuvent être ou ont été qualifié\nd'administrateurs indépendants, ont chacun le droit (i) de recevoir, le 15 juin 2024, une\nattribution unique de droits de souscription (share options) pour 30.000 actions de la Société,\net (ii) chaque année suivante, à compter de l'assemblée générale ordinaire des actionnaires\nqui se tiendra en 2025 et qui aura statué sur les comptes annuels de l'exercice social clôturé\nle 31 décembre 2024, de recevoir des droits de souscription (share options) pour un maximum\nde 10.000 actions de la Société.\n(c) Les règles énoncées au paragraphe (a) s'appliquent à partir du 1 juillet 2024, la rémunération\npour la période allant du 1 juillet 2024 au 31 décembre 2024 étant égale à 50 % de la\nrémunération visée au paragraphe (a).\nPar souci d'exhaustivité, la rémunération des administrateurs décrite ci-dessus remplace, à partir du 1\njuillet 2024, toutes les autres décisions concernant la rémunération des administrateurs approuvées\ndans le passé par l'assemblée générale des actionnaires, y compris la politique de rémunération\napprouvée par l'assemblée générale ordinaire des actionnaires tenue le 27 mai 2021.\nVote: Cette résolution est adoptée comme suit:\n(a) Votes prononcés valides : 13.183.136 sur un total de 27.288.093 actions, soit 48,31% du\ncapital.\n(b) Votes pour ladite résolution : 11.871.700\n(c) Votes contre ladite résolution : 1.306.497\n(d) Abstentions : 4.939\n* * *\n10\nL'ordre du jour étant épuisé et plus aucun sujet n'étant soulevé par les actionnaires, la séance est levée à 15 h 02\npar le Président.\nLe présent procès-verbal est signé en trois exemplaires originaux par tous les membres du bureau.\nPar: [Signé] Par: [Signé]\nAhok BV, Loore De Weirt\nreprésentée par M. Koen Hoffman Secrétaire\nPrésident\n11\nANNEXE A\nPIECES AFFERENTES AUX CONVOCATIONS\n12\nANNEXE B\nREGISTRE\n13\nANNEXE C\nLISTE DE PRESENCE - PROCURATIONS\n14\nANNEXE D\nCOPIE (A) DU RAPPORT ANNUEL COMBINÉ DU CONSEIL D'ADMINISTRATION SUR LES COMPTES ANNUELS\nCONSOLIDÉS ET STATUTAIRES (NON CONSOLIDÉS) DE LA SOCIÉTÉ POUR L'EXERCICE SOCIAL CLÔTURÉ AU 31\nDÉCEMBRE 2023, (B) DU RAPPORT DU COMMISSAIRE SUR LES COMPTES ANNUELS STATUTAIRES (NON\nCONSOLIDÉS) DE LA SOCIÉTÉ POUR L'EXERCICE SOCIAL CLÔTURÉ AU 31 DÉCEMBRE 2023, ET (C) DU\nRAPPORT DU COMMISSAIRE SUR LES COMPTES ANNUELS CONSOLIDÉS DE LA SOCIÉTÉ POUR L'EXERCICE\nSOCIAL CLÔTURÉ AU 31 DÉCEMBRE 2023\n15\nANNEXE E\nCOPIE DES COMPTES ANNUELS STATUTAIRES (NON CONSOLIDÉS) POUR L'EXERCICE SOCIAL CLÔTURÉ AU 31\nDÉCEMBRE 2023\n16\nANNEXE F\nCOPIE DES COMPTES ANNUELS CONSOLIDÉS DE LA SOCIÉTÉ POUR L'EXERCICE SOCIAL CLÔTURÉ LE 31\nDÉCEMBRE 2023\n17"
        },
        {
          "title": "Shareholder Meeting Minutes May 30, 2024 (FR)",
          "url": "https://mdxhealth.com/wp-content/uploads/2024/06/MDxHealth-AGM-Minutes-ENG-Conformed.pdf",
          "content": "Unofficial English translation - For informational purposes only\nMDxHealth SA\nLimited Liability Company\n(société anonyme)\nCAP Business Center\nZone Industrielle des Hauts-Sarts\nRue d'Abhooz 31\n4040 Herstal, Belgium\nVAT BE 0479.292.440 (RLP Liège, division Liège)\nMINUTES OF THE\nORDINARY GENERAL SHAREHOLDERS’ MEETING\nheld on Thursday, 30 May 2024, at 3:00 p.m.\nOn 30 May 2024, the ordinary general shareholders' meeting of MDxHealth SA (the \"Company\") is held at the\noffices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium.\nOPENING OF THE MEETING\nThe ordinary general shareholders' meeting is opened at 3.00 p.m. by Ahok BV, represented by Mr. Koen\nHoffman, director and chair of the board of directors (the \"Chair\").\nThe Chair notes that, in accordance with applicable law, French is the applicable working language for the\nmeeting.\nCOMPOSITION OF THE BUREAU\nIn accordance with the Company's articles of association, the Chair of the meeting designates Loore De Weirt as\nsecretary of the meeting.\nIn view of the limited number of people present at the meeting, no tellers are appointed.\nThe Chair, together with the secretary, constitute the bureau of the general shareholders' meeting.\nDECLARATIONS BY THE CHAIR\nThe Chair makes the following declarations with respect to the convening and composition of the meeting.\nAgenda\nThe Chair states that the meeting was convened with the following agenda and proposed resolutions:\n1. Report on the annual statutory financial statements and on the consolidated financial statements\nSubmission of, and discussion on, (a) the combined annual report of the board of directors on the\nconsolidated and (non-consolidated) statutory financial statements of the Company for the financial\nyear ended on 31 December 2023, (b) the report of the statutory auditor on the (non-consolidated)\nstatutory financial statements of the Company for the financial year ended on 31 December 2023, and\n(c) the report of the statutory auditor on the consolidated financial statements of the Company for the\nfinancial year ended on 31 December 2023.\n2. Approval of the annual (non-consolidated) statutory financial statements\nSubmission of, discussion on, and approval of the annual (non-consolidated) statutory financial\nstatements for the financial year ended on 31 December 2023, and approval of the allocation of the\nresult as proposed by the board of directors.\n1\nUnofficial English translation - For informational purposes only\nProposed resolution: The general shareholders' meeting resolves to approve the annual (non-\nconsolidated) statutory financial statements of the Company for the financial year ended on 31\nDecember 2023 and to approve the allocation of the annual result as proposed by the board of directors.\n3. Consolidated financial statements\nSubmission of, and discussion on, the consolidated financial statements of the Company for the\nfinancial year ended on 31 December 2023.\n4. Discharge from liability of the directors\nDischarge from liability of the directors for the exercise of their mandates during the financial year\nended on 31 December 2023.\nProposed resolution: The general shareholders' meeting resolves to grant discharge from liability to\neach of the directors who was in office during the financial year ended on 31 December 2023, for the\nperformance of its, his or her mandate during that financial year.\n5. Discharge from liability of the statutory auditor\nDischarge from liability of the statutory auditor for the exercise of its mandate during the financial year\nended on 31 December 2023.\nProposed resolution: The general shareholders' meeting resolves to grant discharge from liability to the\nstatutory auditor which was in office during the financial year ended on 31 December 2023, for the\nperformance of its mandate during that financial year.\n6. Re-appointment of directors\nThe board of directors recommends that (a) Ahok BV, represented by Koen Hoffman as permanent\nrepresentative, and (b) Qaly-Co BV, represented by Lieve Verplancke as permanent representative, be\nre-appointed as directors of the Company, each for a term of two years.\nProposed resolutions:\n(a) The general shareholders' meeting resolves to re-appoint Ahok BV, represented by Koen\nHoffman as permanent representative, as director of the Company for a term of two years, up\nto and including the closing of the ordinary general shareholders' meeting to be held in 2026\nwhich will have decided upon the financial statements for the financial year ended on 31\nDecember 2025. The mandate of the director shall be remunerated, which remuneration shall\nbe as decided by the general shareholders' meeting from time to time.\n(b) The general shareholders' meeting resolves to re-appoint Qaly-Co BV, represented by Lieve\nVerplancke as permanent representative, as director of the Company for a term of two years,\nup to and including the closing of the ordinary general shareholders' meeting to be held in\n2026 which will have decided upon the financial statements for the financial year ended on 31\nDecember 2025. The mandate of the director shall be remunerated, which remuneration shall\nbe as decided by the general shareholders' meeting from time to time.\nNote: If the proposed resolutions set out in point 6 are approved by the general shareholders' meeting,\nthe Company's board of directors will be composed of (1) Michael K. McGarrity, chief executive\nofficer (CEO), executive director and managing director (until 2026), (2) Ahok BV, represented by\nKoen Hoffman, director and chair of the board of directors (until 2026), (3) Hilde Windels BV,\nrepresented by Hilde Windels, director (until 2025), (4) Qaly-Co BV, represented by Lieve Verplancke,\ndirector (until 2026), (5) Donnie M. Hardison Jr., director (until 2025), (6) Regine Slagmulder BV,\nrepresented by Regine Slagmulder, director (until 2025), and (7) Eric Bednarski, director (until 2025).\n2\nUnofficial English translation - For informational purposes only\n7. Remuneration of directors\nTaking into account the recommendation of the Compensation Committee of the board of directors, the\nboard of directors proposes that the remuneration of the members of the board of directors be amended\nas set out in the proposed resolution.\nProposed resolution: The general shareholders' meeting resolves that the remuneration of the members\nof the board of directors of the Company shall be as follows:\n(a) The mandate of the directors of the Company shall be remunerated as follows:\n(i) Each director shall be entitled to a maximum annual fixed remuneration of\nUSD 40,000.00 (ca. EUR 37,120.00).\n(ii) The chairperson of the board of directors shall be entitled to an additional maximum\nannual fixed remuneration of USD 64,400.00 (ca. EUR 59,762.00).\n(iii) The chairperson of the Audit Committee shall be entitled to an additional maximum\nannual fixed remuneration of USD 19,000.00 (ca. EUR 17,632.00), and the other\nmembers of the Audit Committee (other than the chairperson of this committee) shall\nbe entitled to an additional maximum annual fixed remuneration of USD 9,500 (ca.\nEUR 8,816.00).\n(iv) The chairperson of the Corporate Governance and Nominating Committee shall be\nentitled to an additional maximum annual fixed remuneration of USD 10,000.00 (ca.\nEUR 9,280.00), and the other members of the Corporate Governance and Nominating\nCommittee (other than the chairperson of this committee) shall be entitled to an\nadditional maximum annual fixed remuneration of USD 5,000.00 (ca.\nEUR 4,640.00).\n(v) The chairperson of the Compensation Committee shall be entitled to an additional\nmaximum annual fixed remuneration of USD 13,500.00 (ca. EUR 12,528.00), and\nthe other members of the Compensation Committee (other than the chairperson of\nthis committee) shall be entitled to an additional maximum annual fixed\nremuneration of USD 6,800.00 (ca. EUR 6,310.00).\n(vi) The remuneration set out in paragraphs (ii), (iii), (iv) and (v) shall be in addition to\nthe remuneration set out in paragraph (i) and can be combined, depending on whether\nthe eligibility criteria set out in these paragraphs have been met. The remuneration\ncan be reduced pro rata temporis depending on the duration of the mandate,\nchairpersonship or membership of a director during a given year. All amounts are\nexclusive of VAT and similar charges.\n(b) Notwithstanding the foregoing, directors whom, in accordance with the rules and regulations\nof U.S. law and/or Nasdaq can be, or have been, qualified as independent directors, shall each\nbe entitled (i) to receive, on 15 June 2024, a one-time grant of share options for 30,000 shares\nof the Company, and (ii) each year thereafter, commencing with the ordinary general\nshareholders' meeting to be held in 2025 which will have decided upon the financial\nstatements for the financial year ended on 31 December 2024, to receive share options for a\nmaximum of 10,000 shares of the Company.\n(c) The rules set out in paragraph (a) shall apply as from 1 July 2024, whereby the remuneration\nfor the period from 1 July 2024 until 31 December 2024 shall be 50% of the remuneration\nreferred to in paragraph (a).\nFor the sake of completeness, the above remuneration of the directors replaces, as from 1 July 2024, all\nother decisions regarding remuneration of directors approved in the past by the general shareholders'\nmeeting, including the remuneration policy approved by the ordinary general shareholders' meeting\nheld on 27 May 2021.\n3\nUnofficial English translation - For informational purposes only\nConvening notices\nThe Chair declares that, according to article 7:127 of the Belgian Companies and Associations Code, the notices\nconvening this general shareholders' meeting, containing amongst others, the agenda, the proposed resolutions\nand other information required by the Belgian Companies and Associations Code, have been published fifteen\n(15) calendar days prior this meeting in:\n- the Belgian Official Gazette on 15 May 2024; and\n- l'Echo on 15 May 2024.\nCopies of the publications are submitted to the bureau and initialled by the members of the bureau. These will\nbe kept in the files of the Company together with the minutes of this meeting.\nThe Chair declares that, according to article 7:127 and 7:132 of the Belgian Companies and Associations Code,\nthe notices convening the ordinary general shareholders' meeting have also been sent by mail and (as relevant)\nby email at least (15) calendar days before the date of the meeting to the directors of the Company, the statutory\nauditor of the Company, the holders of registered shares issued by the Company and the holders of subscription\nrights.\nProofs of the convening notices are being submitted as evidence to the meeting, for consultation. The proofs will\nbe attached to these minutes as Annex A and kept in the Company's files together with the minutes of this\nmeeting.\nIn addition, as from 15 May 2024, the following documentation has been made available to the public and the\nholders of securities issued by the Company on the Company's website (www.mdxhealth.com) (in addition to\nany documentation related to the extraordinary general shareholders' meeting also to be held on 30 May 2024):\n- the convening notice to the ordinary general shareholders' meeting;\n- the documents to be submitted to the ordinary general shareholders' meeting as referred to in the\nagenda;\n- an attendance form for holders of securities issued by the Company; and\n- a proxy form to allow holders of securities issued by the Company to be represented at the ordinary\ngeneral shareholders' meeting.\nThe proofs will be kept in the files of the Company together with the minutes of this meeting.\nParticipation to the general meeting\nHolders of securities issued by the Company that wished to participate to the ordinary general shareholders'\nmeeting of the Company had to take into account the formalities and procedures described in the notice\nconvening the ordinary general shareholders' meeting.\nSince the completion, on 18 December 2023, of the Company's transition from a dual listing of the Company's\nformer American Depositary Shares on Nasdaq and shares on Euronext Brussels to a sole listing of its shares on\nNasdaq, the Company's shares are comprised of:\n- shares that are reflected in the component of the Company's share register that is held in Belgium and\nwhich is managed by Euroclear Belgium (the \"Belgian Share Register\" and, the shares reflected in the\nBelgian Share Register, the \"European Shares\"), and that cannot be traded on Nasdaq until they have\nbeen repositioned into U.S. Shares (as defined below); and\n- shares that are reflected directly or indirectly in the component of the Company's share register that is\nheld in the United States and which is managed by Computershare (the \"U.S. Share Register\" and, the\nshare reflected in the U.S. Share Register, the \"U.S. Shares\"), and that can be traded on Nasdaq.\n4\nUnofficial English translation - For informational purposes only\nRegister and attendance list\nThe registration date of the ordinary general shareholders' meeting was Friday, 24 May 2024, at midnight (12.00\na.m., Belgian Time) (the \"Registration Date\"), as set out in the notice convening the general shareholder's\nmeeting in accordance with article 32 of the Company's articles of association and article 7:134 of the Belgian\nCompanies and Associations Code.\nA register has been prepared in which, for each shareholder having notified its intention to participate to the\nmeeting, the following information was included: (i) the name of the shareholder and its address or registered\noffice, (ii) the number of shares owned on the Registration Date, and (iii) a description of the documents which\nindicate the holding of the shares on the Registration Date. This register is attached to these minutes as\nAnnex B.\nIn addition, an attendance list has been prepared indicating (i) the identity of the shareholders that are present or\nrepresented to the meeting, (ii) the domicile or registered office of such shareholders, (iii) if applicable, the\nidentity of the proxy-holder of such shareholders, and (iv) the number of shares that the shareholders held on the\nRegistration Date and with which such shareholders are participating in the voting. The attendance list also\nindicates the directors and the statutory auditor that are present or represented at the meeting, as well as the\nholders of subscription rights previously issued by the Company present or represented at the meeting. The\nattendance list has been signed by the proxy holders of, or (as the case may be) the Chair on behalf of, the\nshareholders, directors, statutory auditor and holders of subscription rights who are represented at the meeting.\nThe attendance list is attached to these minutes as Annex C. The proxies will also be kept with the attendance\nlist in the files of the Company together with the minutes of this meeting.\nThe aforementioned list and the register are submitted to the bureau and are subsequently closed, initialled and\nsigned by the members of the bureau. The list as well as the register will be kept in the files of the Company\ntogether with the minutes of this meeting.\nAll holders of securities issued by the Company that are present or represented at the meeting included in the\nregister and in the aforementioned list have complied with the formalities in order to be admitted to the ordinary\ngeneral shareholders' meeting in accordance with the Company's articles of association and the Belgian\nCompanies and Associations Code and as set out in the convening notice.\nThe following documentation will be kept in the files of the Company together with the minutes of this meeting:\n(i) the notifications and attendance forms submitted with respect to European Shares in registered form; (ii) the\nnotifications, attendance forms and certificates submitted with respect to European Shares in dematerialised\nform; (iii) the notifications and attendance forms submitted with respect to U.S. Shares that are reflected directly\n(not through DTCC) in the U.S. Share Register; (iv) the notifications, attendance forms and certificates with\nrespect to U.S. Shares reflected indirectly in the U.S. Share Register, through CEDE &Co.; and (v) the proxies\nthat have been submitted by the holders of securities.\nAttendance\nThe Chair indicates that the Company's share capital amounts to EUR 164,302,752.89 and is represented by\n27,288,093 shares, without nominal value, each representing the same fraction of the Company's share capital.\nBased on the aforementioned attendance list and the verification of the admission to the ordinary general\nshareholders' meeting, it appears that 13,183,136 shares in total or 48.31% of the outstanding and existing shares\nare present or represented at the meeting.\nVoting rights\nShares\nThe Chair declares that, according to article 7:83 of the Belgian Companies and Associations Code, no person\ncan participate in the voting of a general shareholders' meeting with dematerialised voting securities that\nrepresent 25% or more than 25% of the total number of voting rights at the date of this general meeting, if such\na holder of securities did not do the declarations required by §1 of article 7:83 of the Belgian Companies and\nAssociations Code.\nFor all of the shareholders present or represented, it is confirmed that they can participate in the vote with all the\nshares submitted for voting.\n5\nUnofficial English translation - For informational purposes only\nSubscription Rights\nThe Chair declares that, according to article 7:135 of the Belgian Companies and Associations Code, the holders\nof subscription rights have the right to participate to the ordinary general shareholders' meeting, but with an\nadvisory vote only.\nQuorum and voting\nAccording to the Belgian Companies and Associations Code, there is no quorum requirement for the voting on\nthe respective items referred to in the aforementioned agenda of the ordinary general shareholders' meeting.\nEach of the proposed resolutions under the respective items included in the aforementioned agenda shall be\npassed if it is approved by a simple majority of the votes validly casted.\nEach share is entitled to one vote.\nThird parties admitted to the meeting\nA number of persons attend the meeting, such as third parties engaged by the Company to provide services in\nconnection with the general shareholders' meeting. Upon proposal of the Chair, the meeting allows such persons\nto attend. The aforementioned persons have signed the attendance list regarding persons that are not a\nshareholder or that are a shareholder but have not complied with the formalities to be admitted to the meeting\nVERIFICATION OF THE CONVENING AND COMPOSITION OF THE MEETING\nThe aforementioned statements by the Chair are verified and approved by all members of the ordinary general\nshareholders' meeting. Subsequently, the ordinary general shareholders' meeting determines and confirms that it\nhas been validly convened and is validly constituted, and that it is authorized to deliberate and vote on the items\non the agenda of the meeting.\nDELIBERATIONS AND VOTING\nUpon proposal by the Chair, the meeting begins with the deliberation on the items on the agenda.\nSubmission of documentation\nThe Chair summarises the items of the agenda of the meeting.\nThe Chair submits to the meeting the following documentation that has been mentioned in the first items on the\nagenda of the meeting:\n- the combined annual report of the board of directors on the consolidated and (non-consolidated)\nstatutory financial statements of the Company for the financial year ended on 31 December 2023;\n- the report of the statutory auditor on the (non-consolidated) statutory financial statements of the\nCompany for the financial year ended on 31 December 2023;\n- the report of the statutory auditor on the consolidated financial statements of the Company for the\nfinancial year ended on 31 December 2023;\n- the annual (non-consolidated) statutory financial statements for the financial year ended on 31\nDecember 2023; and\n- the consolidated financial statements of the Company for the financial year ended on 31 December\n2023.\nThe Chair states that these documents have been made available to the directors, the statutory auditor and the\nholders of securities issued by the Company in accordance with the Company's articles of association and the\nBelgian Companies and Associations Code. The Chair also states that these documents have been made\n6\nUnofficial English translation - For informational purposes only\navailable to the holders of securities issued by the Company and to the public on the Company's website. The\ndocuments concerned will be kept in the files of the Company together with the minutes of this meeting.\nThe meeting takes note of the fact that this documentation has been submitted. The meeting releases the Chair\nfrom reading the documentation that has been submitted.\nQuestions\nEach holder of securities issued by the Company had the right to ask questions to the directors and\nthe statutory auditor related to items on the agenda of a general shareholders' meetings. The\nChair informs the meeting that no holders of securities have submitted written questions prior\nto the meeting in accordance with article 7:139 of the Belgian Companies and Associations Code.\nFurthermore, after the discussion, no question is asked by the meeting in accordance with article 7:139 of the\nBelgian Companies and Associations Code, with respect to the documents that have been submitted to the\nmeeting and with respect to the items of the agenda of the meeting.\nDeliberations and voting\nSubsequently, upon proposal of the Chair, the meeting proceeds with the deliberation and voting with respect to\neach of the items on the agenda.\nThe items on the agenda are separately voted upon.\n1. Report on the annual statutory financial statements and on the consolidated financial statements\nThis agenda item relates to the submission of, and discussion on, (a) the combined annual report of the\nboard of directors on the consolidated and (non-consolidated) statutory financial statements of the\nCompany for the financial year ended on 31 December 2023, (b) the report of the statutory auditor on\nthe (non-consolidated) statutory financial statements of the Company for the financial year ended on 31\nDecember 2023, and (c) the report of the statutory auditor on the consolidated financial statements of\nthe Company for the financial year ended on 31 December 2023.\nThe Chair requires that a copy of such documents be attached to these minutes as Annex D.\nThis agenda item requires no further resolution.\n2. Approval of the annual (non-consolidated) statutory financial statements\nThis agenda item relates to the submission of, discussion on, and approval of the annual (non-\nconsolidated) statutory financial statements for the financial year ended on 31 December 2023, and\napproval of the allocation of the result as proposed by the board of directors.\nThe Chair requires that a copy of such document be attached to these minutes as Annex E.\nThe following resolution is passed with a majority of 99.78%:\nThe general shareholders' meeting resolves to approve the annual (non-consolidated)\nstatutory financial statements of the Company for the financial year ended on 31 December\n2023 and to approve the allocation of the annual result as proposed by the board of directors.\nVote: This resolution is passed as follows:\n(a) Valid registered votes: 13,183,136 out of a total of 27,288,093 shares, i.e., 48.31% of the\nshare capital.\n(b) Votes for such resolution: 13,154,174\n(c) Votes against such resolution: 24,307\n(d) Abstentions: 4,655\n7\nUnofficial English translation - For informational purposes only\n3. Consolidated financial statements\nThis agenda item relates to the submission of, and discussion on, the consolidated financial statements\nof the Company for the financial year ended on 31 December 2023.\nThe Chair requires that a copy of such document be attached to these minutes as Annex F.\nThis agenda item requires no further resolution.\n4. Discharge from liability of the directors\nThis agenda item relates to the discharge from liability of the directors for the exercise of their\nmandates during the financial year ended on 31 December 2023.\nThe following resolution is passed with a majority of 98.60%:\nThe general shareholders' meeting resolves to grant discharge from liability to each of the\ndirectors who was in office during the financial year ended on 31 December 2023, for the\nperformance of its, his or her mandate during that financial year.\nVote: This resolution is passed as follows:\n(a) Valid registered votes: 13,183,136 out of a total of 27,288,093 shares, i.e., 48.31% of the\nshare capital.\n(b) Votes for such resolution: 12,999,060\n(c) Votes against such resolution: 64,514\n(d) Abstentions: 119,562\n5. Discharge from liability of the statutory auditor\nThis agenda item relates to the discharge from liability of the statutory auditor for the exercise of its\nmandate during the financial year ended on 31 December 2023.\nThe following resolution is passed with a majority of 98.61%:\nThe general shareholders' meeting resolves to grant discharge from liability to the statutory\nauditor which was in office during the financial year ended on 31 December 2023, for the\nperformance of its mandate during that financial year.\nVote: This resolution is passed as follows:\n(a) Valid registered votes: 13,183,136 out of a total of 27,288,093 shares, i.e., 48.31% of the\nshare capital.\n(b) Votes for such resolution: 12,999,260\n(c) Votes against such resolution: 64,439\n(d) Abstentions: 119,437\n6. Re-appointment of directors\nThis agenda item relates to the re-appointment of directors.\nThe board of directors recommends that (a) Ahok BV, represented by Koen Hoffman as permanent\nrepresentative, and (b) Qaly-Co BV, represented by Lieve Verplancke as permanent representative, be\nre-appointed as directors of the Company, each for a term of two years.\nThe following resolutions are passed:\n(a) The general shareholders' meeting resolves to re-appoint Ahok BV, represented by Koen\nHoffman as permanent representative, as director of the Company for a term of two years, up\nto and including the closing of the ordinary general shareholders' meeting to be held in 2026\n8\nUnofficial English translation - For informational purposes only\nwhich will have decided upon the financial statements for the financial year ended on 31\nDecember 2025. The mandate of the director shall be remunerated, which remuneration shall\nbe as decided by the general shareholders' meeting from time to time.\nVote: This resolution is passed with a majority of 87.97% as follows:\n(a) Valid registered votes: 13,183,136 out of a total of 27,288,093 shares, i.e., 48.31% of the\nshare capital.\n(b) Votes for such resolution: 11,596,880\n(c) Votes against such resolution: 343,685\n(d) Abstentions: 1,242,571\n(b) The general shareholders' meeting resolves to re-appoint Qaly-Co BV, represented by Lieve\nVerplancke as permanent representative, as director of the Company for a term of two years,\nup to and including the closing of the ordinary general shareholders' meeting to be held in\n2026 which will have decided upon the financial statements for the financial year ended on 31\nDecember 2025. The mandate of the director shall be remunerated, which remuneration shall\nbe as decided by the general shareholders' meeting from time to time.\nVote: This resolution is passed with a majority of 90.37% as follows:\n(a) Valid registered votes: 13,183,136 out of a total of 27,288,093 shares, i.e., 48.31% of the\nshare capital.\n(b) Votes for such resolution: 11,913,931\n(c) Votes against such resolution: 26,634\n(d) Abstentions: 1,242,571\nAs a result of the approval of the resolutions set out in point 6, the Company's board of directors is now\ncomposed of (1) Michael K. McGarrity, chief executive officer (CEO), executive director and\nmanaging director (until 2026), (2) Ahok BV, represented by Koen Hoffman, director and chair of the\nboard of directors (until 2026), (3) Hilde Windels BV, represented by Hilde Windels, director (until\n2025), (4) Qaly-Co BV, represented by Lieve Verplancke, director (until 2026), (5) Donnie M.\nHardison Jr., director (until 2025), (6) Regine Slagmulder BV, represented by Regine Slagmulder,\ndirector (until 2025), and (7) Eric Bednarski, director (until 2025).\n7. Remuneration of directors\nThis agenda item relates to the remuneration of directors.\nTaking into account the recommendation of the Compensation Committee of the board of directors, the\nboard of directors proposes that the remuneration of the members of the board of directors be amended\nas set out in the proposed resolution.\nThe following resolution is passed with a majority of 90.05%:\nThe general shareholders' meeting resolves that the remuneration of the members of the board of\ndirectors of the Company shall be as follows:\n(a) The mandate of the directors of the Company shall be remunerated as follows:\n(i) Each director shall be entitled to a maximum annual fixed remuneration of\nUSD 40,000.00 (ca. EUR 37,120.00).\n(ii) The chairperson of the board of directors shall be entitled to an additional maximum\nannual fixed remuneration of USD 64,400.00 (ca. EUR 59,762.00).\n(iii) The chairperson of the Audit Committee shall be entitled to an additional maximum\nannual fixed remuneration of USD 19,000.00 (ca. EUR 17,632.00), and the other\nmembers of the Audit Committee (other than the chairperson of this committee) shall\n9\nUnofficial English translation - For informational purposes only\nbe entitled to an additional maximum annual fixed remuneration of USD 9,500 (ca.\nEUR 8,816.00).\n(iv) The chairperson of the Corporate Governance and Nominating Committee shall be\nentitled to an additional maximum annual fixed remuneration of USD 10,000.00 (ca.\nEUR 9,280.00), and the other members of the Corporate Governance and\nNominating Committee (other than the chairperson of this committee) shall be\nentitled to an additional maximum annual fixed remuneration of USD 5,000.00 (ca.\nEUR 4,640.00).\n(v) The chairperson of the Compensation Committee shall be entitled to an additional\nmaximum annual fixed remuneration of USD 13,500.00 (ca. EUR 12,528.00), and the\nother members of the Compensation Committee (other than the chairperson of this\ncommittee) shall be entitled to an additional maximum annual fixed remuneration of\nUSD 6,800.00 (ca. EUR 6,310.00).\n(vi) The remuneration set out in paragraphs (ii), (iii), (iv) and (v) shall be in addition to\nthe remuneration set out in paragraph (i) and can be combined, depending on\nwhether the eligibility criteria set out in these paragraphs have been met. The\nremuneration can be reduced pro rata temporis depending on the duration of the\nmandate, chairpersonship or membership of a director during a given year. All\namounts are exclusive of VAT and similar charges.\n(b) Notwithstanding the foregoing, directors whom, in accordance with the rules and regulations\nof U.S. law and/or Nasdaq can be, or have been, qualified as independent directors, shall\neach be entitled (i) to receive, on 15 June 2024, a one-time grant of share options for 30,000\nshares of the Company, and (ii) each year thereafter, commencing with the ordinary general\nshareholders' meeting to be held in 2025 which will have decided upon the financial\nstatements for the financial year ended on 31 December 2024, to receive share options for a\nmaximum of 10,000 shares of the Company.\n(c) The rules set out in paragraph (a) shall apply as from 1 July 2024, whereby the remuneration\nfor the period from 1 July 2024 until 31 December 2024 shall be 50% of the remuneration\nreferred to in paragraph (a).\nFor the sake of completeness, the above remuneration of the directors replaces, as from 1 July 2024,\nall other decisions regarding remuneration of directors approved in the past by the general\nshareholders' meeting, including the remuneration policy approved by the ordinary general\nshareholders' meeting held on 27 May 2021.\nVote: This resolution is passed as follows:\n(a) Valid registered votes: 13,183,136 out of a total of 27,288,093 shares, i.e., 48.31% of the\nshare capital.\n(b) Votes for such resolution: 11,871,700\n(c) Votes against such resolution: 1,306,497\n(d) Abstentions: 4,939\n* * *\n10\nUnofficial English translation - For informational purposes only\nThere being no further business and since no further items were raised, the meeting is adjourned by the Chair at\n3:02 p.m.\nThese minutes are signed in three original copies by all members of the bureau.\n[Signed] [Signed]\nBy: _______________________ By: _______________________\nAhok BV Loore De Weirt\nrepresented by Mr. Koen Hoffman Secretary\nChair\n11\nUnofficial English translation - For informational purposes only\nANNEX A\nPROOFS OF THE CONVENING NOTICES\n12\nUnofficial English translation - For informational purposes only\nANNEX B\nREGISTER\n13\nUnofficial English translation - For informational purposes only\nANNEX C\nATTENDANCE LIST - PROXIES\n14\nUnofficial English translation - For informational purposes only\nANNEX D\nCOPY OF (A) THE COMBINED ANNUAL REPORT OF THE BOARD OF DIRECTORS ON THE CONSOLIDATED AND\n(NON-CONSOLIDATED) STATUTORY FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR\nENDED ON 31 DECEMBER 2023, (B) THE REPORT OF THE STATUTORY AUDITOR ON THE (NON-CONSOLIDATED)\nSTATUTORY FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER\n2023, AND (C) THE REPORT OF THE STATUTORY AUDITOR ON THE CONSOLIDATED FINANCIAL STATEMENTS OF\nTHE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2023\n15\nUnofficial English translation - For informational purposes only\nANNEX E\nCOPY OF THE ANNUAL (NON-CONSOLIDATED) STATUTORY FINANCIAL STATEMENTS FOR THE FINANCIAL\nYEAR ENDED ON 31 DECEMBER 2023\n16\nUnofficial English translation - For informational purposes only\nANNEX F\nCOPY OF THE CONSOLIDATED FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED\nON 31 DECEMBER 2023\n17"
        },
        {
          "title": "2024 Share Option Plan (FR)",
          "url": "https://mdxhealth.com/wp-content/uploads/2024/05/11FR-Plan-dOption-sur-Action-de-2024-FR-.pdf",
          "content": "PLAN D'OPTION SUR ACTION DE 2024\nMDXHEALTH SA\nMDxHealth SA • Rue d'Abhooz 31 - CAP Business Center, 4040 Herstal, Belgique\nwww.mdxhealth.com • Tel (32) 4.257.70.21 • Fax (32) 4.259.78.75\nTVA BE 0479.292.440 RPM (Liège) • KBC Bank 736-0304341-19\n1\nARTICLE 1 - OBJECTIF DU PLAN\nLe présent Plan d'Option sur Action de 2024 (ci-après le \"Plan\") décrit les termes et conditions\ngénérales des Share Options que la Société pourrait octroyer aux Participants Sélectionnés.\nLe but du Plan est de réaliser les objectifs suivants en matière d'esprit d'entreprise et de ressources\nhumaines:\n(i) encourager, motiver et fidéliser les Participants Sélectionnés;\n(ii) permettre à la Société et à ses Filiales d'attirer et de fidéliser le Personnel bénéficiant de\nl'expérience et des compétences requises; et\n(iii) faire davantage correspondre l'intérêt des Participants Sélectionnés avec les intérêts des\nactionnaires de la Société en leur donnant l'opportunité de bénéficier de la croissance de la\nSociété.\nARTICLE 2 - DEFINITIONS ET INTERPRETATION\nDans le cadre du Plan, les termes repris ci-dessous auront la signification suivante:\nAction Une action de la Société, représentant le capital de la Société.\nAdministrateur Un membre du conseil d'administration de la Société ou d'une Filiale.\nBénéficiaire En ce qui concerne les personnes physiques, toute personne\nvalablement désignée par le Participant Sélectionné, à savoir soit\nl'époux(se), soit les héritiers légaux, soit le partenaire cohabitant du\nParticipant Sélectionné, afin d'exercer les droits du Participant\nSélectionné en vertu du Plan postérieurement au décès du Participant\nSélectionné. Toute désignation, révocation et nouvelle désignation\nd'un Bénéficiaire devra être effectuée par écrit en conformité avec la\nlégislation applicable. En l'absence d'une désignation valable, les\nhéritiers du Participant Sélectionné en fonction de la législation\nsuccessorale applicable seront présumés être Bénéficiaires. Dans\nl'éventualité où il existerait plusieurs héritiers, tous les héritiers\nagissant conjointement ou la personne désignée par tous les héritiers\nagissant conjointement seront présumés être les Bénéficiaires.\nCession – Céder Toute opération entre vifs qui a pour objet la vente, l'acquisition,\nl'octroi ou l'acceptation d'options, l'échange, la renonciation, l'apport\nà une société, la cession de quelque manière que ce soit, en échange\nou non d'une compensation financière, l'octroi de paiements ou\ngages, l'acceptation de paiements ou gages ou généralement tout\nengagement qui a pour objet la cession future ou immédiate d'un titre\nde propriété.\nCode des Sociétés et des Le Code des Sociétés et des Associations et des associations du 23\nAssociations mars 2019 (tel que modifié de temps à autre).\nConseil d'Administration Le conseil d'administration de la Société.\n2\nContrôle Le pouvoir de droit ou de fait d'exercer une influence décisive sur la\nnomination de la majorité des membres du Conseil d'Administration\nou sur l'orientation de la gestion de la Société, tel que déterminé aux\narticles 1.14 et suivants du Code des Sociétés et des Associations.\nDate de Fin du mandat La date effective de fin du mandat d'Administrateur, du contrat de\nd'Administrateur, du contrat travail, du contrat de management ou du contrat similaire du\nde travail, du contrat de Participant Sélectionné, qu'elle qu'en soit la raison, à l'exception de\nmanagement ou du contrat la résiliation d'un contrat de management ou similaire\nsimilaire du Participant immédiatement suivie de la conclusion d'un contrat de travail ou d'un\nSélectionné nouveau contrat de management ou similaire avec la Société ou une\nFiliale, de la résiliation d'un contrat de travail immédiatement suivie\nde la signature d'un nouveau contrat de travail ou d'un contrat de\nmanagement ou similaire avec la Société ou une Filiale, et de la fin\nd'un mandat d'Administrateur immédiatement suivie du\nrenouvellement du mandat d'Administrateur.\nDate d'Émission La date à laquelle les Share Options seront émis en vertu d'une\ndécision d'une assemblée générale extraordinaire tenue le [•] 2024.\nDate d'Octroi La date à laquelle l'offre des Share Options aux Participants\nSélectionnés est réalisée.\nFiliale Toute société ou organisation qui se trouve directement ou\nindirectement sous le Contrôle de la Société.\nJour ouvrable Un jour durant lequel les banques sont ouvertes en Belgique, et aux\nÉtats-Unis d'Amérique à l'exclusion des samedis et dimanches.\nNotification Toute lettre rédigée par écrit envoyée au domicile légal ou au siège\ndu destinataire au moyen (i) soit d'un courrier avec accusé de\nréception, (ii) soit d'une lettre recommandée, (iii) soit d'un courrier\nélectronique envoyé à l'adresse électronique du destinataire. La date\nde la Notification est: (i) soit la date de la signature de l'accusé de\nréception, (ii) soit, à défaut, la date du cachet de la poste de la lettre\nrecommandée, (iii) soit la date d'envoi du courrier électronique, pour\nautant que ce courrier électronique ait été envoyé à l'adresse\nélectronique correcte du destinataire.\nParticipant(s) Sélectionné(s) Tout Membre du Personnel à qui des Share Options sont émis en\nvertu de, ou sous, ce Plan.\nPériode d'Exercice La période durant laquelle le Participant Sélectionné peut exercer les\nShare Options qui lui ont été octroyés, à condition que et dans la\nmesure où les Share Options peuvent être exercés en conformité avec\nles conditions énoncées dans le Plan ainsi que dans toute autre\nconvention qui pourrait exister entre le Participant Sélectionné et la\nSociété.\nPersonnel Toute personne qui est un membre du personnel de la Société ou\nd'une Filiale au sens de l'article 1:27 du Code des Sociétés et des\nAssociations.\nPlan Le présent Plan d'Options sur Actions de 2024.\n3\nPrix d'Exercice Le prix déterminé par le Conseil d'Administration, ou tout autre\ncomité crée ou personne nommée par le Conseil d'Administration\nconformément à l'article 4, auquel chaque Action faisant l'objet d'un\nShare Option peut être acquise/souscrite suite à l'exercice de ce Share\nOption.\nPrix d'un Share Option Le prix éventuel que le Participant Sélectionné doit payer à la Société\nafin d'acquérir le Share Option lui-même.\nSociété MDxHealth SA, société de droit belge, dont le siège est établi Rue\nd'Abhooz 31 - CAP Business Center, 4040 Herstal, Belgique, inscrite\nau Registre des Personnes Morales sous le numéro 0479.292.440.\nShare Option Un droit de souscription émis par la Société donnant droit au\nParticipant Sélectionné d'acquérir / de souscrire une (1) Action en\nvertu du Plan durant une certaine période pour un certain prix.\nShare Options Définitivement Les Share Options qui ont été définitivement acquis par le Participant\nAcquis Sélectionné en conformité avec les conditions reprises dans le Plan,\nsans préjudice de l'éventualité où les Share Options sont annulés dans\nles cas où ils ne sont pas ou ne peuvent plus être exercés en vertu du\nPlan.\nSauf dans le cas où le contexte l'exige autrement, (i) les mots apparaissant au singulier incluront le\npluriel et vice versa et (ii) les mots apparaissant au masculin incluront le féminin et vice versa.\nARTICLE 3 - TYPE ET NOMBRE DE SHARE OPTIONS\nLe nombre total de Share Options émis en vertu du Plan est de deux millions (2.000.000). Tous ces\nShare Options peuvent être qualifiées de \"incentive stock option\" au sens de la Section 422 du U.S.\nInternal Revenue Code de 1986, tel que modifié. Seul le Personnel qui sont des employés assujettis à\nl'impôt américain à la Date d'Octroi applicable peuvent prétendre à recevoir de tels \"incentive stock\noptions\".\nChaque Share Option permettra au Participant Sélectionné d'acquérir une (1) Action.\nLes nouvelles Actions émises lors de l'exercice des Share Options auront les mêmes droits et bénéfices\nque, et seront à tous égards pari passu, en ce compris en ce qui concerne les droits aux distributions\ndividendes, avec les Actions existantes et en circulation de la Société au moment de leur émission, et\nauront droit aux dividendes et autres distributions pour lesquelles la date d'enregistrement ou la date\nd'échéance applicable tombe à, ou après, la date d'émission des nouvelles Actions.\nUne Action nouvelle représentera la même fraction du capital de la Société que les autres Actions\nexistantes de la Société à ce moment.\nARTICLE 4 - ADMINISTRATION\nLe Conseil d'Administration administrera le Plan. Le Conseil d'Administration aura la possibilité de\ndéléguer ses pouvoirs ou certains de ses pouvoirs à certaines personnes du management et/ou à certains\ncomités qui pourraient être créés par le Conseil d'Administration, en conformité avec le Code des\nSociétés et des Associations et les règles de gouvernance internes de la Société.\nSous réserve des dispositions du Plan et pour autant que les décisions respectent l'objectif du Plan, le\nConseil d'Administration, ou tout autre comité créé ou personne nommée par le Conseil\n4\nd'Administration, a le droit de fixer, définir et interpréter toutes les règles, réglementations et autres\nmesures requises ou utiles pour l'administration du Plan. Le Conseil d'Administration peut résilier le\nPlan à tout moment. Les Share Options ayant été octroyés avant cette résiliation restent valables et\npeuvent être exercées conformément au Plan.\nARTICLE 5 - CONDITIONS DES SHARE OPTIONS\n5.1 Prix des Share Options\nSauf si le Conseil d'Administration, ou tout autre comité crée ou personne nommée par le Conseil\nd'Administration conformément à l'article 4, en décide autrement, de façon individuelle, le Participant\nSélectionné ne devra payer aucun prix à la Société lors de la souscription ou l'acceptation des Share\nOptions.\nSi un prix était dû pour les Share Options, il serait comptabilisé comme une prime d'émission. Cette\nprime d'émission serait inscrite au passif du bilan de la Société dans son capital, et le compte sur lequel\nla prime d'émission serait comptabilisée servirait, au même titre que le capital, de garantie pour les tiers,\net ne pourrait être réduit que sur la base d'une résolution validement adoptée par l'assemblée générale\ndes actionnaires de la manière requise pour une modification des statuts de la Société.\n5.2 Prix d'Exercice\nLe Prix d'Exercice d'un Share Option sera déterminé par le Conseil d'Administration, ou tout autre\ncomité crée ou personne nommée par le Conseil d'Administration conformément à l'article 4, à la Date\nd'Octroi de celui-ci. Sauf décision contraire du Conseil d’Administration ou de tout autre comité crée\nou personne nommée par le Conseil d'Administration conformément à l'article 4, avant, au moment de,\nou après la Date d’Octroi, le Prix d'Exercice ne sera pas inférieur au prix le plus bas entre (i) le cours\ndes Actions sur le marché boursier concerné sur lequel les Actions sont admises à la cotation et à la\nnégociation au jour précédant le Date d'Octroi (si les Actions ou les titres sont admis à la cotation et à\nla négociation sur le Nasdaq, le Nasdaq doit être utilisé comme marché de référence) et (ii) le cours\nmoyen des Actions sur le marché boursier concerné sur lequel les Actions sont admises à la cotation et\nà la négociation durant une période de 30 jours précédant la Date d'Octroi du Share Option concerné (si\nles Actions ou les titres sont admis à la cotation et à la négociation sur le Nasdaq, le Nasdaq doit être\nutilisé comme marché de référence).\nLors de l'exercice des Share Options et de l'émission de nouvelles actions, le montant total du Prix\nd'Exercice des Share Options sera alloué au capital de la Société. Dans la mesure où le Prix d'Exercice\ndu Share Option par Action à émettre lors de l'exercice du Share Option serait supérieur au pair\ncomptable des Actions de la Société existant immédiatement avant l'émission des nouvelles Actions\nconcernées, une partie du Prix d'Exercice par Action à émettre lors de l'exercice du Share Option, égale\nà ce pair comptable, sera comptabilisée en tant que capital, tandis que le solde sera comptabilisé en tant\nque prime d'émission. Conformément à l'article 7:178 du Code des Sociétés et des Associations, suite à\nl'augmentation de capital et l'émission de nouvelles Actions, chaque Action nouvelle et existante\nreprésentera la même fraction du capital de la Société.\nLors de l'exercice des Share Options :\n• si le capital de la Société est exprimé en euros et que le montant total du Prix d'Exercice de\nl'exercice de tels Share Options est payé par le Participant Sélectionné concerné (ou son\nBénéficiaire, le cas échéant) en dollars américains, le montant égal au Prix d'Exercice total de\nces Share Options sera converti en euros sur la base du taux de change USD/EUR publié par la\nBanque Centrale Européenne (\"BCE\") sur le site\nhttps://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/\nhtml/index.fr.html (ou tout autre site Internet pertinent de la BCE) (le \"Taux de change\") le\n5\ndeuxième Jour Ouvrable précédant la date de l'acte notarié pertinent dans lequel l'émission des\nnouvelles Actions concernées et l'augmentation de capital correspondante sont établies, et où\nle montant final en euros sera arrondi aux deux décimales inférieures les plus proches ; et\n• si le capital de la Société est exprimé en dollars américains et que le montant total du Prix\nd'Exercice de l'exercice de tels Share Options est payé par le Participant Sélectionné concerné\n(ou son Bénéficiaire, le cas échéant) en euros, le montant égal au Prix d'Exercice total de cet\nexercice des Share Options sera converti en dollars américains sur la base du taux de change\nUSD/EUR publié par la BCE sur le site\nhttps://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/\nhtml/index.fr.html (ou tout autre site Internet pertinent de la BCE) (le \"Taux de change\") le\ndeuxième Jour Ouvrable précédant la date de l'acte notarié pertinent dans lequel l'émission des\nnouvelles Actions concernées et l'augmentation de capital correspondante sont établies, et où\nle montant final en dollars américains sera arrondi aux deux décimales inférieures les plus\nproches.\n5.3 Durée des Share Options\nLa durée d'un Share Option sera de dix (10) ans à compter de la Date d'Émission. Cependant, le Conseil\nd'Administration, ou tout autre comité crée ou personne nommée par le Conseil d'Administration\nconformément à l'article 4, aura le droit de réduire cette durée. A moins qu'une durée plus courte ne soit\nprévue par le Conseil d'Administration, ou tout autre comité crée ou personne nommée par le Conseil\nd'Administration conformément à l'article 4, un Share Option est donc (en tout état de cause)\nautomatiquement nul, non avenu et sans valeur à 24h00 (minuit) CET, au jour de la date du dixième\n(10e) anniversaire de la Date d'Émission.\n5.4 Caractère nominatif\nLes Share Options sont et resteront nominatifs et seront inscrits au registre des détenteurs de droits de\nsouscription qui sera tenu au siège de la Société. La Société délivrera à chaque Participant Sélectionné\net Bénéficiaire, sans frais, un certificat confirmant que le Participant Sélectionné est dûment inscrit(e)\ndans le registre des détenteurs de droits de souscription en tant que propriétaire des Share Options.\n5.5 Droits en tant qu'actionnaire\nLe Participant Sélectionné n'est pas (en sa capacité de détenteur de Share Options) actionnaire de la\nSociété, ni ne détiendra aucun droit ou privilège qui, en règle générale, appartient à un actionnaire de\nla Société, aussi longtemps que le Participant Sélectionné n'aura pas exercé les Share Options détenus\npar le Participant Sélectionné.\nARTICLE 6 – CESSION DES SHARE OPTIONS\n6.1 Décès\nAu cas où le détenteur des Share Options est une personne physique, les règles suivantes seront\nd'application: en cas de décès d'un Participant Sélectionné, tous les Share Options (y compris les Share\nOptions Définitivement Acquis au moment du décès) seront cédés de plein droit au Bénéficiaire du\nParticipant Sélectionné et pourront être exercés (ou continueront à pouvoir être exercés en ce qui\nconcerne les Share Options Définitivement Acquis) au moment prévu et selon les conditions établies\nen vertu du présent Plan.\n6\n6.2 Cessibilité des Share Options\nSous réserve de la cession pour cause de décès visée à l'article 6.1 ci-dessus et sauf si le Conseil\nd'Administration, ou tout autre comité crée ou personne nommée par le Conseil d'Administration\nconformément à l'article 4, devait admettre une Cession des Share Options, les Share Options ne\npeuvent pas être Cédés par un Participant Sélectionné une fois qu'ils lui ont été octroyés.\nARTICLE 7 - EXERCICE DES SHARE OPTIONS\nLes Share Options peuvent être exercés uniquement durant une Période d'Exercice (telle que spécifiée\nà l'article 7.2 ci-dessous), si et dans la mesure où ils sont devenus des Share Options Définitivement\nAcquis et peuvent être exercés (en conformité avec l'article 7.1 ci-dessous) préalablement à ou durant\nune Période d'Exercice donnée.\n7.1. Acquisition Définitive et conditions d'exercice des Share Options\nLe plan d'acquisition définitive d'un Share Option, c.à.d. les dates et conditions en vertu desquelles il\ndeviendra un Share Option Définitivement Acquis, seront tels que déterminés dans ce Plan, sauf dans\nl'hypothèse où, pour des Share Options octroyés à des Participants Sélectionnés en une quelconque de\nleurs qualités autre que leur qualité d'administrateur non-exécutif de la Société, le Conseil\nd'Administration, ou tout autre comité crée ou personne nommée par le Conseil d'Administration\nconformément à l'article 4, détermine autrement et où, pour les Share Options octroyés aux Participants\nSélectionnés en leur qualité d'administrateur non-exécutif de la Société, l'assemblée générale\nextraordinaire des actionnaires détermine autrement. Le plan d'acquisition définitive et la période avant\nqu'un Share Option puisse devenir exerçable peuvent donc être plus courts que les périodes mentionnées\nci-dessous dans cet article 7.1.\n7.1.1 Règles générales concernant l'acquisition définitive des Share Options\nSauf si déterminé autrement par le Conseil d'Administration, ou tout autre comité crée ou personne\nnommée par le Conseil d'Administration conformément à l'article 4, les Share Options souscrits par un\nParticipant Sélectionné en une qualité autre que la qualité d'administrateur non-exécutif de la Société,\nseront acquis définitivement, c'est-à-dire deviendront des Share Options Définitivement Acquis, par\ntranches de vingt-cinq pourcent (25%) par an durant une période de quatre (4) ans à partir de la Date\nd'Octroi, de la manière suivante:\n• à la première date d'anniversaire de la Date d'Octroi : 25%;\n• pendant la deuxième année à compter de la Date d'Octroi: maximum 25%, c'est-à-dire\nmaximum 50% au total au cours des deux premières années après la Date d'Octroi;\n• pendant la troisième année à compter de la Date d'Octroi: maximum 25%, c'est-à-dire 75% au\ntotal au cours des trois premières années après la Date d'Octroi;\n• au cours de la quatrième année à compter de la Date d'Octroi: maximum 25%, c'est-à-dire\nmaximum 100% au total au cours des quatre premières années après la Date d'Octroi.\nAu cours des deuxième, troisième et quatrième années après la Date d'Octroi, les Share Options\nsouscrits par un Participant Sélectionné en toute autre qualité que celle d'administrateur non-exécutif\nde la Société, seront définitivement acquis pro rata temporis sur une base trimestrielle, c'est-à-dire pour\nun nombre qui représente la même portion du nombre maximum de Share Options qui peuvent être\nacquis définitivement pendant cette période que celle constituée par le nombre de trimestres (entiers)\nécoulés pendant cette période donnée par rapport au nombre total de trimestres de cette période. Par\nexemple, un an et sept mois après la Date d'Octroi, un maximum de 37,5% des Share Options octroyés\nau Participant Sélectionné pourraient être des Share Options Définitivement Acquis.\n7\nLes Share Options octroyés à un administrateur non-exécutif de la Société seront tous définitivement\nacquis, c.à.d. deviendront des Share Options Définitivement Acquis, à la date de l'assemblée générale\nordinaire des actionnaires ayant lieu au cours de l'année calendrier suivant l'année calendrier au cours\nde laquelle les Share Options furent octroyés, à condition qu'à la date précédant la date de la précédente\nassemblée générale ordinaire des actionnaires, le mandat d'un tel administrateur non-exécutif de la\nSociété n'ait pas pris fin (sans préjudice de la clause 7.1.3. du Plan).\nNonobstant ce qui précède, tous les Share Options souscrits par un Participant Sélectionné seront\ndéfinitivement acquis de plein droit (s'ils n'ont pas encore été définitivement acquis) et deviendront des\nShare Options Définitivement Acquis lors d'un changement de Contrôle. Un changement de Contrôle\nsera réputé avoir eu lieu si (i) une \"personne\" ou un \"groupe\" (au sens de la Rule 13d-5 du U.S. Securities\nAct of 1934, tel que modifié) détient, directement ou indirectement, à titre bénéficiaire ou officiel, sur\nune base entièrement diluée, plus de 35 % des titres ou des intérêts de toute catégorie ou nature ayant\nhabituellement le pouvoir de voter pour l'élection des Administrateurs de la Société, (ii) une majorité\ndes mandats (autres que les mandats vacants) au sein du Conseil d'Administration de la Société sont\nexercés par des personnes dont la nomination en tant qu'Administrateur (A) n'a pas été proposée à\nl'assemblée générale des actionnaires de la Société par (la majorité du) Conseil d'Administration de la\nSociété, ou (B) n'a pas été soutenue ou approuvée par (une majorité du) Conseil d'Administration de la\nSociété, ou (iii) toute personne acquiert (ou a acquis au cours de la période de douze (12) mois se\nterminant à la date de l'acquisition la plus récente par cette personne) des actifs de la Société dont la\njuste valeur marchande brute totale est égale ou supérieure à cinquante pour cent (50 %) de la juste\nvaleur marchande brute totale de tous les actifs de la Société immédiatement avant cette acquisition ou\nces acquisitions ; à condition, toutefois, que les éléments suivants ne constituent pas un changement de\npropriété d'une partie substantielle des actifs de la Société : (A) un transfert d'actifs à une entité qui est\ndirectement ou indirectement contrôlée par les actionnaires de la Société immédiatement après le\ntransfert, ou (B) un transfert d'actifs par la Société à : (1) un actionnaire de la Société (immédiatement\navant le transfert d'actifs) en échange ou en relation avec les Actions de la Société, (2) une entité dont\ncinquante pour cent (50 %) ou plus de la valeur totale ou des droits de vote sont détenus, directement\nou indirectement, par la Société, ou (3) une personne qui détient, directement ou indirectement,\ncinquante pour cent (50 %) ou plus de la valeur totale ou des droits de vote de toutes les Actions en\ncirculation de la Société. Aux fins de ce qui précède, on entend par juste valeur marchande brute la\nvaleur des actifs de la Société, ou la valeur des actifs en cours de cession, déterminée sans tenir compte\ndes dettes liées à ces actifs.\n7.1.2 Conditions d'exercice des Share Options\nLes Participants Sélectionnés sont autorisés à exercer tous Share Options Définitivement Acquis au\ncours de toute Période d'Exercice à partir de et depuis le moment auquel leurs Share Options sont\ndevenus des Share Options Définitivement Acquis. Les règles établies dans la clause 7.1.3 ci-dessous\nprévaudront toutefois sur les règles établies dans la présente clause 7.1.2.\n7.1.3 Conséquences de la fin du mandat d'Administrateur, du contrat de travail, du contrat de\nmanagement ou du contrat similaire\nSans préjudice des dispositions des paragraphes suivants et sauf disposition contraire du Conseil\nd’Administration, ou tout autre comité crée ou personne nommée par le Conseil d'Administration\nconformément à l'article 4, lorsque (i) le mandat d'Administrateur d'un Participant Sélectionné prend\nfin pour d'autres raisons qu'un manquement à ses devoirs d'Administrateur, (ii) le contrat de travail d'un\nParticipant Sélectionné prend fin pour toute raison autre qu'un motif grave, ou (iii) le contrat de\nmanagement ou similaire d'un Participant Sélectionné prend fin pour des raisons autres que la violation\ndudit contrat, dans chacun de ces cas, le Participant Sélectionné peut exercer tous ses Share Options qui\nsont devenus des Share Options Définitivement Acquis au moment de la Date de Fin du mandat\nd'Administrateur, du contrat de travail, du contrat de management ou du contrat similaire du Participant\n8\nSélectionné, tel qu'applicable, au moment et conformément aux conditions définies dans le Plan,\nendéans une période d'un an après la Date de Fin du mandat d'Administrateur, du contrat de travail, du\ncontrat de management ou du contrat similaire du Participant Sélectionné.\nSauf décision contraire du Conseil d'Administration, ou de tout autre comité créé ou personne désignée\npar le Conseil d'Administration conformément à l'article 4, les Share Options Définitivement Acquis\nqui ne sont pas exercés endéans cette période à laquelle il est fait référence au paragraphe précédant\nexpireront et deviendront nuls et sans valeur. Les Share Options qui ne sont pas des Share Options\nDéfinitivement Acquis à la Date de Fin du mandat d'Administrateur, du contrat de travail, du contrat de\nmanagement ou du contrat similaire du Participant Sélectionné expireront et deviendront nuls et sans\nvaleur.\nLorsqu'il est mis fin (i) au mandat d'Administrateur d'un Participant Sélectionné pour manquement à\nses devoirs d'Administrateur, (ii) au contrat de travail d'un Participant Sélectionné pour motif grave, ou\n(iii) au contrat de management ou similaire d'un Participant Sélectionné pour violation dudit contrat,\nsauf décision contraire du Conseil d’Administration, ou de tout autre comité créé ou personne désignée\npar le Conseil d'Administration conformément à l'article 4, tous les Share Options, qu'ils soient\ndéfinitivement acquis ou non, ne sont définitivement plus exerçables à compter de la Date de Fin du\nmandat d'Administrateur, du contrat de travail ou, du contrat de management ou similaire, tel\nqu'applicable.\n7.1.4 Conséquences du départ à la retraite, de l'incapacité ou de la maladie grave\nAu cas où le détenteur des Share Options est une personne physique, les règles suivantes seront\nd'application: s'il est mis fin au mandat d'Administrateur, au contrat de travail, ou, au contrat de\nmanagement ou similaire du Participant Sélectionné, tel qu'applicable, pour cause de départ à la retraite,\nd'incapacité ou de maladie grave, tous les Share Options Définitivement Acquis (à ce moment-là)\npourront toujours être exercés pendant la durée des Share Options restant à courir conformément aux\nconditions énoncées dans le Plan.\n7.2 Période d'Exercice\nLes Share Options Définitivement Acquis ne peuvent être exercés qu'au cours des périodes suivantes:\npendant la durée des Share Options, entre le 1 mars et le 31 mars et entre le 1 septembre et le 30\nseptembre. Chaque Période d'Exercice sera clôturée le dernier Jour Ouvrable de la Période d'Exercice\nen question.\nLe Conseil d'Administration, ou tout autre comité créé ou personne désignée par le Conseil\nd'Administration conformément à l'article 4, peut, à son absolue discrétion, néanmoins prévoir des\nPériodes d'Exercice supplémentaires, ce qu'il fera par exemple en cas de changement de Contrôle de la\nSociété (c'est-à-dire au cas où tous les Share Options sont définitivement acquis de plein droit\nconformément à l'article 7.1.1 in fine ci-dessus).\n7.3 Exercice partiel\nUn Participant Sélectionné peut exercer tout ou partie de ses Share Options Définitivement Acquis.\nCependant, il n'est pas possible d'exercer un Share Option portant sur des fractions d'Actions.\n7.4 Procédure d'exercice\nUn Share Option sera présumé avoir été exercé dès la réception par la Société, au plus tard le dernier\nJour Ouvrable de la Période d'Exercice:\n(i) d'une Notification signée par le Participant Sélectionné et précisant qu'un Share Option ou un\n9\nnombre déterminé de Share Options est exercé;\n(ii) de la preuve du paiement intégral du Prix d'Exercice, dans les trente (30) jours calendrier à\ncompter du dernier Jour Ouvrable de la Période d'Exercice durant laquelle les Share Options\nont été exercés, pour le nombre d'Actions tel qu'indiqué dans la Notification prévue sous (i),\npar virement bancaire sur un compte bloqué de la Société dont le numéro est communiqué par\nla Société;\n(iii) de la preuve appropriée du droit de la personne concernée ou des personnes concernées à\nexercer le Share Option, dans l'hypothèse où un Share Option est exercé par une personne ou\ndes personnes autres que le Participant Sélectionné; et\n(iv) de toutes les déclarations et documents que le Conseil d'Administration, ou tout autre comité\ncréé ou personne désignée par le Conseil d'Administration conformément à l'article 4, peut\njuger nécessaires ou souhaitables afin de se conformer à toutes les prescriptions légales et\nréglementaires applicables, et dont la présentation est une condition requise par le Conseil\nd'Administration, ou tout autre comité créé ou personne désignée par le Conseil\nd'Administration conformément à l'article 4.\n7.5 Conditions d'émission des Actions\n7.5.1 L'obligation pour la Société d'émettre les Actions suite à l'exercice de Share Options, par\nl'inscription dans le registre des actions nominatives de la Société ou de toute autre manière\nautorisée par le Code des Sociétés et des Associations, ne naîtra qu'au moment où toutes les\nconditions énoncées à l'article 7.4 ci-dessus auront été remplies et après la réalisation de\nl'augmentation de capital visée ci-après.\n7.5.2 Le Conseil d'Administration, ou un de ses membres ou toute autre personne spécifiquement\ndéléguée à cet effet, fera, conformément à l'article 7:187 du Code des Sociétés et Associations\n(ou toute autre disposition ayant le même objet), acter devant notaire l'augmentation de capital\nrésultant de l'exercice des Share Options et la libération entière des Actions ainsi souscrites,\ndans les soixante (60) jours suivant la clôture de la Période d'Exercice au cours de laquelle les\nShare Options ont été exercés.\n7.5.3 Si, au moment de l'exercice des Share Options, les Actions sont admises à la cotation et/ou à la\nnégociation sur le Nasdaq, un autre marché boursier ou une autre plateforme de négociation, la\nSociété devra mettre en œuvre des efforts raisonnable afin de prendre les mesures et effectuer\nles dépôts nécessaires pour que les Actions émises lors de l'exercice des Share Options\nconcernés soient admises à la cotation et/ou à la négociation sur le Nasdaq, un autre marché\nboursier, ou cette autre plateforme de négociation selon le calendrier qui sera décidé par le\nConseil d'Administration.\n7.5.4 La Société peut à sa discrétion postposer la remise des Actions, si cela est nécessaire pour se\nconformer aux réglementations ou dispositions applicables de quelque nature que ce soit, y\ncompris mais non limité en matière d'offre publique, d'enregistrement et d'autres obligations en\nrapport avec les Actions de la Société, ceci selon ce que la Société estime approprié.\nARTICLE 8 – CHANGEMENT DANS LA STRUCTURE DU CAPITAL DE LA SOCIETE –\nEXERCICE DES SHARE OPTIONS EN VERTU DE LA LOI\n8.1 Changement dans la structure du capital de la Société\nPar dérogation à l'article 7:71 du Code des Sociétés et des Associations, la Société se réserve\nexpressément le droit de prendre toutes les décisions possibles et de prendre part à toutes les opérations\n10\npossibles qui peuvent avoir un impact sur son capital, sur la distribution des bénéfices ou sur la\ndistribution du produit de la liquidation ou qui peuvent autrement affecter les droits des Participants\nSélectionnés.\nSi les droits du Participant Sélectionné sont affectés par une telle décision ou opération, le Participant\nSélectionné n'aura pas droit à une modification du Prix d'Exercice, ni à une modification des conditions\nd'exercice, ni à aucune autre forme de compensation (financière ou autre), à moins qu'une telle décision\nou opération n'ait pour objectif principal de porter préjudice aux droits des détenteurs des Share Options.\nEn cas de fusion, scission ou scission d'actions de la Société, les droits des Share Options en circulation\net/ou le Prix d'Exercice des Share Options seront adaptés sur base des rapports de conversion appliqués\naux autres actionnaires à l'occasion de la fusion, de la scission ou la scission d'actions.\n8.2 Exercice des Share Options en vertu de la loi\nSi un Share Option qui n'est pas exerçable ou qui ne peut être exercé en vertu des conditions d'émission\n(telles que déterminées dans ce Plan), devient prématurément exerçable sur base de l'article 7:71 du\nCode des Sociétés et des Associations et est exercé en vertu de cet article, les Actions obtenues en\nexerçant le Share Option ne pourront être cédées, sauf accord exprès du Conseil d'Administration de la\nSociété, ou de tout autre comité créé ou personne désignée par le Conseil d'Administration\nconformément à l'article 4, qu'à compter du moment où les Share Options sous-jacents auraient pu être\nexercés conformément au Plan.\nARTICLE 9 – DIVERS\n9.1 Impôts et sécurité sociale\nLa Société ou une Filiale sera en droit, en conformité avec la législation ou la pratique applicable, de\nretenir de tout paiement en espèces fait à un Participant Sélectionné, et/ou le Participant Sélectionné\nsera obligé de payer à la Société ou à une Filiale (en cas de demande en ce sens par la Société ou par\nune Filiale), le montant de tout impôt éventuel et/ou toute cotisation de sécurité sociale éventuelle, soit\napplicable en raison de l'octroi, de l'acquisition définitive ou de l'exercice de tout Share Option, soit\napplicable en raison de la remise des Actions.\nLa Société ou une Filiale sera également en droit, en conformité avec la législation ou la pratique\napplicable, de rédiger les fiches nécessaires, requises en raison de l'octroi des Share Options, de leur\nacquisition définitive, du fait qu'ils deviennent exerçables ou de la remise des Actions.\n9.2 Frais\nLes droits de timbres et autres droits ou taxes similaires exigibles à l'occasion de l'exercice des Share\nOptions et/ou de la remise des nouvelles Actions seront à charge du Participant Sélectionné.\nLes frais afférents à l'augmentation de capital qui aura lieu lors de l'exercice des Share Options seront\nà charge de la Société.\n9.3 Droit applicable et tribunaux compétents\nLe Plan est régi par le droit belge. Tout litige relèvera de la compétence exclusive des cours et tribunaux\nde la juridiction dans laquelle la Société a son siège.\nLes Share Options souscrits en vertu du Plan seront régis par et interprétés en conformité avec le droit\nbelge.\n11\n9.4 Notifications\nToute Notification à un Participant Sélectionné sera effectuée à l'adresse mentionnée au registre des\ndétenteurs de droits de souscription ou dans les détails de notification pertinents tels que déterminés\ndans la convention entre la Société et le Participant Sélectionné en vertu de laquelle les Share Options\nsont octroyés. Toute Notification à la Société, à une Filiale, au Conseil d'Administration ou à tout autre\ncomité créé ou personne désignée par le Conseil d'Administration conformément à l'article 4, sera\nvalablement effectuée à l'adresse du siège de la Société. Les changements d'adresse doivent être\ncommuniqués en conformité avec la présente disposition.\n9.5 Relation avec le contrat du Participant Sélectionné\nNonobstant toute disposition du Plan, les droits et les obligations d'un Participant Sélectionné tels que\ndéterminés par les termes de son contrat de travail ou, de son contrat de management ou similaire au\nsein de la Société ou une Filiale ne seront pas affectés par sa participation au Plan ou par tout droit que\nle Participant Sélectionné pourrait avoir à y participer. Tout Participant Sélectionné qui souscrit des\nShare Options en conformité avec le Plan n'aura aucun droit à compensation ou dommages et intérêts\ns'il est mis fin à son de son contrat de travail ou, son contrat de management ou similaire au sein de la\nSociété ou d'une Filiale pour une quelconque raison que ce soit, dans la mesure où ce droit émane ou\npeut émaner de la perte de ses droits ou de sa faculté à exercer des Share Options conformément aux\ndispositions du Plan suite à la fin de son de son contrat de travail ou, de son contrat de management ou\nsimilaire, ou de la perte ou de la réduction de valeur de tels droits ou avantages.\n12"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Financial Report January 2024",
          "url": "https://mdxhealth.com/financials/",
          "content": "![logo](data:,)\n\n## This website uses cookies\n\nWe use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. You consent to our cookies if you continue to use our website.\n\nDo not sell or share my personal information\n\n[Use necessary cookies only ](#)[Allow all cookies ](#)[Show details](#)\n\n[OK](#)\n\n[Use necessary cookies only ](#)[Allow selection ](#)[Allow all cookies](#)\n\nNecessary\n\nPreferences\n\nStatistics\n\nMarketing\n\n[Show details](#)\n\n[Cookie declaration ](#)[[#IABV2SETTINGS#] ](#)[About](#)\n\n[Necessary (15)](#) [Preferences (1)](#) [Statistics (11)](#) [Marketing (32)](#) [Unclassified (7)](#)\n\nNecessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \n__RequestVerificationToken| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Helps prevent Cross-Site Request Forgery (CSRF) attacks.| Session| HTTP Cookie  \nak_bmsc| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| 1 day| HTTP Cookie  \nbm_mi| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Used in context with the website's BotManager. The BotManager detects, categorizes and compiles reports on potential bots trying to access the website.| Session| HTTP Cookie  \n_GRECAPTCHA| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| 180 days| HTTP Cookie  \nrc::a| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| Persistent| HTML Local Storage  \nrc::b| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. | Session| HTML Local Storage  \nrc::c| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. | Session| HTML Local Storage  \nrc::f| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. | Persistent| HTML Local Storage  \n1.gif| [Cookiebot](https://www.cookiebot.com/goto/privacy-policy/ \"Cookiebot's privacy policy\")| Used to count the number of sessions to the website, necessary for optimizing CMP product delivery. | Session| Pixel Tracker  \nCookieConsent| [Cookiebot](https://www.cookiebot.com/goto/privacy-policy/ \"Cookiebot's privacy policy\")| Stores the user's cookie consent state for the current domain| 1 year| HTTP Cookie  \nelementor| mdxhealth.com| Used in context with the website's WordPress theme. The cookie allows the website owner to implement or change the website's content in real-time.| Persistent| HTML Local Storage  \nwpEmojiSettingsSupports| mdxhealth.com| This cookie is part of a bundle of cookies which serve the purpose of content delivery and presentation. The cookies keep the correct state of font, blog/picture sliders, color themes and other website settings.| Session| HTML Local Storage  \nASP.NET_SessionId| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Preserves the visitor's session state across page requests.| Session| HTTP Cookie  \n__cf_bm| [Vimeo](https://vimeo.com/privacy \"Vimeo's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| 1 day| HTTP Cookie  \n_cfuvid| [Vimeo](https://vimeo.com/privacy \"Vimeo's privacy policy\")| This cookie is a part of the services provided by Cloudflare - Including load-balancing, deliverance of website content and serving DNS connection for website operators. | Session| HTTP Cookie  \n  \nPreference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nFormsWebSessionId| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| The cookie is used if the visitor has filled in personal information on a formula. This information will be filled in automatically on other formulas. This process is used to optimize visitor experience. | 30 days| HTTP Cookie  \n  \nStatistic cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nc.gif| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Collects data on the user’s navigation and behavior on the website. This is used to compile statistical reports and heatmaps for the website owner.| Session| Pixel Tracker  \ncollect| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.| Session| Pixel Tracker  \nhjActiveViewportIds| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| This cookie contains an ID string on the current session. This contains non-personal information on what subpages the visitor enters – this information is used to optimize the visitor's experience.| Persistent| HTML Local Storage  \nhjViewportId| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| Saves the user's screen size in order to adjust the size of images on the website.| Session| HTML Local Storage  \n_ga| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Registers a unique ID that is used to generate statistical data on how the visitor uses the website.| 2 years| HTTP Cookie  \n_ga_#| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used by Google Analytics to collect data on the number of times a user has visited the website as well as dates for the first and most recent visit. | 2 years| HTTP Cookie  \n_gat| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used by Google Analytics to throttle request rate| 1 day| HTTP Cookie  \n_gid| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Registers a unique ID that is used to generate statistical data on how the visitor uses the website.| 1 day| HTTP Cookie  \n_hjSession_#| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| Collects statistics on the visitor's visits to the website, such as the number of visits, average time spent on the website and what pages have been read.| 1 day| HTTP Cookie  \n_hjSessionUser_#| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| Collects statistics on the visitor's visits to the website, such as the number of visits, average time spent on the website and what pages have been read.| 1 year| HTTP Cookie  \nvuid| [Vimeo](https://vimeo.com/privacy \"Vimeo's privacy policy\")| Collects data on the user's visits to the website, such as which pages have been read.| 2 years| HTTP Cookie  \n  \nMarketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nMR [x2]| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences. | 7 days| HTTP Cookie  \nMUID [x3]| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")forms.cloud.microsoft| Used widely by Microsoft as a unique user ID. The cookie enables user tracking by synchronising the ID across many Microsoft domains.| 1 year| HTTP Cookie  \nSRM_B| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Tracks the user’s interaction with the website’s search-bar-function. This data can be used to present the user with relevant products or services. | 1 year| HTTP Cookie  \nANONCHK| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Registers data on visitors from multiple visits and on multiple websites. This information is used to measure the efficiency of advertisement on websites. | 1 day| HTTP Cookie  \nSM| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Registers a unique ID that identifies the user's device during return visits across websites that use the same ad network. The ID is used to allow targeted ads.| Session| HTTP Cookie  \nNID| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 6 months| HTTP Cookie  \nGNWTracker| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Used to implement blog or article content onto the website from other websites. This implementation also allows the origin-website to track on the website. | Session| HTTP Cookie  \ntimes_to_show| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used to determine when and where certain pop-ups on the website should be presented for the user and remember whether the user has closed these, to keep them from showing multiple times.| Persistent| HTML Local Storage  \n#-#| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTML Local Storage  \n__Secure-ROLLOUT_TOKEN| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Pending| 180 days| HTTP Cookie  \niU5q-!O9@$| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Registers a unique ID to keep statistics of what videos from YouTube the user has seen.| Session| HTML Local Storage  \nLAST_RESULT_ENTRY_KEY| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTTP Cookie  \nLogsDatabaseV2:V#||LogsRequestsStore| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Persistent| IndexedDB  \nnextId| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTTP Cookie  \nremote_sid| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Necessary for the implementation and functionality of YouTube video-content on the website. | Session| HTTP Cookie  \nrequests| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTTP Cookie  \nTESTCOOKIESENABLED| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| 1 day| HTTP Cookie  \nVISITOR_INFO1_LIVE| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Tries to estimate the users' bandwidth on pages with integrated YouTube videos.| 180 days| HTTP Cookie  \nYSC| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Registers a unique ID to keep statistics of what videos from YouTube the user has seen.| Session| HTTP Cookie  \nyt.innertube::nextId| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Registers a unique ID to keep statistics of what videos from YouTube the user has seen.| Persistent| HTML Local Storage  \nytidb::LAST_RESULT_ENTRY_KEY| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Persistent| HTML Local Storage  \nYtIdbMeta#databases| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Persistent| IndexedDB  \nyt-remote-cast-available| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-cast-installed| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-connected-devices| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Persistent| HTML Local Storage  \nyt-remote-device-id| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Persistent| HTML Local Storage  \nyt-remote-fast-check-period| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-session-app| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-session-name| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \n  \nUnclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nMuidSyncDomain| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Pending| Persistent| HTML Local Storage  \nMuidSyncTimestamp| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Pending| Persistent| HTML Local Storage  \nRevSpringHistory| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 1 year| HTTP Cookie  \nRevSpringRef| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 1 day| HTTP Cookie  \nRevSpringUserAlias| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 1 year| HTTP Cookie  \nRevSpringVisit| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| Session| HTTP Cookie  \nGNWUserSessionId| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Pending| Session| HTTP Cookie  \n  \n[[#IABV2_LABEL_PURPOSES#]](#) [[#IABV2_LABEL_FEATURES#]](#) [[#IABV2_LABEL_PARTNERS#]](#)\n\n[#IABV2_BODY_PURPOSES#]\n\n[#IABV2_BODY_FEATURES#]\n\n[#IABV2_BODY_PARTNERS#]\n\nCookies are small text files that can be used by websites to make a user's experience more efficient.The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission.This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.You can at any time change or withdraw your consent from the Cookie Declaration on our website.Learn more about who we are, how you can contact us and how we process personal data in our Privacy Policy.\n\nCookie declaration last updated on 12/1/24 by [Cookiebot](https://www.cookiebot.com \"Cookiebot\")\n\n  * [ Physician Portal ](https://mdxhealthsecure.com/)\n  * [ Pay My Bill ](/paymybill/)\n\n\n\n[ ![MDxHealth Logo_Full Color_KO_RGB](/wp-content/uploads/elementor/thumbs/MDxHealth-Logo_Full-Color_KO_RGB-1-qn8ye5yd7qzmvsyx0iqzls921um9s37hndqaovfadq.png) ](https://mdxhealth.com)\n\n  * [About](https://mdxhealth.com/about/)\n\n##### About\n\n    * [ Mission ](/about/#mission)\n    * [ Leadership ](/about/#leadership)\n    * [ Licensure & Accreditations ](/about/#licensure&accreditations)\n\n    * [ Science ](/science/)\n    * [ Careers ](/careers/)\n    * [ Multimedia ](/multimedia/)\n\n    * [ Mission ](https://mdxhealth.com/about/#mission)\n    * [ Leadership ](https://mdxhealth.com/about/#leadership)\n    * [ Licensure & Accreditations ](https://mdxhealth.com/about/#licensure&accreditations)\n    * Science\n    * Careers\n    * [ Multimedia ](https://mdxhealth.com/multimedia/)\n\n  * [Tests](https://mdxhealth.com/tests/)\n\n##### Prostate Cancer \n\n###### For Physicians\n\n    * [ Select mdx ](/select-mdx-for-physicians/)\n    * [ Confirm mdx ](/confirm-mdx-for-physicians/)\n    * [ Genomic Prostate Score ](/gps-physician/)\n\n###### For Patients\n\n    * [ Select mdx ](/select-mdx-for-patients/)\n    * [ Confirm mdx ](/confirm-mdx-for-patients/)\n    * [ Genomic Prostate Score ](/gps-patient/)\n\n##### Infectious Disease\n\n###### For Physicians\n\n    * [ Resolve mdx ](/resolve-mdx-for-physicians/)\n\n###### For Patients\n\n    * [ Resolve mdx  ](/resolve-mdx-for-patients/)\n\n###### Prostate Cancer (For Physicians)\n\n    * [ Select mdx ](https://mdxhealth.com/select-mdx-for-physicians/)\n    * [ Confirm mdx ](https://mdxhealth.com/confirm-mdx-for-physicians/)\n    * [ Genomic Prostate Score ](https://mdxhealth.com/gps-physician/)\n\n###### Prostate Cancer (For Patients)\n\n    * [ Select mdx ](https://mdxhealth.com/select-mdx-for-patients/)\n    * [ Confirm mdx ](https://mdxhealth.com/confirm-mdx-for-patients/)\n    * [ Genomic Prostate Score ](https://mdxhealth.com/gps-patient/)\n\n###### Infectious Disease (For Physicians)\n\n    * [ Resolve mdx  ](https://mdxhealth.com/resolve-mdx-for-physicians/)\n\n###### Infectious Disease (For Patients)\n\n    * [ Resolve mdx  ](https://mdxhealth.com/resolve-mdx-for-patients/)\n\n  * [Investors](https://mdxhealth.com/financials/)\n\n##### Investors\n\n    * [ Financials ](/financials/)\n    * [ Shareholder Information ](/shareholder-information/)\n    * [ Transition to Nasdaq ](/proposed-transition-to-a-single-listing-on-nasdaq/)\n\n    * [ Analyst Coverage ](/analyst-coverage/)\n    * [ Presentations & Events ](/presentations-events/)\n    * [ Press Releases ](/press-releases-events/)\n\n    * [ Financials ](https://mdxhealth.com/financials/)\n    * [ Shareholder Information ](https://mdxhealth.com/shareholder-information/)\n    * [ Transition to Nasdaq ](https://mdxhealth.com/proposed-transition-to-a-single-listing-on-nasdaq/)\n    * [ Analyst Coverage ](https://mdxhealth.com/analyst-coverage/)\n    * [ Presentation & Events ](https://mdxhealth.com/presentations-events/)\n    * [ Press Releases ](https://mdxhealth.com/press-releases-events/)\n\n  * [Support](https://mdxhealth.com/xpert-one/)\n\n    * [ Xpert One Support ](/xpert-one/)\n    * [ Contact Us ](/contact-us/)\n\n\n\n\n[ ](https://mdxhealth.com)\n\nX\n\n## Financials\n\n[Overview](https://mdxhealth.com/financials/#overview) · [Financial Reports](https://mdxhealth.com/financials/#financial-reports) · [SEC Filings](https://mdxhealth.com/financials/#secfilings) · [IR Contact](https://mdxhealth.com/financials/#ir-contact)\n\n#### Overview\n\nMdxhealth operates on a calendar basis with its accounting year ending on Dec. 31. The company reports its consolidated financial statements under International Financial Reporting Standards (IFRS) and all amounts are in US Dollars. Mdxhealth publishes a consolidated and audited Annual Report on an annual basis, a consolidated Interim Report for its June 30 half-year financial figures, and business/financial updates at the end of Q1 and Q3.\n\nFurthermore, for the Annual General Shareholders’ Meeting, the company also publishes the non-consolidated Belgian-GAAP financial statements of the parent company. Prior to October 5, 2010, mdxhealth operated under the name OncoMethylome Sciences.\n\n### Financial Reports\n\n2024\n\n2023\n\n2022\n\n2021\n\n2020\n\n2019\n\n2018\n\n2024\n\n#### 2024\n\n2024 Consolidated figures for the First quarter ended March 31, 2023: [English](/wp-content/uploads/2024/05/MDXH-1Q24.pdf)\n\n2024 Interim Report for the six months ended June 30, 2024: [English](/wp-content/uploads/2024/09/MDXH-Interim-Report-1H24.pdf)\n\n2023\n\n#### 2023\n\n2023 Consolidated figures for the First quarter ended March 31, 2023: [English](https://mdxhealth.com/wp-content/uploads/2023/05/MDXH-1Q23-financials-FINAL.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2023/05/MDXH-1Q23-financials_FR_FINAL.pdf)\n\n2023 Interim Report for the six months ended June 30, 2023: [English I ](https://mdxhealth.com/wp-content/uploads/2023/08/MDXH-Interim-Report-1H23-EN.pdf)[Français](https://mdxhealth.com/wp-content/uploads/2023/08/MDXH-Interim-Report-1H23-FINAL-FRENCH.pdf)\n\n2023 Financial statements for the periods ended September 30, 2023: [English](https://mdxhealth.com/wp-content/uploads/2023/11/Q3-financial-statements.pdf \"https://mdxhealth.com/wp-content/uploads/2023/01/MDXH-Interim-Report-3Q22-FINAL.pdf\")\n\n2023 Annual Report on Form 20-F: [English](/wp-content/uploads/2024/05/2023-Form-20-F.pdf)\n\n2023 Combined Statutory and Consolidated Board Report: [English](/wp-content/uploads/2024/05/6EN-Combined-Report-of-the-Board-of-Directors-on-the-Consolidated-and-non-consolidated-Statutory-Financial-Statements-ENG.pdf) I [Francais](/wp-content/uploads/2024/05/6FR-MDxHealth-AGM-_-EGM-2024-Combined-report-on-2023-statutory-and-consolidated-accounts-Final_FR.pdf)\n\n2023 Full Non-consolidated Statutory Accounts: [Francais](/wp-content/uploads/2024/05/4FR-MDXH-comptes-annuels-2023.pdf)\n\n2023 Auditor Opinion:[English](/wp-content/uploads/2024/05/8EN-PIE-IFRS-Report-conso-financial-statements-MDxHealth-FY2023-English.pdf) I [Francais](/wp-content/uploads/2024/05/8FR-PIE-IFRS-Rapport-consolide.pdf)\n\n2022\n\n#### 2022\n\n2022 Interim Report for the six months ended June 30, 2022: [English ](https://mdxhealth.com/wp-content/uploads/2022/08/MDXH-Interim-Report-1H22-FINAL.pdf)I [Français](https://mdxhealth.com/wp-content/uploads/2022/08/MDXH-Interim-Report-1H22-FINAL-FR.pdf)\n\n2022 Interim Report for the nine months ended September 30, 2022: [English](https://mdxhealth.com/wp-content/uploads/2023/01/MDXH-Interim-Report-3Q22-FINAL.pdf)\n\n2022 Consolidated Figures: [English](https://mdxhealth.com/wp-content/uploads/2023/03/2022-Financials-v7-FINAL.docx)\n\n2022 Combined Statutory and Consolidated Board Report: [English ](https://mdxhealth.com/wp-content/uploads/2023/04/2022-Combined-statutory-and-consolidated-report-ENG.pdf)I [Français](https://mdxhealth.com/wp-content/uploads/2023/04/2022-Combined-statutory-and-consolidated-report-FR.pdf)\n\n2022 Full Non-consolidated Statutory Accounts: [Français](https://mdxhealth.com/wp-content/uploads/2023/04/2022-Full-Non-Consolidated-Statutory-Accounts-FR.pdf)\n\n2022 Annual Report: [English](https://mdxhealth.com/wp-content/uploads/2023/04/2022-Annual-Report-ENG.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2023/05/2022-Annual-Report-FR-FINAL.pdf)\n\n2022 Annual Report (XBRL ZIP): [English](https://mdxhealth.com/wp-content/uploads/2023/05/2022-Annual-Report-XBRL-ENG.zip) I [Français](https://mdxhealth.com/wp-content/uploads/2023/05/2022-Annual-Report-XBRL-FR.zip) I [View XBRL](https://mdxhealth.com/documents/2023/2022-AnnualReport/xrbl/mdxhealth-2022-12-31-en_preview.xhtml)\n\n2022 Auditor Opinion: [English](https://mdxhealth.com/wp-content/uploads/2023/05/Auditor-opinion-consolidated-ESEF-EN.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2023/05/Auditor-opinion-consolidated-ESEF-FR.pdf)\n\n2021\n\n#### 2021\n\n2021 Interim Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/1-2021-Interim-Report-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/2-2021-Interim-Report-French.pdf)\n\n2021 Consolidated Figures: [English](https://mdxhealth.com/wp-content/uploads/2022/06/3-2021-Consolidated-Figures-English.pdf)\n\n2021 Board Report on Financial Statements: [English](https://mdxhealth.com/wp-content/uploads/2022/06/4-2021-Board-Report-on-Financial-Statements-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/5-2021-Board-Report-on-Financial-Statements-French.pdf)\n\n2021 Full Non-consolidated Statutory Accounts: [Français](https://mdxhealth.com/wp-content/uploads/2022/06/6-2021-Full-Non-consolidated-Statutory-Accounts-French.pdf)\n\n2021 Annual Report (PDF): [English](https://mdxhealth.com/wp-content/uploads/2022/06/7-2021-Annual-Report-PDF-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/8-2021-Annual-Report-PDF-French.pdf)\n\n2021 Annual Report (XBRL ZIP): [English](https://mdxhealth.com/wp-content/uploads/2022/06/9-2021-Annual-Report-XBRL-ZIP-English.zip) | [Français](https://mdxhealth.com/wp-content/uploads/2022/06/10-2021-Annual-Report-XBRL-ZIP-French.zip) I [View XBRL](https://simplescience-client-assets.s3.us-west-1.amazonaws.com/mdxhealth/website-assets/2021/2021-report-xbrl.html)\n\n2021 Auditor Opinion: [English](https://mdxhealth.com/wp-content/uploads/2022/06/11-2021-Auditor-Opinion-English.pdf) I [ Français](https://mdxhealth.com/wp-content/uploads/2022/06/12-2021-Auditor-Opinion-French.pdf)\n\n2020\n\n#### 2020\n\n2020 Interim Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/1-2020-Interim-Report-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/2-2020-Interim-Report-French.pdf)\n\n2020 Consolidated Figures: [English](https://mdxhealth.com/wp-content/uploads/2022/06/3-2020-Consolidated-Figures-English.pdf)\n\n2020 Board Report on Financial Statements: [English](https://mdxhealth.com/wp-content/uploads/2022/06/4-2020-Board-Report-on-Financial-Statements-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/5-2020-Board-Report-on-Financial-Statements-French.pdf)\n\n2020 Full Non-consolidated Statutory Accounts: [Français](https://mdxhealth.com/wp-content/uploads/2022/06/6-2020-Full-Non-consolidated-Statutory-Accounts-French.pdf)\n\n2020 Annual Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/7-2020-Annual-Report-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/8-2020-Annual-Report-French.pdf)\n\n2020 Auditor Opinion: [English](https://mdxhealth.com/wp-content/uploads/2022/06/9-2020-Auditor-Opinion-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/10-2020-Auditor-Opinion-French.pdf)\n\n2019\n\n#### 2019\n\n2019 Interim Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/1-2019-Interim-Report-EN.pdf) | [Français](https://mdxhealth.com/wp-content/uploads/2022/06/2-2019-Interim-Report-FR.pdf)\n\n2019 Consolidated Figures: [English](https://mdxhealth.com/wp-content/uploads/2022/06/3-2019-Consolidated-Figures-EN.pdf)\n\n2019 Board Report on Financial Statements: [English](https://mdxhealth.com/wp-content/uploads/2022/06/4-2019-Board-Report-on-Financial-Statements-EN.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/5-2019-Board-Report-on-Financial-Statements-FR.pdf)\n\n2019 Full Non-consolidated Statutory Accounts: [Français](https://mdxhealth.com/wp-content/uploads/2022/06/6-2019-Full-Non-consolidated-Statutory-Accounts-French.pdf)\n\n2019 Annual Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/7-2019-Annual-Report-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/8-2019-Annual-Report-French.pdf)\n\n2019 Auditor Opinion: [English](https://mdxhealth.com/wp-content/uploads/2022/06/9-2019-Auditor-Opinion-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/10-2019-Auditor-Opinion-French.pdf)\n\n2018\n\n#### 2018\n\n2018 Interim Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/1-2018-Interim-Report-English.pdf) | [Français](https://mdxhealth.com/wp-content/uploads/2022/06/2-2018-Interim-Report-French.pdf)\n\n2018 Consolidated Figures: [English](https://mdxhealth.com/wp-content/uploads/2022/06/3-2018-Consolidated-Figures-English.pdf)\n\n2018 Board Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/4-2018-Board-Report-Enlgish.pdf)\n\n2018 Full non consolidated statutory Accounts: [Français](https://mdxhealth.com/wp-content/uploads/2022/06/5-2018-Full-non-consolidated-statutory-Accounts-French.pdf)\n\n2018 Annual Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/6-2018-Annual-Report-English.pdf) | [Français](https://mdxhealth.com/wp-content/uploads/2022/06/7-2018-Annual-Report-French.pdf)\n\n2018 Auditor Opinion: [English](https://mdxhealth.com/wp-content/uploads/2022/06/8-2018-Auditor-Opinion-English.pdf) | [Français](https://mdxhealth.com/wp-content/uploads/2022/06/9-2018-Auditor-Opinion-French.pdf)\n\n### SEC Filings\n\n### Investor Relations Contact\n\nFor all investor related questions please call or email:\n\nLifeSci Advisor (PR & IR)\n\n**US: +1.949.271.9223****ir@mdxhealth.com**\n\n[ ![](/wp-content/uploads/2022/04/MDxHealth-Logo_Full-Color_KO_RGB-1.png) ](https://mdxhealth.com)\n\nToll Free: (866) 259-5644 Email: info@mdxhealth.com\n\n[ Facebook ](https://www.facebook.com/mdxhealth/) [ Twitter ](https://twitter.com/mdxhealth?s=11&t=RI_iHL03YQlKMvkiHxV93g) [ Linkedin ](https://www.linkedin.com/company/1344641/admin/feed/posts/)\n\n###### Our Company\n\n  * [ About  ](https://mdxhealth.com/about/)\n  * [ Science ](https://mdxhealth.com/science/)\n  * [ Careers ](https://mdxhealth.com/careers/)\n  * [ News ](https://mdxhealth.com/press-releases-events/)\n  * [ Contact Us ](https://mdxhealth.com/contact-us/)\n  * [ Connect with a rep ](https://mdxhealth.com/connect/)\n  * [ Xpert One Support ](https://mdxhealth.com/xpert-one/)\n\n\n\n###### Tests\n\nFor Physicians\n\n  * [ Select mdx ](https://mdxhealth.com/select-mdx-for-physicians/)\n  * [ Confirm mdx  ](https://mdxhealth.com/confirm-mdx-for-physicians/)\n  * [ Genomic Prostate Score ](https://mdxhealth.com/gps-physician/)\n  * [ Resolve mdx  ](https://mdxhealth.com/resolve-mdx-for-physicians/)\n  * [ Physician Portal ](https://mdxhealthsecure.com)\n  * [ Report Access ](https://mdxhealth.com/securemdx/)\n  * [ Order Supplies ](https://mdxhealth.com/testkits/)\n  * [ FedEx Pick Up ](https://mdxhealth.com/fedex/)\n\n\n\nFor Patients\n\n  * [ Select mdx ](https://mdxhealth.com/select-mdx-for-patients/)\n  * [ Confirm mdx ](https://mdxhealth.com/confirm-mdx-for-patients/)\n  * [ Genomic Prostate Score ](https://mdxhealth.com/gps-patient/)\n  * [ Resolve mdx ](https://mdxhealth.com/resolve-mdx-for-patients/)\n  * [ Pay My Bill ](https://mdxhealth.com/paymybill/)\n\n\n\n###### Investors\n\n  * [ Financials ](https://mdxhealth.com/financials/)\n  * [ Shareholder Information ](https://mdxhealth.com/shareholder-information/)\n  * [ Transition to Nasdaq ](https://mdxhealth.com/proposed-transition-to-a-single-listing-on-nasdaq/)\n  * [ Analyst Coverage ](https://mdxhealth.com/analyst-coverage/)\n  * [ Presentations & Events ](https://mdxhealth.com/presentations-events/)\n  * [ Press Releases  ](https://mdxhealth.com/press-releases-events/)\n\n\n\n#### Shadowbox User Guides for download\n\n  * [Clinician User Guide](/wp-content/uploads/2024/10/SB-MKT-SHADOWBOX-IRIS-USER-GUIDE-2024.pdf)\n  * [IRIS Update Prompts Guide](/wp-content/uploads/2024/10/SB-MKT-SHADOWBOX-IRIS-UPDATE-PROMPTS-FOR-INSTALL-2024.pdf)\n  * [IRIS Install (with login automatically selected) Guide](/wp-content/uploads/2024/10/SB-MKT-SHADOWBOX-IRIS-INSTALL-WITH-LOGIN-AUTOMATICALLY-SELECTED-2024.pdf)\n\n\n\nCLOSE \n\n### How to Order Resolve mdx\n\n  1. To order Resolve mdx urine transport kits or test requisition forms: [Order Supplies Online](https://mdxhealthdotcom-dev.azurewebsites.nettestkits/) Call: 866.259.5644 Email: client.services@mdxhealth.com\n  2. Once urine transport kits are received, complete the Resolve mdx’s test requisition form in its entirety.\n  3. Carefully follow the steps in the enclosed Instructions For Use to collect the urine specimen.\n  4. Send completed test request form along with the sealed urine transportation kit to: 7000 Preston Road, Suite 1500, Plano, TX 75024\n\n\n\n[Schedule FedEx Pick Up](https://mdxhealthdotcom-dev.azurewebsites.netfedex/)\n\nView and Download [Resolve mdx Test Requisition Form (TRF)](/wp-content/uploads/2024/10/PL-FORM-0095-R06-Resolve-mdx-Test-Requisition-Form-for-UTI-and-STI-FNL.pdf) View and Download [Resolve mdx Specimen Collection and Shipping Instructions](/wp-content/uploads/2022/08/Resolve-mdx-Specimen-Collection-and-Shipping-Instructions.pdf) View and Download Resolve mdx [Specimen Requirements and Patient Eligibility](/wp-content/uploads/2022/08/Resolve-mdx-Specimen-Requirements.pdf)\n\nCLOSE \n\n# Licensure & Accreditations\n\n### United States:\n\n**Irvine, CA Laboratory**\n\n[College of American Pathologists (CAP) Accreditation](/wp-content/uploads/2024/06/CAP-2024.pdf)\n\n[Centers for Medicare & Medicaid Services Certificate of Accreditation (CLIA)](/wp-content/uploads/2022/06/Certificate-of-Accreditation-Ruben-Gamez.pdf)\n\n[New York State Department of Health License](/wp-content/uploads/2024/07/New-York-State-Clinical-Laboratory-Permit-exp-2025JUN30.pdf)\n\n[State of California Department of Public Health Clinical Laboratory License](/wp-content/uploads/2024/01/CDPH-License-Certificate_CDF-00341675-exp-13FEB2025.pdf)\n\n[State of Maryland License](/wp-content/uploads/2023/05/Maryland-State-License-Irvine.pdf)\n\n[State of Pennsylvania License](/wp-content/uploads/2022/06/PA-Irvine-Laboratory-Permit-EXP-08-25.pdf)\n\n[State of Rhode Island License](/wp-content/uploads/2024/02/Rhode-Island-License.pdf)\n\n[Health Canada License](/wp-content/uploads/2022/06/Health-Canada-Medical-Device-Establishment-License-scaled-2.jpg)\n\n**Plano, Texas Laboratory**\n\n[College of American Pathologists (CAP) Accreditation ](/wp-content/uploads/2023/03/PLANO-CAP_CERT.pdf)\n\n[Centers for Medicare & Medicaid Services Certificate of Accreditation (CLIA)](/wp-content/uploads/2023/05/CLIA_LICENSE_2023_PLANO.pdf)\n\n[State of California Department of Public Health Clinical Laboratory ](/wp-content/uploads/2024/10/CA-License-Certificate_CDS-90008054_Exp-2025OCT24.pdf)\n\n[State of Maryland License](/wp-content/uploads/2023/04/MARYLAND_STATE_LICENSE.pdf)\n\n[State of Pennsylvania License](/wp-content/uploads/2022/06/PA-Plano-Laboratory-Permit-EXP-08-25.pdf)\n\n[State of Rhode Island License ](/wp-content/uploads/2023/05/RHODE_ISLAND_LICENSE.pdf)\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/hardison.png)\n\n## Don Hardison\n\n### Independent Director\n\nMr. Hardison was most recently the President and Chief Executive Officer, and served on the board of directors, of Biotheranostics, Inc., a molecular diagnostic company focused on oncology, from February 2017 until it was acquired by Hologic, Inc. in February 2021. From April 2010 to March 2016, Mr. Hardison was the President and Chief Executive Officer of Good Start Genetics, a molecular genetic testing and information company. For more than 20 years prior to that, Mr. Hardison held various executive and senior management positions at companies including Laboratory Corporation of America (LabCorp), Exact Sciences Corporation, Quest Diagnostics Inc., and Smith Kline Beecham Corporation. He currently serves as an independent director on the boards of directors of Stemina Biomarker Discovery, Inc., Seventh Sense Biosystems, BioPorto, Inc. and IQuity, Inc. He also formerly served on the board of directors of Exact Sciences Corporation (Nasdaq: EXAS) from May 2000, through its initial public offering in February 2001, until August 2007. Mr. Hardison received his Bachelor of Arts degree, in political science, from the University of North Carolina, Chapel Hill.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.net/wp-content/uploads/2024/07/SSiegel.png)\n\n## Sanford J. Siegel, M.D. \n\n### Independent Director\n\nDr. Siegel has more the 45 years of experience as a practicing urologist and over 35 years of executive leadership experience. Dr. Siegel currently serves as the Chairman of the Board of United Urology Group, having previously served as its Chief Executive Officer. United Urology Group, which was acquired by Audax in 2016, was formed under Dr. Siegel’s leadership and is one of the nation’s leading urology networks. Previously, Dr. Siegel served as the President and Chief Executive Officer of Chesapeake Urology Associates, which he founded in 1999. Dr. Siegel is a founding member of the Large Urology Group Practice Association (LUGPA), which was formed in 2008. He was a board member of the Urology Care Foundation (UCF) from 2016 until 2023 and The Urology Times. As a recognized leader in the field of medicine, Dr. Siegel has been honored with official citations for outstanding commitment and leadership from both the Governor and the General Assembly of Maryland. Dr. Siegel earned his medical degree from the University of Maryland School of Medicine and completed his specialty training in urology at Temple University Hospital in Philadelphia. He has been certified by the American Board of Urology and as Fellow of the American College of Surgeons.\n\nCLOSE \n\n### How to Order Select mdx\n\n##### United States\n\n  1. To order Select mdx urine transport kits or test requisition forms: [Order Supplies Online](/testkits/) Call: 866.259.5644 Email: cs@mdxhealth.com\n  2. Once urine transport kits are received, complete the Select mdx’s test requisition form in its entirety.\n  3. Carefully follow the steps in the enclosed Instructions For Use to collect the urine specimen.\n  4. Send completed test request form along with the sealed urine transportation kit to: 15279 Alton Parkway, Suite 100, Irvine, CA 92618\n\n\n\n[Schedule FedEx Pick Up](/fedex/) View and Download [Select mdx Test Requisition Form (TRF)](/wp-content/uploads/2024/01/Select-mdx-Test-Requisition-Form7497-2.pdf) View and Download [Urine Collection and Preparation Instructions](/wp-content/uploads/2024/01/Urine-Collection-and-Transportation-Instructions-Brochure.pdf) View and Download [Specimen Requirements and Patient Eligibility](/wp-content/uploads/2024/01/Select-mdx-Specimen-Requirements.pdf)\n\n##### Europe\n\n  1. To order Select mdx urine transportation kits contact MDxHealth at +31 (0) 88 327 2727 or email clientservices.eu@mdxhealth.com.\n  2. Once urine transportation kits are received, please fill out the Select mdx test request form in its entirety.\n  3. Carefully follow the instructions for use to collect the urine specimen.\n  4. Place the completed test request form and urine specimen inside the Select mdx urine transportation kit. Follow the instructions on the kit to contact your local DHL office and arrange the return shipment to the mdxhealth laboratory.\n\n\n\nView and Download Test Request Form [DE](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_DE-v7_PRINT.pdf) | [EN](/wp-content/uploads/2022/06/MDX500-Requisition-form_EN-v4-2.pdf) | [ES](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_ES-v6-FER_elec.pdf) | [FR](/wp-content/uploads/2022/06/MDX500-Requisition-form_FR-v2.pdf) | [IT](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_IT-v9_PRINT.pdf) | [NL](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_NL-v7_PRINT.pdf) | [PL](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_PL-v4.pdf) View and Download [Select mdx Instructions for Use](/wp-content/uploads/2022/06/MDX521-SelectMDx-IFU-Booklet-v5.pdf) View and Download [UrNCollect Instructions for Use ](/wp-content/uploads/2022/06/MDX514-UrNCollect-v3.pdf)\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/regine-Slagmulder.png)\n\n## Regine Slagmulder\n\n### Independent Director, representing Regine Slagmulder BV\n\n**_Dr. Regine Slagmulder_** , Independent Non-Executive Director of our Company, is a full professor in management accounting & control at Vlerick Business School, a visiting professor of accounting & control at INSEAD, and the Knowledge & Academic Director (a.i.) at Guberna, the Belgian Institute for Directors. Previously, she worked as a strategy practice consultant at McKinsey & Company. She also previously worked as a professor of management accounting at INSEAD and at the University of Tilburg. She serves as an independent director and member of the audit committee on the board of the investment company Quest for Growth (since 2011) and as an independent director and chair of the audit committee of Ekopak (since 2021), both listed on Euronext. Dr. Slagmulder graduated in civil electrotechnical engineering and industrial management from the University of Gent, after which she received a management doctorate at Vlerick Business School. As part of her research activities, she was a research fellow attached to INSEAD, Boston University (USA) and the P. Drucker Graduate Management Center at Claremont University (USA). She is an INSEAD certified director (IDP-C).\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Hilde-Windels.png)\n\n## Hilde Windels\n\n### Independent Director, representing Hilde Windels BVBA\n\n**_Hilde Windels_** , Independent Non-Executive Director of our Company, has over 20 years of experience in the biotechnology sector with a track record of building and structuring organizations, fundraising, M&A, public capital markets and corporate strategies. Currently, Mrs. Windels serves as a board member at PHAXIAM Therapeutics, GIMV NV, MCROPHYT SA, and Celyad. Previously, she served as CEO of immunodiagnostic company Antelope Dx BV, and as CEO ad interim and Deputy CEO of Biocartis from September 2015 until September 2017 and as CFO of Biocartis from 2011 until September 2015. Mrs. Windels has also worked as independent CFO for several private biotech companies and from 1999 to 2008 she was CFO of Devgen. In the past, she also served on the boards of Devgen, Biocartis, Ablynx, VIB and FlandersBio. Mrs. Windels holds a Masters in Economics (commercial engineer) from the University of Leuven, Belgium.\n\nCLOSE \n\n### How to Order Confirm mdx\n\n##### Physician Office\n\nTo Order Pre-printed Test Requisition Forms:\n\n[Order Supplies Online](https://mdxhealthdotcom-dev.azurewebsites.nettestkits/) Call: 866.259.5644 Email: cs@mdxhealth.com\n\nView and Download [Confirm mdx Test Requisition Form (TRF)](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2024/01/Confirm-mdx-Test-Requisition-Form.pdf) View and Download [Confirm mdxSpecimen Requirements and Patient Eligibility](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2024/02/Confirm-mdx-Specimen-Requirements.pdf)\n\n  1. Complete the Confirm mdx test requisition form (TRF). Include patient demographics, copy of insurance card(s), and pathology report.\n  2. Forward the completed Confirm mdx TRF to MDxHealth Client Services. Mdxhealth will contact the pathology laboratory and request specimens as indicated on the TRF in “Section 7 – ConfirmMDx Specimen Request”.\n\n\n\n##### Pathology Laboratory\n\nTo order Confirm mdx Tissue Transport Kits:\n\n[Order Supplies Online](https://mdxhealthdotcom-dev.azurewebsites.netorder-supplies/) Call: 866.259.5644 Email: client.services@mdxhealth.com\n\n  1. Pathology lab will include specimens, completed test requisition form (including copies of patient demographics, insurance, and pathology report) inside the transportation kit.\n  2. Ship to: mdxhealth, 15279 Alton Parkway, Suite 100, Irvine, CA 92618.\n\n\n\n[Schedule FedEx Pick Up](https://mdxhealthdotcom-dev.azurewebsites.netfedex/)\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2023/11/Jason-Poole.png)\n\n## Jason Poole\n\n### Chief Scientific Officer\n\nDr. Poole has more than 25 years of research experience and specializes in the development of high complexity diagnostic testing for use in human health and disease. His expertise lies in product development using advanced technologies such as Next Generation Sequencing, qPCR, and nucleic acid sample preparation. Mr. Poole was most recently the VP of R&D at Active Motif, Inc. he spear-headed the development of products in the epigenetic research space including DNA methylation, chromatin modifications and epigenetic specific antibody development. Dr. Poole received his M.S. in Molecular Endocrinology from Northwestern University and his Ph.D. in Molecular Genetics from the University of Illinois College of Medicine in Chicago, IL.\n\nCLOSE \n\n## Tailored reports that connect insights for the next step in care\n\n### Low-Risk Report\n\n**The low-risk report integrates clinical, pathological, and genomic insights into actionable information on active surveillance 1**\n\n  * Predicts tumor aggressiveness to help inform the decision between active surveillance and immediate treatment\n  * Focuses on an actionable endpoint adverse pathology, with the most comprehensive definition\n  * The Genomic Prostate Score(GPS) test is the only commercially available test to provide all these endpoints: \n    * Risk of high-grade (≥Grade Group 3) disease\n    * Risk of pT3a+ disease\n    * Risk of metastasis within 10 years\n    * Risk of PCa-specific death within 10 years\n\n\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/212-low-risk-report-1024x627.png)\n\n##### [DOWNLOAD LOW-RISK SAMPLE REPORT](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2023/07/MDX.Brochures.GPS_.LowRiskReport_r2-SAMPLE.pdf)\n\n### High-Risk Report\n\n**The high-risk report provides a defined cut point with actionable information on treatment intensity 2**\n\n  * Helps determine the right level of treatment\n  * Clearly stratifies patient risk into lower or higher likelihood of disease progression\n  * Simple bell curve helps you and your patient understand the patient’s risk relative to other patients of same clinical risk group\n\n\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/211and212highrisk-1024x380.png)\n\n##### [DOWNLOAD HIGH-RISK SAMPLE REPORT](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2023/07/MDX.Brochures.GPS_.HighRiskReport_r3-SAMPLE.pdf)\n\nReferences:\n\n  1. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.  _Eur Urol_. 2014;66(3):550-560.\n  2. Cullen J, Kuo HC, Shan J, Lu R, Aboushwareb T, Van Den Eeden SK. The 17-gene genomic prostate score test as a predictor of outcomes in men with unfavorable intermediate risk prostate cancer. _Urology_. 2020;143:103-111.\n\n\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Mike-M.-Headshot-website.png)\n\n## Michael K. McGarrity\n\n### Chief Executive Officer, Director\n\nMr. McGarrity has more than 25 years of experience in the healthcare industry with a unique combination of device, diagnostics and biotechnology experience. Mr. McGarrity was most recently the CEO of Sterilis Medical. Prior to Sterilis Mr. McGarrity was the CEO of Nanosphere (NASDAQ: NSPH), a nanotechnology-based molecular diagnostics company, where he engineered an operational and strategic turnaround that resulted in its successful sale to Luminex (NASDAQ: LMNX) in 2016. Prior to Nanosphere, Mr. McGarrity spent 13 years at Stryker Corporation (NYSE: SYK) where he served in leadership roles in sales and marketing and led Stryker into new growth markets such as post-operative pain management, surgical fluid waste management and interventional pain management. Mr. McGarrity also had executive general management responsibility for a newly created business unit focused on interventional spine pain management. Mr. McGarrity received a Bachelor of Arts degree from the University of Notre Dame and began his career in commercial banking.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Ron-K-headshot-website.png)\n\n## Ron Kalfus\n\n### Chief Financial Officer\n\nMr. Kalfus has over 20 years of leadership experience in both public and private companies within diagnostics/biotech and other sectors, and brings extensive knowledge in financial operations, management, and strategic transactions. Mr. Kalfus joined mdxhealth from Rosetta Genomics, where he helped lead efforts to reposition the company for commercial success with its oncology diagnostic products, and raised over $60 million in capital to fund these efforts. Prior to Rosetta, Mr. Kalfus served as the CFO and Treasurer of MabCure, a Belgium-based publicly-traded biotechnology startup in the field of early cancer detection using antibodies. Mr. Kalfus received his Master’s degree in Accounting from Fairleigh Dickinson University and his Bachelor’s degree in Finance from the University of Georgia. Mr. Kalfus is a Certified Public Accountant, licensed in the State of New Jersey.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Valiance-Jan-Pensaert.png)\n\n## Mr. Jan Pensaert\n\n### Director, representing Valiance Advisors LLP\n\nJan Pensaert is the Founding Managing Partner of Valiance. He brings over 20 years of experience in growth investing. He leads the Investment Committee for the Valiance Funds and is responsible for all aspects of the Funds’ investment processes. Jan currently serves on the Board of several Valiance entities funds and portfolio companies including MDxHealth, JenaValve, NeoSync, and 4Tech. Prior to founding Valiance, Jan was CEO of La Fayette, where during his tenure the La Fayette Funds increased in AUM from $750 million to $5.5 billion. Before that, he was responsible for the Permal Group’s European-based investment management and research activities, and prior to that, he worked at Lazard in Corporate Finance M&A. Jan holds a BA in Business Economics from Gent University in Belgium, and a Masters in Banking & Finance from the University of Aix-Marseille, France.\n\nCLOSE \n\n**Analytical Validity**  \n---  \n· Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, et al. Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 2013;14: 690.  \n**Economic Utility**  \n· Albala D, Kemeter MJ, Febbo PG, Lu R, John V, Stoy D et al. Health economic impact and prospective clinical utility of Oncotype DX Genomic Prostate Score. Rev Urol. 2016; 18(3):123-132.  \n**Clinical Utility**  \n· Albala D, Kemeter MJ, Febbo PG, Lu R, John V, Stoy D et al. Health economic impact and prospective clinical utility of Oncotype DX Genomic Prostate Score. Rev Urol. 2016; 18(3):123-132. · Dall’Era MA, Maddala T, Polychronopoulos L, Gallagher JR, Febbo PG, and Denes BS. Utility of the Oncotype DX® Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A Retrospective Chart Review Analysis. Urology Practice. 2015;2(6):343-348. · Eure G, Germany R, Given R, Lu R, Shnidel AW, Rothney M, et al. Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort. Urology. 2017;107:67-75. · Lynch JA, Rothney MP, Salup RR, Ercole CE, Mathur SC, Duchene DA, et al. Improving Risk Stratification Among Veterans Diagnosed With Prostate Cancer: Impact of the 17-Gene Genomic Prostate Score Assay. Am J Manag Care. 2017;24(1 Suppl):S4-S10. · Murphy AB, Abern MR, Liu L, Wang H, Hollowell CMP, Sharifi R, Vidal P, et al. Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial. J Clin Oncol. 2021;39(15):1660-1670.  \n**Clinical Validity**  \n· Brooks MA, Thomas L, Magi-Galluzzi C, Li J, Crager MR, Lu R et al. GPS assay association with long-term cancer outcomes: twenty-year risk of distant metastasis and prostate cancer-specific mortality. JCO Precis Oncol. 2021;5:PO.20.00325. · Brooks MA, Thomas L, Magi-Galluzzi C, Li J, Crager MR, Lu R et al. Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy. Urol Oncol. 2022;40(3):104.e1-104.e7. · Covas Moschovas M, Chew C, Bhat S, Sandri M, Rogers T, Dell’Oglio P, et al. Association Between Oncotype DX Genomic Prostate Score and Adverse Tumor Pathology After Radical Prostatectomy. Eur Urol Focus. 2022;8(2):418-424. · Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol. 2015;69(1):123-131. · Cullen J, Kuo HC, Shan J, Aboushwareb T, and Van Den Eeden SK. The 17-gene genomic prostate score test as a predictor of outcomes in men with unfavorable intermediate-risk prostate cancer. Urology. 2020;143:103-111. · Cullen J, Lynch JA, Klein EA, Van Den Eeden SK, Carroll PR, Mohler JL, et al. Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer. J Urol. 2021;205(4):1047-1054. · Eggener S, Karsh LI, Richardson T, Shindel AW, Lu R, Rosenberg A et al. A 17-gene panel for prediction of adverse prostate cancer pathologic features: prospective clinical validation and utility. Urology. 2019;126:76-82. · Helfand BT, Paterakos M, Wang CH, Talaty P, Abran J, Bennett J et al. The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer. PLoS One. 2022;17(9):e0273782. · Helfand BT, Paterakos M, Wang CH, Talaty P, Abran J, Bennett J et al. The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer. PLoS One. 2022;17(9):e0273782. · Janes JL, Boyer MJ, Bennett JP, Thomas VM, De Hoedt AM, Edwards DK, et al. Prognostic for outcomes after primary external beam radiation therapy in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2023;115(1):120-131. · Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. _Eur Urol._ 2014;66(3):550–560. · Kornberg Z, Cowan JE, Westphalen AC, Cooperberg MR, Chan JM, Zhao S, et al. Genomic prostate score, PI-RADS version 2 and progression in men with prostate cancer on active surveillance. J Urol. 2019;201:300-307. · Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg M, et al. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate-risk prostate cancer. PLoS One. 2017;12(10):e0185535. · Lin D, Zheng Y, McKenney JK, Brown MD, Lu R, Crager M, et al. 17-gene genomic prostate score test results in the Canary Prostate Active Surveillance Study (PASS) cohort. J Clin Oncol. 2020;38(14):1549-1557. · Magi-Galluzzi C, Isharwal S, Falzarano SM, Tsiatis A, Dee A, Maddala T et al. The 17-gene genomic prostate score assay predicts outcomes after radical prostatectomy independent of PTEN status. Urology. 2018;121:132-138. · Murphy AB, Carbunaru S, Nettey OS, Gornbein C, Dixon MA, Macias V, et al. A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men. Urology. 2020; 142:166-173. · Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk Jr AE et al. A 17-gene Genomic Prostate Score assay provides independent information on adverse pathology in the setting of combined multiparametric magnetic resonance fusion-targeted and systematic prostate biopsy. J Urol. 2018;200(3):564-572. · Van Den Eeden SK, Lu R, Zhang N, Queensberry Jr CP, Shan J, Han JS, et al. A biopsy-based 17-gene genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease. Eur Urol. 2017;73(1):129-138.  \n**Meta-analysis**  \n· Bennett J, Flake D. Patient-specific meta-analysis of three clinical validation studies to predict risk of distant metastasis and prostate cancer death in higher risk prostate cancer patients after definitive radiotherapy of radical prostatectomy. EXAS Internal Data 2022. · Brand TC, Zhang N, Crager MR, Maddala T, Dee A, Sesterhenn IA, et al. Patient-specific meta-analysis of 2 clinical validation studies to predict pathologic outcomes in prostate cancer using the 17-gene Genomic Prostate Score. Urology. 2016;89:69-75.  \n  \nCLOSE \n\n### Insurance & Billing Policy\n\nWe are committed to making our tests accessible and affordable to your patients. Mdxhealth’s Patient First Promise Program was created to assist patients throughout the billing process. We will work directly with each patient to ensure their complete satisfaction.\n\n##### Dedicated Patient Advocate Team\n\n  * Our specially trained Patient Advocates are ready to answer patients’ questions about insurance coverage and personalized payment options.\n  * Toll Free: 866-259-7001, Monday – Friday, 6:00AM – 4:30PM PT\n  * Email: patientfirst@mdxhealth.com\n\n\n\n##### Personalized Payment Options\n\n  * Interest-Free Payment Plan\n  * Financial Assistance Program\n\n\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Koen-Hoffman.png)\n\n## Mr. Koen Hoffman\n\n### Chairman and Independent Director, representing Ahok BV\n\nKoen Hoffman has served as Independent Chairman of the Board of Directors of Fagron NV since May 8, 2017. He obtained a Master in Applied Economics at the University of Ghent in 1990 and a Master in Business Administration at Vlerick Business School in Ghent in 1991. Mr. Hoffman was appointed Chief Executive Officer of Value Square in August 2016. Prior to joining Value Square, he was Chief Executive Officer of KBC Securities, member of the supervisory board of Patria Securities and member of the board of directors of Omnia Travel Belgium. He started his career at the corporate finance department of KBC Bank in 1992.\n\nCLOSE \n\n## Understanding your GPS results\n\n### Deciding the most appropriate course of treatment for your prostate cancer is important. Your GPS result may help.\n\nThe GPS test measures prostate cancer gene levels to assess how aggressively your cancer will grow or spread. Since certain genes influence this more than others, knowing which ones are active in your tumor helps determine your personal GPS result.\n\n### Your personal GPS result and risk category\n\nYour score is based on a scale of 0-100. Your genomic risk will indicate how your tumor behaves and can help you and your doctor determine the most appropriate course of treatment.\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/211and212highrisk-1024x380.png)\n\n### Current and future risk\n\nThese results can predict both your chance of:\n\n  1. Dying from prostate cancer and\n  2. Your cancer spreading (metastasis) in the next 10 years\n\n\n\n### Personalized assessment for individualized treatment\n\nThe GPS test provides a personalized assessment of how aggressive your prostate cancer is, helping you and your doctor discuss next steps with confidence.\n\n[**DOWNLOAD SAMPLE REPORT OVERVIEW FOR CLINICALLY HIGH-RISK PROSTATE CANCER**](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/Clinically-High-Risk-Report-Overview-PDF.pdf)\n\nCLOSE \n\n## Understand your test results\n\n### Deciding between active surveillance and immediate treatment for your prostate cancer is important. Your GPS result may help.\n\nThe GPS test measures prostate cancer gene levels to assess how aggressively your cancer will grow or spread. Since certain genes influence this more than others, knowing which ones are active in your tumor helps determine your personal GPS result.\n\n### Your personal GPS result\n\nThe bell curve illustrates where your GPS result falls in relation to the GPS results of other men in the same risk category.\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/212-low-risk-report-1024x627.png)\n\n### Current and future risk\n\nThese results can predict both your chance of:\n\n  1. Your cancer spreading (metastasis) and\n  2. Dying from prostate cancer in the next 10 years\n\n\n\n## Personalized assessment for individualized treatment\n\n### Additional pathology endpoints (provided for men with Gleason score 3+4)\n\n  1. **Adverse Pathology** predicts the probability your doctor would find more aggressive disease than expected from your biopsy. This helps your doctor know if you are a candidate for active surveillance or if immediate treatment is most appropriate for you.\n  2. **High-Grade Disease** shows the likelihood that cancer cells within your tumor are abnormal when compared to typical cells.\n  3. **Non–Organ-Confined Disease** indicates the likelihood that your cancer has already spread outside your prostate.\n\n\n\nThe GPS test provides a personalized assessment of how aggressive your prostate cancer is, helping you and your doctor discuss next steps with confidence.\n\n[**DOWNLOAD SAMPLE REPORT OVERVIEW FOR CLINICALLY LOW-RISK PROSTATE CANCER**](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/Clinically-Low-Risk-Report-Overview-PDF.pdf)\n\nCLOSE \n\n### Test Cancellation Policy\n\nMdxhealth will honor test cancellation requests any time prior to the start of the analytical testing phase. Test cancellation requests must be submitted from the person authorized to cancel a test, following the instructions below:\n\nContact Client Services at **866-259-5644** for test cancellation.\n\nA Test Cancellation Form will be sent to the authorized person for signature.\n\nReturn the completed and signed Test Cancellation Form by fax to mdxhealth **949-788-0014**.\n\nIf the cancellation request is received after the specimen has entered in the analytical testing phase, the request cannot be honored and the usual test charge will be assessed.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Eric-Bednarski.png)\n\n## Eric Bednarski\n\n### Director\n\nDr. Bednarski currently serves as a Partner of MVM Partners LLP. Before joining MVM in 2008, he was a Partner at Advent Healthcare Ventures and a Principal at Advent International Corporation. Prior to Advent, he was a Director in the Corporate Finance Group of Silicon Valley Bank. Dr. Bednarski has a B.S. degree in Neural Science from Brown University and a Ph.D. in Biological Sciences from the University of California, Irvine.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Mike-M-Headhsot-BW.png)\n\n## Michael K. McGarrity\n\n### Chief Executive Officer, Director\n\nMr. McGarrity has more than 25 years of experience in the healthcare industry with a unique combination of device, diagnostics and biotechnology experience. Michael was most recently the CEO of Sterilis Medical. Prior to Sterilis Michael was the CEO of Nanosphere (NASDAQ: NSPH), a nanotechnology-based molecular diagnostics company, where he engineered an operational and strategic turnaround that resulted in its successful sale to Luminex (NASDAQ: LMNX) in 2016. Prior to Nanosphere, McGarrity spent 13 years at Stryker Corporation (NYSE: SYK). McGarrity served in leadership roles in sales and marketing and led Stryker into new growth markets such as post-operative pain management, surgical fluid waste management and interventional pain management. He also had executive general management responsibility for a newly created business unit focused on interventional spine pain management. Michael received a Bachelor of Arts degree from the University of Notre Dame and began his career in commercial banking.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/John-B-headshot-website.png)\n\n## John Bellano\n\n### Chief Commercial Officer\n\nMr. Bellano has more than 25 years of experience in the Healthcare Industry. Mr. Bellano started his career in Pharmaceuticals and transitioned to molecular diagnostics where he has spent the past 20 years of his career. Most recently the Chief Commercial Officer of Sterilis Solutions Prior to Sterilis Solutions he served as the commercial leader for Pharmacogenomic companies Assurex Health and AltheaDx. While at Assurex Health (Myriad Genetics) revenue grew from $700k to a run rate of $100 Million during his 5 year span with the organization.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Mimi-Reyes-headshot_.png)\n\n## Miriam Reyes\n\n### Executive Vice President of Operations\n\nMiriam Reyes has 25 years of experience in life science and laboratory operations, and R&D. She has served as Operations Leader at MDxHealth since its US inception in 2011. Prior to MDxHealth, Mrs. Reyes was Director of Laboratory Operations at Agendia where she established/built and led the CLIA lab for the Agendia’s FDA cleared MammaPrint breast cancer test. In addition to Agendia, she established laboratory operations at Combimatrix (Invitae) Molecular Diagnostics and developed commercial assays at both IBIS Biosciences and US Labs (LabCorp.).\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Joe-Sollee-Headshot.png)\n\n## Joseph Sollee\n\n### Executive Vice President of Corporate Development and General Counsel\n\nMr. Sollee has more than 20 years of experience in the healthcare industry, including senior management roles in both private and publicly listed pharmaceuticals, health information technology and molecular diagnostics companies. He has served as chief legal counsel to MDxHealth since its inception in 2003. Prior to MDxHealth, he led the Life Sciences Practice Group at the law firm of Kennedy Covington (now K&LGates) and held senior legal and management positions at TherapyEdge and Triangle Pharmaceuticals. In addition, he has practiced as a corporate attorney in the Washington D.C. legal firm Swidler & Berlin and as an investment banker at Smith Barney in New York. Mr. Sollee received a Juris Doctorate in Law and a Masters degree in International Law from Duke University, a BA degree from Harvard University, and has been awarded New York, Washington D.C. and North Carolina legal bar certifications.\n\nCLOSE \n"
        },
        {
          "title": "Financial Report October 2023",
          "url": "https://mdxhealth.com/financials/",
          "content": "![logo](data:,)\n\n## This website uses cookies\n\nWe use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. You consent to our cookies if you continue to use our website.\n\nDo not sell or share my personal information\n\n[Use necessary cookies only ](#)[Allow all cookies ](#)[Show details](#)\n\n[OK](#)\n\n[Use necessary cookies only ](#)[Allow selection ](#)[Allow all cookies](#)\n\nNecessary\n\nPreferences\n\nStatistics\n\nMarketing\n\n[Show details](#)\n\n[Cookie declaration ](#)[[#IABV2SETTINGS#] ](#)[About](#)\n\n[Necessary (15)](#) [Preferences (1)](#) [Statistics (11)](#) [Marketing (32)](#) [Unclassified (7)](#)\n\nNecessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \n__RequestVerificationToken| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Helps prevent Cross-Site Request Forgery (CSRF) attacks.| Session| HTTP Cookie  \nak_bmsc| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| 1 day| HTTP Cookie  \nbm_mi| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Used in context with the website's BotManager. The BotManager detects, categorizes and compiles reports on potential bots trying to access the website.| Session| HTTP Cookie  \n_GRECAPTCHA| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| 180 days| HTTP Cookie  \nrc::a| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| Persistent| HTML Local Storage  \nrc::b| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. | Session| HTML Local Storage  \nrc::c| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. | Session| HTML Local Storage  \nrc::f| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. | Persistent| HTML Local Storage  \n1.gif| [Cookiebot](https://www.cookiebot.com/goto/privacy-policy/ \"Cookiebot's privacy policy\")| Used to count the number of sessions to the website, necessary for optimizing CMP product delivery. | Session| Pixel Tracker  \nCookieConsent| [Cookiebot](https://www.cookiebot.com/goto/privacy-policy/ \"Cookiebot's privacy policy\")| Stores the user's cookie consent state for the current domain| 1 year| HTTP Cookie  \nelementor| mdxhealth.com| Used in context with the website's WordPress theme. The cookie allows the website owner to implement or change the website's content in real-time.| Persistent| HTML Local Storage  \nwpEmojiSettingsSupports| mdxhealth.com| This cookie is part of a bundle of cookies which serve the purpose of content delivery and presentation. The cookies keep the correct state of font, blog/picture sliders, color themes and other website settings.| Session| HTML Local Storage  \nASP.NET_SessionId| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Preserves the visitor's session state across page requests.| Session| HTTP Cookie  \n__cf_bm| [Vimeo](https://vimeo.com/privacy \"Vimeo's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| 1 day| HTTP Cookie  \n_cfuvid| [Vimeo](https://vimeo.com/privacy \"Vimeo's privacy policy\")| This cookie is a part of the services provided by Cloudflare - Including load-balancing, deliverance of website content and serving DNS connection for website operators. | Session| HTTP Cookie  \n  \nPreference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nFormsWebSessionId| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| The cookie is used if the visitor has filled in personal information on a formula. This information will be filled in automatically on other formulas. This process is used to optimize visitor experience. | 30 days| HTTP Cookie  \n  \nStatistic cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nc.gif| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Collects data on the user’s navigation and behavior on the website. This is used to compile statistical reports and heatmaps for the website owner.| Session| Pixel Tracker  \ncollect| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.| Session| Pixel Tracker  \nhjActiveViewportIds| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| This cookie contains an ID string on the current session. This contains non-personal information on what subpages the visitor enters – this information is used to optimize the visitor's experience.| Persistent| HTML Local Storage  \nhjViewportId| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| Saves the user's screen size in order to adjust the size of images on the website.| Session| HTML Local Storage  \n_ga| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Registers a unique ID that is used to generate statistical data on how the visitor uses the website.| 2 years| HTTP Cookie  \n_ga_#| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used by Google Analytics to collect data on the number of times a user has visited the website as well as dates for the first and most recent visit. | 2 years| HTTP Cookie  \n_gat| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used by Google Analytics to throttle request rate| 1 day| HTTP Cookie  \n_gid| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Registers a unique ID that is used to generate statistical data on how the visitor uses the website.| 1 day| HTTP Cookie  \n_hjSession_#| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| Collects statistics on the visitor's visits to the website, such as the number of visits, average time spent on the website and what pages have been read.| 1 day| HTTP Cookie  \n_hjSessionUser_#| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| Collects statistics on the visitor's visits to the website, such as the number of visits, average time spent on the website and what pages have been read.| 1 year| HTTP Cookie  \nvuid| [Vimeo](https://vimeo.com/privacy \"Vimeo's privacy policy\")| Collects data on the user's visits to the website, such as which pages have been read.| 2 years| HTTP Cookie  \n  \nMarketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nMR [x2]| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences. | 7 days| HTTP Cookie  \nMUID [x3]| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")forms.cloud.microsoft| Used widely by Microsoft as a unique user ID. The cookie enables user tracking by synchronising the ID across many Microsoft domains.| 1 year| HTTP Cookie  \nSRM_B| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Tracks the user’s interaction with the website’s search-bar-function. This data can be used to present the user with relevant products or services. | 1 year| HTTP Cookie  \nANONCHK| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Registers data on visitors from multiple visits and on multiple websites. This information is used to measure the efficiency of advertisement on websites. | 1 day| HTTP Cookie  \nSM| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Registers a unique ID that identifies the user's device during return visits across websites that use the same ad network. The ID is used to allow targeted ads.| Session| HTTP Cookie  \nNID| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 6 months| HTTP Cookie  \nGNWTracker| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Used to implement blog or article content onto the website from other websites. This implementation also allows the origin-website to track on the website. | Session| HTTP Cookie  \ntimes_to_show| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used to determine when and where certain pop-ups on the website should be presented for the user and remember whether the user has closed these, to keep them from showing multiple times.| Persistent| HTML Local Storage  \n#-#| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTML Local Storage  \n__Secure-ROLLOUT_TOKEN| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Pending| 180 days| HTTP Cookie  \niU5q-!O9@$| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Registers a unique ID to keep statistics of what videos from YouTube the user has seen.| Session| HTML Local Storage  \nLAST_RESULT_ENTRY_KEY| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTTP Cookie  \nLogsDatabaseV2:V#||LogsRequestsStore| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Persistent| IndexedDB  \nnextId| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTTP Cookie  \nremote_sid| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Necessary for the implementation and functionality of YouTube video-content on the website. | Session| HTTP Cookie  \nrequests| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTTP Cookie  \nTESTCOOKIESENABLED| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| 1 day| HTTP Cookie  \nVISITOR_INFO1_LIVE| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Tries to estimate the users' bandwidth on pages with integrated YouTube videos.| 180 days| HTTP Cookie  \nYSC| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Registers a unique ID to keep statistics of what videos from YouTube the user has seen.| Session| HTTP Cookie  \nyt.innertube::nextId| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Registers a unique ID to keep statistics of what videos from YouTube the user has seen.| Persistent| HTML Local Storage  \nytidb::LAST_RESULT_ENTRY_KEY| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Persistent| HTML Local Storage  \nYtIdbMeta#databases| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Persistent| IndexedDB  \nyt-remote-cast-available| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-cast-installed| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-connected-devices| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Persistent| HTML Local Storage  \nyt-remote-device-id| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Persistent| HTML Local Storage  \nyt-remote-fast-check-period| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-session-app| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-session-name| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \n  \nUnclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nMuidSyncDomain| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Pending| Persistent| HTML Local Storage  \nMuidSyncTimestamp| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Pending| Persistent| HTML Local Storage  \nRevSpringHistory| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 1 year| HTTP Cookie  \nRevSpringRef| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 1 day| HTTP Cookie  \nRevSpringUserAlias| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 1 year| HTTP Cookie  \nRevSpringVisit| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| Session| HTTP Cookie  \nGNWUserSessionId| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Pending| Session| HTTP Cookie  \n  \n[[#IABV2_LABEL_PURPOSES#]](#) [[#IABV2_LABEL_FEATURES#]](#) [[#IABV2_LABEL_PARTNERS#]](#)\n\n[#IABV2_BODY_PURPOSES#]\n\n[#IABV2_BODY_FEATURES#]\n\n[#IABV2_BODY_PARTNERS#]\n\nCookies are small text files that can be used by websites to make a user's experience more efficient.The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission.This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.You can at any time change or withdraw your consent from the Cookie Declaration on our website.Learn more about who we are, how you can contact us and how we process personal data in our Privacy Policy.\n\nCookie declaration last updated on 12/1/24 by [Cookiebot](https://www.cookiebot.com \"Cookiebot\")\n\n  * [ Physician Portal ](https://mdxhealthsecure.com/)\n  * [ Pay My Bill ](/paymybill/)\n\n\n\n[ ![MDxHealth Logo_Full Color_KO_RGB](/wp-content/uploads/elementor/thumbs/MDxHealth-Logo_Full-Color_KO_RGB-1-qn8ye5yd7qzmvsyx0iqzls921um9s37hndqaovfadq.png) ](https://mdxhealth.com)\n\n  * [About](https://mdxhealth.com/about/)\n\n##### About\n\n    * [ Mission ](/about/#mission)\n    * [ Leadership ](/about/#leadership)\n    * [ Licensure & Accreditations ](/about/#licensure&accreditations)\n\n    * [ Science ](/science/)\n    * [ Careers ](/careers/)\n    * [ Multimedia ](/multimedia/)\n\n    * [ Mission ](https://mdxhealth.com/about/#mission)\n    * [ Leadership ](https://mdxhealth.com/about/#leadership)\n    * [ Licensure & Accreditations ](https://mdxhealth.com/about/#licensure&accreditations)\n    * Science\n    * Careers\n    * [ Multimedia ](https://mdxhealth.com/multimedia/)\n\n  * [Tests](https://mdxhealth.com/tests/)\n\n##### Prostate Cancer \n\n###### For Physicians\n\n    * [ Select mdx ](/select-mdx-for-physicians/)\n    * [ Confirm mdx ](/confirm-mdx-for-physicians/)\n    * [ Genomic Prostate Score ](/gps-physician/)\n\n###### For Patients\n\n    * [ Select mdx ](/select-mdx-for-patients/)\n    * [ Confirm mdx ](/confirm-mdx-for-patients/)\n    * [ Genomic Prostate Score ](/gps-patient/)\n\n##### Infectious Disease\n\n###### For Physicians\n\n    * [ Resolve mdx ](/resolve-mdx-for-physicians/)\n\n###### For Patients\n\n    * [ Resolve mdx  ](/resolve-mdx-for-patients/)\n\n###### Prostate Cancer (For Physicians)\n\n    * [ Select mdx ](https://mdxhealth.com/select-mdx-for-physicians/)\n    * [ Confirm mdx ](https://mdxhealth.com/confirm-mdx-for-physicians/)\n    * [ Genomic Prostate Score ](https://mdxhealth.com/gps-physician/)\n\n###### Prostate Cancer (For Patients)\n\n    * [ Select mdx ](https://mdxhealth.com/select-mdx-for-patients/)\n    * [ Confirm mdx ](https://mdxhealth.com/confirm-mdx-for-patients/)\n    * [ Genomic Prostate Score ](https://mdxhealth.com/gps-patient/)\n\n###### Infectious Disease (For Physicians)\n\n    * [ Resolve mdx  ](https://mdxhealth.com/resolve-mdx-for-physicians/)\n\n###### Infectious Disease (For Patients)\n\n    * [ Resolve mdx  ](https://mdxhealth.com/resolve-mdx-for-patients/)\n\n  * [Investors](https://mdxhealth.com/financials/)\n\n##### Investors\n\n    * [ Financials ](/financials/)\n    * [ Shareholder Information ](/shareholder-information/)\n    * [ Transition to Nasdaq ](/proposed-transition-to-a-single-listing-on-nasdaq/)\n\n    * [ Analyst Coverage ](/analyst-coverage/)\n    * [ Presentations & Events ](/presentations-events/)\n    * [ Press Releases ](/press-releases-events/)\n\n    * [ Financials ](https://mdxhealth.com/financials/)\n    * [ Shareholder Information ](https://mdxhealth.com/shareholder-information/)\n    * [ Transition to Nasdaq ](https://mdxhealth.com/proposed-transition-to-a-single-listing-on-nasdaq/)\n    * [ Analyst Coverage ](https://mdxhealth.com/analyst-coverage/)\n    * [ Presentation & Events ](https://mdxhealth.com/presentations-events/)\n    * [ Press Releases ](https://mdxhealth.com/press-releases-events/)\n\n  * [Support](https://mdxhealth.com/xpert-one/)\n\n    * [ Xpert One Support ](/xpert-one/)\n    * [ Contact Us ](/contact-us/)\n\n\n\n\n[ ](https://mdxhealth.com)\n\nX\n\n## Financials\n\n[Overview](https://mdxhealth.com/financials/#overview) · [Financial Reports](https://mdxhealth.com/financials/#financial-reports) · [SEC Filings](https://mdxhealth.com/financials/#secfilings) · [IR Contact](https://mdxhealth.com/financials/#ir-contact)\n\n#### Overview\n\nMdxhealth operates on a calendar basis with its accounting year ending on Dec. 31. The company reports its consolidated financial statements under International Financial Reporting Standards (IFRS) and all amounts are in US Dollars. Mdxhealth publishes a consolidated and audited Annual Report on an annual basis, a consolidated Interim Report for its June 30 half-year financial figures, and business/financial updates at the end of Q1 and Q3.\n\nFurthermore, for the Annual General Shareholders’ Meeting, the company also publishes the non-consolidated Belgian-GAAP financial statements of the parent company. Prior to October 5, 2010, mdxhealth operated under the name OncoMethylome Sciences.\n\n### Financial Reports\n\n2024\n\n2023\n\n2022\n\n2021\n\n2020\n\n2019\n\n2018\n\n2024\n\n#### 2024\n\n2024 Consolidated figures for the First quarter ended March 31, 2023: [English](/wp-content/uploads/2024/05/MDXH-1Q24.pdf)\n\n2024 Interim Report for the six months ended June 30, 2024: [English](/wp-content/uploads/2024/09/MDXH-Interim-Report-1H24.pdf)\n\n2023\n\n#### 2023\n\n2023 Consolidated figures for the First quarter ended March 31, 2023: [English](https://mdxhealth.com/wp-content/uploads/2023/05/MDXH-1Q23-financials-FINAL.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2023/05/MDXH-1Q23-financials_FR_FINAL.pdf)\n\n2023 Interim Report for the six months ended June 30, 2023: [English I ](https://mdxhealth.com/wp-content/uploads/2023/08/MDXH-Interim-Report-1H23-EN.pdf)[Français](https://mdxhealth.com/wp-content/uploads/2023/08/MDXH-Interim-Report-1H23-FINAL-FRENCH.pdf)\n\n2023 Financial statements for the periods ended September 30, 2023: [English](https://mdxhealth.com/wp-content/uploads/2023/11/Q3-financial-statements.pdf \"https://mdxhealth.com/wp-content/uploads/2023/01/MDXH-Interim-Report-3Q22-FINAL.pdf\")\n\n2023 Annual Report on Form 20-F: [English](/wp-content/uploads/2024/05/2023-Form-20-F.pdf)\n\n2023 Combined Statutory and Consolidated Board Report: [English](/wp-content/uploads/2024/05/6EN-Combined-Report-of-the-Board-of-Directors-on-the-Consolidated-and-non-consolidated-Statutory-Financial-Statements-ENG.pdf) I [Francais](/wp-content/uploads/2024/05/6FR-MDxHealth-AGM-_-EGM-2024-Combined-report-on-2023-statutory-and-consolidated-accounts-Final_FR.pdf)\n\n2023 Full Non-consolidated Statutory Accounts: [Francais](/wp-content/uploads/2024/05/4FR-MDXH-comptes-annuels-2023.pdf)\n\n2023 Auditor Opinion:[English](/wp-content/uploads/2024/05/8EN-PIE-IFRS-Report-conso-financial-statements-MDxHealth-FY2023-English.pdf) I [Francais](/wp-content/uploads/2024/05/8FR-PIE-IFRS-Rapport-consolide.pdf)\n\n2022\n\n#### 2022\n\n2022 Interim Report for the six months ended June 30, 2022: [English ](https://mdxhealth.com/wp-content/uploads/2022/08/MDXH-Interim-Report-1H22-FINAL.pdf)I [Français](https://mdxhealth.com/wp-content/uploads/2022/08/MDXH-Interim-Report-1H22-FINAL-FR.pdf)\n\n2022 Interim Report for the nine months ended September 30, 2022: [English](https://mdxhealth.com/wp-content/uploads/2023/01/MDXH-Interim-Report-3Q22-FINAL.pdf)\n\n2022 Consolidated Figures: [English](https://mdxhealth.com/wp-content/uploads/2023/03/2022-Financials-v7-FINAL.docx)\n\n2022 Combined Statutory and Consolidated Board Report: [English ](https://mdxhealth.com/wp-content/uploads/2023/04/2022-Combined-statutory-and-consolidated-report-ENG.pdf)I [Français](https://mdxhealth.com/wp-content/uploads/2023/04/2022-Combined-statutory-and-consolidated-report-FR.pdf)\n\n2022 Full Non-consolidated Statutory Accounts: [Français](https://mdxhealth.com/wp-content/uploads/2023/04/2022-Full-Non-Consolidated-Statutory-Accounts-FR.pdf)\n\n2022 Annual Report: [English](https://mdxhealth.com/wp-content/uploads/2023/04/2022-Annual-Report-ENG.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2023/05/2022-Annual-Report-FR-FINAL.pdf)\n\n2022 Annual Report (XBRL ZIP): [English](https://mdxhealth.com/wp-content/uploads/2023/05/2022-Annual-Report-XBRL-ENG.zip) I [Français](https://mdxhealth.com/wp-content/uploads/2023/05/2022-Annual-Report-XBRL-FR.zip) I [View XBRL](https://mdxhealth.com/documents/2023/2022-AnnualReport/xrbl/mdxhealth-2022-12-31-en_preview.xhtml)\n\n2022 Auditor Opinion: [English](https://mdxhealth.com/wp-content/uploads/2023/05/Auditor-opinion-consolidated-ESEF-EN.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2023/05/Auditor-opinion-consolidated-ESEF-FR.pdf)\n\n2021\n\n#### 2021\n\n2021 Interim Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/1-2021-Interim-Report-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/2-2021-Interim-Report-French.pdf)\n\n2021 Consolidated Figures: [English](https://mdxhealth.com/wp-content/uploads/2022/06/3-2021-Consolidated-Figures-English.pdf)\n\n2021 Board Report on Financial Statements: [English](https://mdxhealth.com/wp-content/uploads/2022/06/4-2021-Board-Report-on-Financial-Statements-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/5-2021-Board-Report-on-Financial-Statements-French.pdf)\n\n2021 Full Non-consolidated Statutory Accounts: [Français](https://mdxhealth.com/wp-content/uploads/2022/06/6-2021-Full-Non-consolidated-Statutory-Accounts-French.pdf)\n\n2021 Annual Report (PDF): [English](https://mdxhealth.com/wp-content/uploads/2022/06/7-2021-Annual-Report-PDF-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/8-2021-Annual-Report-PDF-French.pdf)\n\n2021 Annual Report (XBRL ZIP): [English](https://mdxhealth.com/wp-content/uploads/2022/06/9-2021-Annual-Report-XBRL-ZIP-English.zip) | [Français](https://mdxhealth.com/wp-content/uploads/2022/06/10-2021-Annual-Report-XBRL-ZIP-French.zip) I [View XBRL](https://simplescience-client-assets.s3.us-west-1.amazonaws.com/mdxhealth/website-assets/2021/2021-report-xbrl.html)\n\n2021 Auditor Opinion: [English](https://mdxhealth.com/wp-content/uploads/2022/06/11-2021-Auditor-Opinion-English.pdf) I [ Français](https://mdxhealth.com/wp-content/uploads/2022/06/12-2021-Auditor-Opinion-French.pdf)\n\n2020\n\n#### 2020\n\n2020 Interim Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/1-2020-Interim-Report-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/2-2020-Interim-Report-French.pdf)\n\n2020 Consolidated Figures: [English](https://mdxhealth.com/wp-content/uploads/2022/06/3-2020-Consolidated-Figures-English.pdf)\n\n2020 Board Report on Financial Statements: [English](https://mdxhealth.com/wp-content/uploads/2022/06/4-2020-Board-Report-on-Financial-Statements-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/5-2020-Board-Report-on-Financial-Statements-French.pdf)\n\n2020 Full Non-consolidated Statutory Accounts: [Français](https://mdxhealth.com/wp-content/uploads/2022/06/6-2020-Full-Non-consolidated-Statutory-Accounts-French.pdf)\n\n2020 Annual Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/7-2020-Annual-Report-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/8-2020-Annual-Report-French.pdf)\n\n2020 Auditor Opinion: [English](https://mdxhealth.com/wp-content/uploads/2022/06/9-2020-Auditor-Opinion-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/10-2020-Auditor-Opinion-French.pdf)\n\n2019\n\n#### 2019\n\n2019 Interim Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/1-2019-Interim-Report-EN.pdf) | [Français](https://mdxhealth.com/wp-content/uploads/2022/06/2-2019-Interim-Report-FR.pdf)\n\n2019 Consolidated Figures: [English](https://mdxhealth.com/wp-content/uploads/2022/06/3-2019-Consolidated-Figures-EN.pdf)\n\n2019 Board Report on Financial Statements: [English](https://mdxhealth.com/wp-content/uploads/2022/06/4-2019-Board-Report-on-Financial-Statements-EN.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/5-2019-Board-Report-on-Financial-Statements-FR.pdf)\n\n2019 Full Non-consolidated Statutory Accounts: [Français](https://mdxhealth.com/wp-content/uploads/2022/06/6-2019-Full-Non-consolidated-Statutory-Accounts-French.pdf)\n\n2019 Annual Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/7-2019-Annual-Report-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/8-2019-Annual-Report-French.pdf)\n\n2019 Auditor Opinion: [English](https://mdxhealth.com/wp-content/uploads/2022/06/9-2019-Auditor-Opinion-English.pdf) I [Français](https://mdxhealth.com/wp-content/uploads/2022/06/10-2019-Auditor-Opinion-French.pdf)\n\n2018\n\n#### 2018\n\n2018 Interim Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/1-2018-Interim-Report-English.pdf) | [Français](https://mdxhealth.com/wp-content/uploads/2022/06/2-2018-Interim-Report-French.pdf)\n\n2018 Consolidated Figures: [English](https://mdxhealth.com/wp-content/uploads/2022/06/3-2018-Consolidated-Figures-English.pdf)\n\n2018 Board Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/4-2018-Board-Report-Enlgish.pdf)\n\n2018 Full non consolidated statutory Accounts: [Français](https://mdxhealth.com/wp-content/uploads/2022/06/5-2018-Full-non-consolidated-statutory-Accounts-French.pdf)\n\n2018 Annual Report: [English](https://mdxhealth.com/wp-content/uploads/2022/06/6-2018-Annual-Report-English.pdf) | [Français](https://mdxhealth.com/wp-content/uploads/2022/06/7-2018-Annual-Report-French.pdf)\n\n2018 Auditor Opinion: [English](https://mdxhealth.com/wp-content/uploads/2022/06/8-2018-Auditor-Opinion-English.pdf) | [Français](https://mdxhealth.com/wp-content/uploads/2022/06/9-2018-Auditor-Opinion-French.pdf)\n\n### SEC Filings\n\n### Investor Relations Contact\n\nFor all investor related questions please call or email:\n\nLifeSci Advisor (PR & IR)\n\n**US: +1.949.271.9223****ir@mdxhealth.com**\n\n[ ![](/wp-content/uploads/2022/04/MDxHealth-Logo_Full-Color_KO_RGB-1.png) ](https://mdxhealth.com)\n\nToll Free: (866) 259-5644 Email: info@mdxhealth.com\n\n[ Facebook ](https://www.facebook.com/mdxhealth/) [ Twitter ](https://twitter.com/mdxhealth?s=11&t=RI_iHL03YQlKMvkiHxV93g) [ Linkedin ](https://www.linkedin.com/company/1344641/admin/feed/posts/)\n\n###### Our Company\n\n  * [ About  ](https://mdxhealth.com/about/)\n  * [ Science ](https://mdxhealth.com/science/)\n  * [ Careers ](https://mdxhealth.com/careers/)\n  * [ News ](https://mdxhealth.com/press-releases-events/)\n  * [ Contact Us ](https://mdxhealth.com/contact-us/)\n  * [ Connect with a rep ](https://mdxhealth.com/connect/)\n  * [ Xpert One Support ](https://mdxhealth.com/xpert-one/)\n\n\n\n###### Tests\n\nFor Physicians\n\n  * [ Select mdx ](https://mdxhealth.com/select-mdx-for-physicians/)\n  * [ Confirm mdx  ](https://mdxhealth.com/confirm-mdx-for-physicians/)\n  * [ Genomic Prostate Score ](https://mdxhealth.com/gps-physician/)\n  * [ Resolve mdx  ](https://mdxhealth.com/resolve-mdx-for-physicians/)\n  * [ Physician Portal ](https://mdxhealthsecure.com)\n  * [ Report Access ](https://mdxhealth.com/securemdx/)\n  * [ Order Supplies ](https://mdxhealth.com/testkits/)\n  * [ FedEx Pick Up ](https://mdxhealth.com/fedex/)\n\n\n\nFor Patients\n\n  * [ Select mdx ](https://mdxhealth.com/select-mdx-for-patients/)\n  * [ Confirm mdx ](https://mdxhealth.com/confirm-mdx-for-patients/)\n  * [ Genomic Prostate Score ](https://mdxhealth.com/gps-patient/)\n  * [ Resolve mdx ](https://mdxhealth.com/resolve-mdx-for-patients/)\n  * [ Pay My Bill ](https://mdxhealth.com/paymybill/)\n\n\n\n###### Investors\n\n  * [ Financials ](https://mdxhealth.com/financials/)\n  * [ Shareholder Information ](https://mdxhealth.com/shareholder-information/)\n  * [ Transition to Nasdaq ](https://mdxhealth.com/proposed-transition-to-a-single-listing-on-nasdaq/)\n  * [ Analyst Coverage ](https://mdxhealth.com/analyst-coverage/)\n  * [ Presentations & Events ](https://mdxhealth.com/presentations-events/)\n  * [ Press Releases  ](https://mdxhealth.com/press-releases-events/)\n\n\n\n#### Shadowbox User Guides for download\n\n  * [Clinician User Guide](/wp-content/uploads/2024/10/SB-MKT-SHADOWBOX-IRIS-USER-GUIDE-2024.pdf)\n  * [IRIS Update Prompts Guide](/wp-content/uploads/2024/10/SB-MKT-SHADOWBOX-IRIS-UPDATE-PROMPTS-FOR-INSTALL-2024.pdf)\n  * [IRIS Install (with login automatically selected) Guide](/wp-content/uploads/2024/10/SB-MKT-SHADOWBOX-IRIS-INSTALL-WITH-LOGIN-AUTOMATICALLY-SELECTED-2024.pdf)\n\n\n\nCLOSE \n\n### How to Order Resolve mdx\n\n  1. To order Resolve mdx urine transport kits or test requisition forms: [Order Supplies Online](https://mdxhealthdotcom-dev.azurewebsites.nettestkits/) Call: 866.259.5644 Email: client.services@mdxhealth.com\n  2. Once urine transport kits are received, complete the Resolve mdx’s test requisition form in its entirety.\n  3. Carefully follow the steps in the enclosed Instructions For Use to collect the urine specimen.\n  4. Send completed test request form along with the sealed urine transportation kit to: 7000 Preston Road, Suite 1500, Plano, TX 75024\n\n\n\n[Schedule FedEx Pick Up](https://mdxhealthdotcom-dev.azurewebsites.netfedex/)\n\nView and Download [Resolve mdx Test Requisition Form (TRF)](/wp-content/uploads/2024/10/PL-FORM-0095-R06-Resolve-mdx-Test-Requisition-Form-for-UTI-and-STI-FNL.pdf) View and Download [Resolve mdx Specimen Collection and Shipping Instructions](/wp-content/uploads/2022/08/Resolve-mdx-Specimen-Collection-and-Shipping-Instructions.pdf) View and Download Resolve mdx [Specimen Requirements and Patient Eligibility](/wp-content/uploads/2022/08/Resolve-mdx-Specimen-Requirements.pdf)\n\nCLOSE \n\n# Licensure & Accreditations\n\n### United States:\n\n**Irvine, CA Laboratory**\n\n[College of American Pathologists (CAP) Accreditation](/wp-content/uploads/2024/06/CAP-2024.pdf)\n\n[Centers for Medicare & Medicaid Services Certificate of Accreditation (CLIA)](/wp-content/uploads/2022/06/Certificate-of-Accreditation-Ruben-Gamez.pdf)\n\n[New York State Department of Health License](/wp-content/uploads/2024/07/New-York-State-Clinical-Laboratory-Permit-exp-2025JUN30.pdf)\n\n[State of California Department of Public Health Clinical Laboratory License](/wp-content/uploads/2024/01/CDPH-License-Certificate_CDF-00341675-exp-13FEB2025.pdf)\n\n[State of Maryland License](/wp-content/uploads/2023/05/Maryland-State-License-Irvine.pdf)\n\n[State of Pennsylvania License](/wp-content/uploads/2022/06/PA-Irvine-Laboratory-Permit-EXP-08-25.pdf)\n\n[State of Rhode Island License](/wp-content/uploads/2024/02/Rhode-Island-License.pdf)\n\n[Health Canada License](/wp-content/uploads/2022/06/Health-Canada-Medical-Device-Establishment-License-scaled-2.jpg)\n\n**Plano, Texas Laboratory**\n\n[College of American Pathologists (CAP) Accreditation ](/wp-content/uploads/2023/03/PLANO-CAP_CERT.pdf)\n\n[Centers for Medicare & Medicaid Services Certificate of Accreditation (CLIA)](/wp-content/uploads/2023/05/CLIA_LICENSE_2023_PLANO.pdf)\n\n[State of California Department of Public Health Clinical Laboratory ](/wp-content/uploads/2024/10/CA-License-Certificate_CDS-90008054_Exp-2025OCT24.pdf)\n\n[State of Maryland License](/wp-content/uploads/2023/04/MARYLAND_STATE_LICENSE.pdf)\n\n[State of Pennsylvania License](/wp-content/uploads/2022/06/PA-Plano-Laboratory-Permit-EXP-08-25.pdf)\n\n[State of Rhode Island License ](/wp-content/uploads/2023/05/RHODE_ISLAND_LICENSE.pdf)\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/hardison.png)\n\n## Don Hardison\n\n### Independent Director\n\nMr. Hardison was most recently the President and Chief Executive Officer, and served on the board of directors, of Biotheranostics, Inc., a molecular diagnostic company focused on oncology, from February 2017 until it was acquired by Hologic, Inc. in February 2021. From April 2010 to March 2016, Mr. Hardison was the President and Chief Executive Officer of Good Start Genetics, a molecular genetic testing and information company. For more than 20 years prior to that, Mr. Hardison held various executive and senior management positions at companies including Laboratory Corporation of America (LabCorp), Exact Sciences Corporation, Quest Diagnostics Inc., and Smith Kline Beecham Corporation. He currently serves as an independent director on the boards of directors of Stemina Biomarker Discovery, Inc., Seventh Sense Biosystems, BioPorto, Inc. and IQuity, Inc. He also formerly served on the board of directors of Exact Sciences Corporation (Nasdaq: EXAS) from May 2000, through its initial public offering in February 2001, until August 2007. Mr. Hardison received his Bachelor of Arts degree, in political science, from the University of North Carolina, Chapel Hill.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.net/wp-content/uploads/2024/07/SSiegel.png)\n\n## Sanford J. Siegel, M.D. \n\n### Independent Director\n\nDr. Siegel has more the 45 years of experience as a practicing urologist and over 35 years of executive leadership experience. Dr. Siegel currently serves as the Chairman of the Board of United Urology Group, having previously served as its Chief Executive Officer. United Urology Group, which was acquired by Audax in 2016, was formed under Dr. Siegel’s leadership and is one of the nation’s leading urology networks. Previously, Dr. Siegel served as the President and Chief Executive Officer of Chesapeake Urology Associates, which he founded in 1999. Dr. Siegel is a founding member of the Large Urology Group Practice Association (LUGPA), which was formed in 2008. He was a board member of the Urology Care Foundation (UCF) from 2016 until 2023 and The Urology Times. As a recognized leader in the field of medicine, Dr. Siegel has been honored with official citations for outstanding commitment and leadership from both the Governor and the General Assembly of Maryland. Dr. Siegel earned his medical degree from the University of Maryland School of Medicine and completed his specialty training in urology at Temple University Hospital in Philadelphia. He has been certified by the American Board of Urology and as Fellow of the American College of Surgeons.\n\nCLOSE \n\n### How to Order Select mdx\n\n##### United States\n\n  1. To order Select mdx urine transport kits or test requisition forms: [Order Supplies Online](/testkits/) Call: 866.259.5644 Email: cs@mdxhealth.com\n  2. Once urine transport kits are received, complete the Select mdx’s test requisition form in its entirety.\n  3. Carefully follow the steps in the enclosed Instructions For Use to collect the urine specimen.\n  4. Send completed test request form along with the sealed urine transportation kit to: 15279 Alton Parkway, Suite 100, Irvine, CA 92618\n\n\n\n[Schedule FedEx Pick Up](/fedex/) View and Download [Select mdx Test Requisition Form (TRF)](/wp-content/uploads/2024/01/Select-mdx-Test-Requisition-Form7497-2.pdf) View and Download [Urine Collection and Preparation Instructions](/wp-content/uploads/2024/01/Urine-Collection-and-Transportation-Instructions-Brochure.pdf) View and Download [Specimen Requirements and Patient Eligibility](/wp-content/uploads/2024/01/Select-mdx-Specimen-Requirements.pdf)\n\n##### Europe\n\n  1. To order Select mdx urine transportation kits contact MDxHealth at +31 (0) 88 327 2727 or email clientservices.eu@mdxhealth.com.\n  2. Once urine transportation kits are received, please fill out the Select mdx test request form in its entirety.\n  3. Carefully follow the instructions for use to collect the urine specimen.\n  4. Place the completed test request form and urine specimen inside the Select mdx urine transportation kit. Follow the instructions on the kit to contact your local DHL office and arrange the return shipment to the mdxhealth laboratory.\n\n\n\nView and Download Test Request Form [DE](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_DE-v7_PRINT.pdf) | [EN](/wp-content/uploads/2022/06/MDX500-Requisition-form_EN-v4-2.pdf) | [ES](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_ES-v6-FER_elec.pdf) | [FR](/wp-content/uploads/2022/06/MDX500-Requisition-form_FR-v2.pdf) | [IT](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_IT-v9_PRINT.pdf) | [NL](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_NL-v7_PRINT.pdf) | [PL](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_PL-v4.pdf) View and Download [Select mdx Instructions for Use](/wp-content/uploads/2022/06/MDX521-SelectMDx-IFU-Booklet-v5.pdf) View and Download [UrNCollect Instructions for Use ](/wp-content/uploads/2022/06/MDX514-UrNCollect-v3.pdf)\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/regine-Slagmulder.png)\n\n## Regine Slagmulder\n\n### Independent Director, representing Regine Slagmulder BV\n\n**_Dr. Regine Slagmulder_** , Independent Non-Executive Director of our Company, is a full professor in management accounting & control at Vlerick Business School, a visiting professor of accounting & control at INSEAD, and the Knowledge & Academic Director (a.i.) at Guberna, the Belgian Institute for Directors. Previously, she worked as a strategy practice consultant at McKinsey & Company. She also previously worked as a professor of management accounting at INSEAD and at the University of Tilburg. She serves as an independent director and member of the audit committee on the board of the investment company Quest for Growth (since 2011) and as an independent director and chair of the audit committee of Ekopak (since 2021), both listed on Euronext. Dr. Slagmulder graduated in civil electrotechnical engineering and industrial management from the University of Gent, after which she received a management doctorate at Vlerick Business School. As part of her research activities, she was a research fellow attached to INSEAD, Boston University (USA) and the P. Drucker Graduate Management Center at Claremont University (USA). She is an INSEAD certified director (IDP-C).\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Hilde-Windels.png)\n\n## Hilde Windels\n\n### Independent Director, representing Hilde Windels BVBA\n\n**_Hilde Windels_** , Independent Non-Executive Director of our Company, has over 20 years of experience in the biotechnology sector with a track record of building and structuring organizations, fundraising, M&A, public capital markets and corporate strategies. Currently, Mrs. Windels serves as a board member at PHAXIAM Therapeutics, GIMV NV, MCROPHYT SA, and Celyad. Previously, she served as CEO of immunodiagnostic company Antelope Dx BV, and as CEO ad interim and Deputy CEO of Biocartis from September 2015 until September 2017 and as CFO of Biocartis from 2011 until September 2015. Mrs. Windels has also worked as independent CFO for several private biotech companies and from 1999 to 2008 she was CFO of Devgen. In the past, she also served on the boards of Devgen, Biocartis, Ablynx, VIB and FlandersBio. Mrs. Windels holds a Masters in Economics (commercial engineer) from the University of Leuven, Belgium.\n\nCLOSE \n\n### How to Order Confirm mdx\n\n##### Physician Office\n\nTo Order Pre-printed Test Requisition Forms:\n\n[Order Supplies Online](https://mdxhealthdotcom-dev.azurewebsites.nettestkits/) Call: 866.259.5644 Email: cs@mdxhealth.com\n\nView and Download [Confirm mdx Test Requisition Form (TRF)](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2024/01/Confirm-mdx-Test-Requisition-Form.pdf) View and Download [Confirm mdxSpecimen Requirements and Patient Eligibility](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2024/02/Confirm-mdx-Specimen-Requirements.pdf)\n\n  1. Complete the Confirm mdx test requisition form (TRF). Include patient demographics, copy of insurance card(s), and pathology report.\n  2. Forward the completed Confirm mdx TRF to MDxHealth Client Services. Mdxhealth will contact the pathology laboratory and request specimens as indicated on the TRF in “Section 7 – ConfirmMDx Specimen Request”.\n\n\n\n##### Pathology Laboratory\n\nTo order Confirm mdx Tissue Transport Kits:\n\n[Order Supplies Online](https://mdxhealthdotcom-dev.azurewebsites.netorder-supplies/) Call: 866.259.5644 Email: client.services@mdxhealth.com\n\n  1. Pathology lab will include specimens, completed test requisition form (including copies of patient demographics, insurance, and pathology report) inside the transportation kit.\n  2. Ship to: mdxhealth, 15279 Alton Parkway, Suite 100, Irvine, CA 92618.\n\n\n\n[Schedule FedEx Pick Up](https://mdxhealthdotcom-dev.azurewebsites.netfedex/)\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2023/11/Jason-Poole.png)\n\n## Jason Poole\n\n### Chief Scientific Officer\n\nDr. Poole has more than 25 years of research experience and specializes in the development of high complexity diagnostic testing for use in human health and disease. His expertise lies in product development using advanced technologies such as Next Generation Sequencing, qPCR, and nucleic acid sample preparation. Mr. Poole was most recently the VP of R&D at Active Motif, Inc. he spear-headed the development of products in the epigenetic research space including DNA methylation, chromatin modifications and epigenetic specific antibody development. Dr. Poole received his M.S. in Molecular Endocrinology from Northwestern University and his Ph.D. in Molecular Genetics from the University of Illinois College of Medicine in Chicago, IL.\n\nCLOSE \n\n## Tailored reports that connect insights for the next step in care\n\n### Low-Risk Report\n\n**The low-risk report integrates clinical, pathological, and genomic insights into actionable information on active surveillance 1**\n\n  * Predicts tumor aggressiveness to help inform the decision between active surveillance and immediate treatment\n  * Focuses on an actionable endpoint adverse pathology, with the most comprehensive definition\n  * The Genomic Prostate Score(GPS) test is the only commercially available test to provide all these endpoints: \n    * Risk of high-grade (≥Grade Group 3) disease\n    * Risk of pT3a+ disease\n    * Risk of metastasis within 10 years\n    * Risk of PCa-specific death within 10 years\n\n\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/212-low-risk-report-1024x627.png)\n\n##### [DOWNLOAD LOW-RISK SAMPLE REPORT](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2023/07/MDX.Brochures.GPS_.LowRiskReport_r2-SAMPLE.pdf)\n\n### High-Risk Report\n\n**The high-risk report provides a defined cut point with actionable information on treatment intensity 2**\n\n  * Helps determine the right level of treatment\n  * Clearly stratifies patient risk into lower or higher likelihood of disease progression\n  * Simple bell curve helps you and your patient understand the patient’s risk relative to other patients of same clinical risk group\n\n\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/211and212highrisk-1024x380.png)\n\n##### [DOWNLOAD HIGH-RISK SAMPLE REPORT](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2023/07/MDX.Brochures.GPS_.HighRiskReport_r3-SAMPLE.pdf)\n\nReferences:\n\n  1. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.  _Eur Urol_. 2014;66(3):550-560.\n  2. Cullen J, Kuo HC, Shan J, Lu R, Aboushwareb T, Van Den Eeden SK. The 17-gene genomic prostate score test as a predictor of outcomes in men with unfavorable intermediate risk prostate cancer. _Urology_. 2020;143:103-111.\n\n\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Mike-M.-Headshot-website.png)\n\n## Michael K. McGarrity\n\n### Chief Executive Officer, Director\n\nMr. McGarrity has more than 25 years of experience in the healthcare industry with a unique combination of device, diagnostics and biotechnology experience. Mr. McGarrity was most recently the CEO of Sterilis Medical. Prior to Sterilis Mr. McGarrity was the CEO of Nanosphere (NASDAQ: NSPH), a nanotechnology-based molecular diagnostics company, where he engineered an operational and strategic turnaround that resulted in its successful sale to Luminex (NASDAQ: LMNX) in 2016. Prior to Nanosphere, Mr. McGarrity spent 13 years at Stryker Corporation (NYSE: SYK) where he served in leadership roles in sales and marketing and led Stryker into new growth markets such as post-operative pain management, surgical fluid waste management and interventional pain management. Mr. McGarrity also had executive general management responsibility for a newly created business unit focused on interventional spine pain management. Mr. McGarrity received a Bachelor of Arts degree from the University of Notre Dame and began his career in commercial banking.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Ron-K-headshot-website.png)\n\n## Ron Kalfus\n\n### Chief Financial Officer\n\nMr. Kalfus has over 20 years of leadership experience in both public and private companies within diagnostics/biotech and other sectors, and brings extensive knowledge in financial operations, management, and strategic transactions. Mr. Kalfus joined mdxhealth from Rosetta Genomics, where he helped lead efforts to reposition the company for commercial success with its oncology diagnostic products, and raised over $60 million in capital to fund these efforts. Prior to Rosetta, Mr. Kalfus served as the CFO and Treasurer of MabCure, a Belgium-based publicly-traded biotechnology startup in the field of early cancer detection using antibodies. Mr. Kalfus received his Master’s degree in Accounting from Fairleigh Dickinson University and his Bachelor’s degree in Finance from the University of Georgia. Mr. Kalfus is a Certified Public Accountant, licensed in the State of New Jersey.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Valiance-Jan-Pensaert.png)\n\n## Mr. Jan Pensaert\n\n### Director, representing Valiance Advisors LLP\n\nJan Pensaert is the Founding Managing Partner of Valiance. He brings over 20 years of experience in growth investing. He leads the Investment Committee for the Valiance Funds and is responsible for all aspects of the Funds’ investment processes. Jan currently serves on the Board of several Valiance entities funds and portfolio companies including MDxHealth, JenaValve, NeoSync, and 4Tech. Prior to founding Valiance, Jan was CEO of La Fayette, where during his tenure the La Fayette Funds increased in AUM from $750 million to $5.5 billion. Before that, he was responsible for the Permal Group’s European-based investment management and research activities, and prior to that, he worked at Lazard in Corporate Finance M&A. Jan holds a BA in Business Economics from Gent University in Belgium, and a Masters in Banking & Finance from the University of Aix-Marseille, France.\n\nCLOSE \n\n**Analytical Validity**  \n---  \n· Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, et al. Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 2013;14: 690.  \n**Economic Utility**  \n· Albala D, Kemeter MJ, Febbo PG, Lu R, John V, Stoy D et al. Health economic impact and prospective clinical utility of Oncotype DX Genomic Prostate Score. Rev Urol. 2016; 18(3):123-132.  \n**Clinical Utility**  \n· Albala D, Kemeter MJ, Febbo PG, Lu R, John V, Stoy D et al. Health economic impact and prospective clinical utility of Oncotype DX Genomic Prostate Score. Rev Urol. 2016; 18(3):123-132. · Dall’Era MA, Maddala T, Polychronopoulos L, Gallagher JR, Febbo PG, and Denes BS. Utility of the Oncotype DX® Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A Retrospective Chart Review Analysis. Urology Practice. 2015;2(6):343-348. · Eure G, Germany R, Given R, Lu R, Shnidel AW, Rothney M, et al. Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort. Urology. 2017;107:67-75. · Lynch JA, Rothney MP, Salup RR, Ercole CE, Mathur SC, Duchene DA, et al. Improving Risk Stratification Among Veterans Diagnosed With Prostate Cancer: Impact of the 17-Gene Genomic Prostate Score Assay. Am J Manag Care. 2017;24(1 Suppl):S4-S10. · Murphy AB, Abern MR, Liu L, Wang H, Hollowell CMP, Sharifi R, Vidal P, et al. Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial. J Clin Oncol. 2021;39(15):1660-1670.  \n**Clinical Validity**  \n· Brooks MA, Thomas L, Magi-Galluzzi C, Li J, Crager MR, Lu R et al. GPS assay association with long-term cancer outcomes: twenty-year risk of distant metastasis and prostate cancer-specific mortality. JCO Precis Oncol. 2021;5:PO.20.00325. · Brooks MA, Thomas L, Magi-Galluzzi C, Li J, Crager MR, Lu R et al. Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy. Urol Oncol. 2022;40(3):104.e1-104.e7. · Covas Moschovas M, Chew C, Bhat S, Sandri M, Rogers T, Dell’Oglio P, et al. Association Between Oncotype DX Genomic Prostate Score and Adverse Tumor Pathology After Radical Prostatectomy. Eur Urol Focus. 2022;8(2):418-424. · Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol. 2015;69(1):123-131. · Cullen J, Kuo HC, Shan J, Aboushwareb T, and Van Den Eeden SK. The 17-gene genomic prostate score test as a predictor of outcomes in men with unfavorable intermediate-risk prostate cancer. Urology. 2020;143:103-111. · Cullen J, Lynch JA, Klein EA, Van Den Eeden SK, Carroll PR, Mohler JL, et al. Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer. J Urol. 2021;205(4):1047-1054. · Eggener S, Karsh LI, Richardson T, Shindel AW, Lu R, Rosenberg A et al. A 17-gene panel for prediction of adverse prostate cancer pathologic features: prospective clinical validation and utility. Urology. 2019;126:76-82. · Helfand BT, Paterakos M, Wang CH, Talaty P, Abran J, Bennett J et al. The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer. PLoS One. 2022;17(9):e0273782. · Helfand BT, Paterakos M, Wang CH, Talaty P, Abran J, Bennett J et al. The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer. PLoS One. 2022;17(9):e0273782. · Janes JL, Boyer MJ, Bennett JP, Thomas VM, De Hoedt AM, Edwards DK, et al. Prognostic for outcomes after primary external beam radiation therapy in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2023;115(1):120-131. · Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. _Eur Urol._ 2014;66(3):550–560. · Kornberg Z, Cowan JE, Westphalen AC, Cooperberg MR, Chan JM, Zhao S, et al. Genomic prostate score, PI-RADS version 2 and progression in men with prostate cancer on active surveillance. J Urol. 2019;201:300-307. · Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg M, et al. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate-risk prostate cancer. PLoS One. 2017;12(10):e0185535. · Lin D, Zheng Y, McKenney JK, Brown MD, Lu R, Crager M, et al. 17-gene genomic prostate score test results in the Canary Prostate Active Surveillance Study (PASS) cohort. J Clin Oncol. 2020;38(14):1549-1557. · Magi-Galluzzi C, Isharwal S, Falzarano SM, Tsiatis A, Dee A, Maddala T et al. The 17-gene genomic prostate score assay predicts outcomes after radical prostatectomy independent of PTEN status. Urology. 2018;121:132-138. · Murphy AB, Carbunaru S, Nettey OS, Gornbein C, Dixon MA, Macias V, et al. A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men. Urology. 2020; 142:166-173. · Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk Jr AE et al. A 17-gene Genomic Prostate Score assay provides independent information on adverse pathology in the setting of combined multiparametric magnetic resonance fusion-targeted and systematic prostate biopsy. J Urol. 2018;200(3):564-572. · Van Den Eeden SK, Lu R, Zhang N, Queensberry Jr CP, Shan J, Han JS, et al. A biopsy-based 17-gene genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease. Eur Urol. 2017;73(1):129-138.  \n**Meta-analysis**  \n· Bennett J, Flake D. Patient-specific meta-analysis of three clinical validation studies to predict risk of distant metastasis and prostate cancer death in higher risk prostate cancer patients after definitive radiotherapy of radical prostatectomy. EXAS Internal Data 2022. · Brand TC, Zhang N, Crager MR, Maddala T, Dee A, Sesterhenn IA, et al. Patient-specific meta-analysis of 2 clinical validation studies to predict pathologic outcomes in prostate cancer using the 17-gene Genomic Prostate Score. Urology. 2016;89:69-75.  \n  \nCLOSE \n\n### Insurance & Billing Policy\n\nWe are committed to making our tests accessible and affordable to your patients. Mdxhealth’s Patient First Promise Program was created to assist patients throughout the billing process. We will work directly with each patient to ensure their complete satisfaction.\n\n##### Dedicated Patient Advocate Team\n\n  * Our specially trained Patient Advocates are ready to answer patients’ questions about insurance coverage and personalized payment options.\n  * Toll Free: 866-259-7001, Monday – Friday, 6:00AM – 4:30PM PT\n  * Email: patientfirst@mdxhealth.com\n\n\n\n##### Personalized Payment Options\n\n  * Interest-Free Payment Plan\n  * Financial Assistance Program\n\n\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Koen-Hoffman.png)\n\n## Mr. Koen Hoffman\n\n### Chairman and Independent Director, representing Ahok BV\n\nKoen Hoffman has served as Independent Chairman of the Board of Directors of Fagron NV since May 8, 2017. He obtained a Master in Applied Economics at the University of Ghent in 1990 and a Master in Business Administration at Vlerick Business School in Ghent in 1991. Mr. Hoffman was appointed Chief Executive Officer of Value Square in August 2016. Prior to joining Value Square, he was Chief Executive Officer of KBC Securities, member of the supervisory board of Patria Securities and member of the board of directors of Omnia Travel Belgium. He started his career at the corporate finance department of KBC Bank in 1992.\n\nCLOSE \n\n## Understanding your GPS results\n\n### Deciding the most appropriate course of treatment for your prostate cancer is important. Your GPS result may help.\n\nThe GPS test measures prostate cancer gene levels to assess how aggressively your cancer will grow or spread. Since certain genes influence this more than others, knowing which ones are active in your tumor helps determine your personal GPS result.\n\n### Your personal GPS result and risk category\n\nYour score is based on a scale of 0-100. Your genomic risk will indicate how your tumor behaves and can help you and your doctor determine the most appropriate course of treatment.\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/211and212highrisk-1024x380.png)\n\n### Current and future risk\n\nThese results can predict both your chance of:\n\n  1. Dying from prostate cancer and\n  2. Your cancer spreading (metastasis) in the next 10 years\n\n\n\n### Personalized assessment for individualized treatment\n\nThe GPS test provides a personalized assessment of how aggressive your prostate cancer is, helping you and your doctor discuss next steps with confidence.\n\n[**DOWNLOAD SAMPLE REPORT OVERVIEW FOR CLINICALLY HIGH-RISK PROSTATE CANCER**](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/Clinically-High-Risk-Report-Overview-PDF.pdf)\n\nCLOSE \n\n## Understand your test results\n\n### Deciding between active surveillance and immediate treatment for your prostate cancer is important. Your GPS result may help.\n\nThe GPS test measures prostate cancer gene levels to assess how aggressively your cancer will grow or spread. Since certain genes influence this more than others, knowing which ones are active in your tumor helps determine your personal GPS result.\n\n### Your personal GPS result\n\nThe bell curve illustrates where your GPS result falls in relation to the GPS results of other men in the same risk category.\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/212-low-risk-report-1024x627.png)\n\n### Current and future risk\n\nThese results can predict both your chance of:\n\n  1. Your cancer spreading (metastasis) and\n  2. Dying from prostate cancer in the next 10 years\n\n\n\n## Personalized assessment for individualized treatment\n\n### Additional pathology endpoints (provided for men with Gleason score 3+4)\n\n  1. **Adverse Pathology** predicts the probability your doctor would find more aggressive disease than expected from your biopsy. This helps your doctor know if you are a candidate for active surveillance or if immediate treatment is most appropriate for you.\n  2. **High-Grade Disease** shows the likelihood that cancer cells within your tumor are abnormal when compared to typical cells.\n  3. **Non–Organ-Confined Disease** indicates the likelihood that your cancer has already spread outside your prostate.\n\n\n\nThe GPS test provides a personalized assessment of how aggressive your prostate cancer is, helping you and your doctor discuss next steps with confidence.\n\n[**DOWNLOAD SAMPLE REPORT OVERVIEW FOR CLINICALLY LOW-RISK PROSTATE CANCER**](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/Clinically-Low-Risk-Report-Overview-PDF.pdf)\n\nCLOSE \n\n### Test Cancellation Policy\n\nMdxhealth will honor test cancellation requests any time prior to the start of the analytical testing phase. Test cancellation requests must be submitted from the person authorized to cancel a test, following the instructions below:\n\nContact Client Services at **866-259-5644** for test cancellation.\n\nA Test Cancellation Form will be sent to the authorized person for signature.\n\nReturn the completed and signed Test Cancellation Form by fax to mdxhealth **949-788-0014**.\n\nIf the cancellation request is received after the specimen has entered in the analytical testing phase, the request cannot be honored and the usual test charge will be assessed.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Eric-Bednarski.png)\n\n## Eric Bednarski\n\n### Director\n\nDr. Bednarski currently serves as a Partner of MVM Partners LLP. Before joining MVM in 2008, he was a Partner at Advent Healthcare Ventures and a Principal at Advent International Corporation. Prior to Advent, he was a Director in the Corporate Finance Group of Silicon Valley Bank. Dr. Bednarski has a B.S. degree in Neural Science from Brown University and a Ph.D. in Biological Sciences from the University of California, Irvine.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Mike-M-Headhsot-BW.png)\n\n## Michael K. McGarrity\n\n### Chief Executive Officer, Director\n\nMr. McGarrity has more than 25 years of experience in the healthcare industry with a unique combination of device, diagnostics and biotechnology experience. Michael was most recently the CEO of Sterilis Medical. Prior to Sterilis Michael was the CEO of Nanosphere (NASDAQ: NSPH), a nanotechnology-based molecular diagnostics company, where he engineered an operational and strategic turnaround that resulted in its successful sale to Luminex (NASDAQ: LMNX) in 2016. Prior to Nanosphere, McGarrity spent 13 years at Stryker Corporation (NYSE: SYK). McGarrity served in leadership roles in sales and marketing and led Stryker into new growth markets such as post-operative pain management, surgical fluid waste management and interventional pain management. He also had executive general management responsibility for a newly created business unit focused on interventional spine pain management. Michael received a Bachelor of Arts degree from the University of Notre Dame and began his career in commercial banking.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/John-B-headshot-website.png)\n\n## John Bellano\n\n### Chief Commercial Officer\n\nMr. Bellano has more than 25 years of experience in the Healthcare Industry. Mr. Bellano started his career in Pharmaceuticals and transitioned to molecular diagnostics where he has spent the past 20 years of his career. Most recently the Chief Commercial Officer of Sterilis Solutions Prior to Sterilis Solutions he served as the commercial leader for Pharmacogenomic companies Assurex Health and AltheaDx. While at Assurex Health (Myriad Genetics) revenue grew from $700k to a run rate of $100 Million during his 5 year span with the organization.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Mimi-Reyes-headshot_.png)\n\n## Miriam Reyes\n\n### Executive Vice President of Operations\n\nMiriam Reyes has 25 years of experience in life science and laboratory operations, and R&D. She has served as Operations Leader at MDxHealth since its US inception in 2011. Prior to MDxHealth, Mrs. Reyes was Director of Laboratory Operations at Agendia where she established/built and led the CLIA lab for the Agendia’s FDA cleared MammaPrint breast cancer test. In addition to Agendia, she established laboratory operations at Combimatrix (Invitae) Molecular Diagnostics and developed commercial assays at both IBIS Biosciences and US Labs (LabCorp.).\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Joe-Sollee-Headshot.png)\n\n## Joseph Sollee\n\n### Executive Vice President of Corporate Development and General Counsel\n\nMr. Sollee has more than 20 years of experience in the healthcare industry, including senior management roles in both private and publicly listed pharmaceuticals, health information technology and molecular diagnostics companies. He has served as chief legal counsel to MDxHealth since its inception in 2003. Prior to MDxHealth, he led the Life Sciences Practice Group at the law firm of Kennedy Covington (now K&LGates) and held senior legal and management positions at TherapyEdge and Triangle Pharmaceuticals. In addition, he has practiced as a corporate attorney in the Washington D.C. legal firm Swidler & Berlin and as an investment banker at Smith Barney in New York. Mr. Sollee received a Juris Doctorate in Law and a Masters degree in International Law from Duke University, a BA degree from Harvard University, and has been awarded New York, Washington D.C. and North Carolina legal bar certifications.\n\nCLOSE \n"
        }
      ]
    },
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://mdxhealth.com/press-releases-events/",
          "content": "![logo](data:,)\n\n## This website uses cookies\n\nWe use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. You consent to our cookies if you continue to use our website.\n\nDo not sell or share my personal information\n\n[Use necessary cookies only ](#)[Allow all cookies ](#)[Show details](#)\n\n[OK](#)\n\n[Use necessary cookies only ](#)[Allow selection ](#)[Allow all cookies](#)\n\nNecessary\n\nPreferences\n\nStatistics\n\nMarketing\n\n[Show details](#)\n\n[Cookie declaration ](#)[[#IABV2SETTINGS#] ](#)[About](#)\n\n[Necessary (15)](#) [Preferences (1)](#) [Statistics (11)](#) [Marketing (32)](#) [Unclassified (7)](#)\n\nNecessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \n__RequestVerificationToken| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Helps prevent Cross-Site Request Forgery (CSRF) attacks.| Session| HTTP Cookie  \nak_bmsc| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| 1 day| HTTP Cookie  \nbm_mi| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Used in context with the website's BotManager. The BotManager detects, categorizes and compiles reports on potential bots trying to access the website.| Session| HTTP Cookie  \n_GRECAPTCHA| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| 180 days| HTTP Cookie  \nrc::a| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| Persistent| HTML Local Storage  \nrc::b| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. | Session| HTML Local Storage  \nrc::c| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. | Session| HTML Local Storage  \nrc::f| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| This cookie is used to distinguish between humans and bots. | Persistent| HTML Local Storage  \n1.gif| [Cookiebot](https://www.cookiebot.com/goto/privacy-policy/ \"Cookiebot's privacy policy\")| Used to count the number of sessions to the website, necessary for optimizing CMP product delivery. | Session| Pixel Tracker  \nCookieConsent| [Cookiebot](https://www.cookiebot.com/goto/privacy-policy/ \"Cookiebot's privacy policy\")| Stores the user's cookie consent state for the current domain| 1 year| HTTP Cookie  \nelementor| mdxhealth.com| Used in context with the website's WordPress theme. The cookie allows the website owner to implement or change the website's content in real-time.| Persistent| HTML Local Storage  \nwpEmojiSettingsSupports| mdxhealth.com| This cookie is part of a bundle of cookies which serve the purpose of content delivery and presentation. The cookies keep the correct state of font, blog/picture sliders, color themes and other website settings.| Session| HTML Local Storage  \nASP.NET_SessionId| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Preserves the visitor's session state across page requests.| Session| HTTP Cookie  \n__cf_bm| [Vimeo](https://vimeo.com/privacy \"Vimeo's privacy policy\")| This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.| 1 day| HTTP Cookie  \n_cfuvid| [Vimeo](https://vimeo.com/privacy \"Vimeo's privacy policy\")| This cookie is a part of the services provided by Cloudflare - Including load-balancing, deliverance of website content and serving DNS connection for website operators. | Session| HTTP Cookie  \n  \nPreference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nFormsWebSessionId| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| The cookie is used if the visitor has filled in personal information on a formula. This information will be filled in automatically on other formulas. This process is used to optimize visitor experience. | 30 days| HTTP Cookie  \n  \nStatistic cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nc.gif| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Collects data on the user’s navigation and behavior on the website. This is used to compile statistical reports and heatmaps for the website owner.| Session| Pixel Tracker  \ncollect| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.| Session| Pixel Tracker  \nhjActiveViewportIds| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| This cookie contains an ID string on the current session. This contains non-personal information on what subpages the visitor enters – this information is used to optimize the visitor's experience.| Persistent| HTML Local Storage  \nhjViewportId| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| Saves the user's screen size in order to adjust the size of images on the website.| Session| HTML Local Storage  \n_ga| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Registers a unique ID that is used to generate statistical data on how the visitor uses the website.| 2 years| HTTP Cookie  \n_ga_#| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used by Google Analytics to collect data on the number of times a user has visited the website as well as dates for the first and most recent visit. | 2 years| HTTP Cookie  \n_gat| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used by Google Analytics to throttle request rate| 1 day| HTTP Cookie  \n_gid| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Registers a unique ID that is used to generate statistical data on how the visitor uses the website.| 1 day| HTTP Cookie  \n_hjSession_#| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| Collects statistics on the visitor's visits to the website, such as the number of visits, average time spent on the website and what pages have been read.| 1 day| HTTP Cookie  \n_hjSessionUser_#| [Hotjar](https://www.hotjar.com/legal/policies/privacy/ \"Hotjar's privacy policy\")| Collects statistics on the visitor's visits to the website, such as the number of visits, average time spent on the website and what pages have been read.| 1 year| HTTP Cookie  \nvuid| [Vimeo](https://vimeo.com/privacy \"Vimeo's privacy policy\")| Collects data on the user's visits to the website, such as which pages have been read.| 2 years| HTTP Cookie  \n  \nMarketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nMR [x2]| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences. | 7 days| HTTP Cookie  \nMUID [x3]| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")forms.cloud.microsoft| Used widely by Microsoft as a unique user ID. The cookie enables user tracking by synchronising the ID across many Microsoft domains.| 1 year| HTTP Cookie  \nSRM_B| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Tracks the user’s interaction with the website’s search-bar-function. This data can be used to present the user with relevant products or services. | 1 year| HTTP Cookie  \nANONCHK| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Registers data on visitors from multiple visits and on multiple websites. This information is used to measure the efficiency of advertisement on websites. | 1 day| HTTP Cookie  \nSM| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Registers a unique ID that identifies the user's device during return visits across websites that use the same ad network. The ID is used to allow targeted ads.| Session| HTTP Cookie  \nNID| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 6 months| HTTP Cookie  \nGNWTracker| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Used to implement blog or article content onto the website from other websites. This implementation also allows the origin-website to track on the website. | Session| HTTP Cookie  \ntimes_to_show| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Used to determine when and where certain pop-ups on the website should be presented for the user and remember whether the user has closed these, to keep them from showing multiple times.| Persistent| HTML Local Storage  \n#-#| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTML Local Storage  \n__Secure-ROLLOUT_TOKEN| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Pending| 180 days| HTTP Cookie  \niU5q-!O9@$| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Registers a unique ID to keep statistics of what videos from YouTube the user has seen.| Session| HTML Local Storage  \nLAST_RESULT_ENTRY_KEY| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTTP Cookie  \nLogsDatabaseV2:V#||LogsRequestsStore| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Persistent| IndexedDB  \nnextId| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTTP Cookie  \nremote_sid| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Necessary for the implementation and functionality of YouTube video-content on the website. | Session| HTTP Cookie  \nrequests| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Session| HTTP Cookie  \nTESTCOOKIESENABLED| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| 1 day| HTTP Cookie  \nVISITOR_INFO1_LIVE| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Tries to estimate the users' bandwidth on pages with integrated YouTube videos.| 180 days| HTTP Cookie  \nYSC| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Registers a unique ID to keep statistics of what videos from YouTube the user has seen.| Session| HTTP Cookie  \nyt.innertube::nextId| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Registers a unique ID to keep statistics of what videos from YouTube the user has seen.| Persistent| HTML Local Storage  \nytidb::LAST_RESULT_ENTRY_KEY| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Persistent| HTML Local Storage  \nYtIdbMeta#databases| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Used to track user’s interaction with embedded content.| Persistent| IndexedDB  \nyt-remote-cast-available| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-cast-installed| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-connected-devices| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Persistent| HTML Local Storage  \nyt-remote-device-id| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Persistent| HTML Local Storage  \nyt-remote-fast-check-period| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-session-app| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \nyt-remote-session-name| [YouTube](https://business.safety.google/privacy/ \"YouTube's privacy policy\")| Stores the user's video player preferences using embedded YouTube video| Session| HTML Local Storage  \n  \nUnclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.\n\nName| Provider| Purpose| Maximum Storage Duration| Type  \n---|---|---|---|---  \nMuidSyncDomain| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Pending| Persistent| HTML Local Storage  \nMuidSyncTimestamp| [Microsoft](https://privacy.microsoft.com/en-US/privacystatement \"Microsoft's privacy policy\")| Pending| Persistent| HTML Local Storage  \nRevSpringHistory| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 1 year| HTTP Cookie  \nRevSpringRef| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 1 day| HTTP Cookie  \nRevSpringUserAlias| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| 1 year| HTTP Cookie  \nRevSpringVisit| [Google](https://business.safety.google/privacy/ \"Google's privacy policy\")| Pending| Session| HTTP Cookie  \nGNWUserSessionId| [West](http://www.globenewswire.com/Home/about/Privacy \"West's privacy policy\")| Pending| Session| HTTP Cookie  \n  \n[[#IABV2_LABEL_PURPOSES#]](#) [[#IABV2_LABEL_FEATURES#]](#) [[#IABV2_LABEL_PARTNERS#]](#)\n\n[#IABV2_BODY_PURPOSES#]\n\n[#IABV2_BODY_FEATURES#]\n\n[#IABV2_BODY_PARTNERS#]\n\nCookies are small text files that can be used by websites to make a user's experience more efficient.The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission.This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.You can at any time change or withdraw your consent from the Cookie Declaration on our website.Learn more about who we are, how you can contact us and how we process personal data in our Privacy Policy.\n\nCookie declaration last updated on 12/1/24 by [Cookiebot](https://www.cookiebot.com \"Cookiebot\")\n\n  * [ Physician Portal ](https://mdxhealthsecure.com/)\n  * [ Pay My Bill ](/paymybill/)\n\n\n\n[ ![MDxHealth Logo_Full Color_KO_RGB](/wp-content/uploads/elementor/thumbs/MDxHealth-Logo_Full-Color_KO_RGB-1-qn8ye5yd7qzmvsyx0iqzls921um9s37hndqaovfadq.png) ](https://mdxhealth.com)\n\n  * [About](https://mdxhealth.com/about/)\n\n##### About\n\n    * [ Mission ](/about/#mission)\n    * [ Leadership ](/about/#leadership)\n    * [ Licensure & Accreditations ](/about/#licensure&accreditations)\n\n    * [ Science ](/science/)\n    * [ Careers ](/careers/)\n    * [ Multimedia ](/multimedia/)\n\n    * [ Mission ](https://mdxhealth.com/about/#mission)\n    * [ Leadership ](https://mdxhealth.com/about/#leadership)\n    * [ Licensure & Accreditations ](https://mdxhealth.com/about/#licensure&accreditations)\n    * Science\n    * Careers\n    * [ Multimedia ](https://mdxhealth.com/multimedia/)\n\n  * [Tests](https://mdxhealth.com/tests/)\n\n##### Prostate Cancer \n\n###### For Physicians\n\n    * [ Select mdx ](/select-mdx-for-physicians/)\n    * [ Confirm mdx ](/confirm-mdx-for-physicians/)\n    * [ Genomic Prostate Score ](/gps-physician/)\n\n###### For Patients\n\n    * [ Select mdx ](/select-mdx-for-patients/)\n    * [ Confirm mdx ](/confirm-mdx-for-patients/)\n    * [ Genomic Prostate Score ](/gps-patient/)\n\n##### Infectious Disease\n\n###### For Physicians\n\n    * [ Resolve mdx ](/resolve-mdx-for-physicians/)\n\n###### For Patients\n\n    * [ Resolve mdx  ](/resolve-mdx-for-patients/)\n\n###### Prostate Cancer (For Physicians)\n\n    * [ Select mdx ](https://mdxhealth.com/select-mdx-for-physicians/)\n    * [ Confirm mdx ](https://mdxhealth.com/confirm-mdx-for-physicians/)\n    * [ Genomic Prostate Score ](https://mdxhealth.com/gps-physician/)\n\n###### Prostate Cancer (For Patients)\n\n    * [ Select mdx ](https://mdxhealth.com/select-mdx-for-patients/)\n    * [ Confirm mdx ](https://mdxhealth.com/confirm-mdx-for-patients/)\n    * [ Genomic Prostate Score ](https://mdxhealth.com/gps-patient/)\n\n###### Infectious Disease (For Physicians)\n\n    * [ Resolve mdx  ](https://mdxhealth.com/resolve-mdx-for-physicians/)\n\n###### Infectious Disease (For Patients)\n\n    * [ Resolve mdx  ](https://mdxhealth.com/resolve-mdx-for-patients/)\n\n  * [Investors](https://mdxhealth.com/financials/)\n\n##### Investors\n\n    * [ Financials ](/financials/)\n    * [ Shareholder Information ](/shareholder-information/)\n    * [ Transition to Nasdaq ](/proposed-transition-to-a-single-listing-on-nasdaq/)\n\n    * [ Analyst Coverage ](/analyst-coverage/)\n    * [ Presentations & Events ](/presentations-events/)\n    * [ Press Releases ](/press-releases-events/)\n\n    * [ Financials ](https://mdxhealth.com/financials/)\n    * [ Shareholder Information ](https://mdxhealth.com/shareholder-information/)\n    * [ Transition to Nasdaq ](https://mdxhealth.com/proposed-transition-to-a-single-listing-on-nasdaq/)\n    * [ Analyst Coverage ](https://mdxhealth.com/analyst-coverage/)\n    * [ Presentation & Events ](https://mdxhealth.com/presentations-events/)\n    * [ Press Releases ](https://mdxhealth.com/press-releases-events/)\n\n  * [Support](https://mdxhealth.com/xpert-one/)\n\n    * [ Xpert One Support ](/xpert-one/)\n    * [ Contact Us ](/contact-us/)\n\n\n\n\n[ ](https://mdxhealth.com)\n\nX\n\n## Press Releases\n\n##### Press Release filters\n\nYear 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014\n\nLanguage\n\n[ Reset Filters ](https://tinyurl.com/32wcnfhd)\n\n##### Sign up to receive updates from mdxhealth\n\nClick the button below to fill in your contact information and receive updates from mdxhealth. \n\n[ Receive Updates ](https://mdxhealth.com/receive-updates/)\n\n###  [ MDxHealth to Present Third Quarter 2023 Financial Results and Corporate Update on November 8 ](https://mdxhealth.com/press_release/mdxhealth-to-present-third-quarter-2023-financial-results-and-corporate-update-on-november-8-2/)\n\nNEWS RELEASE25 OCTOBER 2023, 4PM ET / 22:00 CET MDxHealth to Present Third Quarter 2023 Financial Results and Corporate Update on November 8 Company to\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-to-present-third-quarter-2023-financial-results-and-corporate-update-on-november-8-2/)\n\n###  [ Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer ](https://mdxhealth.com/press_release/mdxhealth-signs-research-collaboration-with-university-of-oxford-to-assess-the-correlation-of-the-gps-test-with-prostate-cancer-progression-following-treatment-for-localized-prostate-cancer-2/)\n\nNEWS RELEASE September 26, 2023, 5:00PM EDT / 23:00 CET Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-signs-research-collaboration-with-university-of-oxford-to-assess-the-correlation-of-the-gps-test-with-prostate-cancer-progression-following-treatment-for-localized-prostate-cancer-2/)\n\n###  [ MDxHealth annonce la réalisation de sa transition vers une cotation unique sur le Nasdaq ](https://mdxhealth.com/2023/12/18/mdxhealth-annonce-la-realisation-de-sa-transition-vers-une-cotation-unique-sur-le-nasdaq/)\n\nCOMMUNIQUÉ DE PRESSE – INFORMATION RÉGLEMENTÉE18 DECEMBRE 2023, 01:00 ET / 07:00 CET MDxHealth annonce la réalisation de sa transition vers une cotation\n\n[ Read More » ](https://mdxhealth.com/2023/12/18/mdxhealth-annonce-la-realisation-de-sa-transition-vers-une-cotation-unique-sur-le-nasdaq/)\n\n###  [ MDxHealth Announces Completion of Transition to Single Listing on Nasdaq ](https://mdxhealth.com/press_release/mdxhealth-announces-completion-of-transition-to-single-listing-on-nasdaq/)\n\nNEWS RELEASE – REGULATED INFORMATIONDECEMBER 18, 2023, 1:00 AM ET / 07:00 AM CET MDxHealth Announces Completion of Transition to Single Listing on\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-completion-of-transition-to-single-listing-on-nasdaq/)\n\n###  [ MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq ](https://mdxhealth.com/press_release/mdxhealth-announces-completion-of-mandatory-ads-exchange-and-commencement-of-transition-period-to-single-listing-on-nasdaq-2/)\n\nNEWS RELEASE – REGULATED INFORMATIONNOVEMBER 27, 2023, 1:00 am ET / 7:00 am CET MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-completion-of-mandatory-ads-exchange-and-commencement-of-transition-period-to-single-listing-on-nasdaq-2/)\n\n###  [ MDxHealth annonce la réalisation de l’échange obligatoire d’ADS et le début de la période de transition vers une cotation unique sur le Nasdaq ](https://mdxhealth.com/2023/11/27/mdxhealth-annonce-la-realisation-de-lechange-obligatoire-dads-et-le-debut-de-la-periode-de-transition-vers-une-cotation-unique-sur-le-nasdaq/)\n\nCOMMUNIQUÉ DE PRESSE – INFORMATION RÉGLEMENTÉE27 NOVEMBRE 2023, 1:00 EDT / 7:00 CET MDxHealth annonce la réalisation de l’échange obligatoire d’ADS et le début de\n\n[ Read More » ](https://mdxhealth.com/2023/11/27/mdxhealth-annonce-la-realisation-de-lechange-obligatoire-dads-et-le-debut-de-la-periode-de-transition-vers-une-cotation-unique-sur-le-nasdaq/)\n\n###  [ MDxHealth to Participate in the 35th Annual Piper Sandler Healthcare Conference ](https://mdxhealth.com/press_release/mdxhealth-to-participate-in-the-35th-annual-piper-sandler-healthcare-conference/)\n\nNEWS RELEASENovember 14, 2023, 4PM ET/ 22:00 CET MDxHealth to Participate in the 35th Annual Piper Sandler Healthcare Conference IRVINE, CA,\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-to-participate-in-the-35th-annual-piper-sandler-healthcare-conference/)\n\n###  [ MDxHealth annonce la réalisation de son regroupement d’actions, et la mise à jour des actions et des droits de vote en circulation ](https://mdxhealth.com/2023/11/13/mdxhealth-annonce-la-realisation-de-son-regroupement-dactions-et-la-mise-a-jour-des-actions-et-des-droits-de-vote-en-circulation/)\n\nCOMMUNIQUÉ DE PRESSE – INFORMATION RÉGLEMENTÉEINFORMATION PRIVILÉGIÉE13 NOVEMBRE 2023, 16:00 ET / 22:00 CET MDxHealth annonce la réalisation de son regroupement d’actions, et la mise\n\n[ Read More » ](https://mdxhealth.com/2023/11/13/mdxhealth-annonce-la-realisation-de-son-regroupement-dactions-et-la-mise-a-jour-des-actions-et-des-droits-de-vote-en-circulation/)\n\n###  [ MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rights ](https://mdxhealth.com/press_release/mdxhealth-announces-completion-of-share-consolidation-and-update-of-outstanding-shares-and-voting-rights/)\n\nNEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONNOVEMBER 13, 2023, 4:00 PM ET / 22:00 CET MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-completion-of-share-consolidation-and-update-of-outstanding-shares-and-voting-rights/)\n\n###  [ MDxHealth communique ses résultats pour le troisième trimestre et la période de neuf mois clôturée le 30 septembre 2023 ](https://mdxhealth.com/2023/11/08/mdxhealth-communique-ses-resultats-pour-le-troisieme-trimestre-et-la-periode-de-neuf-mois-cloturee-le-30-septembre-2023/)\n\nCOMMUNIQUÉ DE PRESSE — INFORMATIONS RÉGLEMENTÉES8 NOVEMBRE 2023, 16 h 00 EDT/22 h 00 CET MDxHealth communique ses résultats pour le troisième trimestre et la période de neuf mois\n\n[ Read More » ](https://mdxhealth.com/2023/11/08/mdxhealth-communique-ses-resultats-pour-le-troisieme-trimestre-et-la-periode-de-neuf-mois-cloturee-le-30-septembre-2023/)\n\n###  [ MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023 ](https://mdxhealth.com/press_release/mdxhealth-reports-results-for-the-third-quarter-and-nine-month-period-ended-september-30-2023/)\n\nNEWS RELEASE – REGULATED INFORMATION8 NOVEMBER 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-reports-results-for-the-third-quarter-and-nine-month-period-ended-september-30-2023/)\n\n###  [ MDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share Consolidation ](https://mdxhealth.com/press_release/mdxhealth-announces-the-approval-by-its-shareholders-of-the-proposed-transition-to-a-sole-listing-of-shares-on-nasdaq-and-details-of-the-share-consolidation/)\n\nNEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONNOVEMBER 6, 2023, 1:00 AM ET / 7:00 CET MDxHealth Announces the Approval by its Shareholders of the\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-the-approval-by-its-shareholders-of-the-proposed-transition-to-a-sole-listing-of-shares-on-nasdaq-and-details-of-the-share-consolidation/)\n\n###  [ MDxHealth annonce l’approbation par ses actionnaires de la proposition de transition vers une cotation unique des actions sur le Nasdaq, ainsi que les détails du regroupement d’actions ](https://mdxhealth.com/2023/11/06/mdxhealth-annonce-lapprobation-par-ses-actionnaires-de-la-proposition-de-transition-vers-une-cotation-unique-des-actions-sur-le-nasdaq-ainsi-que-les-details-du-regroupement-dactions/)\n\nCOMMUNIQUÉ DE PRESSE – INFORMATION RÉGLEMENTÉEINFORMATION PRIVILÉGIÉE6 NOVEMBRE 2023, 1:00 ET / 7:00 CET MDxHealth annonce l’approbation par ses actionnaires de la proposition\n\n[ Read More » ](https://mdxhealth.com/2023/11/06/mdxhealth-annonce-lapprobation-par-ses-actionnaires-de-la-proposition-de-transition-vers-une-cotation-unique-des-actions-sur-le-nasdaq-ainsi-que-les-details-du-regroupement-dactions/)\n\n###  [ MDxHealth to Present Third Quarter 2023 Financial Results and Corporate Update on November 8 ](https://mdxhealth.com/press_release/mdxhealth-to-present-third-quarter-2023-financial-results-and-corporate-update-on-november-8/)\n\nNEWS RELEASE25 OCTOBER 2023, 4PM ET / 22:00 CET MDxHealth to Present Third Quarter 2023 Financial Results and Corporate Update on November 8 Company to\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-to-present-third-quarter-2023-financial-results-and-corporate-update-on-november-8/)\n\n###  [ Nouveau montant du capital et nouveau nombre d’actions de Mdxhealth ](https://mdxhealth.com/2023/10/20/nouveau-montant-du-capital-et-nouveau-nombre-dactions-de-mdxhealth-324/)\n\nCOMMUNIQUÉ DE PRESSE – INFORMATION RÉGLEMENTÉE20 octobre 2023, 16:00 EDT / 22:00 CET Nouveau montant du capital et nouveau nombre d’actions de\n\n[ Read More » ](https://mdxhealth.com/2023/10/20/nouveau-montant-du-capital-et-nouveau-nombre-dactions-de-mdxhealth-324/)\n\n###  [ Mdxhealth’s New Share Capital Amount and New Number of Shares ](https://mdxhealth.com/press_release/mdxhealths-new-share-capital-amount-and-new-number-of-shares-8/)\n\nNEWS RELEASE – REGULATED INFORMATION October 20, 2023, 4:00 PM EDT / 22:00 CET Mdxhealth’s New Share Capital Amount and New Number of Shares\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealths-new-share-capital-amount-and-new-number-of-shares-8/)\n\n###  [ MDxHealth communique ses revenus préliminaires pour le troisième trimestre de 2023 ](https://mdxhealth.com/2023/10/09/mdxhealth-communique-ses-revenus-preliminaires-pour-le-troisieme-trimestre-de-2023/)\n\nCOMMUNIQUÉ DE PRESSE – INFORMATION RÉGLEMENTÉE ET PRIVILÉGIÉE Le 9 OCTOBRE 2023, 16h00 EDT / 22h00 CET MDxHealth communique ses revenus préliminaires pour\n\n[ Read More » ](https://mdxhealth.com/2023/10/09/mdxhealth-communique-ses-revenus-preliminaires-pour-le-troisieme-trimestre-de-2023/)\n\n###  [ MDxHealth Reports Preliminary Q3-2023 Revenues ](https://mdxhealth.com/press_release/mdxhealth-reports-preliminary-q3-2023-revenues/)\n\nNEWS RELEASE – INSIDE AND REGULATED INFORMATION9 OCTOBER 2023, 4PM ET / 22:00 CET MDxHealth Reports Preliminary Q3-2023 Revenues IRVINE, CA, and HERSTAL,\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-reports-preliminary-q3-2023-revenues/)\n\n###  [ MDxHealth annonce une proposition de transition vers une cotation unique de ses actions sur le Nasdaq et convoque une assemblée générale extraordinaire des actionnaires ](https://mdxhealth.com/2023/10/02/mdxhealth-annonce-une-proposition-de-transition-vers-une-cotation-unique-de-ses-actions-sur-le-nasdaq-et-convoque-une-assemblee-generale-extraordinaire-des-actionnaires/)\n\nCOMMUNIQUÉ DE PRESSE – INFORMATION RÉGLEMENTÉEINFORMATION PRIVILÉGIÉELE 2 OCTOBRE 2023, 16h00 EDT / 22h00 CET MDxHealth annonce une proposition de transition vers une cotation unique\n\n[ Read More » ](https://mdxhealth.com/2023/10/02/mdxhealth-annonce-une-proposition-de-transition-vers-une-cotation-unique-de-ses-actions-sur-le-nasdaq-et-convoque-une-assemblee-generale-extraordinaire-des-actionnaires/)\n\n###  [ MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting ](https://mdxhealth.com/press_release/mdxhealth-announces-proposed-transition-to-a-sole-listing-of-shares-on-nasdaq-and-convenes-an-extraordinary-general-shareholders-meeting/)\n\nNEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONOCTOBER 2, 2023, 4:00pm ET / 22:00 CET MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-proposed-transition-to-a-sole-listing-of-shares-on-nasdaq-and-convenes-an-extraordinary-general-shareholders-meeting/)\n\n###  [ Mdxhealth signe une collaboration de recherche avec l’Université d’Oxford pour évaluer la corrélation entre le test GPS et la progression du cancer de la prostate après un traitement pour un cancer de la prostate localisé ](https://mdxhealth.com/2023/09/26/mdxhealth-signe-une-collaboration-de-recherche-avec-luniversite-doxford-pour-evaluer-la-correlation-entre-le-test-gps-et-la-progression-du-cancer-de-la-prostate-apres-un-traitement-pour-un-canc/)\n\nCOMMUNIQUÉ DE PRESSE 26 septembre 2023, 17h00 EDT / 22h00 CET Mdxhealth signe une collaboration de recherche avec l’Université d’Oxford pour évaluer la\n\n[ Read More » ](https://mdxhealth.com/2023/09/26/mdxhealth-signe-une-collaboration-de-recherche-avec-luniversite-doxford-pour-evaluer-la-correlation-entre-le-test-gps-et-la-progression-du-cancer-de-la-prostate-apres-un-traitement-pour-un-canc/)\n\n###  [ Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer ](https://mdxhealth.com/press_release/mdxhealth-signs-research-collaboration-with-university-of-oxford-to-assess-the-correlation-of-the-gps-test-with-prostate-cancer-progression-following-treatment-for-localized-prostate-cancer/)\n\nNEWS RELEASE September 26, 2023, 5:00PM EDT / 23:00 CET Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-signs-research-collaboration-with-university-of-oxford-to-assess-the-correlation-of-the-gps-test-with-prostate-cancer-progression-following-treatment-for-localized-prostate-cancer/)\n\n###  [ MDxHealth communique ses résultats financiers T2 et S1 2023 ](https://mdxhealth.com/2023/08/23/mdxhealth-communique-ses-resultats-financiers-t2-et-s1-2023/)\n\nCOMMUNIQUÉ DE PRESSE – INFORMATIONS RÉGLEMENTÉES23 AOÛT 2023, 16 h 00 EDT, 22 h 00 CET MDxHealth communique ses résultats financiers T2 et S1 2023 Les revenus du T2 ont\n\n[ Read More » ](https://mdxhealth.com/2023/08/23/mdxhealth-communique-ses-resultats-financiers-t2-et-s1-2023/)\n\n###  [ MDxHealth Reports Q2 and Half Year 2023 Results ](https://mdxhealth.com/press_release/mdxhealth-reports-q2-and-half-year-2023-results/)\n\nNEWS RELEASE – REGULATED INFORMATION23 AUGUST 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Q2 and Half Year 2023 Results Year-over-year Q2 revenues\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-reports-q2-and-half-year-2023-results/)\n\n###  [ MDxHealth to Present Q2 and Half Year 2023 Financial Results and Corporate Update on August 23 ](https://mdxhealth.com/press_release/mdxhealth-to-present-q2-and-half-year-2023-financial-results-and-corporate-update-on-august-23/)\n\nNEWS RELEASE10 AUGUST 2023, 4PM ET / 22:00 CET MDxHealth to Present Q2 and Half Year 2023 Financial Results and Corporate Update on\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-to-present-q2-and-half-year-2023-financial-results-and-corporate-update-on-august-23/)\n\n###  [ Cigna Expands Commercial and Medicare Advantage Coverage to Include Mdxhealth’s Select mdx for Prostate Cancer Test ](https://mdxhealth.com/press_release/cigna-expands-commercial-and-medicare-advantage-coverage-to-include-mdxhealths-select-mdx-for-prostate-cancer-test/)\n\nNEWS RELEASE9 AUGUST 2023, 4PM ET / 22:00 CET Cigna Expands Commercial and Medicare AdvantageCoverage to Include Mdxhealth’s Select mdx for Prostate Cancer\n\n[ Read More » ](https://mdxhealth.com/press_release/cigna-expands-commercial-and-medicare-advantage-coverage-to-include-mdxhealths-select-mdx-for-prostate-cancer-test/)\n\n###  [ MDxHealth annonce les résultats de son assemblée générale extraordinaire des actionnaires ](https://mdxhealth.com/2023/06/30/mdxhealth-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-des-actionnaires/)\n\nCOMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE 30 juin 2023, 2200 CEST MDxHealth annonce les résultats de son assemblée générale extraordinaire des actionnaires IRVINE, CA, et\n\n[ Read More » ](https://mdxhealth.com/2023/06/30/mdxhealth-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-des-actionnaires/)\n\n###  [ MDxHealth Announces Results of its Extraordinary General Shareholders’ Meeting ](https://mdxhealth.com/press_release/mdxhealth-announces-results-of-its-extraordinary-general-shareholders-meeting/)\n\nNEWS RELEASE – REGULATED INFORMATION 30 June 2023, 10:00 p.m. CEST MDxHealth Announces Results of its Extraordinary General Shareholders’ Meeting IRVINE, CA, and HERSTAL, BELGIUM –\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-results-of-its-extraordinary-general-shareholders-meeting/)\n\n###  [ MDxHealth Announces its Extraordinary General Shareholders’ Meeting ](https://mdxhealth.com/press_release/mdxhealth-announces-its-extraordinary-general-shareholders-meeting/)\n\nNEWS RELEASE – REGULATED INFORMATION JUNE 5, 2023, 5:30 pm ET/ 23:30 CEST MDxHealth Announces its Extraordinary General Shareholders’ Meeting IRVINE, CA, and\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-its-extraordinary-general-shareholders-meeting/)\n\n###  [ MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings ](https://mdxhealth.com/press_release/mdxhealth-announces-results-of-its-annual-and-extraordinary-general-shareholders-meetings-2/)\n\nNEWS RELEASE – REGULATED INFORMATION 25 May 2023, 22:30 CET MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings IRVINE, CA, and HERSTAL, BELGIUM\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-results-of-its-annual-and-extraordinary-general-shareholders-meetings-2/)\n\n###  [ MDxHealth to Present at the 43rd Annual William Blair Growth Stock Conference ](https://mdxhealth.com/press_release/mdxhealth-to-present-at-the-43rd-annual-william-blair-growth-stock-conference/)\n\nNEWS RELEASEMay 23, 2023, 4PM ET/ 22:00 CET MDxHealth to Present at the 43rd Annual William Blair Growth Stock Conference IRVINE, CA,\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-to-present-at-the-43rd-annual-william-blair-growth-stock-conference/)\n\n###  [ MDxHealth Reports Q1-2023 Results ](https://mdxhealth.com/press_release/mdxhealth-reports-q1-2023-results/)\n\nNEWS RELEASE – REGULATED INFORMATION15 MAY 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Q1-2023 Results Year-over-year revenues increase by 141% to $14.7\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-reports-q1-2023-results/)\n\n###  [ MDxHealth to Present First Quarter 2023 Financial Results on May 15 ](https://mdxhealth.com/press_release/mdxhealth-to-present-first-quarter-2023-financial-results-on-may-15/)\n\nNEWS RELEASE 1 MAY 2023, 4PM ET / 22:00 CET MDxHealth to Present First Quarter 2023 Financial Results on May 15 Company to Host\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-to-present-first-quarter-2023-financial-results-on-may-15/)\n\n###  [ MDxHealth Announces its Ordinary and Extraordinary General Shareholders’ Meetings ](https://mdxhealth.com/press_release/mdxhealth-announces-its-ordinary-and-extraordinary-general-shareholders-meetings-3/)\n\nNEWS RELEASE – REGULATED INFORMATIONAPRIL 25, 2023, 4:00 pm ET/ 22:00 CET IRVINE, CA, and HERSTAL, BELGIUM – April 25, 2023 – MDxHealth SA (Nasdaq\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-its-ordinary-and-extraordinary-general-shareholders-meetings-3/)\n\n###  [ Foundational LCD Covers Select mdx for Prostate Cancer ](https://mdxhealth.com/press_release/foundational-lcd-covers-select-mdx-for-prostate-cancer/)\n\nNEWS RELEASE – INSIDE INFORMATIONApril 19, 2023, 4:00PM EDT / 22:00 CET IRVINE, CA, and HERSTAL, BELGIUM – April 19, 2023 – MDxHealth SA (NASDAQ/Euronext:\n\n[ Read More » ](https://mdxhealth.com/press_release/foundational-lcd-covers-select-mdx-for-prostate-cancer/)\n\n###  [ MDxHealth Shareholder Transparency Declaration ](https://mdxhealth.com/press_release/mdxhealth-shareholder-transparency-declaration-6/)\n\nNEWS RELEASE – REGULATED INFORMATION APRIL 7, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – April 7, 2023 – MDxHealth SA\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-shareholder-transparency-declaration-6/)\n\n###  [ MDxHealth Confirms No Exposure to Silicon Valley Bank or Silvergate Bank ](https://mdxhealth.com/press_release/mdxhealth-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank/)\n\nNEWS RELEASE 13 MARCH 2023, 2:00 AM ET / 08:00 CET IRVINE, CA, and HERSTAL, BELGIUM – March 13, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank/)\n\n###  [ MDxHealth Reports Financial Year 2022 Results and Provides Business Update and Outlook for 2023 ](https://mdxhealth.com/press_release/mdxhealth-reports-financial-year-2022-results-and-provides-business-update-and-outlook-for-2023mdxhealth-reports-financial-year-2022-results/)\n\nNEWS RELEASE – REGULATED INFORMATION8 MARCH 2023, 4:00 PM EST / 22:00 CET Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-reports-financial-year-2022-results-and-provides-business-update-and-outlook-for-2023mdxhealth-reports-financial-year-2022-results/)\n\n###  [ MDxHealth Announces Update of Outstanding Shares and Voting Rights ](https://mdxhealth.com/press_release/mdxhealth-announces-update-of-outstanding-shares-and-voting-rights-2/)\n\nNEWS RELEASE – REGULATED INFORMATIONMARCH 8, 2023, 5:00 pm ET/ 23:00 CET IRVINE, CA, and HERSTAL, BELGIUM – March 8, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH)\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-update-of-outstanding-shares-and-voting-rights-2/)\n\n###  [ MDxHealth Announces Exercise of Option ](https://mdxhealth.com/press_release/mdxhealth-announces-exercise-of-option-2/)\n\nNEWS RELEASE – REGULATED INFORMATIONMARCH 6, 2023, 5:30 pm ET/ 23:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 6, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth”\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-exercise-of-option-2/)\n\n###  [ MDxHealth Shareholder Transparency Declarations ](https://mdxhealth.com/press_release/mdxhealth-shareholder-transparency-declarations-5/)\n\nNEWS RELEASE – REGULATED INFORMATION MARCH 3, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 3, 2023 – MDxHealth SA\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-shareholder-transparency-declarations-5/)\n\n###  [ MDxHealth Shareholder Transparency Declaration ](https://mdxhealth.com/press_release/mdxhealth-shareholder-transparency-declaration-4/)\n\nNEWS RELEASE – REGULATED INFORMATIONFEBRUARY 21, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – 21 February 2023 – MDxHealth SA\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-shareholder-transparency-declaration-4/)\n\n###  [ MDxHealth to Participate in 43rd Annual Cowen Healthcare Conference ](https://mdxhealth.com/press_release/mdxhealth-to-participate-in-43rd-annual-cowen-healthcare-conference-2/)\n\nNEWS RELEASEFEBRUARY 28, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 28, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels:\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-to-participate-in-43rd-annual-cowen-healthcare-conference-2/)\n\n###  [ MDxHealth to Participate in 43rd Annual Cowen Healthcare Conference ](https://mdxhealth.com/press_release/mdxhealth-to-participate-in-43rd-annual-cowen-healthcare-conference/)\n\nNEWS RELEASEFEBRUARY 28, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 28, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH), a commercial-stage\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-to-participate-in-43rd-annual-cowen-healthcare-conference/)\n\n###  [ MDxHealth to Present Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023 ](https://mdxhealth.com/press_release/mdxhealth-to-present-fourth-quarter-and-full-year-2022-financial-results-on-march-8-2023/)\n\nNEWS RELEASEFEBRUARY 22, 2023, 4:30pm ET/ 22:30 CET Company to Host Conference Call with Live Q&A, March 8, 2023 at 4:30pm ET/ 22:30 CET IRVINE,\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-to-present-fourth-quarter-and-full-year-2022-financial-results-on-march-8-2023/)\n\n###  [ MDxHealth to Present Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023 ](https://mdxhealth.com/press_release/mdxhealth-to-present-fourth-quarter-and-full-year-2022-financial-results-on-march-8-2023-2/)\n\nNEWS RELEASEFEBRUARY 22, 2023, 4:30pm ET/ 22:30 CET Company to Host Conference Call with Live Q&A, March 8, 2023 at 4:30pm ET/ 22:30\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-to-present-fourth-quarter-and-full-year-2022-financial-results-on-march-8-2023-2/)\n\n###  [ MDxHealth Announces Update of Outstanding Shares and Voting Rights and Update of Financial Calendar ](https://mdxhealth.com/press_release/mdxhealth-announces-update-of-outstanding-shares-and-voting-rights-and-update-of-financial-calendar-2/)\n\nNEWS RELEASE – REGULATED INFORMATIONFEBRUARY 15, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 15, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH)\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-update-of-outstanding-shares-and-voting-rights-and-update-of-financial-calendar-2/)\n\n###  [ MDxHealth Announces Update of Outstanding Shares and Voting Rights and Update of Financial Calendar ](https://mdxhealth.com/press_release/mdxhealth-announces-update-of-outstanding-shares-and-voting-rights-and-update-of-financial-calendar/)\n\nNEWS RELEASE – REGULATED INFORMATION FEBRUARY 15, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 15, 2023 – MDxHealth SA (NASDAQ/Euronext:\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-update-of-outstanding-shares-and-voting-rights-and-update-of-financial-calendar/)\n\n###  [ MDxHealth Announces UnitedHealthcare to Provide Commercial Coverage for the Genomic Prostate Score (GPS) Test ](https://mdxhealth.com/press_release/mdxhealth-announces-unitedhealthcare-to-provide-commercial-coverage-for-the-genomic-prostate-score-gps-test/)\n\nNEWS RELEASE 13 FEBRUARY 2023, 4:00PM ET / 22:00 CET UnitedHealthcare singles out mdxheath’s GPS test as its only commercially-covered test to risk stratify men\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-unitedhealthcare-to-provide-commercial-coverage-for-the-genomic-prostate-score-gps-test/)\n\n###  [ MDxHealth Announces Pricing of Offering of ADSs in the United States ](https://mdxhealth.com/press_release/mdxhealth-announces-pricing-of-offering-of-adss-in-the-united-states-2/)\n\nNEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONFEBRUARY 3, 2023, 8:00 am ET/ 14:00 CET MDxHealth Announces Pricing of Offering of ADSsin the United States IRVINE, CA,\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-pricing-of-offering-of-adss-in-the-united-states-2/)\n\n###  [ MDxHealth Announces Pricing of Offering of ADSs in the United States ](https://mdxhealth.com/press_release/mdxhealth-announces-pricing-of-offering-of-adss-in-the-united-states/)\n\nNEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION FEBRUARY 3, 2023, 8:00 am ET/ 14:00 CET IRVINE, CA, and HERSTAL, BELGIUM – February 3, 2023 – MDxHealth\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-pricing-of-offering-of-adss-in-the-united-states/)\n\n###  [ MDxHealth Announces Launch of Offering of ADSs in the United States ](https://mdxhealth.com/press_release/mdxhealth-announces-launch-of-offering-of-adss-in-the-united-states-2/)\n\nNEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION FEBRUARY 1, 2023, 4PM ET/ 22:00 CET IRVINE, CA, and HERSTAL, BELGIUM –February 1, 2023 – MDxHealth SA (NASDAQ/Euronext:\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-announces-launch-of-offering-of-adss-in-the-united-states-2/)\n\n###  [ MDxHealth Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test ](https://mdxhealth.com/press_release/mdxhealth-provides-updated-and-supplemental-financial-information-related-to-acquisition-of-gps-test/)\n\nNEWS RELEASE –REGULATED INFORMATION 20 JANUARY 2023, 1:00 am ET / 7:00 am CET IRVINE, CA, and HERSTAL, BELGIUM – January 20, 2023 – MDxHealth SA\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-provides-updated-and-supplemental-financial-information-related-to-acquisition-of-gps-test/)\n\n###  [ MDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance ](https://mdxhealth.com/press_release/mdxhealth-reports-preliminary-2022-revenues-and-reaffirms-2023-revenue-guidance-2/)\n\nNEWS RELEASE – INSIDE AND REGULATED INFORMATION 9 JANUARY 2023, 4PM ET / 22:00 CET IRVINE, CA, and HERSTAL, BELGIUM – January 9, 2023 –\n\n[ Read More » ](https://mdxhealth.com/press_release/mdxhealth-reports-preliminary-2022-revenues-and-reaffirms-2023-revenue-guidance-2/)\n\n###  [ MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings and Resignation of Director ](https://mdxhealth.com/2022/05/25/mdxhealth-announces-results-of-its-annual-and-extraordinary-general-shareholders-meetings-and-resignation-of-director-2/)\n\nNEWS RELEASE – REGULATED INFORMATION 25 May 2022, 4:00 p.m. EDT / 22:00 CET MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings and\n\n[ Read More » ](https://mdxhealth.com/2022/05/25/mdxhealth-announces-results-of-its-annual-and-extraordinary-general-shareholders-meetings-and-resignation-of-director-2/)\n\n###  [ Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx for Prostate Cancer ](https://mdxhealth.com/2022/05/19/palmetto-gbas-moldx-issues-foundational-lcd-covering-the-indication-for-selectmdx-for-prostate-cancer-2/)\n\nNEWS RELEASE – REGULATED INFORMATIONMay 19, 2022, 4:00PM EDT / 22:00 CET Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx® for\n\n[ Read More » ](https://mdxhealth.com/2022/05/19/palmetto-gbas-moldx-issues-foundational-lcd-covering-the-indication-for-selectmdx-for-prostate-cancer-2/)\n\n###  [ MDxHealth Reports Q1-2022 Results ](https://mdxhealth.com/2022/04/27/mdxhealth-reports-q1-2022-results-2/)\n\nNEWS RELEASE – REGULATED INFORMATION27 APRIL 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q1-2022 Results IRVINE, CA, and HERSTAL, BELGIUM – April\n\n[ Read More » ](https://mdxhealth.com/2022/04/27/mdxhealth-reports-q1-2022-results-2/)\n\n###  [ MDxHealth Announces its Ordinary and Extraordinary General Shareholders’ Meetings ](https://mdxhealth.com/2022/04/25/mdxhealth-announces-its-ordinary-and-extraordinary-general-shareholders-meetings-4/)\n\nNEWS RELEASE – REGULATED INFORMATION 25 April 2022, 10:00 p.m. CET MDxHealth Announces its Ordinary and Extraordinary General Shareholders’ Meetings IRVINE, CA, and HERSTAL, BELGIUM\n\n[ Read More » ](https://mdxhealth.com/2022/04/25/mdxhealth-announces-its-ordinary-and-extraordinary-general-shareholders-meetings-4/)\n\n###  [ MDxHealth to Participate in the 14th Annual Kempen Life Sciences Conference ](https://mdxhealth.com/2022/03/30/mdxhealth-to-participate-in-the-14th-annual-kempen-life-sciences-conference-2/)\n\nNEWS RELEASEMarch 30, 2022, 4:30 PM EST / 22:30 CET MDxHealth to Participate in the 14th Annual Kempen Life Sciences Conference IRVINE, CA, and HERSTAL,\n\n[ Read More » ](https://mdxhealth.com/2022/03/30/mdxhealth-to-participate-in-the-14th-annual-kempen-life-sciences-conference-2/)\n\n###  [ MDxHealth Reports Financial Year 2021 Results and Provides Outlook and Guidance for 2022 ](https://mdxhealth.com/2022/03/02/mdxhealth-reports-financial-year-2021-results-and-provides-outlook-and-guidance-for-2022-2/)\n\nNEWS RELEASE – REGULATED INFORMATION2 MARCH 2022, 4:00 PM EST / 22:00 CET MDxHealth Reports Financial Year 2021 Results and Provides Outlook and Guidance\n\n[ Read More » ](https://mdxhealth.com/2022/03/02/mdxhealth-reports-financial-year-2021-results-and-provides-outlook-and-guidance-for-2022-2/)\n\n###  [ MDxHealth to Present Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 2nd ](https://mdxhealth.com/2022/02/17/mdxhealth-to-present-fourth-quarter-and-full-year-2021-financial-results-and-corporate-update-on-march-2nd-2/)\n\nNEWS RELEASE 17 February 2022, 4:00 PM EST / 22:00 CET MDxHealth to Present Fourth Quarter and Full Year 2021 Financial Results and Corporate Update\n\n[ Read More » ](https://mdxhealth.com/2022/02/17/mdxhealth-to-present-fourth-quarter-and-full-year-2021-financial-results-and-corporate-update-on-march-2nd-2/)\n\n###  [ MDxHealth to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference ](https://mdxhealth.com/2022/02/09/mdxhealth-to-present-at-btig-medtech-digital-health-life-science-diagnostic-tools-conference-2/)\n\nNEWS RELEASE9 FEBRUARY 2022, 4:00 PM EST / 22:00 CET MDxHealth to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference\n\n[ Read More » ](https://mdxhealth.com/2022/02/09/mdxhealth-to-present-at-btig-medtech-digital-health-life-science-diagnostic-tools-conference-2/)\n\n###  [ MDxHealth Shareholder Transparency Declaration ](https://mdxhealth.com/2021/12/10/mdxhealth-shareholder-transparency-declaration-2/)\n\nNEWS RELEASE – REGULATED INFORMATION 10 December 2021, 23:55 CET MDxHealth Shareholder Transparency Declaration IRVINE, CA, and HERSTAL, BELGIUM – 10 December 2021 – MDxHealth\n\n[ Read More » ](https://mdxhealth.com/2021/12/10/mdxhealth-shareholder-transparency-declaration-2/)\n\n###  [ MDxHealth Shareholder Transparency Declarations ](https://mdxhealth.com/2021/11/22/mdxhealth-shareholder-transparency-declarations-5/)\n\nNEWS RELEASE – REGULATED INFORMATION 22 November 2021, 11:00 p.m. CET MDxHealth Shareholder Transparency Declarations IRVINE, CA, and HERSTAL, BELGIUM – 22 November 2021 –\n\n[ Read More » ](https://mdxhealth.com/2021/11/22/mdxhealth-shareholder-transparency-declarations-5/)\n\n###  [ MDxHealth Announces Completion of Initial Public Offering of ADSs in the United States ](https://mdxhealth.com/2021/11/15/mdxhealth-announces-completion-of-initial-public-offering-of-adss-in-the-united-states-3/)\n\nNEWS RELEASE – REGULATED INFORMATION 15 November 2021, 11:00 p.m. CET MDxHealth Shareholder Transparency Declarations IRVINE, CA, and HERSTAL, BELGIUM – 15 November 2021 –\n\n[ Read More » ](https://mdxhealth.com/2021/11/15/mdxhealth-announces-completion-of-initial-public-offering-of-adss-in-the-united-states-3/)\n\n###  [ MDxHealth Announces Completion of Initial Public Offering of ADSs in the United States ](https://mdxhealth.com/2021/11/08/mdxhealth-announces-completion-of-initial-public-offering-of-adss-in-the-united-states-2/)\n\nNEWS RELEASE – REGULATED INFORMATIONNOVEMBER 8, 2021, 22:30 CET MDxHealth Announces Completion of Initial Public Offering of ADSs in the United States IRVINE, CA, and HERSTAL,\n\n[ Read More » ](https://mdxhealth.com/2021/11/08/mdxhealth-announces-completion-of-initial-public-offering-of-adss-in-the-united-states-2/)\n\n###  [ MDxHealth Announces Pricing of Initial Public Offering of ADSs in the United States ](https://mdxhealth.com/2021/11/04/mdxhealth-announces-pricing-of-initial-public-offering-of-adss-in-the-united-states-2/)\n\nNEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATION4 NOVEMBER 2021, 13:00 CET MDxHealth Announces Pricing of Initial Public Offering of ADSsin the United States IRVINE, CA, and\n\n[ Read More » ](https://mdxhealth.com/2021/11/04/mdxhealth-announces-pricing-of-initial-public-offering-of-adss-in-the-united-states-2/)\n\n###  [ MDxHealth Announces Launch of Proposed Initial Public Offering of ADSs in the United States ](https://mdxhealth.com/2021/10/28/mdxhealth-announces-launch-of-proposed-initial-public-offering-of-adss-in-the-united-states-2/)\n\nNEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATION28 OCTOBER 2021, 07:00 CEST MDxHealth Announces Launch of Proposed Initial Public Offering of ADSsin the United States IRVINE, CA,\n\n[ Read More » ](https://mdxhealth.com/2021/10/28/mdxhealth-announces-launch-of-proposed-initial-public-offering-of-adss-in-the-united-states-2/)\n\n###  [ MDxHealth Provides Q3-2021 Business Update ](https://mdxhealth.com/2021/10/21/mdxhealth-provides-q3-2021-business-update-2/)\n\nNEWS RELEASE – REGULATED INFORMATION21 OCTOBER 2021, 07:00 A.M. CET MDxHealth Provides Q3-2021 Business Update IRVINE, CA, and HERSTAL, BELGIUM – October 21, 2021 –\n\n[ Read More » ](https://mdxhealth.com/2021/10/21/mdxhealth-provides-q3-2021-business-update-2/)\n\n###  [ MDxHealth files Registration Statement for Proposed Initial Public Offering in the United States ](https://mdxhealth.com/2021/10/13/mdxhealth-files-registration-statement-for-proposed-initial-public-offering-in-the-united-states-2/)\n\nNEWS RELEASE – REGULATED INFORMATION13 OCTOBER 2021, 19:30 CET MDxHealth files Registration Statement for Proposed Initial Public Offering in the United States IRVINE, CA, and\n\n[ Read More » ](https://mdxhealth.com/2021/10/13/mdxhealth-files-registration-statement-for-proposed-initial-public-offering-in-the-united-states-2/)\n\n###  [ MDxHealth Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States ](https://mdxhealth.com/2021/09/01/mdxhealth-announces-submission-of-draft-registration-statement-for-proposed-public-listing-in-the-united-states-2/)\n\nNEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONSeptember 1, 2021, 18:00 CEST MDxHealth Announces Submission of Draft Registration Statement For Proposed Public Listing in the United\n\n[ Read More » ](https://mdxhealth.com/2021/09/01/mdxhealth-announces-submission-of-draft-registration-statement-for-proposed-public-listing-in-the-united-states-2/)\n\n###  [ MDxHealth Reports Half Year 2021 Results ](https://mdxhealth.com/2021/08/26/mdxhealth-reports-half-year-2021-results-2/)\n\nNEWS RELEASE – REGULATED INFORMATION26 AUGUST 2021, 18:00 CET MDxHealth Reports Half Year 2021 Results Conference call with Q&A today at 19:00 CET / 1PM\n\n[ Read More » ](https://mdxhealth.com/2021/08/26/mdxhealth-reports-half-year-2021-results-2/)\n\n###  [ MDxHealth to Present First Half 2021 Financial Results and Corporate Update on August 26 ](https://mdxhealth.com/2021/08/11/mdxhealth-to-present-first-half-2021-financial-results-and-corporate-update-on-august-26-2/)\n\nCompany to Host Conference Call and Live Q&A Session, August 26, 2021, at 10:00am PT/ 1:00pm ET/ 19:00 CET IRVINE, CA, and HERSTAL, BELGIUM – August\n\n[ Read More » ](https://mdxhealth.com/2021/08/11/mdxhealth-to-present-first-half-2021-financial-results-and-corporate-update-on-august-26-2/)\n\n###  [ MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings ](https://mdxhealth.com/2021/05/27/mdxhealth-announces-results-of-its-annual-and-extraordinary-general-shareholders-meetings-2/)\n\nNEWS RELEASE – REGULATED INFORMATION 27 May 2021, 23:00 p.m. CET IRVINE, CA, and HERSTAL, BELGIUM – 27 May 2021 – MDxHealth SA (Euronext Brussels:\n\n[ Read More » ](https://mdxhealth.com/2021/05/27/mdxhealth-announces-results-of-its-annual-and-extraordinary-general-shareholders-meetings-2/)\n\n[ ![](/wp-content/uploads/2022/04/MDxHealth-Logo_Full-Color_KO_RGB-1.png) ](https://mdxhealth.com)\n\nToll Free: (866) 259-5644 Email: info@mdxhealth.com\n\n[ Facebook ](https://www.facebook.com/mdxhealth/) [ Twitter ](https://twitter.com/mdxhealth?s=11&t=RI_iHL03YQlKMvkiHxV93g) [ Linkedin ](https://www.linkedin.com/company/1344641/admin/feed/posts/)\n\n###### Our Company\n\n  * [ About  ](https://mdxhealth.com/about/)\n  * [ Science ](https://mdxhealth.com/science/)\n  * [ Careers ](https://mdxhealth.com/careers/)\n  * [ News ](https://mdxhealth.com/press-releases-events/)\n  * [ Contact Us ](https://mdxhealth.com/contact-us/)\n  * [ Connect with a rep ](https://mdxhealth.com/connect/)\n  * [ Xpert One Support ](https://mdxhealth.com/xpert-one/)\n\n\n\n###### Tests\n\nFor Physicians\n\n  * [ Select mdx ](https://mdxhealth.com/select-mdx-for-physicians/)\n  * [ Confirm mdx  ](https://mdxhealth.com/confirm-mdx-for-physicians/)\n  * [ Genomic Prostate Score ](https://mdxhealth.com/gps-physician/)\n  * [ Resolve mdx  ](https://mdxhealth.com/resolve-mdx-for-physicians/)\n  * [ Physician Portal ](https://mdxhealthsecure.com)\n  * [ Report Access ](https://mdxhealth.com/securemdx/)\n  * [ Order Supplies ](https://mdxhealth.com/testkits/)\n  * [ FedEx Pick Up ](https://mdxhealth.com/fedex/)\n\n\n\nFor Patients\n\n  * [ Select mdx ](https://mdxhealth.com/select-mdx-for-patients/)\n  * [ Confirm mdx ](https://mdxhealth.com/confirm-mdx-for-patients/)\n  * [ Genomic Prostate Score ](https://mdxhealth.com/gps-patient/)\n  * [ Resolve mdx ](https://mdxhealth.com/resolve-mdx-for-patients/)\n  * [ Pay My Bill ](https://mdxhealth.com/paymybill/)\n\n\n\n###### Investors\n\n  * [ Financials ](https://mdxhealth.com/financials/)\n  * [ Shareholder Information ](https://mdxhealth.com/shareholder-information/)\n  * [ Transition to Nasdaq ](https://mdxhealth.com/proposed-transition-to-a-single-listing-on-nasdaq/)\n  * [ Analyst Coverage ](https://mdxhealth.com/analyst-coverage/)\n  * [ Presentations & Events ](https://mdxhealth.com/presentations-events/)\n  * [ Press Releases  ](https://mdxhealth.com/press-releases-events/)\n\n\n\n#### Shadowbox User Guides for download\n\n  * [Clinician User Guide](/wp-content/uploads/2024/10/SB-MKT-SHADOWBOX-IRIS-USER-GUIDE-2024.pdf)\n  * [IRIS Update Prompts Guide](/wp-content/uploads/2024/10/SB-MKT-SHADOWBOX-IRIS-UPDATE-PROMPTS-FOR-INSTALL-2024.pdf)\n  * [IRIS Install (with login automatically selected) Guide](/wp-content/uploads/2024/10/SB-MKT-SHADOWBOX-IRIS-INSTALL-WITH-LOGIN-AUTOMATICALLY-SELECTED-2024.pdf)\n\n\n\nCLOSE \n\n### How to Order Resolve mdx\n\n  1. To order Resolve mdx urine transport kits or test requisition forms: [Order Supplies Online](https://mdxhealthdotcom-dev.azurewebsites.nettestkits/) Call: 866.259.5644 Email: client.services@mdxhealth.com\n  2. Once urine transport kits are received, complete the Resolve mdx’s test requisition form in its entirety.\n  3. Carefully follow the steps in the enclosed Instructions For Use to collect the urine specimen.\n  4. Send completed test request form along with the sealed urine transportation kit to: 7000 Preston Road, Suite 1500, Plano, TX 75024\n\n\n\n[Schedule FedEx Pick Up](https://mdxhealthdotcom-dev.azurewebsites.netfedex/)\n\nView and Download [Resolve mdx Test Requisition Form (TRF)](/wp-content/uploads/2024/10/PL-FORM-0095-R06-Resolve-mdx-Test-Requisition-Form-for-UTI-and-STI-FNL.pdf) View and Download [Resolve mdx Specimen Collection and Shipping Instructions](/wp-content/uploads/2022/08/Resolve-mdx-Specimen-Collection-and-Shipping-Instructions.pdf) View and Download Resolve mdx [Specimen Requirements and Patient Eligibility](/wp-content/uploads/2022/08/Resolve-mdx-Specimen-Requirements.pdf)\n\nCLOSE \n\n# Licensure & Accreditations\n\n### United States:\n\n**Irvine, CA Laboratory**\n\n[College of American Pathologists (CAP) Accreditation](/wp-content/uploads/2024/06/CAP-2024.pdf)\n\n[Centers for Medicare & Medicaid Services Certificate of Accreditation (CLIA)](/wp-content/uploads/2022/06/Certificate-of-Accreditation-Ruben-Gamez.pdf)\n\n[New York State Department of Health License](/wp-content/uploads/2024/07/New-York-State-Clinical-Laboratory-Permit-exp-2025JUN30.pdf)\n\n[State of California Department of Public Health Clinical Laboratory License](/wp-content/uploads/2024/01/CDPH-License-Certificate_CDF-00341675-exp-13FEB2025.pdf)\n\n[State of Maryland License](/wp-content/uploads/2023/05/Maryland-State-License-Irvine.pdf)\n\n[State of Pennsylvania License](/wp-content/uploads/2022/06/PA-Irvine-Laboratory-Permit-EXP-08-25.pdf)\n\n[State of Rhode Island License](/wp-content/uploads/2024/02/Rhode-Island-License.pdf)\n\n[Health Canada License](/wp-content/uploads/2022/06/Health-Canada-Medical-Device-Establishment-License-scaled-2.jpg)\n\n**Plano, Texas Laboratory**\n\n[College of American Pathologists (CAP) Accreditation ](/wp-content/uploads/2023/03/PLANO-CAP_CERT.pdf)\n\n[Centers for Medicare & Medicaid Services Certificate of Accreditation (CLIA)](/wp-content/uploads/2023/05/CLIA_LICENSE_2023_PLANO.pdf)\n\n[State of California Department of Public Health Clinical Laboratory ](/wp-content/uploads/2024/10/CA-License-Certificate_CDS-90008054_Exp-2025OCT24.pdf)\n\n[State of Maryland License](/wp-content/uploads/2023/04/MARYLAND_STATE_LICENSE.pdf)\n\n[State of Pennsylvania License](/wp-content/uploads/2022/06/PA-Plano-Laboratory-Permit-EXP-08-25.pdf)\n\n[State of Rhode Island License ](/wp-content/uploads/2023/05/RHODE_ISLAND_LICENSE.pdf)\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/hardison.png)\n\n## Don Hardison\n\n### Independent Director\n\nMr. Hardison was most recently the President and Chief Executive Officer, and served on the board of directors, of Biotheranostics, Inc., a molecular diagnostic company focused on oncology, from February 2017 until it was acquired by Hologic, Inc. in February 2021. From April 2010 to March 2016, Mr. Hardison was the President and Chief Executive Officer of Good Start Genetics, a molecular genetic testing and information company. For more than 20 years prior to that, Mr. Hardison held various executive and senior management positions at companies including Laboratory Corporation of America (LabCorp), Exact Sciences Corporation, Quest Diagnostics Inc., and Smith Kline Beecham Corporation. He currently serves as an independent director on the boards of directors of Stemina Biomarker Discovery, Inc., Seventh Sense Biosystems, BioPorto, Inc. and IQuity, Inc. He also formerly served on the board of directors of Exact Sciences Corporation (Nasdaq: EXAS) from May 2000, through its initial public offering in February 2001, until August 2007. Mr. Hardison received his Bachelor of Arts degree, in political science, from the University of North Carolina, Chapel Hill.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.net/wp-content/uploads/2024/07/SSiegel.png)\n\n## Sanford J. Siegel, M.D. \n\n### Independent Director\n\nDr. Siegel has more the 45 years of experience as a practicing urologist and over 35 years of executive leadership experience. Dr. Siegel currently serves as the Chairman of the Board of United Urology Group, having previously served as its Chief Executive Officer. United Urology Group, which was acquired by Audax in 2016, was formed under Dr. Siegel’s leadership and is one of the nation’s leading urology networks. Previously, Dr. Siegel served as the President and Chief Executive Officer of Chesapeake Urology Associates, which he founded in 1999. Dr. Siegel is a founding member of the Large Urology Group Practice Association (LUGPA), which was formed in 2008. He was a board member of the Urology Care Foundation (UCF) from 2016 until 2023 and The Urology Times. As a recognized leader in the field of medicine, Dr. Siegel has been honored with official citations for outstanding commitment and leadership from both the Governor and the General Assembly of Maryland. Dr. Siegel earned his medical degree from the University of Maryland School of Medicine and completed his specialty training in urology at Temple University Hospital in Philadelphia. He has been certified by the American Board of Urology and as Fellow of the American College of Surgeons.\n\nCLOSE \n\n### How to Order Select mdx\n\n##### United States\n\n  1. To order Select mdx urine transport kits or test requisition forms: [Order Supplies Online](/testkits/) Call: 866.259.5644 Email: cs@mdxhealth.com\n  2. Once urine transport kits are received, complete the Select mdx’s test requisition form in its entirety.\n  3. Carefully follow the steps in the enclosed Instructions For Use to collect the urine specimen.\n  4. Send completed test request form along with the sealed urine transportation kit to: 15279 Alton Parkway, Suite 100, Irvine, CA 92618\n\n\n\n[Schedule FedEx Pick Up](/fedex/) View and Download [Select mdx Test Requisition Form (TRF)](/wp-content/uploads/2024/01/Select-mdx-Test-Requisition-Form7497-2.pdf) View and Download [Urine Collection and Preparation Instructions](/wp-content/uploads/2024/01/Urine-Collection-and-Transportation-Instructions-Brochure.pdf) View and Download [Specimen Requirements and Patient Eligibility](/wp-content/uploads/2024/01/Select-mdx-Specimen-Requirements.pdf)\n\n##### Europe\n\n  1. To order Select mdx urine transportation kits contact MDxHealth at +31 (0) 88 327 2727 or email clientservices.eu@mdxhealth.com.\n  2. Once urine transportation kits are received, please fill out the Select mdx test request form in its entirety.\n  3. Carefully follow the instructions for use to collect the urine specimen.\n  4. Place the completed test request form and urine specimen inside the Select mdx urine transportation kit. Follow the instructions on the kit to contact your local DHL office and arrange the return shipment to the mdxhealth laboratory.\n\n\n\nView and Download Test Request Form [DE](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_DE-v7_PRINT.pdf) | [EN](/wp-content/uploads/2022/06/MDX500-Requisition-form_EN-v4-2.pdf) | [ES](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_ES-v6-FER_elec.pdf) | [FR](/wp-content/uploads/2022/06/MDX500-Requisition-form_FR-v2.pdf) | [IT](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_IT-v9_PRINT.pdf) | [NL](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_NL-v7_PRINT.pdf) | [PL](/wp-content/uploads/2022/06/MDX500-SelectMDx-Requisition_PL-v4.pdf) View and Download [Select mdx Instructions for Use](/wp-content/uploads/2022/06/MDX521-SelectMDx-IFU-Booklet-v5.pdf) View and Download [UrNCollect Instructions for Use ](/wp-content/uploads/2022/06/MDX514-UrNCollect-v3.pdf)\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/regine-Slagmulder.png)\n\n## Regine Slagmulder\n\n### Independent Director, representing Regine Slagmulder BV\n\n**_Dr. Regine Slagmulder_** , Independent Non-Executive Director of our Company, is a full professor in management accounting & control at Vlerick Business School, a visiting professor of accounting & control at INSEAD, and the Knowledge & Academic Director (a.i.) at Guberna, the Belgian Institute for Directors. Previously, she worked as a strategy practice consultant at McKinsey & Company. She also previously worked as a professor of management accounting at INSEAD and at the University of Tilburg. She serves as an independent director and member of the audit committee on the board of the investment company Quest for Growth (since 2011) and as an independent director and chair of the audit committee of Ekopak (since 2021), both listed on Euronext. Dr. Slagmulder graduated in civil electrotechnical engineering and industrial management from the University of Gent, after which she received a management doctorate at Vlerick Business School. As part of her research activities, she was a research fellow attached to INSEAD, Boston University (USA) and the P. Drucker Graduate Management Center at Claremont University (USA). She is an INSEAD certified director (IDP-C).\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Hilde-Windels.png)\n\n## Hilde Windels\n\n### Independent Director, representing Hilde Windels BVBA\n\n**_Hilde Windels_** , Independent Non-Executive Director of our Company, has over 20 years of experience in the biotechnology sector with a track record of building and structuring organizations, fundraising, M&A, public capital markets and corporate strategies. Currently, Mrs. Windels serves as a board member at PHAXIAM Therapeutics, GIMV NV, MCROPHYT SA, and Celyad. Previously, she served as CEO of immunodiagnostic company Antelope Dx BV, and as CEO ad interim and Deputy CEO of Biocartis from September 2015 until September 2017 and as CFO of Biocartis from 2011 until September 2015. Mrs. Windels has also worked as independent CFO for several private biotech companies and from 1999 to 2008 she was CFO of Devgen. In the past, she also served on the boards of Devgen, Biocartis, Ablynx, VIB and FlandersBio. Mrs. Windels holds a Masters in Economics (commercial engineer) from the University of Leuven, Belgium.\n\nCLOSE \n\n### How to Order Confirm mdx\n\n##### Physician Office\n\nTo Order Pre-printed Test Requisition Forms:\n\n[Order Supplies Online](https://mdxhealthdotcom-dev.azurewebsites.nettestkits/) Call: 866.259.5644 Email: cs@mdxhealth.com\n\nView and Download [Confirm mdx Test Requisition Form (TRF)](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2024/01/Confirm-mdx-Test-Requisition-Form.pdf) View and Download [Confirm mdxSpecimen Requirements and Patient Eligibility](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2024/02/Confirm-mdx-Specimen-Requirements.pdf)\n\n  1. Complete the Confirm mdx test requisition form (TRF). Include patient demographics, copy of insurance card(s), and pathology report.\n  2. Forward the completed Confirm mdx TRF to MDxHealth Client Services. Mdxhealth will contact the pathology laboratory and request specimens as indicated on the TRF in “Section 7 – ConfirmMDx Specimen Request”.\n\n\n\n##### Pathology Laboratory\n\nTo order Confirm mdx Tissue Transport Kits:\n\n[Order Supplies Online](https://mdxhealthdotcom-dev.azurewebsites.netorder-supplies/) Call: 866.259.5644 Email: client.services@mdxhealth.com\n\n  1. Pathology lab will include specimens, completed test requisition form (including copies of patient demographics, insurance, and pathology report) inside the transportation kit.\n  2. Ship to: mdxhealth, 15279 Alton Parkway, Suite 100, Irvine, CA 92618.\n\n\n\n[Schedule FedEx Pick Up](https://mdxhealthdotcom-dev.azurewebsites.netfedex/)\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2023/11/Jason-Poole.png)\n\n## Jason Poole\n\n### Chief Scientific Officer\n\nDr. Poole has more than 25 years of research experience and specializes in the development of high complexity diagnostic testing for use in human health and disease. His expertise lies in product development using advanced technologies such as Next Generation Sequencing, qPCR, and nucleic acid sample preparation. Mr. Poole was most recently the VP of R&D at Active Motif, Inc. he spear-headed the development of products in the epigenetic research space including DNA methylation, chromatin modifications and epigenetic specific antibody development. Dr. Poole received his M.S. in Molecular Endocrinology from Northwestern University and his Ph.D. in Molecular Genetics from the University of Illinois College of Medicine in Chicago, IL.\n\nCLOSE \n\n## Tailored reports that connect insights for the next step in care\n\n### Low-Risk Report\n\n**The low-risk report integrates clinical, pathological, and genomic insights into actionable information on active surveillance 1**\n\n  * Predicts tumor aggressiveness to help inform the decision between active surveillance and immediate treatment\n  * Focuses on an actionable endpoint adverse pathology, with the most comprehensive definition\n  * The Genomic Prostate Score(GPS) test is the only commercially available test to provide all these endpoints: \n    * Risk of high-grade (≥Grade Group 3) disease\n    * Risk of pT3a+ disease\n    * Risk of metastasis within 10 years\n    * Risk of PCa-specific death within 10 years\n\n\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/212-low-risk-report-1024x627.png)\n\n##### [DOWNLOAD LOW-RISK SAMPLE REPORT](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2023/07/MDX.Brochures.GPS_.LowRiskReport_r2-SAMPLE.pdf)\n\n### High-Risk Report\n\n**The high-risk report provides a defined cut point with actionable information on treatment intensity 2**\n\n  * Helps determine the right level of treatment\n  * Clearly stratifies patient risk into lower or higher likelihood of disease progression\n  * Simple bell curve helps you and your patient understand the patient’s risk relative to other patients of same clinical risk group\n\n\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/211and212highrisk-1024x380.png)\n\n##### [DOWNLOAD HIGH-RISK SAMPLE REPORT](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2023/07/MDX.Brochures.GPS_.HighRiskReport_r3-SAMPLE.pdf)\n\nReferences:\n\n  1. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.  _Eur Urol_. 2014;66(3):550-560.\n  2. Cullen J, Kuo HC, Shan J, Lu R, Aboushwareb T, Van Den Eeden SK. The 17-gene genomic prostate score test as a predictor of outcomes in men with unfavorable intermediate risk prostate cancer. _Urology_. 2020;143:103-111.\n\n\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Mike-M.-Headshot-website.png)\n\n## Michael K. McGarrity\n\n### Chief Executive Officer, Director\n\nMr. McGarrity has more than 25 years of experience in the healthcare industry with a unique combination of device, diagnostics and biotechnology experience. Mr. McGarrity was most recently the CEO of Sterilis Medical. Prior to Sterilis Mr. McGarrity was the CEO of Nanosphere (NASDAQ: NSPH), a nanotechnology-based molecular diagnostics company, where he engineered an operational and strategic turnaround that resulted in its successful sale to Luminex (NASDAQ: LMNX) in 2016. Prior to Nanosphere, Mr. McGarrity spent 13 years at Stryker Corporation (NYSE: SYK) where he served in leadership roles in sales and marketing and led Stryker into new growth markets such as post-operative pain management, surgical fluid waste management and interventional pain management. Mr. McGarrity also had executive general management responsibility for a newly created business unit focused on interventional spine pain management. Mr. McGarrity received a Bachelor of Arts degree from the University of Notre Dame and began his career in commercial banking.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Ron-K-headshot-website.png)\n\n## Ron Kalfus\n\n### Chief Financial Officer\n\nMr. Kalfus has over 20 years of leadership experience in both public and private companies within diagnostics/biotech and other sectors, and brings extensive knowledge in financial operations, management, and strategic transactions. Mr. Kalfus joined mdxhealth from Rosetta Genomics, where he helped lead efforts to reposition the company for commercial success with its oncology diagnostic products, and raised over $60 million in capital to fund these efforts. Prior to Rosetta, Mr. Kalfus served as the CFO and Treasurer of MabCure, a Belgium-based publicly-traded biotechnology startup in the field of early cancer detection using antibodies. Mr. Kalfus received his Master’s degree in Accounting from Fairleigh Dickinson University and his Bachelor’s degree in Finance from the University of Georgia. Mr. Kalfus is a Certified Public Accountant, licensed in the State of New Jersey.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Valiance-Jan-Pensaert.png)\n\n## Mr. Jan Pensaert\n\n### Director, representing Valiance Advisors LLP\n\nJan Pensaert is the Founding Managing Partner of Valiance. He brings over 20 years of experience in growth investing. He leads the Investment Committee for the Valiance Funds and is responsible for all aspects of the Funds’ investment processes. Jan currently serves on the Board of several Valiance entities funds and portfolio companies including MDxHealth, JenaValve, NeoSync, and 4Tech. Prior to founding Valiance, Jan was CEO of La Fayette, where during his tenure the La Fayette Funds increased in AUM from $750 million to $5.5 billion. Before that, he was responsible for the Permal Group’s European-based investment management and research activities, and prior to that, he worked at Lazard in Corporate Finance M&A. Jan holds a BA in Business Economics from Gent University in Belgium, and a Masters in Banking & Finance from the University of Aix-Marseille, France.\n\nCLOSE \n\n**Analytical Validity**  \n---  \n· Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, et al. Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 2013;14: 690.  \n**Economic Utility**  \n· Albala D, Kemeter MJ, Febbo PG, Lu R, John V, Stoy D et al. Health economic impact and prospective clinical utility of Oncotype DX Genomic Prostate Score. Rev Urol. 2016; 18(3):123-132.  \n**Clinical Utility**  \n· Albala D, Kemeter MJ, Febbo PG, Lu R, John V, Stoy D et al. Health economic impact and prospective clinical utility of Oncotype DX Genomic Prostate Score. Rev Urol. 2016; 18(3):123-132. · Dall’Era MA, Maddala T, Polychronopoulos L, Gallagher JR, Febbo PG, and Denes BS. Utility of the Oncotype DX® Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A Retrospective Chart Review Analysis. Urology Practice. 2015;2(6):343-348. · Eure G, Germany R, Given R, Lu R, Shnidel AW, Rothney M, et al. Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort. Urology. 2017;107:67-75. · Lynch JA, Rothney MP, Salup RR, Ercole CE, Mathur SC, Duchene DA, et al. Improving Risk Stratification Among Veterans Diagnosed With Prostate Cancer: Impact of the 17-Gene Genomic Prostate Score Assay. Am J Manag Care. 2017;24(1 Suppl):S4-S10. · Murphy AB, Abern MR, Liu L, Wang H, Hollowell CMP, Sharifi R, Vidal P, et al. Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial. J Clin Oncol. 2021;39(15):1660-1670.  \n**Clinical Validity**  \n· Brooks MA, Thomas L, Magi-Galluzzi C, Li J, Crager MR, Lu R et al. GPS assay association with long-term cancer outcomes: twenty-year risk of distant metastasis and prostate cancer-specific mortality. JCO Precis Oncol. 2021;5:PO.20.00325. · Brooks MA, Thomas L, Magi-Galluzzi C, Li J, Crager MR, Lu R et al. Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy. Urol Oncol. 2022;40(3):104.e1-104.e7. · Covas Moschovas M, Chew C, Bhat S, Sandri M, Rogers T, Dell’Oglio P, et al. Association Between Oncotype DX Genomic Prostate Score and Adverse Tumor Pathology After Radical Prostatectomy. Eur Urol Focus. 2022;8(2):418-424. · Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol. 2015;69(1):123-131. · Cullen J, Kuo HC, Shan J, Aboushwareb T, and Van Den Eeden SK. The 17-gene genomic prostate score test as a predictor of outcomes in men with unfavorable intermediate-risk prostate cancer. Urology. 2020;143:103-111. · Cullen J, Lynch JA, Klein EA, Van Den Eeden SK, Carroll PR, Mohler JL, et al. Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer. J Urol. 2021;205(4):1047-1054. · Eggener S, Karsh LI, Richardson T, Shindel AW, Lu R, Rosenberg A et al. A 17-gene panel for prediction of adverse prostate cancer pathologic features: prospective clinical validation and utility. Urology. 2019;126:76-82. · Helfand BT, Paterakos M, Wang CH, Talaty P, Abran J, Bennett J et al. The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer. PLoS One. 2022;17(9):e0273782. · Helfand BT, Paterakos M, Wang CH, Talaty P, Abran J, Bennett J et al. The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer. PLoS One. 2022;17(9):e0273782. · Janes JL, Boyer MJ, Bennett JP, Thomas VM, De Hoedt AM, Edwards DK, et al. Prognostic for outcomes after primary external beam radiation therapy in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2023;115(1):120-131. · Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. _Eur Urol._ 2014;66(3):550–560. · Kornberg Z, Cowan JE, Westphalen AC, Cooperberg MR, Chan JM, Zhao S, et al. Genomic prostate score, PI-RADS version 2 and progression in men with prostate cancer on active surveillance. J Urol. 2019;201:300-307. · Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg M, et al. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate-risk prostate cancer. PLoS One. 2017;12(10):e0185535. · Lin D, Zheng Y, McKenney JK, Brown MD, Lu R, Crager M, et al. 17-gene genomic prostate score test results in the Canary Prostate Active Surveillance Study (PASS) cohort. J Clin Oncol. 2020;38(14):1549-1557. · Magi-Galluzzi C, Isharwal S, Falzarano SM, Tsiatis A, Dee A, Maddala T et al. The 17-gene genomic prostate score assay predicts outcomes after radical prostatectomy independent of PTEN status. Urology. 2018;121:132-138. · Murphy AB, Carbunaru S, Nettey OS, Gornbein C, Dixon MA, Macias V, et al. A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men. Urology. 2020; 142:166-173. · Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk Jr AE et al. A 17-gene Genomic Prostate Score assay provides independent information on adverse pathology in the setting of combined multiparametric magnetic resonance fusion-targeted and systematic prostate biopsy. J Urol. 2018;200(3):564-572. · Van Den Eeden SK, Lu R, Zhang N, Queensberry Jr CP, Shan J, Han JS, et al. A biopsy-based 17-gene genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease. Eur Urol. 2017;73(1):129-138.  \n**Meta-analysis**  \n· Bennett J, Flake D. Patient-specific meta-analysis of three clinical validation studies to predict risk of distant metastasis and prostate cancer death in higher risk prostate cancer patients after definitive radiotherapy of radical prostatectomy. EXAS Internal Data 2022. · Brand TC, Zhang N, Crager MR, Maddala T, Dee A, Sesterhenn IA, et al. Patient-specific meta-analysis of 2 clinical validation studies to predict pathologic outcomes in prostate cancer using the 17-gene Genomic Prostate Score. Urology. 2016;89:69-75.  \n  \nCLOSE \n\n### Insurance & Billing Policy\n\nWe are committed to making our tests accessible and affordable to your patients. Mdxhealth’s Patient First Promise Program was created to assist patients throughout the billing process. We will work directly with each patient to ensure their complete satisfaction.\n\n##### Dedicated Patient Advocate Team\n\n  * Our specially trained Patient Advocates are ready to answer patients’ questions about insurance coverage and personalized payment options.\n  * Toll Free: 866-259-7001, Monday – Friday, 6:00AM – 4:30PM PT\n  * Email: patientfirst@mdxhealth.com\n\n\n\n##### Personalized Payment Options\n\n  * Interest-Free Payment Plan\n  * Financial Assistance Program\n\n\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Koen-Hoffman.png)\n\n## Mr. Koen Hoffman\n\n### Chairman and Independent Director, representing Ahok BV\n\nKoen Hoffman has served as Independent Chairman of the Board of Directors of Fagron NV since May 8, 2017. He obtained a Master in Applied Economics at the University of Ghent in 1990 and a Master in Business Administration at Vlerick Business School in Ghent in 1991. Mr. Hoffman was appointed Chief Executive Officer of Value Square in August 2016. Prior to joining Value Square, he was Chief Executive Officer of KBC Securities, member of the supervisory board of Patria Securities and member of the board of directors of Omnia Travel Belgium. He started his career at the corporate finance department of KBC Bank in 1992.\n\nCLOSE \n\n## Understanding your GPS results\n\n### Deciding the most appropriate course of treatment for your prostate cancer is important. Your GPS result may help.\n\nThe GPS test measures prostate cancer gene levels to assess how aggressively your cancer will grow or spread. Since certain genes influence this more than others, knowing which ones are active in your tumor helps determine your personal GPS result.\n\n### Your personal GPS result and risk category\n\nYour score is based on a scale of 0-100. Your genomic risk will indicate how your tumor behaves and can help you and your doctor determine the most appropriate course of treatment.\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/211and212highrisk-1024x380.png)\n\n### Current and future risk\n\nThese results can predict both your chance of:\n\n  1. Dying from prostate cancer and\n  2. Your cancer spreading (metastasis) in the next 10 years\n\n\n\n### Personalized assessment for individualized treatment\n\nThe GPS test provides a personalized assessment of how aggressive your prostate cancer is, helping you and your doctor discuss next steps with confidence.\n\n[**DOWNLOAD SAMPLE REPORT OVERVIEW FOR CLINICALLY HIGH-RISK PROSTATE CANCER**](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/Clinically-High-Risk-Report-Overview-PDF.pdf)\n\nCLOSE \n\n## Understand your test results\n\n### Deciding between active surveillance and immediate treatment for your prostate cancer is important. Your GPS result may help.\n\nThe GPS test measures prostate cancer gene levels to assess how aggressively your cancer will grow or spread. Since certain genes influence this more than others, knowing which ones are active in your tumor helps determine your personal GPS result.\n\n### Your personal GPS result\n\nThe bell curve illustrates where your GPS result falls in relation to the GPS results of other men in the same risk category.\n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/212-low-risk-report-1024x627.png)\n\n### Current and future risk\n\nThese results can predict both your chance of:\n\n  1. Your cancer spreading (metastasis) and\n  2. Dying from prostate cancer in the next 10 years\n\n\n\n## Personalized assessment for individualized treatment\n\n### Additional pathology endpoints (provided for men with Gleason score 3+4)\n\n  1. **Adverse Pathology** predicts the probability your doctor would find more aggressive disease than expected from your biopsy. This helps your doctor know if you are a candidate for active surveillance or if immediate treatment is most appropriate for you.\n  2. **High-Grade Disease** shows the likelihood that cancer cells within your tumor are abnormal when compared to typical cells.\n  3. **Non–Organ-Confined Disease** indicates the likelihood that your cancer has already spread outside your prostate.\n\n\n\nThe GPS test provides a personalized assessment of how aggressive your prostate cancer is, helping you and your doctor discuss next steps with confidence.\n\n[**DOWNLOAD SAMPLE REPORT OVERVIEW FOR CLINICALLY LOW-RISK PROSTATE CANCER**](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/08/Clinically-Low-Risk-Report-Overview-PDF.pdf)\n\nCLOSE \n\n### Test Cancellation Policy\n\nMdxhealth will honor test cancellation requests any time prior to the start of the analytical testing phase. Test cancellation requests must be submitted from the person authorized to cancel a test, following the instructions below:\n\nContact Client Services at **866-259-5644** for test cancellation.\n\nA Test Cancellation Form will be sent to the authorized person for signature.\n\nReturn the completed and signed Test Cancellation Form by fax to mdxhealth **949-788-0014**.\n\nIf the cancellation request is received after the specimen has entered in the analytical testing phase, the request cannot be honored and the usual test charge will be assessed.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Eric-Bednarski.png)\n\n## Eric Bednarski\n\n### Director\n\nDr. Bednarski currently serves as a Partner of MVM Partners LLP. Before joining MVM in 2008, he was a Partner at Advent Healthcare Ventures and a Principal at Advent International Corporation. Prior to Advent, he was a Director in the Corporate Finance Group of Silicon Valley Bank. Dr. Bednarski has a B.S. degree in Neural Science from Brown University and a Ph.D. in Biological Sciences from the University of California, Irvine.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Mike-M-Headhsot-BW.png)\n\n## Michael K. McGarrity\n\n### Chief Executive Officer, Director\n\nMr. McGarrity has more than 25 years of experience in the healthcare industry with a unique combination of device, diagnostics and biotechnology experience. Michael was most recently the CEO of Sterilis Medical. Prior to Sterilis Michael was the CEO of Nanosphere (NASDAQ: NSPH), a nanotechnology-based molecular diagnostics company, where he engineered an operational and strategic turnaround that resulted in its successful sale to Luminex (NASDAQ: LMNX) in 2016. Prior to Nanosphere, McGarrity spent 13 years at Stryker Corporation (NYSE: SYK). McGarrity served in leadership roles in sales and marketing and led Stryker into new growth markets such as post-operative pain management, surgical fluid waste management and interventional pain management. He also had executive general management responsibility for a newly created business unit focused on interventional spine pain management. Michael received a Bachelor of Arts degree from the University of Notre Dame and began his career in commercial banking.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/John-B-headshot-website.png)\n\n## John Bellano\n\n### Chief Commercial Officer\n\nMr. Bellano has more than 25 years of experience in the Healthcare Industry. Mr. Bellano started his career in Pharmaceuticals and transitioned to molecular diagnostics where he has spent the past 20 years of his career. Most recently the Chief Commercial Officer of Sterilis Solutions Prior to Sterilis Solutions he served as the commercial leader for Pharmacogenomic companies Assurex Health and AltheaDx. While at Assurex Health (Myriad Genetics) revenue grew from $700k to a run rate of $100 Million during his 5 year span with the organization.\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Mimi-Reyes-headshot_.png)\n\n## Miriam Reyes\n\n### Executive Vice President of Operations\n\nMiriam Reyes has 25 years of experience in life science and laboratory operations, and R&D. She has served as Operations Leader at MDxHealth since its US inception in 2011. Prior to MDxHealth, Mrs. Reyes was Director of Laboratory Operations at Agendia where she established/built and led the CLIA lab for the Agendia’s FDA cleared MammaPrint breast cancer test. In addition to Agendia, she established laboratory operations at Combimatrix (Invitae) Molecular Diagnostics and developed commercial assays at both IBIS Biosciences and US Labs (LabCorp.).\n\nCLOSE \n\n![](https://mdxhealthdotcom-dev.azurewebsites.netwp-content/uploads/2022/06/Joe-Sollee-Headshot.png)\n\n## Joseph Sollee\n\n### Executive Vice President of Corporate Development and General Counsel\n\nMr. Sollee has more than 20 years of experience in the healthcare industry, including senior management roles in both private and publicly listed pharmaceuticals, health information technology and molecular diagnostics companies. He has served as chief legal counsel to MDxHealth since its inception in 2003. Prior to MDxHealth, he led the Life Sciences Practice Group at the law firm of Kennedy Covington (now K&LGates) and held senior legal and management positions at TherapyEdge and Triangle Pharmaceuticals. In addition, he has practiced as a corporate attorney in the Washington D.C. legal firm Swidler & Berlin and as an investment banker at Smith Barney in New York. Mr. Sollee received a Juris Doctorate in Law and a Masters degree in International Law from Duke University, a BA degree from Harvard University, and has been awarded New York, Washington D.C. and North Carolina legal bar certifications.\n\nCLOSE \n"
        }
      ]
    }
  ]
}